<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003557.pub4" GROUP_ID="WOUNDS" ID="999002012816240149" MERGED_FROM="" MODIFIED="2014-01-09 09:36:30 +0000" MODIFIED_BY="Sally Bell-Syer" REVIEW_NO="052" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2014-01-09 09:36:30 +0000" MODIFIED_BY="Sally Bell-Syer">
<TITLE MODIFIED="2009-06-22 16:49:22 +0100" MODIFIED_BY="Sue O'Meara">Antibiotics and antiseptics for venous leg ulcers</TITLE>
<CONTACT MODIFIED="2014-01-09 09:36:30 +0000" MODIFIED_BY="Sally Bell-Syer"><PERSON ID="13913" ROLE="AUTHOR"><FIRST_NAME>Susan</FIRST_NAME><LAST_NAME>O'Meara</LAST_NAME><POSITION>Senior Research Fellow in Wounds</POSITION><EMAIL_1>s.m.omeara@leeds.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Healthcare</DEPARTMENT><ORGANISATION>University of Leeds</ORGANISATION><ADDRESS_1>Room LG.12, Baines Wing</ADDRESS_1><CITY>Leeds</CITY><ZIP>LS2 9JT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 113-343-7552</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-01-09 09:36:30 +0000" MODIFIED_BY="Sally Bell-Syer"><PERSON ID="13913" ROLE="AUTHOR"><FIRST_NAME>Susan</FIRST_NAME><LAST_NAME>O'Meara</LAST_NAME><POSITION>Senior Research Fellow in Wounds</POSITION><EMAIL_1>s.m.omeara@leeds.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Healthcare</DEPARTMENT><ORGANISATION>University of Leeds</ORGANISATION><ADDRESS_1>Room LG.12, Baines Wing</ADDRESS_1><CITY>Leeds</CITY><ZIP>LS2 9JT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 113-343-7552</PHONE_1></ADDRESS></PERSON><PERSON ID="4214090982E26AA201D1E765E561892F" ROLE="AUTHOR"><FIRST_NAME>Deyaa</FIRST_NAME><LAST_NAME>Al-Kurdi</LAST_NAME><EMAIL_1>deyaak@hotmail.com</EMAIL_1><MOBILE_PHONE>07795012276</MOBILE_PHONE><ADDRESS><DEPARTMENT>The Cochrane Wounds Group</DEPARTMENT><ORGANISATION>University of York</ORGANISATION><ADDRESS_1>Area 2 Seebohm Rowntree Building</ADDRESS_1><CITY>York</CITY><ZIP>YO10 5DD</ZIP><REGION>North Yorkshire</REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="63D3382E82E26AA201066D88275F4C6F" ROLE="AUTHOR"><FIRST_NAME>Yemisi</FIRST_NAME><LAST_NAME>Ologun</LAST_NAME><EMAIL_1>yemisiologun@yahoo.com</EMAIL_1><ADDRESS><ORGANISATION>Chesterfield Royal Hospital</ORGANISATION><ADDRESS_1>Room BG .01, Beech Court</ADDRESS_1><ADDRESS_2>Chesterfield Royal Hospital</ADDRESS_2><CITY>Calow</CITY><ZIP>S44 5BL</ZIP><REGION>Derbyshire</REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="16774" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Liza</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Ovington</LAST_NAME><POSITION>Associate Medical Director</POSITION><EMAIL_1>lovingt@ethus.jnj.com</EMAIL_1><ADDRESS><ORGANISATION>Ethicon, Inc</ORGANISATION><ADDRESS_1>PO Box 151</ADDRESS_1><CITY>Somerville</CITY><ZIP>08876</ZIP><REGION>New Jersey</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 484 951 2045</PHONE_1></ADDRESS></PERSON><PERSON ID="27104705101266158585110621145227" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Marrissa</FIRST_NAME><LAST_NAME>Martyn-St James</LAST_NAME><EMAIL_1>m.martyn-stjames@sheffield.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Health and Related Research (ScHARR)</DEPARTMENT><ORGANISATION>University of Sheffield</ORGANISATION><ADDRESS_1>Regent Court, 30 Regent Street</ADDRESS_1><CITY>Sheffield</CITY><ZIP>S1 4DA</ZIP><REGION>South Yorkshire</REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="ED5081C282E26AA20078D4E60BA50A05" ROLE="AUTHOR"><FIRST_NAME>Rachel</FIRST_NAME><LAST_NAME>Richardson</LAST_NAME><POSITION>Reviewer</POSITION><EMAIL_1>rachel.richardson@york.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Health Sciences</DEPARTMENT><ORGANISATION>University of York</ORGANISATION><ADDRESS_2>Heslington</ADDRESS_2><CITY>York</CITY><ZIP>YO10 5DD</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1904 321863</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-01-09 09:28:37 +0000" MODIFIED_BY="Sally Bell-Syer">
<UP_TO_DATE>
<DATE DAY="24" MONTH="5" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="5" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="2" MONTH="2" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2014-01-09 09:32:49 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-01-09 09:32:49 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="1" YEAR="2014"/>
<DESCRIPTION>
<P>minor text amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-01-09 09:29:18 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<P>Conclusions updated, additional review authors joined the team.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-12-16 15:16:30 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<P>Second update, new search; 18 trials added (<LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>; <LINK REF="STD-Blair-1988" TYPE="STUDY">Blair 1988</LINK>; <LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>; <LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>; <LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK>; <LINK REF="STD-Chaloner-2004" TYPE="STUDY">Chaloner 2004</LINK>; <LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>; <LINK REF="STD-Kuznetsov-2009" TYPE="STUDY">Kuznetsov 2009</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Bini_x0107_-2010" TYPE="STUDY">Bini&#263; 2010</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>; <LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-01-09 09:29:18 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-09-10 17:13:04 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="8" YEAR="2010"/>
<DESCRIPTION>
<P>Declaration of interest and sources of support amended</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-08-11 14:01:57 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>New search, 3 additional studies included, 14 studies added to the Table of excluded studies, 2 studies awaiting assessment. No change to conclusions. Risk of bias table added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2010-08-11 14:01:53 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Additional author joined the review team</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-04 16:40:16 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Contact details updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-11 16:43:32 +0000" MODIFIED_BY="Sally Bell-Syer">
<DATE DAY="18" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="12" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-12-16 15:25:23 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2013-12-15 18:06:35 +0000" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>Department of Health Sciences, University of York</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2013-12-15 18:06:35 +0000" MODIFIED_BY="[Empty name]">
<NAME>School of Healthcare, University of Leeds</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2013-12-16 15:25:23 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-08-11 14:08:45 +0100" MODIFIED_BY="[Empty name]">
<NAME>NIHR/Department of Health (England) Cochrane Review Incentive Scheme 2006</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>North Yorkshire &amp; East Coast Foundation School</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2010-08-13 11:49:13 +0100" MODIFIED_BY="[Empty name]">
<NAME>NIHR Programme Grants for Applied Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2013-12-16 15:25:23 +0000" MODIFIED_BY="[Empty name]">
<NAME>NIHR/Department of Health (England), Cochrane Wounds Group</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-01-09 09:33:24 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-12-02 19:36:26 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-05-21 16:47:36 +0100" MODIFIED_BY="[Empty name]">Antibiotics and antiseptics to help healing venous leg ulcers</TITLE>
<SUMMARY_BODY MODIFIED="2013-12-02 19:36:26 +0000" MODIFIED_BY="[Empty name]">
<P>Venous leg ulcers are a type of wound that can take a long time to heal. These ulcers can become infected, and this might cause further delay to healing. Two types of treatment are available to treat infection: systemic antibiotics (i.e. antibiotics taken by mouth or by injection) and topical preparations (i.e. treatments applied directly to the wound). Whether systemic or topical preparations are used, patients will also usually have a wound dressing and bandage over the wound. This review was undertaken to find out whether using antibiotics and antiseptics works better than usual care in healing venous leg ulcers, and if so, to find out which antibiotic and antiseptic preparations are better than others. In terms of topical preparations, some evidence is available to support the use of cadexomer iodine (a topical agent thought to have cleansing and antibacterial effects). Current evidence does not support the use of honey- or silver-based products. Further good quality research is required before definitive conclusions can be drawn about the effectiveness of antibiotic tablets and topical agents such as povidone-iodine, peroxide-based products and other topical antibiotics and antiseptics in healing venous leg ulceration.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-01-09 09:33:07 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-12-01 19:19:59 +0000" MODIFIED_BY="[Empty name]">
<P>Venous leg ulcers are a type of chronic wound affecting up to 1% of adults in developed countries at some point during their lives. Many of these wounds are colonised by bacteria or show signs of clinical infection. The presence of infection may delay ulcer healing. Two main strategies are used to prevent and treat clinical infection in venous leg ulcers: systemic antibiotics and topical antibiotics or antiseptics.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-01-09 09:33:07 +0000" MODIFIED_BY="[Empty name]">
<P>The objective of this review was to determine the effects of systemic antibiotics and topical antibiotics and antiseptics on the healing of venous ulcers.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-12-06 12:12:58 +0000" MODIFIED_BY="Sue O'Meara">
<P>In May 2013, for this second update, we searched the Cochrane Wounds Group Specialised Register (searched 24 May 2013); the Cochrane Central Register of Controlled Trials (CENTRAL 2013, Issue 4); Ovid MEDLINE (1948 to Week 3 May 2013); Ovid MEDLINE (In-Process &amp; Other Non-indexed Citations, 22 May 2013); Ovid EMBASE (1980 to Week 20 2013); and EBSCO CINAHL (1982 to 17 May 2013). No language or publication date restrictions were applied.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-12-01 19:20:59 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) recruiting people with venous leg ulceration, evaluating at least one systemic antibiotic, topical antibiotic or topical antiseptic that reported an objective assessment of wound healing (e.g. time to complete healing, frequency of complete healing, change in ulcer surface area) were eligible for inclusion. Selection decisions were made by two review authors while working independently.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-12-01 19:21:15 +0000" MODIFIED_BY="Sue O'Meara">
<P>Information on the characteristics of participants, interventions and outcomes was recorded on a standardised data extraction form. In addition, aspects of trial methods were extracted, including randomisation, allocation concealment, blinding of participants and outcome assessors, incomplete outcome data and study group comparability at baseline. Data extraction and validity assessment were conducted by one review author and were checked by a second. Data were pooled when appropriate.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-12-15 17:53:29 +0000" MODIFIED_BY="[Empty name]">
<P>Forty-five RCTs reporting 53 comparisons and recruiting a total of 4486 participants were included, Many RCTs were small, and most were at high or unclear risk of bias. Ulcer infection status at baseline and duration of follow-up varied across RCTs. Five RCTs reported eight comparisons of systemic antibiotics, and the remainder evaluated topical preparations: cadexomer iodine (11 RCTs reporting 12 comparisons); povidone-iodine (six RCTs reporting seven comparisons); peroxide-based preparations (four RCTs reporting four comparisons); honey-based preparations (two RCTs reporting two comparisons); silver-based preparations (12 RCTs reporting 13 comparisons); other topical antibiotics (three RCTs reporting five comparisons); and other topical antiseptics (two RCTs reporting two comparisons). Few RCTs provided a reliable estimate of time to healing; most reported the proportion of participants with complete healing during the trial period.</P>
<P>
<B>Systemic antibiotics</B>
</P>
<P>More participants were healed when they were prescribed levamisole (normally used to treat roundworm infection) compared with placebo: risk ratio (RR) 1.31 (95% CI 1.06 to 1.62). No between-group differences were detected in terms of complete healing for other comparisons: antibiotics given according to antibiogram versus usual care; ciprofloxacin versus standard care/placebo; trimethoprim versus placebo; ciprofloxacin versus trimethoprim; and amoxicillin versus topical povidone-iodine.</P>
<P>
<B>Topical antibiotics and antiseptics</B>
</P>
<P>Cadexomer iodine: more participants were healed when given cadexomer iodine compared with standard care. The pooled estimate from four RCTs for complete healing at four to 12 weeks was RR 2.17 (95% CI 1.30 to 3.60). No between-group differences in complete healing were detected when cadexomer iodine was compared with the following: hydrocolloid dressing; paraffin gauze dressing; dextranomer; and silver-impregnated dressings.</P>
<P>Povidone iodine: no between-group differences in complete healing were detected when povidone-iodine was compared with the following: hydrocolloid; moist or foam dressings according to wound status; and growth factor. Time to healing estimates for povidone-iodine versus dextranomer, and for povidone-iodine versus hydrocolloid, were likely to be unreliable.</P>
<P>Peroxide-based preparations: four RCTs reported findings in favour of peroxide-based preparations when compared with usual care for surrogate healing outcomes (change in ulcer area). There was no report of complete healing.</P>
<P>Honey-based preparations: no between-group difference in time to healing or complete healing was detected for honey-based products when compared with usual care.</P>
<P>Silver-based preparations: no between-group differences in complete healing were detected when 1% silver sulphadiazine ointment was compared with standard care/placebo and tripeptide copper complex; or when different brands of silver-impregnated dressings were compared; or when silver-impregnated dressings were compared with non-antimicrobial dressings.</P>
<P>Other topical antibiotics: data from one RCT suggested that more participants healed at four weeks when treated with an enzymatic cleanser (a non-antibiotic preparation) compared with a chloramphenicol-containing ointment (additional active ingredients also included in the ointment): RR 0.13 (95% CI 0.02 to 0.99). No between-group differences in complete healing were detected for framycetin sulphate ointment versus enzymatic cleanser; chloramphenicol ointment versus framycetin sulphate ointment; mupirocin ointment versus vehicle; and topical antibiotics given according to antibiogram versus an herbal ointment.</P>
<P>Other topical antiseptics: data from one RCT suggested that more participants receiving an antiseptic ointment (ethacridine lactate) had responsive ulcers (defined as &gt; 20% reduction in area) at four weeks when compared with placebo: RR 1.45 (95% CI 1.21 to 1.73). Complete healing was not reported. No between-group difference was detected between chlorhexidine solution and usual care.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-12-01 19:33:13 +0000" MODIFIED_BY="[Empty name]">
<P>At present, no evidence is available to support the routine use of systemic antibiotics in promoting healing of venous leg ulcers. However, the lack of reliable evidence means that it is not possible to recommend the discontinuation of any of the agents reviewed. In terms of topical preparations, some evidence supports the use of cadexomer iodine. Current evidence does not support the routine use of honey- or silver-based products. Further good quality research is required before definitive conclusions can be drawn about the effectiveness of povidone-iodine, peroxide-based preparations, ethacridine lactate, chloramphenicol, framycetin, mupirocin, ethacridine or chlorhexidine in healing venous leg ulceration. In light of the increasing problem of bacterial resistance to antibiotics, current prescribing guidelines recommend that antibacterial preparations should be used only in cases of clinical infection, not for bacterial colonisation.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-01-09 09:33:24 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-12-15 19:16:01 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-12-15 19:16:01 +0000" MODIFIED_BY="[Empty name]">
<P>Venous leg ulcers are a common and recurring type of chronic, or complex, wound. They are usually caused by venous insufficiency (impaired venous blood flow) brought about by venous hypertension (<LINK REF="REF-Doughty-2007" TYPE="REFERENCE">Doughty 2007</LINK>). The duration of venous leg ulceration ranges from a matter of weeks to longer than 10 years, and in some people these wounds never heal (<LINK REF="REF-Moffatt-1995" TYPE="REFERENCE">Moffatt 1995</LINK>; <LINK REF="REF-Ruckley-1998" TYPE="REFERENCE">Ruckley 1998</LINK>; <LINK REF="REF-Vowden-2009a" TYPE="REFERENCE">Vowden 2009a</LINK>). Older patient age, longer wound duration and larger ulcer surface area have been reported as independent risk factors for delayed ulcer healing (<LINK REF="REF-Margolis-2004" TYPE="REFERENCE">Margolis 2004</LINK>; <LINK REF="REF-Gohel-2005" TYPE="REFERENCE">Gohel 2005</LINK>).</P>
<P>Reported prevalence rates for leg ulceration are variable. A systematic review of the epidemiological literature from developed countries reported prevalence rates for any aetiology of open lower limb ulceration ranging from 0.1% to 1.1% (cases validated) (<LINK REF="REF-Graham-2003" TYPE="REFERENCE">Graham 2003</LINK>). Another review of 11 venous leg ulceration prevalence studies conducted in Australia and Europe estimated point prevalence as 0.1% to 0.3% (<LINK REF="REF-Nelzen-2008" TYPE="REFERENCE">Nelzen 2008</LINK>). Surveys undertaken in the UK estimated prevalence of venous leg ulceration as 0.023% in Wandsworth, London (<LINK REF="REF-Moffatt-2004" TYPE="REFERENCE">Moffatt 2004</LINK>); 0.044% in Hull and East Yorkshire (<LINK REF="REF-Srinivasaiah-2007" TYPE="REFERENCE">Srinivasaiah 2007</LINK>); and 0.039% in Bradford and Airedale (<LINK REF="REF-Vowden-2009a" TYPE="REFERENCE">Vowden 2009a</LINK>; <LINK REF="REF-Vowden-2009b" TYPE="REFERENCE">Vowden 2009b</LINK>). The lower estimates reported in the UK surveys relative to the worldwide literature might be explained by differences in disease management or case definition, or both. We were unable to identify contemporary prevalence data for non-Western countries during the latest review update. The epidemiological data have consistently suggested that prevalence increases with age and is higher among women (<LINK REF="REF-Margolis-2002" TYPE="REFERENCE">Margolis 2002</LINK>; <LINK REF="REF-Graham-2003" TYPE="REFERENCE">Graham 2003</LINK>; <LINK REF="REF-Lorimer-2003a" TYPE="REFERENCE">Lorimer 2003a</LINK>; <LINK REF="REF-Moffatt-2004" TYPE="REFERENCE">Moffatt 2004</LINK>; <LINK REF="REF-Vowden-2009a" TYPE="REFERENCE">Vowden 2009a</LINK>).</P>
<P>Diagnosis of venous leg ulceration can be made according to the appearance and location of the ulcer. Clinical practice guidelines recommend the use of clinical history, physical examination, laboratory tests and haemodynamic assessment (<LINK REF="REF-RCN-2006" TYPE="REFERENCE">RCN 2006</LINK>; <LINK REF="REF-SIGN-2010" TYPE="REFERENCE">SIGN 2010</LINK>). The latter often includes an assessment of arterial blood supply to the leg using the ankle-brachial pressure index (ABPI), measured by using a hand-held Doppler ultrasound device. An ABPI measurement greater than 0.8 is generally used to rule out the co-existence of clinically significant peripheral arterial disease in a leg ulcer that has been diagnosed as due to venous insufficiency (<LINK REF="REF-Moffatt-2007" TYPE="REFERENCE">Moffatt 2007</LINK>).</P>
<P>Leg ulcers are associated with considerable cost to patients and to healthcare providers. Two systematic reviews summarised the literature on health-related quality of life in patients with leg ulcers (<LINK REF="REF-Persoon-2004" TYPE="REFERENCE">Persoon 2004</LINK>; <LINK REF="REF-Herber-2007" TYPE="REFERENCE">Herber 2007</LINK>). Both included qualitative and quantitative evaluations and reported that the presence of leg ulceration was associated with pain, restriction of work and leisure activities, impaired mobility, sleep disturbance, reduced psychological well-being and social isolation.</P>
<P>The cost of treating an unhealed leg ulcer in the UK has been estimated to be around GBP 1300 per year at 2001 prices (<LINK REF="REF-Iglesias-2004" TYPE="REFERENCE">Iglesias 2004</LINK>). Another evaluation estimated the average cost of treating a venous leg ulcer in the UK (based on costs for material for dressing changes) as falling between EUR 814 and EUR 1994, and, in Sweden as lying between EUR 1332 and EUR 2585 (price year 2002), with higher costs associated with larger and more chronic wounds (<LINK REF="REF-Ragnarson-Tennvall-2005" TYPE="REFERENCE">Ragnarson Tennvall 2005</LINK>). These data reflect findings from a more recent evaluation conducted in Germany, which estimated the total mean annual cost of illness for leg ulcers as EUR 9060 per patient (price year 2006), taking account of direct, indirect and intangible costs from a societal perspective. Estimates ranged from zero cost (i.e. no treatment) to EUR 44,462, with higher costs associated with arterial aetiology of the ulcer, larger wound size and no history of wound closure (<LINK REF="REF-Augustin-2012" TYPE="REFERENCE">Augustin 2012</LINK>). In Bradford, in the UK, GBP 1.69 million was spent on dressings and compression bandages, and GBP 3.08 million on nursing time (estimates derived from resource use data for all wound types, not just venous leg ulcers) during the financial year 2006 to 2007 (<LINK REF="REF-Vowden-2009c" TYPE="REFERENCE">Vowden 2009c</LINK>). We were not able to identify further contemporary international cost data during the latest review update.<BR/>
</P>
<P>The burden of venous leg ulceration may be aggravated by the presence of wound infection. Moist, chronic skin ulcers are an ideal medium for bacterial growth, and a variety of micro-organisms can be cultured from these lesions. Findings from microbiological studies suggest that 80% to 100% of leg ulcers may be colonised with bacteria (<LINK REF="REF-Halbert-1992" TYPE="REFERENCE">Halbert 1992</LINK>; <LINK REF="REF-Brook-1998" TYPE="REFERENCE">Brook 1998</LINK>; <LINK REF="REF-Harker-2001" TYPE="REFERENCE">Harker 2001</LINK>). The most common isolates include <I>Staphylococcus aureus</I> and <I>Pseudomonas aeruginosa</I> (<LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>; <LINK REF="REF-Kontiainen-1988" TYPE="REFERENCE">Kontiainen 1988</LINK>; <LINK REF="REF-Halbert-1992" TYPE="REFERENCE">Halbert 1992</LINK>; <LINK REF="REF-Brook-1998" TYPE="REFERENCE">Brook 1998</LINK>; <LINK REF="REF-Harker-2001" TYPE="REFERENCE">Harker 2001</LINK>; <LINK REF="REF-Moore-2010" TYPE="REFERENCE">Moore 2010</LINK>).</P>
<P>As well as the risk factors already mentioned, it has been suggested that the presence of infection can delay ulcer healing (<LINK REF="REF-Doughty-2007" TYPE="REFERENCE">Doughty 2007</LINK>). A recent study of 66 participants showed bacterial density to be associated with the probability of non-healing in venous leg ulcers when infection was detected using swabs or tissue biopsies (<LINK REF="REF-Davies-2007" TYPE="REFERENCE">Davies 2007</LINK>). Findings from earlier studies are mostly supportive of the notion of a positive correlation between bacterial load and delayed healing (<LINK REF="REF-Halbert-1992" TYPE="REFERENCE">Halbert 1992</LINK>; <LINK REF="REF-Hansson-1995" TYPE="REFERENCE">Hansson 1995</LINK>; <LINK REF="REF-Madsen-1996" TYPE="REFERENCE">Madsen 1996</LINK>; <LINK REF="REF-Trengove-1996" TYPE="REFERENCE">Trengove 1996</LINK>). It has been suggested that chronic wound healing may be influenced not only by bacterial density but also by the diversity of micro-organisms present and their interactions with one another (<LINK REF="REF-Trengove-1996" TYPE="REFERENCE">Trengove 1996</LINK>; <LINK REF="REF-Bowler-2003" TYPE="REFERENCE">Bowler 2003</LINK>; <LINK REF="REF-Davies-2007" TYPE="REFERENCE">Davies 2007</LINK>). In addition, delayed healing may be associated with the presence of certain bacterial strains such as <I>Pseudomonas aeruginosa, Staphylococcus aureus</I> and haemolytic streptococci<I> </I>(<LINK REF="REF-Madsen-1996" TYPE="REFERENCE">Madsen 1996</LINK>). However, other research indicates that healing is not influenced by increasing diversity of organisms or the presence of particular species (<LINK REF="REF-Moore-2010" TYPE="REFERENCE">Moore 2010</LINK>).</P>
<P>The terms 'contamination', 'colonisation', and 'infection' are used frequently in the wound care literature. The term `contamination' describes wounds with non-replicating organisms on their surface (<LINK REF="REF-Dow-1999" TYPE="REFERENCE">Dow 1999</LINK>). 'Colonisation' occurs when bacteria capable of replicating on the ulcer surface inhabit non-viable tissue in the wound in the absence of host immune response (<LINK REF="REF-Ayton-1985" TYPE="REFERENCE">Ayton 1985</LINK>; <LINK REF="REF-Dow-1999" TYPE="REFERENCE">Dow 1999</LINK>). The classic signs of infection include local pain, heat, redness, swelling and purulence; however, it has been suggested that these may not always manifest in patients with venous leg ulcers. In light of this, signs and symptoms of critical colonisation have been proposed as an alternative guide for assessing infection and indicating antimicrobial treatment in chronic wounds. They include: delayed healing; unexpected pain; abnormal odour; pocketing at the base of the wound; discoloured (i.e. unusually dark) granulation tissue; friable granulation tissue; and devitalised (sloughy or necrotic) tissue (<LINK REF="REF-Gardner-2001" TYPE="REFERENCE">Gardner 2001</LINK>; <LINK REF="REF-Cutting-2004" TYPE="REFERENCE">Cutting 2004</LINK>). Prescribing guidelines suggest that dressings impregnated with antibacterial agents should be used only to treat clinically infected wounds, not for bacterial colonisation (<LINK REF="REF-BNF-2013" TYPE="REFERENCE">BNF 2013</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-12-06 12:18:34 +0000" MODIFIED_BY="[Empty name]">
<P>Compression therapy (bandages or stockings) is now considered to be the cornerstone of venous leg ulcer management (<LINK REF="REF-Moffatt-2007" TYPE="REFERENCE">Moffatt 2007</LINK>; <LINK REF="REF-O_x0027_Meara-2012" TYPE="REFERENCE">O'Meara 2012</LINK>). Primary wound contact dressings (i.e. dressings in direct contact with the wound bed) are usually applied underneath compression devices. A range of other interventions may be used concurrently with compression, including debriding agents (<LINK REF="REF-Davies-2005" TYPE="REFERENCE">Davies 2005</LINK>; <LINK REF="REF-Cardinal-2009" TYPE="REFERENCE">Cardinal 2009</LINK>), vasoactive drugs (<LINK REF="REF-Robson-2006" TYPE="REFERENCE">Robson 2006</LINK>), fibrinolytic therapy (<LINK REF="REF-Robson-2006" TYPE="REFERENCE">Robson 2006</LINK>), physical therapies (<LINK REF="REF-Flemming-1999" TYPE="REFERENCE">Flemming 1999</LINK>; <LINK REF="REF-Cullum-2010" TYPE="REFERENCE">Cullum 2010</LINK>; <LINK REF="REF-Aziz-2013" TYPE="REFERENCE">Aziz 2013</LINK>), and topical applications (<LINK REF="REF-Robson-2006" TYPE="REFERENCE">Robson 2006</LINK>). When ulcer infection is suspected, antimicrobial therapy may also be considered.</P>
<P>Two main strategies are used to manage clinical infection in venous leg ulcers: systemic antibiotics; and topical antibiotics and antiseptics.</P>
<P>Antibiotics are substances that destroy or inhibit the growth of micro-organisms (<LINK REF="REF-Macpherson-2004" TYPE="REFERENCE">Macpherson 2004</LINK>). Systemic antibiotics include groups of drugs such as penicillins (e.g. amoxicillin), cephalosporins (e.g. cephalexin), aminoglycosides (e.g. gentamicin, amikacin), macrolides (e.g. erythromycin) and quinolones (e.g. ciprofloxacin). Other drugs include clindamycin, metronidazole, trimethoprim and co-trimoxazole. Most systemic antibiotics work by interfering with aspects of bacterial cell function, for example, by impeding bacterial cell wall synthesis in the case of penicillins and cephalosporins. Clindamycin is associated with antibiotic-induced colitis, a rare but serious adverse event; prescription should be withdrawn immediately in any patient who develops diarrhoea (<LINK REF="REF-BNF-2013" TYPE="REFERENCE">BNF 2013</LINK>).</P>
<P>Topical antimicrobial agents include antibiotics and antiseptics. Antiseptics are thought to prevent the growth of pathogenic micro-organisms without damaging living tissue (<LINK REF="REF-Macpherson-2004" TYPE="REFERENCE">Macpherson 2004</LINK>). Topical preparations may be divided into two categories, according to their function. One group consists of lotions with antimicrobial properties that are used to irrigate or cleanse wounds. These usually have only a brief contact time with the wound surface, unless they are used as a pack or a soak. They include products based on chlorhexidine, povidone-iodine, hydrogen peroxide and potassium permanganate (<LINK REF="REF-BNF-2013" TYPE="REFERENCE">BNF 2013</LINK>). Benzoyl peroxide, normally used as gels and creams to treat acne (<LINK REF="REF-BNF-2013" TYPE="REFERENCE">BNF 2013</LINK>), has been used in a lotion formulation to treat leg ulcers (<LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>; <LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>). Traditional preparations such as the hypochlorites (e.g. Eusol) and gentian violet are currently less favoured but may still be used in some settings (<LINK REF="REF-White-2001" TYPE="REFERENCE">White 2001</LINK>; <LINK REF="REF-Farid-2011" TYPE="REFERENCE">Farid 2011</LINK>).</P>
<P>The second group of topical agents consists of products designed to stay in contact with the wound surface for a longer period of time, ideally until the next dressing change. These include creams, ointments and impregnated dressings. Most topical antibiotics come into this category and include mupirocin and fusidic acid (both available as 2% cream and 2% ointment), and neomycin sulphate (available as 0.5% cream). If large areas of skin are treated with the latter, ototoxicity (damage to the inner ear) is a possible adverse effect. Other products in this group include those based on the peroxides, iodine, silver and honey. Hydrogen peroxide preparations are available as a 1% cream. Iodine-based applications release free iodine (an antiseptic) when in contact with wound exudate. Povidone-iodine is available in a powder spray formulation in concentrations up to 2.5%, and also as 10% ointment and impregnated dressings. Cadexomer iodine products are purported to have the additional effect of absorbing wound exudate and promoting debridement; these are available as ointment, powder, paste (all at 0.9% concentration) or microbeads, or integrated into a hydrogel dressing. Recent years have seen a resurgence of interest in silver- and honey-based preparations for management of leg ulcers. Silver-based products include silver sulphadiazine cream (1%), as well as a variety of coated or impregnated dressings (<LINK REF="REF-BNF-2013" TYPE="REFERENCE">BNF 2013</LINK>). These release silver ions (atoms that have an electrical charge) on contact with wound exudate; this is thought to inhibit bacterial replication. It is suggested that silver products have a broad-spectrum antimicrobial action, and that they are associated less frequently with drug resistance relative to other antibiotics (<LINK REF="REF-Lansdown-2002" TYPE="REFERENCE">Lansdown 2002</LINK>; <LINK REF="REF-Lo-2009" TYPE="REFERENCE">Lo 2009</LINK>; <LINK REF="REF-Siah-2011" TYPE="REFERENCE">Siah 2011</LINK>). Medical grade honey is thought to have antimicrobial and debriding properties. Products are available as sheet dressings or as topical applications. Topical applications are applied directly to the wound and are covered with a primary low-adherent wound dressing; an additional secondary dressing may be required for exuding wounds. Prescribing guidelines recommend that patients with diabetes should be monitored for changes in blood glucose levels during treatment with honey-based wound products (<LINK REF="REF-BNF-2013" TYPE="REFERENCE">BNF 2013</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2013-12-01 19:37:48 +0000" MODIFIED_BY="[Empty name]">
<P>Whether systemic antibiotics, topical antibiotics or topical antiseptics can promote healing in venous leg ulcers remains uncertain. An earlier systematic review of antimicrobial agents used with a range of chronic wounds was not able to generate definitive conclusions about the use of systemic or topical agents in venous leg ulcers because of methodological problems in the primary literature (<LINK REF="REF-O_x0027_Meara-2001" TYPE="REFERENCE">O'Meara 2001</LINK>). Since the time of the first review, additional relevant trials have been published in relation to venous leg ulcers, and so an updated body of evidence has become available. In addition, the scope of the review has been extended for this update to include trials of silver- and honey-based products. Although this leads to a small amount of overlap with other reviews (<LINK REF="REF-Vermeulen-2007" TYPE="REFERENCE">Vermeulen 2007</LINK>; <LINK REF="REF-Jull-2013" TYPE="REFERENCE">Jull 2013</LINK>), it was deemed useful for clinical decision making to include within a single review all relevant evaluations of antibiotic and antiseptic preparations for management of venous leg ulcers. Pertinent questions for clinical practice include whether antibiotics and antiseptics increase healing rates compared with standard care, whether different active agents are more or less effective when compared directly, and whether any differences in outcomes have been reported in relation to the use of systemic and topical agents.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-01-09 09:33:24 +0000" MODIFIED_BY="[Empty name]">
<P>The objective of this review was to determine the effects of systemic antibiotics and topical antibiotics and antiseptics on the healing of venous ulcers.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-12-16 15:26:34 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-12-02 19:39:30 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-12-02 19:38:02 +0000" MODIFIED_BY="[Empty name]">
<P>We included prospective randomised controlled trials (RCTs), published or unpublished, evaluating systemic or topical antibiotics or topical antiseptics in the treatment of venous ulcers, irrespective of the language of the report. RCTs reported in abstract form only were eligible for inclusion, provided adequate information was presented in the abstract or was available from the trial authors. Studies using quasi-randomisation were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-12-01 19:38:30 +0000" MODIFIED_BY="[Empty name]">
<P>RCTs recruiting people described in the primary report as having venous leg ulcers, managed in any care setting, were eligible for inclusion. As the method of diagnosis of venous ulceration may vary, we accepted definitions as used in the RCTs. We included RCTs that recruited people with various types of wounds (e.g. arterial ulcers, diabetic foot ulcers) if the results for participants with venous ulcers were presented separately, or if most participants (at least 75%) had leg ulcers of venous aetiology (origin). Selection of trials was not restricted to those with a certain wound status at baseline (i.e. those with colonised or infected wounds); when information about these variables was given, it was recorded (see <LINK TAG="DATA_EXTRACTION" TYPE="SECTION">Data extraction and management</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-12-02 19:38:19 +0000" MODIFIED_BY="Sue O'Meara">
<P>Interventions of interest included antibiotics (topical or systemic) and antiseptics (topical) as prescribed for venous leg ulceration. Systemic antibiotics could be given orally or by other routes (e.g. intravenously). Control regimens could include placebo, an alternative antibiotic or antiseptic, any other therapy, standard care or no treatment. Both intervention and control regimens could consist of antibiotics and antiseptics administered singly or in combination. Intervention schedules that included concurrent therapies (e.g. compression) were included provided that such treatment was delivered in a standardised way across study arms. Interventions could be delivered in any setting (inpatient, outpatient, nursing home plus any others). The following were excluded: RCTs in which the presence or absence of a specific antibiotic or antiseptic intervention was not the only systematic difference between treatment groups; evaluations of antibiotics or antiseptics used as preparations for skin grafting to treat leg ulceration; and evaluations of physical therapies with purported antimicrobial effects.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-12-02 19:39:30 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-12-01 19:42:00 +0000" MODIFIED_BY="[Empty name]">
<P>The primary outcome for the review was wound healing. Wound healing is measured and reported by trialists in many different ways, including time to complete healing, proportion of wounds healed during follow-up, change in wound size, and rate of change in wound size. For this review, we regarded RCTs that reported one or more of the following as providing the best measures of outcome in terms of relevance and rigour.</P>
<UL>
<LI>Time to complete wound healing (correctly analysed using survival, time-to-event approaches, ideally with adjustment for relevant covariates such as baseline ulcer area and duration).</LI>
<LI>Proportion of ulcers healing during follow-up (frequency of complete healing).</LI>
<LI>Change (or rate of change) in wound size, with adjustment for baseline size.</LI>
</UL>
<P>The following were considered as less rigorous assessments of these outcomes: mean or median time to healing without survival analysis (i.e. treating time to healing as a continuous measure without censoring); and surrogate outcomes for complete healing such as change in wound size, or rate of change in wound size, without adjustment for baseline size. When RCTs reported a surrogate outcome of healing, in addition to complete healing or a reliable estimate of time to healing, or both, we included in the review only estimates of complete healing and time to healing, unless surrogate outcomes were adjusted for baseline values.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-12-02 19:39:30 +0000" MODIFIED_BY="[Empty name]">
<P>When reported, the following outcomes were also recorded.</P>
<UL>
<LI>Changes in signs and/or symptoms of clinical infection.</LI>
<LI>Changes in bacterial flora.</LI>
<LI>Development of bacterial resistance.</LI>
<LI>Ulcer recurrence rates.</LI>
<LI>All reported adverse events.</LI>
<LI>Participant satisfaction.</LI>
<LI>Health-related quality of life (measured using a validated, standardised, generic measure of health status such as EQ-5D, Short Form (SF)-36, SF-12 or SF-6, or a validated disease-specific questionnaire), preferably with follow-up estimates adjusted for baseline scores.</LI>
<LI>Costs (including cost-effectiveness estimations).</LI>
</UL>
<P>Studies were eligible for inclusion only if they reported a primary outcome.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-12-16 15:26:34 +0000" MODIFIED_BY="Sue O'Meara">
<P>The search methods sections of previous versions of this review can be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-12-16 15:26:34 +0000" MODIFIED_BY="Sue O'Meara">
<P>In May 2013, for this second update, we searched the following electronic databases to identify all relevant RCTs, with no restrictions applied in relation to language, date of publication or publication status.</P>
<UL>
<LI>The Cochrane Wounds Group Specialised Register (searched 24 May 2013).</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2013, Issue 4).</LI>
<LI>Ovid MEDLINE (1948 to Week 3 May 2013).</LI>
<LI>Ovid MEDLINE (In-Process &amp; Other Non-indexed Citations 22 May 2013).</LI>
<LI>Ovid EMBASE (1980 to Week 20 2013).</LI>
<LI>EBSCO CINAHL (1982 to 17 May 2013).</LI>
</UL>
<P>The following search string was used with CENTRAL:<BR/>#1 MeSH descriptor: [Anti-Infective Agents] explode all trees 21301<BR/>#2 MeSH descriptor: [Penicillins] explode all trees 4495<BR/>#3 MeSH descriptor: [Cephalosporins] explode all trees 3644<BR/>#4 MeSH descriptor: [Aminoglycosides] explode all trees 6396<BR/>#5 MeSH descriptor: [Quinolones] explode all trees 2917<BR/>#6 MeSH descriptor: [Clindamycin] explode all trees 634<BR/>#7 MeSH descriptor: [Metronidazole] explode all trees 1621<BR/>#8 MeSH descriptor: [Trimethoprim] explode all trees 1064<BR/>#9 MeSH descriptor: [Mupirocin] explode all trees 135<BR/>#10 MeSH descriptor: [Neomycin] explode all trees 408<BR/>#11 MeSH descriptor: [Fusidic Acid] explode all trees 85<BR/>#12 MeSH descriptor: [Framycetin] explode all trees 31<BR/>#13 MeSH descriptor: [Polymyxins] explode all trees 275<BR/>#14 MeSH descriptor: [Chlortetracycline] explode all trees 15<BR/>#15 (antibiotic* or antimicrobial* or antibacterial* or penicillin* or cephalosporin* or aminoglycoside* or quinolone* or clindamycin or metronidazole or trimethoprim or mupirocin or "pseudomonic acid" or neomycin or "fusidic acid" or framycetin or polymyxin* or chlortetracycline):ti,ab,kw 23307<BR/>#16 MeSH descriptor: [Antisepsis] explode all trees 91<BR/>#17 antiseptic*:ti,ab,kw 620<BR/>#18 MeSH descriptor: [Soaps] explode all trees 165<BR/>#19 MeSH descriptor: [Iodophors] explode all trees 411<BR/>#20 MeSH descriptor: [Chlorhexidine] explode all trees 1231<BR/>#21 MeSH descriptor: [Alcohols] explode all trees 28387<BR/>#22 MeSH descriptor: [Hydrogen Peroxide] explode all trees 368<BR/>#23 MeSH descriptor: [Benzoyl Peroxide] explode all trees 127<BR/>#24 MeSH descriptor: [Gentian Violet] explode all trees 31<BR/>#25 MeSH descriptor: [Hypochlorous Acid] explode all trees 274<BR/>#26 MeSH descriptor: [Hexachlorophene] explode all trees 28<BR/>#27 MeSH descriptor: [Potassium Permanganate] explode all trees 5<BR/>#28 MeSH descriptor: [Silver] explode all trees 154<BR/>#29 MeSH descriptor: [Silver Sulfadiazine] explode all trees 133<BR/>#30 MeSH descriptor: [Honey] explode all trees 81<BR/>#31 ("soap" or "soaps" or iodophor* or povidone or iodine or chlorhexidine or betadine or "alcohol" or disinfectant* or "hydrogen peroxide" or "benzoyl peroxide" or "gentian violet" or hypochlorit* or eusol or dakin* or hexachlorophene or benzalkonium or "potassium permanganate" or "silver sulfadiazine" or "silver sulphadiazine" or honey*):ti,ab,kw 15156<BR/>#32 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 80773<BR/>#33 MeSH descriptor: [Leg Ulcer] explode all trees 1076<BR/>#34 ((varicose next ulcer*) or (venous next ulcer*) or (leg next ulcer*) or (foot next ulcer*) or (stasis next ulcer*) or (crural next ulcer*) or "ulcus cruris"):ti,ab,kw 1967<BR/>#35 #33 or #34 2136<BR/>#36 #32 and #35 262<BR/>
</P>
<P>The search strategies used for Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL can be found in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>, <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> and <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>, respectively. The Ovid MEDLINE search was combined with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximizing version (2008 revision), Ovid format (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). The EMBASE and CINAHL searches were combined with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) (<LINK REF="REF-SIGN-2013" TYPE="REFERENCE">SIGN 2013</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-06-17 19:21:18 +0100" MODIFIED_BY="Sue O'Meara">
<P>For both the original review and all subsequent updates, we attempted to contact trialists to obtain unpublished data and information as required, and we searched the reference lists of included RCTs and relevant review articles.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-12-06 13:06:45 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<STUDY_SELECTION MODIFIED="2013-12-01 19:43:19 +0000" MODIFIED_BY="Sue O'Meara">
<P>For the original review and all subsequent updates, at least two review authors independently assessed titles and abstracts for relevance. Full reports of articles were obtained if any review author considered a reference to be potentially relevant. Two review authors then independently checked the full papers for eligibility, with disagreements resolved by discussion. All reasons for exclusion were recorded.</P>
<P>We have presented the study selection process as a flow diagram, according to recommendations provided in the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement (<LINK REF="REF-Liberati-2009" TYPE="REFERENCE">Liberati 2009</LINK>) (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK TAG="SEARCH_RESULTS" TYPE="SECTION">Results of the search</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-12-01 19:43:44 +0000" MODIFIED_BY="Sue O'Meara">
<P>Details of each included RCT were extracted and summarised using a standardised data extraction sheet. If data were missing from reports, trial authors were contacted and were asked to provide missing information. Data from evaluations with multiple associated publications were extracted while ensuring that all relevant data from all reports were included, whilst avoiding duplication. Data were extracted by one review author and were independently checked for accuracy by a second review author. Disagreements about data were resolved by discussion. The following data were extracted.</P>
<UL>
<LI>Trial authors.</LI>
<LI>Year of publication.</LI>
<LI>Country where RCT performed.</LI>
<LI>Setting of care.</LI>
<LI>Trial design details (e.g. pragmatic, pilot).</LI>
<LI>Unit of investigation (participant, limb or wound).</LI>
<LI>Overall sample size and methods used to estimate statistical power (relates to the target number of participants to be recruited, the clinical difference to be detected and the ability of the RCT to detect this difference).</LI>
<LI>Participant selection criteria.</LI>
<LI>Number of participants randomly assigned to each treatment group.</LI>
<LI>Baseline characteristics of participants per treatment group (gender, age, ulcer area, ulcer duration, prevalence of co-morbidities such as diabetes, prevalence of clinically infected or colonised wounds, identity of micro-organisms isolated).</LI>
<LI>Details of interventions applied in each group, including specific antibiotics and antiseptics used, as well as concurrent therapies such as compression.</LI>
<LI>Duration of treatment.</LI>
<LI>Duration of follow-up.</LI>
<LI>Outcomes measured, including assessment methods.</LI>
<LI>Outcome data by treatment group.</LI>
<LI>Withdrawals per treatment group with numbers and reasons.</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-12-06 12:24:14 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>We assessed each included RCT using The Cochrane Collaboration's tool for assessing risk of bias (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). This tool includes the following domains: sequence generation, allocation concealment, blinding of participants, blinding of outcome assessors, incomplete outcome data and other sources of bias, which for this review was baseline comparability (see <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> for details of the criteria on which judgements were based). Previous versions of this review have summarised information about individual domains of risk of bias. For this update, each included RCT was additionally assigned an overall risk of bias rating using the following decision rules. RCTs were classified as being at overall high risk of bias if they were rated as having high risk in relation to at least any one of three key domains (allocation concealment, blinding of outcome assessors and completeness of outcome data - use of intention-to-treat analysis). If none of the key domains was rated as high risk, but one or more were rated as having an unclear risk of bias, the RCT was rated overall as having an unclear risk of bias. To attain an overall low risk of bias, all three key domains had to be rated as low risk individually.</P>
<P>Risk of bias data were extracted by one review author and were independently checked for accuracy by a second review author. Disagreements about ratings were resolved by discussion.</P>
<P>Details of the risk of bias assessment for each included RCT were tabulated (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). In addition, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> shows a cross-tabulation of each individual RCT with each individual risk of bias domain, and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> shows a summary of information across all included RCTs.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-12-01 19:44:33 +0000" MODIFIED_BY="[Empty name]">
<P>We generated estimates for dichotomous outcomes (e.g. number of ulcers healed) as risk ratios (RRs) with associated 95% confidence interval (CIs). We generated estimates for continuous data outcomes (e.g. absolute or relative change in ulcer area) as a difference in means with 95% CI. We planned to report estimates of time to healing and to plot hazard ratio (HR) estimates with 95% CI when available from trial reports. When HRs were not reported, we planned, where possible, to extrapolate HRs using other available data related to time to healing (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-12-01 19:44:44 +0000" MODIFIED_BY="[Empty name]">
<P>We recorded whether RCT reports specified participants, limbs or ulcers as the units of allocation and analysis. In cases where multiple limbs or ulcers of the same individual were studied, we planned to note whether the trialists' analysis was appropriate (i.e. correctly taking account of highly correlated data) or inappropriate (i.e. considering outcomes for multiple ulcers on the same participant as independent). When the number of wounds appeared to equal the number of participants, we assumed that the participant was the unit of analysis, unless otherwise stated.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-12-01 19:45:05 +0000" MODIFIED_BY="[Empty name]">
<P>Missing data are a common problem in RCTs. Excluding randomised participants from the analysis or ignoring those participants lost to follow-up can compromise the process of randomisation and introduce bias. When RCTs reported dichotomous complete healing outcomes for only those participants who completed the RCT (i.e. participants withdrawing and lost to follow-up were excluded from the analysis), we treated the participants who were not included in the analysis as if their wound did not heal (i.e. they were included in the denominator but not in the numerator for healing outcomes). When results were reported for participants who completed the RCT without specifying the numbers randomly assigned per group initially, we presented only complete case data. For other outcomes, we presented data for all participants randomly assigned, when reported; otherwise we based estimates on complete cases only.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-12-01 19:45:56 +0000" MODIFIED_BY="[Empty name]">
<P>We considered clinical heterogeneity (i.e. the degree to which RCTs appear similar in terms of participants, intervention type and duration and outcome type) and statistical heterogeneity. We assessed statistical heterogeneity using the Chi² test (P value less than 0.10 was considered to indicate statistically significant heterogeneity) in conjunction with the I² statistic. The I² statistic examines the percentage of total variation across RCTs due to heterogeneity rather than chance (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We considered that I² values of 40% or less indicated a low level of heterogeneity and values of 75% or higher represented very high heterogeneity (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-12-06 12:27:17 +0000" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. Publication bias is one of a number of possible causes of 'small-study effects' - the tendency for estimates of the intervention effect to be more beneficial in smaller trials. Funnel plots allow a visual assessment of whether small-study effects may be present in a meta-analysis. A funnel plot is a simple scatter plot of the intervention effect estimates from individual RCTs against some measure of each trial&#8217;s size or precision (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>). We planned to present funnel plots for meta-analyses comprising 10 RCTs or more using RevMan 5.2 (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-12-02 19:45:28 +0000" MODIFIED_BY="Sue O'Meara">
<P>A narrative synthesis of all included RCTs was presented, with results grouped according to intervention characteristics. With the use of RevMan 5.2, statistical pooling was undertaken on groups of studies considered to be sufficiently similar in terms of study design and characteristics of participants, interventions and outcomes. The decision to pool data in a meta-analysis depended upon the availability of outcome data and the assessment of between-trial heterogeneity. For comparisons in which no apparent clinical heterogeneity was noted and the I² value was 40% or less, we applied a fixed-effect model. When no clinical heterogeneity was apparent and the I² value was greater than 40%, we planned to apply a random-effects model. However, we planned to refrain from pooling data when heterogeneity was very high (I² values of 75% or greater) (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>).</P>
<P>For dichotomous outcomes, we have presented the summary estimate as an RR with 95% confidence intervals (CIs). When continuous outcomes were measured in the same way across RCTs, we have presented a difference in means with 95% CI. We planned to present a standardised mean difference (SMD) when RCTs measured the same outcome using different methods. For time-to-event data, we planned to plot (and if appropriate pool) estimates of HRs and 95% CIs as they were presented in the RCT reports using the generic inverse variance method provided in RevMan 5.2.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-12-06 13:06:45 +0000" MODIFIED_BY="[Empty name]">
<P>Heterogeneity was investigated as described above. We planned to conduct subgroup analyses according to differences in the following variables: mean baseline ulcer area; presence of signs and/or symptoms of clinical infection at baseline; presence of wound colonisation at baseline; and, in the case of RCTs using compression, the number of components used (i.e. single component versus multiple components) and the level of compression (i.e. high versus moderate/low compression) (<LINK REF="REF-O_x0027_Meara-2012" TYPE="REFERENCE">O'Meara 2012</LINK>).</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-12-15 18:23:20 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-12-06 12:38:05 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-12-06 12:38:04 +0000" MODIFIED_BY="[Empty name]">
<P>For the original review, the search strategy generated 426 records. Of these, 115 appeared to be of possible relevance and were retrieved as full-text articles. After detailed screening with reference to the study selection criteria, 22 articles were included. One article reported two separate RCTs relevant to the review (<LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>; <LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>); therefore 23 RCTs were included.</P>
<P>For the first review update, the search strategy produced 202 records, of which 39 were retrieved as full-text articles. After screening, three articles were included; one article reported two separate, relevant RCTs (<LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK>; <LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>), bringing the then total number of included RCTs to 27.</P>
<P>For the current update, 500 records were generated from the search strategy of which 104 were retrieved as full-text articles. After screening, 17 new articles were included, all reporting a single RCT. An additional new RCT was identified from a previously included paper reporting three separate trials; the trial evaluating silver became eligible for this review update in light of the expanded scope of the review (<LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK>). Therefore, 18 new RCTs were identified during this update, bringing the current total number of included trials to 45.</P>
<P>In the first review update, two studies were classified as awaiting assessment: One of these has now been excluded because it is not an RCT (<LINK REF="STD-Cherry-2003" TYPE="STUDY">Cherry 2003</LINK>), whilst the other is now listed as a secondary reference to a newly included RCT (<LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>). No studies are currently awaiting assessment, and none have been classified as ongoing.</P>
<P>In accordance with recommendations provided in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>), some studies excluded at the full report assessment stage have been listed, together with reasons for exclusion (N = 78; see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). The study selection process for the original review and for both review updates is shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-12-06 12:38:05 +0000" MODIFIED_BY="[Empty name]">
<P>Overall, 45 RCTs reporting 53 relevant comparisons and recruiting 4486 participants are included in the review. The scope of the review was expanded for this update to include trials of silver and honey products. This meant searching databases from inception to retrieve relevant trials on the new interventions, which generated a substantial review update that included 18 new RCTs (<LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>; <LINK REF="STD-Blair-1988" TYPE="STUDY">Blair 1988</LINK>; <LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>; <LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>; <LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK>; <LINK REF="STD-Chaloner-2004" TYPE="STUDY">Chaloner 2004</LINK>; <LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>; <LINK REF="STD-Kuznetsov-2009" TYPE="STUDY">Kuznetsov 2009</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Bini_x0107_-2010" TYPE="STUDY">Bini&#263; 2010</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>; <LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>).</P>
<P>Six RCTs included three study arms each, reporting 18 comparisons in total, of which 14 were relevant to the review (<LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>; <LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>; <LINK REF="STD-Hansson-1998" TYPE="STUDY">Hansson 1998</LINK>; <LINK REF="STD-Casoni-2002" TYPE="STUDY">Casoni 2002</LINK>; <LINK REF="STD-Daroczy-2006" TYPE="STUDY">Daroczy 2006</LINK>). The other included evaluations reported a single RCT involving a single comparison.</P>
<P>The following sections further describe the RCTs and group them according to intervention characteristics. Further details of each included RCT are shown in the table of <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Systemic antibiotics</HEADING>
<P>Five RCTs recruiting 233 participants to eight relevant comparisons of oral systemic antibiotics were identified (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>; <LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>; <LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>; <LINK REF="STD-Daroczy-2006" TYPE="STUDY">Daroczy 2006</LINK>). No new RCTs were identified during this review update. Two trials were conducted in Finland (<LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>), one in Italy (<LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>), one in Hungary (<LINK REF="STD-Daroczy-2006" TYPE="STUDY">Daroczy 2006</LINK>) and one in Belgium (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>). None was described as multi-centre. The number of participants allocated per arm ranged between 8 and 30; <LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK> was the largest trial, recruiting a total of 59 participants. <LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK> and <LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK> recruited people with leg ulcers of different aetiologies; most were of venous origin. The duration of follow-up ranged between 20 days and 20 weeks, with 3 of the 5 trials following participants up for 12 weeks or longer (<LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>; <LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>; <LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cadexomer iodine topical preparations</HEADING>
<P>Cadexomer iodine is a topical agent with debriding and antibacterial effects; it was evaluated in 11 RCTs that recruited 962 participants to 12 relevant comparisons (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Kero-1987" TYPE="STUDY">Kero 1987</LINK>; <LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>; <LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>; <LINK REF="STD-Hansson-1998" TYPE="STUDY">Hansson 1998</LINK>; <LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>); one RCT was newly included in this update (<LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>). Four were multi-centre trials (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Hansson-1998" TYPE="STUDY">Hansson 1998</LINK>; <LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>). Five trials were based in the United Kingdom (<LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>), two in Sweden and Norway (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Hansson-1998" TYPE="STUDY">Hansson 1998</LINK>), and one each in Finland (<LINK REF="STD-Kero-1987" TYPE="STUDY">Kero 1987</LINK>), Poland (<LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>), the USA (<LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>), and Australia (<LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>). The number of people allocated to each arm of these RCTs ranged between 10 and 141; <LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK> was the largest study, with 281 participants recruited overall. The duration of follow-up ranged from four weeks to 24 weeks. Most studies followed up participants for a maximum of eight weeks (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Kero-1987" TYPE="STUDY">Kero 1987</LINK>; <LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>; <LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Povidone-iodine topical preparations</HEADING>
<P>Six trials recruiting 639 participants to seven relevant comparisons evaluated povidone-iodine preparations (<LINK REF="STD-Groenewald-1981" TYPE="STUDY">Groenewald 1981</LINK>; <LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK>; <LINK REF="STD-Ishibashi-1996" TYPE="STUDY">Ishibashi 1996</LINK>; <LINK REF="STD-Casoni-2002" TYPE="STUDY">Casoni 2002</LINK>; <LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK>; <LINK REF="STD-Kuznetsov-2009" TYPE="STUDY">Kuznetsov 2009</LINK>); one RCT was newly included in this update (<LINK REF="STD-Kuznetsov-2009" TYPE="STUDY">Kuznetsov 2009</LINK>). Four were based in Europe: United Kingdom (<LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK>); Germany (<LINK REF="STD-Groenewald-1981" TYPE="STUDY">Groenewald 1981</LINK>); Belgium (<LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK>); and Italy (<LINK REF="STD-Casoni-2002" TYPE="STUDY">Casoni 2002</LINK>). The remaining two evaluations were conducted in Japan (<LINK REF="STD-Ishibashi-1996" TYPE="STUDY">Ishibashi 1996</LINK>) and Russia (<LINK REF="STD-Kuznetsov-2009" TYPE="STUDY">Kuznetsov 2009</LINK>). The number of participants allocated per arm ranged between 15 and 109; the largest RCT recruited 218 participants overall (<LINK REF="STD-Ishibashi-1996" TYPE="STUDY">Ishibashi 1996</LINK>). The duration of follow-up ranged from 21 days to four months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Peroxide-based topical preparations</HEADING>
<P>Four RCTs recruited 72 participants to four relevant comparisons that evaluated peroxide-based topical antiseptics (<LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>; <LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>; <LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>; <LINK REF="STD-Belcaro-2007" TYPE="STUDY">Belcaro 2007</LINK>). No new RCTs were identified during this review update. Two trials were based in Sweden (<LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>; <LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>), and two in Italy (<LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>; <LINK REF="STD-Belcaro-2007" TYPE="STUDY">Belcaro 2007</LINK>). The number of people in each arm ranged between seven and 18; the largest being <LINK REF="STD-Belcaro-2007" TYPE="STUDY">Belcaro 2007</LINK> with 32 people. Duration of follow-up ranged between 10 and 42 days.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Honey-based topical preparations</HEADING>
<P>Two multi-centre RCTs (two comparisons) recruiting 476 participants evaluated honey products; one was conducted in Ireland (<LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>), and the other in New Zealand (<LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>). Both RCTs were added during this review update. <LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK> reported that treatment duration was four weeks with 12-week follow-up. Treatment duration in the trial by <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK> was 12 weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Silver-based topical preparations</HEADING>
<P>Twelve RCTs recruiting 1514 participants to 13 relevant comparisons evaluated silver-based topical preparations (<LINK REF="STD-Blair-1988" TYPE="STUDY">Blair 1988</LINK>; <LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>; <LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>; <LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK>; <LINK REF="STD-Chaloner-2004" TYPE="STUDY">Chaloner 2004</LINK>; <LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>). All were added during this review update. Three RCTs were conducted in the UK (<LINK REF="STD-Blair-1988" TYPE="STUDY">Blair 1988</LINK>; <LINK REF="STD-Chaloner-2004" TYPE="STUDY">Chaloner 2004</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>), and another three in France (<LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>). One was conducted in each of the following countries: Germany (<LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>); Belgium (<LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK>); Greece (<LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>); and the USA (<LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>). Two trials recruited internationally across Europe and the Americas (<LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>). Six RCTs were described as multi-centre (<LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>; <LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>). The number of participants per study arm ranged from 17 to 326; the largest was the international trial performed by Münter et al (<LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>), which recruited 619 participants overall. Two RCTs included participants with mixed aetiology leg ulcers (venous and arterial) (<LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>). Duration of follow-up ranged from four weeks to 12 months. An additional RCT (N = 281) compared a silver dressing with cadexomer iodine and has already been described above under 'Cadexomer iodine topical preparations' (<LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Miscellaneous topical preparations</HEADING>
<P>Five RCTs recruiting 590 participants to seven relevant comparisons were identified that did not easily fit into any of the groups described above (<LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>; <LINK REF="STD-Cameron-1991" TYPE="STUDY">Cameron 1991</LINK>; <LINK REF="STD-Bini_x0107_-2010" TYPE="STUDY">Bini&#263; 2010</LINK>; <LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>; <LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>); two were newly included in this review update (<LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>; <LINK REF="STD-Bini_x0107_-2010" TYPE="STUDY">Bini&#263; 2010</LINK>). Three evaluated topical antibiotics (<LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>; <LINK REF="STD-Cameron-1991" TYPE="STUDY">Cameron 1991</LINK>; <LINK REF="STD-Bini_x0107_-2010" TYPE="STUDY">Bini&#263; 2010</LINK>), and two assessed topical antiseptics (<LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>; <LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>). The RCTs were conducted in the UK (<LINK REF="STD-Cameron-1991" TYPE="STUDY">Cameron 1991</LINK>), Germany (<LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>), Belgium (<LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>) and Serbia (<LINK REF="STD-Bini_x0107_-2010" TYPE="STUDY">Bini&#263; 2010</LINK>). The fifth trial was international, with study centres in Germany, Austria and Switzerland (<LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>); this was the only RCT described as multi-centre. The number of participants per treatment arm ranged from 15 to 129; the largest trial recruited 258 participants overall (<LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>). Inclusion of participants with mixed aetiology leg ulceration was not mentioned in any trial. Follow-up periods ranged from four to 24 weeks.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-12-06 12:32:32 +0000" MODIFIED_BY="[Empty name]">
<P>Details of the risk of bias assessment for each included RCT are shown in the tables of <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. A cross-tabulation of individual trial data with each risk of bias domain is shown in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>. <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> shows the overall information on risk of bias.</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Adequacy of randomisation</HEADING>
<P>Ten RCTs were judged as using a satisfactory method of sequence generation and were deemed to be at low risk of bias for this domain. Specific methods included random number tables (<LINK REF="STD-Blair-1988" TYPE="STUDY">Blair 1988</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>), computerised randomisation (<LINK REF="STD-Chaloner-2004" TYPE="STUDY">Chaloner 2004</LINK>; <LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>), and a remote, independent randomisation service (<LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>). The remaining 35 RCTs did not specify the method of randomisation and were classified as having an unclear risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Adequacy of allocation concealment</HEADING>
<P>Six RCTs reported the use of an adequate method of allocation concealment such as sequentially numbered, sealed, opaque envelopes (<LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>), sequentially numbered drug containers of identical appearance (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>) and a centralised, remote allocation service (<LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>); all were classified as low risk. Information from two RCTs suggested that the group allocation process could have been visible and so they were judged to be at high risk of bias (<LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>; <LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>). None of the other trials provided a clear description of allocation concealment and so were graded as 'unclear'.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Blinding of participants</HEADING>
<P>Satisfactory methods of blinding participants to treatment allocation were described in five RCTs, leading them to be classified as having a low risk of bias for this domain (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>; <LINK REF="STD-Cameron-1991" TYPE="STUDY">Cameron 1991</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>; <LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>; <LINK REF="STD-Belcaro-2007" TYPE="STUDY">Belcaro 2007</LINK>). In all cases, the use of a placebo preparation identical to the active intervention was described; this method was used with systemic agents (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>), and topical applications (<LINK REF="STD-Cameron-1991" TYPE="STUDY">Cameron 1991</LINK>; <LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>; <LINK REF="STD-Belcaro-2007" TYPE="STUDY">Belcaro 2007</LINK>). Ten RCT reports provided information suggesting that participants were not blind to group allocation, with further details as follows: no attempt to use a placebo when this should have been feasible in an evaluation of systemic antibiotics (<LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>); participants involved in their own care (all cadexomer iodine trials) (<LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>); and blinding stated as impossible because of differential characteristics between interventions and comparators (<LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>; <LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>). These ten RCTs were judged to be at high risk of bias for blinding of participants. In the remaining 30 RCTs; it was not clear whether participants had been blinded to treatment allocation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Blinding of outcome assessors</HEADING>
<P>Five RCT reports indicated that outcome assessors had been blinded to treatment allocation, and they were accordingly awarded a low risk of bias for this domain (<LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>; <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>). For four of these trials, a clear statement was made that the personnel evaluating outcomes had not been involved in care provision and were not aware of the treatment allocation (<LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>). The fifth trial did not use blinded outcome, assessment but the primary outcome (healing) was re-analysed using data from a blinded review of ulcer photographs, and this did not change the findings; we judged this to represent a low risk of bias (<LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>). Five RCTs were classified as having a high risk of bias for blinding of outcome assessors because of differential intervention characteristics between interventions and comparators (<LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>; <LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK>; <LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>). The remaining 35 trials did not include any information about blinding of outcome assessors, or the information provided was insufficient to allow a judgement to be made; they were therefore classified as having an unclear risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Incomplete outcome data addressed (description of withdrawals)</HEADING>
<P>Most trials (30/45, 67%) were deemed to be at low risk of bias for this criterion because they provided a report of numbers of participants withdrawing per treatment arm together with reasons, or a clear statement indicated that no participants withdrew (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>; <LINK REF="STD-Groenewald-1981" TYPE="STUDY">Groenewald 1981</LINK>; <LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>; <LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>; <LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>; <LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Kero-1987" TYPE="STUDY">Kero 1987</LINK>; <LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>; <LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>; <LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>; <LINK REF="STD-Ishibashi-1996" TYPE="STUDY">Ishibashi 1996</LINK>; <LINK REF="STD-Hansson-1998" TYPE="STUDY">Hansson 1998</LINK>; <LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>; <LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>; <LINK REF="STD-Kuznetsov-2009" TYPE="STUDY">Kuznetsov 2009</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Bini_x0107_-2010" TYPE="STUDY">Bini&#263; 2010</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>). All of the remaining 15 trials were classified as having an unclear risk of bias. Of these, one reported the number of withdrawals per group caused by ineffectiveness or allergy, but it was not clear whether other withdrawals had occurred (<LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>). Another reported numbers withdrawing together with reasons, but only for the whole sample, and not per group (<LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>). A further three trials reported the numbers who withdrew per study arm but did not provide reasons (<LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>; <LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>; <LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>). The other ten RCTs did not mention withdrawals at all (<LINK REF="STD-Blair-1988" TYPE="STUDY">Blair 1988</LINK>; <LINK REF="STD-Cameron-1991" TYPE="STUDY">Cameron 1991</LINK>; <LINK REF="STD-Casoni-2002" TYPE="STUDY">Casoni 2002</LINK>; <LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK>; <LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK>; <LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>; <LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>; <LINK REF="STD-Chaloner-2004" TYPE="STUDY">Chaloner 2004</LINK>; <LINK REF="STD-Daroczy-2006" TYPE="STUDY">Daroczy 2006</LINK>; <LINK REF="STD-Belcaro-2007" TYPE="STUDY">Belcaro 2007</LINK>). No trial was considered to be at high risk of bias for this domain.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Incomplete outcome data addressed (withdrawal rate acceptable?)</HEADING>
<P>Twenty-two RCTs were classified as being at low risk of bias for this criterion because either it was clear that no withdrawals occurred (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>; <LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>; <LINK REF="STD-Kuznetsov-2009" TYPE="STUDY">Kuznetsov 2009</LINK>; <LINK REF="STD-Bini_x0107_-2010" TYPE="STUDY">Bini&#263; 2010</LINK>), or the withdrawal rate was less than 20% in all treatment arms (<LINK REF="STD-Groenewald-1981" TYPE="STUDY">Groenewald 1981</LINK>; <LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Kero-1987" TYPE="STUDY">Kero 1987</LINK>; <LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>; <LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>; <LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>; <LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>; <LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>; <LINK REF="STD-Ishibashi-1996" TYPE="STUDY">Ishibashi 1996</LINK>; <LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>; <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>).</P>
<P>Twelve RCTs were judged to be at high risk of bias because of differential withdrawal rates between treatment groups (<LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>), or because the withdrawal rate exceeded 20% in at least one arm (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>; <LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>; <LINK REF="STD-Hansson-1998" TYPE="STUDY">Hansson 1998</LINK>; <LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>; <LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>).</P>
<P>Of the remaining 11 RCTs, ten did not provide any information on withdrawals (<LINK REF="STD-Blair-1988" TYPE="STUDY">Blair 1988</LINK>; <LINK REF="STD-Cameron-1991" TYPE="STUDY">Cameron 1991</LINK>; <LINK REF="STD-Casoni-2002" TYPE="STUDY">Casoni 2002</LINK>; <LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK>; <LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK>; <LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>; <LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>; <LINK REF="STD-Chaloner-2004" TYPE="STUDY">Chaloner 2004</LINK>; <LINK REF="STD-Daroczy-2006" TYPE="STUDY">Daroczy 2006</LINK>; <LINK REF="STD-Belcaro-2007" TYPE="STUDY">Belcaro 2007</LINK>), and one did not report full details (<LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>); all of these trials were assigned an unclear risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7. Incomplete outcome data addressed (use of intention-to-treat analysis)</HEADING>
<P>Reports of 14 RCTs suggested that analysis had been conducted according to intention-to-treat, and so these RCTs were viewed as being at low risk of bias (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>; <LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>; <LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>; <LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>; <LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>; <LINK REF="STD-Kuznetsov-2009" TYPE="STUDY">Kuznetsov 2009</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Bini_x0107_-2010" TYPE="STUDY">Bini&#263; 2010</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>). A further two RCTs each excluded one participant from analysis; we considered that this would not have had an important influence on estimates of treatment effect (<LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>; <LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>). These two RCTs were rated as having low risk of bias for this domain.</P>
<P>Seven RCTs were classified as having high risk of bias because at least 20% of randomly assigned participants from one or more treatment groups were excluded from the analysis (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>; <LINK REF="STD-Hansson-1998" TYPE="STUDY">Hansson 1998</LINK>; <LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>), because participants were switched to an alternative treatment arm during the trial and were retained in this group for the analysis (<LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK>), or because participants who withdrew were replaced to maintain the original numbers per group (unclear whether additional patients were randomly assigned) (<LINK REF="STD-Groenewald-1981" TYPE="STUDY">Groenewald 1981</LINK>).</P>
<P>The remaining 22 RCTs were judged as having an unclear risk of bias because it was not clear whether an intention-to-treat analysis had been conducted, or because it was clear that an intention-to-treat analysis had not been conducted, but it was difficult to judge the impact of lower rates of withdrawal (i.e. less than 20%) on estimates of treatment effect, particularly in smaller trials (<LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Kero-1987" TYPE="STUDY">Kero 1987</LINK>; <LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>; <LINK REF="STD-Blair-1988" TYPE="STUDY">Blair 1988</LINK>; <LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>; <LINK REF="STD-Cameron-1991" TYPE="STUDY">Cameron 1991</LINK>; <LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>; <LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>; <LINK REF="STD-Ishibashi-1996" TYPE="STUDY">Ishibashi 1996</LINK>; <LINK REF="STD-Casoni-2002" TYPE="STUDY">Casoni 2002</LINK>; <LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK>; <LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK>; <LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>; <LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>; <LINK REF="STD-Chaloner-2004" TYPE="STUDY">Chaloner 2004</LINK>; <LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>; <LINK REF="STD-Daroczy-2006" TYPE="STUDY">Daroczy 2006</LINK>; <LINK REF="STD-Belcaro-2007" TYPE="STUDY">Belcaro 2007</LINK>; <LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">8. Comparability at baseline</HEADING>
<P>Information available for six RCTs suggested that treatment groups were comparable at baseline, resulting in assignment of low risk of bias (<LINK REF="STD-Blair-1988" TYPE="STUDY">Blair 1988</LINK>; <LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Bini_x0107_-2010" TYPE="STUDY">Bini&#263; 2010</LINK>). Eleven RCTs appeared to have baseline imbalance between treatment groups for at least one predictive covariate and were graded as being at high risk of bias (<LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Kero-1987" TYPE="STUDY">Kero 1987</LINK>; <LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>; <LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>; <LINK REF="STD-Cameron-1991" TYPE="STUDY">Cameron 1991</LINK>; <LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>; <LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>; <LINK REF="STD-Casoni-2002" TYPE="STUDY">Casoni 2002</LINK>; <LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>). The remaining 28 RCTs were classified as unclear risk of bias because information on baseline variables were lacking, or because mean rather than median values were provided for ulcer area and duration (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>; <LINK REF="STD-Groenewald-1981" TYPE="STUDY">Groenewald 1981</LINK>; <LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>; <LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>; <LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>; <LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>; <LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>; <LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>; <LINK REF="STD-Ishibashi-1996" TYPE="STUDY">Ishibashi 1996</LINK>; <LINK REF="STD-Hansson-1998" TYPE="STUDY">Hansson 1998</LINK>; <LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK>; <LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK>; <LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>; <LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>; <LINK REF="STD-Chaloner-2004" TYPE="STUDY">Chaloner 2004</LINK>; <LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>; <LINK REF="STD-Daroczy-2006" TYPE="STUDY">Daroczy 2006</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Belcaro-2007" TYPE="STUDY">Belcaro 2007</LINK>; <LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>; <LINK REF="STD-Kuznetsov-2009" TYPE="STUDY">Kuznetsov 2009</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>; <LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">9. Overall risk of bias</HEADING>
<P>Three RCTs were classified as having a low risk of bias overall (<LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>). Thirteen RCTs were assigned a high risk of bias overall (<LINK REF="STD-Groenewald-1981" TYPE="STUDY">Groenewald 1981</LINK>; <LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>; <LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>; <LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>; <LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK>; <LINK REF="STD-Hansson-1998" TYPE="STUDY">Hansson 1998</LINK>; <LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>). The remaining 29 trials were judged as having an unclear risk of bias overall (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>; <LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>; <LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Kero-1987" TYPE="STUDY">Kero 1987</LINK>; <LINK REF="STD-Blair-1988" TYPE="STUDY">Blair 1988</LINK>; <LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>; <LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>; <LINK REF="STD-Cameron-1991" TYPE="STUDY">Cameron 1991</LINK>; <LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>; <LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>; <LINK REF="STD-Ishibashi-1996" TYPE="STUDY">Ishibashi 1996</LINK>; <LINK REF="STD-Casoni-2002" TYPE="STUDY">Casoni 2002</LINK>; <LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK>; <LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK>; <LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>; <LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>; <LINK REF="STD-Chaloner-2004" TYPE="STUDY">Chaloner 2004</LINK>; <LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>; <LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>; <LINK REF="STD-Daroczy-2006" TYPE="STUDY">Daroczy 2006</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Belcaro-2007" TYPE="STUDY">Belcaro 2007</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>; <LINK REF="STD-Kuznetsov-2009" TYPE="STUDY">Kuznetsov 2009</LINK>; <LINK REF="STD-Bini_x0107_-2010" TYPE="STUDY">Bini&#263; 2010</LINK>).</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-12-15 18:23:20 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Overall, 45 RCTs were included in this review. Results are presented according to the type of intervention, starting with systemic antibiotics. This is followed by topical preparations: cadexomer iodine, povidone-iodine, peroxides, honey, silver and miscellaneous agents (i.e. those not fitting easily into the other groups).</P>
<SUBSECTION>
<HEADING LEVEL="3">Systemic antibiotics</HEADING>
<P>Five RCTs (eight comparisons) recruiting a total of 233 participants evaluated various types of systemic antibiotics (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>; <LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>; <LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>; <LINK REF="STD-Daroczy-2006" TYPE="STUDY">Daroczy 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Systemic antibiotics given according to sensitivities compared with standard care</HEADING>
<P>One RCT at unclear risk of bias overall was identified (<LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>). <LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK> compared standard care alone with a 10-day course of systemic antibiotics (co-trimoxazole, gentamicin or amikacin according to sensitivity) plus standard care. Forty-eight participants with 56 ulcers were recruited. Participants were initially treated as inpatients and were discharged the day after admission. The wounds were not infected at baseline. At 20 days, 7/26 (27%) ulcers had been healed with standard treatment alone compared with 5/30 (17%) in those additionally receiving antibiotics. The RR estimate indicated no difference between groups: RR 0.62 (95% CI 0.22 to 1.72) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Similar proportions of participants between groups had healed when assessed at a later, unspecified, time point: RR 0.91 (95% CI 0.66 to 1.25) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). A discrepancy was noted between the unit of randomisation (participant) and the unit of analysis (ulcer), which can result in a biased estimate of treatment effect (<LINK REF="REF-Altman-1997" TYPE="REFERENCE">Altman 1997</LINK>). The proportion of participants with bacterial eradication was similar between groups: RR 1.60 (95% CI 0.61 to 4.19) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ciprofloxacin compared with standard care/placebo</HEADING>
<P>Two trials were identified, both of which had an unclear risk of bias overall (<LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>). <LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK> compared standard care alone with oral ciprofloxacin combined with standard care. Eligible participants had ulcers colonised by Gram-positive bacteria that were sensitive to ciprofloxacin, but it was not clear whether the wounds were clinically infected at baseline. Participants were treated in both inpatient and outpatient settings, with a treatment duration of three months. At the end of treatment, 3/18 (17%) ulcers in the ciprofloxacin-treated group had healed compared with 0/8 in the control group. The difference in the numbers of participants recruited to the treatment groups was not explained. <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK> conducted a three-arm trial to compare ciprofloxacin, trimethoprim and placebo. The interventions were delivered for 12 weeks in an outpatient setting. It was unclear whether the ulcers were infected at baseline. At 16 weeks, 3/11 (27%) ulcers had healed with placebo compared with 5/13 (38%) with ciprofloxacin. When these two trials were pooled, no difference was revealed between ciprofloxacin and standard care/placebo for complete healing at three to four months: RR 1.74 (95% CI 0.57 to 5.30) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). However, pooled data indicated that antibiotic-resistant strains emerged more frequently in the groups receiving ciprofloxacin: RR 8.65 (95% CI 1.76 to 42.60) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) (<LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>). Data from one RCT suggested no difference between groups in the proportion of participants achieving bacterial eradication: RR 2.67 (95% CI 0.38 to 18.67) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>) (<LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ciprofloxacin compared with trimethoprim</HEADING>
<P>One trial at unclear risk of bias overall was identified (<LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>), previously described in the section above. At 16 weeks, 5/13 (38%) ulcers had healed with ciprofloxacin compared with 3/12 (25%) with trimethoprim. The RR estimate did not suggest a difference between groups: RR 1.54 (95% CI 0.46 to 5.09) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). The frequency of emergence of resistant bacterial strains was the same for both groups, occurring in 8/12 (67%) participants receiving ciprofloxacin and in 6/9 (67%) participants receiving trimethoprim: RR 1.00 (95% CI 0.54 to 1.84) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). The cost of a 12-week course of treatment with ciprofloxacin was USD 600 for ciprofloxacin and USD 120 for trimethoprim (price year not stated). The cost of concurrent topical treatment was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trimethoprim compared with placebo</HEADING>
<P>The trial described in the two preceding sections also compared trimethoprim with placebo (<LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>). At 16 weeks, 3/11 (27%) ulcers had healed with placebo compared with 3/12 (25%) with trimethoprim. The RR estimate did not suggest a difference between groups: RR 0.92 (95% CI 0.23 to 3.63) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). Emergence of resistant bacterial strains occurred in 6/9 (67%) participants receiving trimethoprim and in 1/10 (10%) in the placebo group. No difference between groups was detected: RR 6.67 (95% CI 0.98 to 45.29) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). Although this three-arm trial reported costs of treatment for the groups receiving ciprofloxacin and trimethoprim (see comparison above), costs were not reported for the group allocated placebo (<LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Amoxicillin compared with topical povidone-iodine</HEADING>
<P>One three-arm trial (N = 63 participants) at unclear risk of bias overall was identified for this comparison (<LINK REF="STD-Daroczy-2006" TYPE="STUDY">Daroczy 2006</LINK>). Participants were randomised to the following treatments of 12 weeks duration: topical povidone-iodine alone; povidone-iodine plus compression; and oral amoxicillin plus compression. The setting of treatment was not explained. Ulcers were described as infected in the RCT report but further details of this were not provided. Also, it is not clear whether infection was present at baseline, or whether it occurred during treatment. At 12 weeks, the number of ulcers healed was 13/21 (62%) in the group treated with povidone-iodine alone, 17/21 (81%) in the group treated with povidone -iodine plus compression and 18/21 (86%) in the amoxicillin plus compression group. The RR estimates did not suggest a difference between groups in complete healing when amoxicillin plus compression was compared with povidone-iodine alone, RR 1.38 (95% CI 0.95 to 2.02) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>), nor when the former was compared with povidone-iodine plus compression, RR 1.06 (95% CI 0.81 to 1.39) (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>). Recurrence of ulcer infection was assessed five months after completion of the trial, comparing the group receiving amoxicillin with both povidone-iodine groups combined. The recurrence rate was lower in the group treated with povidone-iodine (11%) compared with amoxicillin (32%) (statistical significance of the between-group difference not reported by the trial authors and not evaluable by the review authors because of the limited nature of data reported in the paper).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Levamisole compared with placebo</HEADING>
<P>One trial at unclear risk of bias overall was identified (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>). This RCT compared levamisole with placebo in an outpatient setting (N = 59 participants). Levamisole, a treatment for roundworm infection (<LINK REF="REF-BNF-2013" TYPE="REFERENCE">BNF 2013</LINK>), is postulated to have an antibacterial action in wounds (<LINK REF="REF-Wilton-1978" TYPE="REFERENCE">Wilton 1978</LINK>; <LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>). Both active drug and identical placebo were given twice daily for two days a week for 20 weeks or until complete healing. It was unclear whether the ulcers were infected at baseline. At 20 weeks all ulcers in the levamisole group had healed compared with 76% in the placebo group, suggesting a benefit of levamisole: RR 1.31 (95% CI 1.06 to 1.62) (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>). Three participants out of 30 (10%) treated with levamisole complained of gastric adverse effects, compared with none in the placebo group. It should be noted that levamisole is unlicensed in the UK, and is only available from 'special order' suppliers for use in treating roundworm infection (<LINK REF="REF-BNF-2013" TYPE="REFERENCE">BNF 2013</LINK>). It was withdrawn from the US market in 1999 because of the risk of associated agranulocytosis (a marked decrease in granulocytes, a type of white blood cell) (<LINK REF="REF-Chang-2010" TYPE="REFERENCE">Chang 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary of evidence for systemic antibiotics</HEADING>
<P>Five RCTs recruiting 233 participants were identified, reporting the following comparisons: co-trimoxazole, gentamicin or amikacin, prescribed according to sensitivity versus standard care (one RCT); ciprofloxacin versus standard care or placebo (two RCTs); ciprofloxacin versus trimethoprim (one RCT); trimethoprim versus placebo (one RCT); amoxicillin versus topical povidone-iodine (one RCT); and levamisole versus placebo (one RCT). More participants healed on levamisole compared to placebo. Levamisole is an oral antimicrobial product normally used to treat roundworm infection; it is not widely available. Other comparisons did not indicate between-group differences for healing. Bacterial resistance developed more frequently with ciprofloxacin compared with standard care or placebo. Otherwise, there were few data on secondary outcomes. All the RCTs were small and had an overall unclear risk of bias. One RCT restricted patient selection to those with non-infected ulcers at baseline, and the others did not clearly report the baseline ulcer infection status. Therefore it cannot be determined from these data whether systemic antibiotics can promote healing in patients with clinically infected ulcers.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cadexomer iodine</HEADING>
<P>Eleven RCTs (12 comparisons) recruiting 962 participants in total evaluated the effects of cadexomer iodine (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Kero-1987" TYPE="STUDY">Kero 1987</LINK>; <LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>; <LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>; <LINK REF="STD-Hansson-1998" TYPE="STUDY">Hansson 1998</LINK>; <LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Cadexomer iodine compared with standard care</HEADING>
<P>Seven trials compared cadexomer iodine with standard care (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>). Four had a high overall risk of bias (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>), and the remainder were unclear (<LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>). In six RCTs, participants were treated in community or outpatient settings (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>), whilst the seventh involved six weeks of bedrest and daily dressings in an inpatient setting (<LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>). Four RCTs mentioned using compression as a concurrent therapy for all participants, however, the information provided was limited and it was not possible to determine whether the level applied was therapeutic (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>). The other three RCTs mentioned the use of light retention or support bandages for all participants (<LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>). Treatment duration ranged from four to 24 weeks. One RCT recruited only participants with infected ulcers (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>). The others did not specify baseline ulcer infection status explicitly, however, it appeared from the information provided that those with infected ulcers would have been allowed entry into the trials (<LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>). Data from four RCTs were pooled for the outcome of complete healing at four to 12 weeks, indicating that 35/106 (33%) healed when given cadexomer iodine and 16/106 (15%) healed on standard care. This suggested a benefit of cadexomer iodine: RR 2.17 (95% CI 1.30 to 3.60) (<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) (<LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>).</P>
<P>Findings from the other three trials were also in favour of cadexomer iodine (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>). Two RCTs reported the mean percentage change in ulcer area, the respective values for cadexomer iodine and standard care being: reductions of 36% and 10% at four weeks (N = 72 participants, P value &lt; 0.01) (<LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>); and a reduction of 34% and an increase of 5% at six weeks (N = 74 participants, P value &lt; 0.02) (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>). The third trial reported mean (standard error of the mean) rate of ulcer healing in cm squared per week at 24 weeks as 0.95 (0.12) for cadexomer iodine versus 0.41 (0.13) for standard care (N = 54 participants analysed, P value 0.0025). Participants were given the option to swap treatments at 12 weeks; healing data at the point of crossover were not reported (<LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>). The review authors did not calculate measures of treatment effect for these trials because of the limited nature of available data (e.g. unclear group denominators). The P values shown here are for the between-group differences, as reported by the trial authors (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>).</P>
<P>One RCT reported statistically significant differences in favour of cadexomer iodine for the number of participants with eradication or improvement of staphylococcal infection (P value &lt; 0.001), <I>Pseudomonas aeruginosa</I> infection (P value &lt; 0.05), and other pathogenic organisms (listed as beta-haemolytic <I>Streptococcus</I>, <I>Proteus</I>, Enterobacteria and <I>Klebsiella</I> (P value &lt; 0.001) (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>). The review authors did not calculate measures of effect for these outcomes, as the relevant denominators were not clearly stated (i.e. number of participants per group at baseline with the respective types of infection).</P>
<P>Three RCTs reported adverse effects (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>); we pooled data from two RCTs (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>); the denominators per group were unclear for <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>. The pooled data suggested a higher incidence of adverse events in those receiving cadexomer iodine: RR 4.59 (95% CI 1.40 to 15.05) (<LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>). <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK> reported that six participants receiving cadexomer iodine experienced adverse events compared with none allocated standard care. The types of adverse events reported by participants allocated cadexomer iodine included itching and pain (all three RCTs), as well as eczema, pruritus, rashes and difficulty in removing cadexomer iodine from the ulcer (<LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>). Those receiving standard care complained of pain (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>); and eczema, pruritus and rashes (<LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cadexomer iodine compared with hydrocolloid dressing</HEADING>
<P>A three-armed RCT recruiting 153 participants compared cadexomer iodine, hydrocolloid dressing and paraffin gauze dressing; all participants received compression (a short-stretch bandage) and interventions were delivered for 12 weeks in an outpatient setting (<LINK REF="STD-Hansson-1998" TYPE="STUDY">Hansson 1998</LINK>). This RCT was at high risk of bias overall. Participants with clinically infected ulcers were excluded. At 12 weeks, the number of ulcers healed was 8/56 (14%) in the cadexomer iodine group and 5/48 (10%) in the hydrocolloid group. The RR estimate did not suggest a difference between groups: RR 1.37 (95% CI 0.48 to 3.91) (<LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>). Nineteen adverse events were reported in the cadexomer iodine group compared with 33 in the hydrocolloid group. The review authors did not calculate a measure of effect as the group denominators were unclear. This trial reported cost of treatment taking into account staff time, materials and transport. The cost presented in terms of USD per percentage ulcer area reduction was lower in the cadexomer iodine group relative to hydrocolloid (USD 8.8 compared with USD 32.5). The price year was not stated. The analysis was based on a subset of 23 participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cadexomer iodine compared with paraffin gauze dressing</HEADING>
<P>The RCT described in the section above also included a comparison of cadexomer iodine with paraffin gauze dressing (<LINK REF="STD-Hansson-1998" TYPE="STUDY">Hansson 1998</LINK>). The frequency of complete healing at 12 weeks was similar for both groups, 8/56 (14%) in the cadexomer iodine group compared with 7/49 (14%) for those treated with paraffin gauze: RR 1.00 (95% CI 0.39 to 2.56) (<LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>). Nineteen adverse events were reported in the cadexomer iodine group compared with 26 in the paraffin gauze group. The cost in terms of USD/percentage of ulcer healed was USD 8.8 for cadexomer iodine and USD 12.9 for paraffin gauze (price year not stated). The analysis was based on a subset of 25 participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cadexomer iodine compared with dextranomer</HEADING>
<P>Two trials compared cadexomer iodine with an alternative debriding agent, dextranomer (<LINK REF="STD-Kero-1987" TYPE="STUDY">Kero 1987</LINK>; <LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>); both RCTs mentioned the use of compression therapy for all participants. One RCT had an overall high risk of bias (<LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>) whilst the other was at unclear risk (<LINK REF="STD-Kero-1987" TYPE="STUDY">Kero 1987</LINK>). Both were conducted in outpatient settings. Neither reported ulcer infection status at baseline. In one RCT, 5/13 (38%) participants healed on dextranomer and 7/14 (50%) healed on cadexomer iodine at eight weeks (<LINK REF="STD-Kero-1987" TYPE="STUDY">Kero 1987</LINK>). The RR estimate did not suggest a difference between groups: RR 1.30 (95% CI 0.55 to 3.09) (<LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>). The second RCT (N = 43 participants) assessed the mean percentage change in ulcer area at six weeks, reporting a reduction of 2% in the group receiving dextranomer and a reduction of 3% in those allocated cadexomer iodine (<LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>). The trial authors reported that the between-group difference was not statistically significant, but no P value was presented. Mean values were read from a graph, and available details were insufficient for the review authors to calculate a measure of treatment effect.</P>
<P>In terms of secondary outcomes, one RCT reported that the incidence of ulcer infection during the trial was 4/21 (19%) for those receiving cadexomer iodine and 3/21 (14%) for dextranomer <LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>. The following values were read from a graph for the same trial, for the proportions of participants eradicating organisms during six weeks of treatment with dextranomer and cadexomer iodine, respectively: beta-haemolytic <I>Streptococcus</I> 0% and 40%; <I>Staphylococcus aureus</I> 42% and 0%; <I>Pseudomonas</I> species 10% and 35%; and <I>Proteus</I> species 25% and 50% (<LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>). No P values were presented for between-group differences. No information about the baseline infection status of ulcers was available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cadexomer iodine compared with silver-impregnated dressing</HEADING>
<P>One RCT compared cadexomer iodine with a silver-impregnated dressing, with all participants receiving compression (<LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>). This RCT was identified to be at high risk of bias overall. All participants had signs of infection or critical colonisation at baseline. The frequency of complete healing at 12 weeks was similar between treatment groups, with 84/141 (60%) participants healing in the cadexomer iodine group compared with 85/140 (61%) in the silver-impregnated dressing group: RR 0.98 (95% CI 0.81 to 1.19) (<LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>). Bacterial growth was assessed by wound swab during the first two weeks of treatment and was categorised by the trial authors as nil/scant/low or moderate/high. In general, the distribution of participants across categories was similar between groups for the following: leucocytes; Gram-positive bacilli; Gram-negative bacilli; Gram-positive cocci; and Gram-negative cocci. <I>Staphylococcus aureus</I> was the commonly identified isolate in both groups. Eight adverse events were reported in the cadexomer iodine group compared with 13 in the silver dressings group; further details (e.g. number of participants per group affected) were not provided. No difference was noted between groups in terms of the proportions of participants expressing complete or moderate acceptability of treatment: RR 0.97 (95% CI 0.89 to 1.06) (<LINK REF="CMP-012.02" TYPE="ANALYSIS">Analysis 12.2</LINK>) (<LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary of evidence for cadexomer iodine</HEADING>
<P>Eleven RCTs recruiting 962 participants evaluated the effects of cadexomer iodine. Comparators were as follows: standard care (7 RCTs); hydrocolloid dressing (one RCT); paraffin gauze dressing (one RCT); dextranomer (two RCTs); and silver-impregnated dressing (one RCT). Healing outcomes were better for cadexomer iodine when compared with standard care, however, the incidence of adverse effects was greater for those receiving cadexomer iodine. Other comparisons did not detect differences in terms of healing. The outcomes of bacterial growth and patient acceptability of treatment were similar for cadexomer iodine and silver-impregnated dressings. Otherwise, data on secondary outcomes were limited. Most the RCTs were small and had either high or unclear risk of bias. One RCT recruited only those with infected ulcers (comparator was standard care), one recruited participants with infection or critical colonisation (comparator was silver-impregnated dressing) and one excluded participants with infected ulcers (comparators were hydrocolloid and paraffin gauze dressings). The other RCTs did not provide a clear report of baseline ulcer infection status, however, it is apparent from information provided in the trial reports that participants with ulcer infection would have been permitted to enter the trials.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Povidone-iodine</HEADING>
<P>Six RCTs (seven comparisons) recruiting a total of 639 participants evaluated povidone-iodine preparations (<LINK REF="STD-Groenewald-1981" TYPE="STUDY">Groenewald 1981</LINK>; <LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK>; <LINK REF="STD-Ishibashi-1996" TYPE="STUDY">Ishibashi 1996</LINK>; <LINK REF="STD-Casoni-2002" TYPE="STUDY">Casoni 2002</LINK>; <LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK>; <LINK REF="STD-Kuznetsov-2009" TYPE="STUDY">Kuznetsov 2009</LINK>). A seventh RCT, which included treatment groups receiving povidone-iodine, was discussed in the earlier section on systemic antibiotics (<LINK REF="STD-Daroczy-2006" TYPE="STUDY">Daroczy 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Povidone-iodine compared with dextranomer</HEADING>
<P>One RCT at high risk of bias overall was identified (<LINK REF="STD-Groenewald-1981" TYPE="STUDY">Groenewald 1981</LINK>). One hundred participants were recruited. Most of the ulcers were colonised by bacteria at baseline, but it was not clear how many were clinically infected (if any). Interventions were provided in an outpatient setting. All participants received compression therapy. The trial authors reported that the mean time to healing was significantly shorter in the group receiving dextranomer: 4.4 weeks versus 5.3 weeks (P value &lt; 0.05); however, it is unclear whether these time to event data were analysed appropriately using survival analysis. The trial authors reported that time to eradication of <I>Staphylococcus aureus</I> colonisation was significantly shorter in the dextranomer group compared with the povidone-iodine group (14.7 days versus 18.7 days; P value &lt; 0.01) (<LINK REF="STD-Groenewald-1981" TYPE="STUDY">Groenewald 1981</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Povidone-iodine and sugar ointment compared with recombinant tissue growth factor</HEADING>
<P>One RCT at unclear risk of bias overall was identified (<LINK REF="STD-Ishibashi-1996" TYPE="STUDY">Ishibashi 1996</LINK>). This trial was conducted in Japan and recruited both inpatients and outpatients. A total of 218 participants with different wound types were recruited; 207 were analysed of which 63 had venous leg ulcers. The growth factor was applied to the ulcer daily as a spray solution (recombinant human basic fibroblast growth factor 0.01%, 0.3 mL) whilst the povidone-iodine (concentration not stated) and sugar ointment was applied once or twice daily. Use of both products was followed by application of a gauze pad with securing tape; compression therapy was not mentioned. Treatment duration was four weeks. Around two-thirds of analysed participants across all wound types had some degree of ulcer infection at baseline, but no breakdown according to wound type was provided. The number of ulcers healed at four weeks was 5/31 (16%) in the group receiving the povidone-iodine and sugar ointment and 9/32 (28%) for those allocated the growth factor. The RR estimate did not suggest a difference between treatment groups: RR 0.57 (95% CI 0.22 to 1.52) (<LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Povidone-iodine compared with hydrocolloid dressing</HEADING>
<P>Three RCTs were identified (<LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK>; <LINK REF="STD-Casoni-2002" TYPE="STUDY">Casoni 2002</LINK>; <LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK>). One had a high risk of bias overall (<LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK>), and the other two were unclear (<LINK REF="STD-Casoni-2002" TYPE="STUDY">Casoni 2002</LINK>; <LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK>). Two RCTs reported time to healing (<LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK>; <LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK>), one additionally reported complete healing (<LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK>), and the third reported change in ulcer surface area (<LINK REF="STD-Casoni-2002" TYPE="STUDY">Casoni 2002</LINK>).</P>
<P>
<LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK> recruited 200 participants and did not state whether the ulcers were infected at baseline. Interventions were delivered in an outpatient setting and consisted of application of 10% povidone-iodine paint to the wound, which was then covered with paraffin gauze, compared with hydrocolloid dressing. All participants received two-layer compression or a compression stocking. Interventions were provided for four months. The trial authors reported that 10% of larger ulcers healed in less than four months in the povidone-iodine group compared with 34% in the hydrocolloid group (P value 0.02). Values for the smaller ulcers were not reported, but examination of the survival plot suggested that over 80% of participants in both groups healed within the four-month trial period. In terms of complete healing for all ulcers at four months, (50/99 (51%) healed in the hydrocolloid group compared with 47/101 (47%) in the povidone-iodine group. The RR estimate did not suggest a difference between treatment groups: RR 0.92 (95% CI 0.69 to 1.23) (<LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>). Cost estimates based on the total cost of dressings and the total cost of nursing time were reported separately for participants with an initial ulcer diameter less than 6 cm, and at least 6 cm. It was not clear why this stratification was used, as it differed from that used at randomisation and in other analyses. Overall, use of povidone-iodine was associated with lower costs. For smaller ulcers, the cost of dressings was GBP 18.55 for povidone-iodine and GBP 32.81 for hydrocolloid. The respective values for nursing time were GBP 38.95 and GBP 48.96. For larger ulcers, the cost of dressings was GBP 68.43 for povidone-iodine and GBP 441.91 for hydrocolloid. The respective estimates for nursing time were GBP 183.75 and GBP 526.63. The price year was not stated.</P>
<P>The second trial recruited 17 participants with two leg ulcers each, who acted as his or her own control (<LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK>). Ulcers were not infected as baseline. One ulcer per participant was randomly assigned to receive 10% povidone-iodine solution plus standard treatment, and the other ulcer was treated with standard treatment alone (comprised saline cleansing, hydrocolloid dressing and a 'compressive bandage' - no further details provided). Interventions were delivered for six weeks. The trial authors reported a statistically significant shorter time to healing for the group receiving the povidone-iodine preparation. Estimation of median (range) weeks to healing derived from Kaplan-Meier survival analysis was 11 (9 to 17) versus 18 (11 to 24) (P value &lt; 0.01; log-rank test). This finding should be treated with caution because of the small number of participants recruited.</P>
<P>In a three-armed, multi-factorial RCT, 74 participants were randomly assigned to receive one of three primary dressings (non-adherent paraffin gauze, hydrocolloid or hyaluronic acid/povidone-iodine) and one of three types of compression bandage (Unna's boot, multi-layer bandage or stockings plus elastic bandage) (<LINK REF="STD-Casoni-2002" TYPE="STUDY">Casoni 2002</LINK>). A full report was not available; data were extracted from conference presentation slides supplied by the trial author. The trial was of three months' duration. The baseline infection status of ulcers was not reported; before the trial, participants with clinically infected wounds were treated with systemic antibiotics. For the comparison of hyaluronic acid/povidone-iodine dressing and hydrocolloid, the median percentage ulcer area reduction at three months was 100% for both groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Povidone-iodine compared with non-adherent paraffin gauze dressing</HEADING>
<P>One trial was identified (already described in the section above), which had an unclear risk of bias overall (<LINK REF="STD-Casoni-2002" TYPE="STUDY">Casoni 2002</LINK>). The trial authors reported a statistically significant difference in median percentage ulcer area reduction at three months in favour of hyaluronic acid/povidone-iodine dressing when compared with non-adherent paraffin gauze dressing (100% versus 90%, P value 0.036).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Povidone-iodine compared with moist or foam dressings</HEADING>
<P>One RCT at unclear risk of bias compared a 10% povidone-iodine dressing with different dressings applied according to ulcer status (a moist wound dressing for necrotic tissue, a foam dressing for ulcers free of necrosis or a silver-impregnated foam dressing for ulcer infection) (<LINK REF="STD-Kuznetsov-2009" TYPE="STUDY">Kuznetsov 2009</LINK>). All participants received short-stretch compression bandaging. Most participants in both groups had bacteria isolated from their ulcers at baseline, but the number with clinically infected wounds was not stated. At four weeks, 2/15 (13%) participants healed in the povidone-iodine group compared with 5/15 (33%) of controls. The RR estimation suggested no difference between groups: RR 0.40 (95% CI 0.09 to 1.75) (<LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK>). The mean cost of a complete course of treatment was lower for the group receiving povidone-iodine dressing: RUB 6669.84 (Roubles) versus RUB 14,360.15 (price year not stated). The mean cost of treatment per participant per day was also lower for those allocated the povidone-iodine dressing: RUB 16.47 versus RUB 36.82.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary of evidence for povidone-iodine</HEADING>
<P>Six RCTs recruiting 639 participants evaluated the effects of povidone-iodine. Comparator interventions were: dextranomer (one RCT); growth factor (one RCT); hydrocolloid dressing (three RCTs); paraffin gauze dressing (one RCT); and moist or foam dressings given according to ulcer status (one RCT). Overall, there was no evidence from healing data to suggest a difference between treatment groups (estimates either indicated no difference, or were likely to be unreliable). Two RCTs reported that use of povidone-iodine was associated with lower costs compared with control interventions (hydrocolloid and moist or foam dressings), however, full economic evaluations were not described. Most the RCTs were small and had either high or unclear risk of bias. Participants with infected ulcers were excluded from one RCT, but ulcer infection status was unclear for the others.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Peroxides</HEADING>
<P>Four RCTs (four comparisons) that recruited a total of 72 participants evaluated the effects of peroxide-based topical preparations (<LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>; <LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>; <LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>; <LINK REF="STD-Belcaro-2007" TYPE="STUDY">Belcaro 2007</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Benzoyl peroxide 10% compared with saline dressing</HEADING>
<P>One RCT at high risk of bias was identified (<LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>). Ten participants with two leg ulcers each were recruited, who acted as his or her own control. Baseline infection status of the ulcers was not described. One ulcer per participant was randomised to receive benzoyl peroxide 10% lotion and the other was treated with normal saline solution. Both study lotions were applied to ulcers by means of an sterile wound dressing sponge, cut to fit the size of the ulcer. Compression therapy was not mentioned. Interventions were delivered for six weeks in an outpatient setting. At the end of the treatment period, benzoyl peroxide lotion 10% was more effective than saline in terms of the mean percentage ulcer area remaining: difference in means -30.40% (95% CI -42.12 to -18.68 (<LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>). The trial authors reported a between-group analysis which took account of the highly correlated healing data from the two interventions groups, and also reported a statistically significant difference in favour of benzoyl peroxide 10% (P value &lt; 0.01). Three participants reported adverse effects associated with use of benzoyl peroxide (severe irritation).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Benzoyl peroxide 20% compared with saline dressing</HEADING>
<P>One RCT at high risk of bias was identified (<LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>), with a similar study protocol to the trial described in the section above, except that the comparison was between benzoyl peroxide 20% lotion and normal saline. Ten participants with two leg ulcers each were recruited, who acted as his or her own control. At the end of the six week treatment period, benzoyl peroxide lotion 20% was more effective than saline in terms of the mean percentage ulcer area remaining: difference in means -34.10% (95% CI -46.22 to -21.98) (<LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>). The trial authors reported a between-group analysis which took account of the highly correlated healing data from the two interventions groups, and also reported a statistically significant difference in favour of benzoyl peroxide 20% (P value &lt; 0.05). No adverse effects were reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hydrogen peroxide compared with placebo</HEADING>
<P>Two RCTs with unclear risk of bias were performed by the same research group (<LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>; <LINK REF="STD-Belcaro-2007" TYPE="STUDY">Belcaro 2007</LINK>). Both trials provided the following treatment regimen. An initial run-in period involved administration of systemic antibiotics for 15 to 20 days to clear any underlying infection. Participants were then randomly assigned to receive hydrogen peroxide 1% cream applied to the ulcer and peri-ulcer area or a placebo cream. For all participants, the wound was covered with tissue paper, and a compression bandage applied. Study treatments were delivered in outpatient settings. Outcomes were assessed after 10 days. Insufficient data were presented to enable calculation of effect sizes, and so data could not be pooled. The earlier trial recruited 20 participants (<LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>). The trial authors reported a statistically significant difference in ulcer area reduction between groups in favour of hydrogen peroxide (median decrease 35%, range 12% to 44%) when compared with placebo (median decrease 11%, range 0% to 23.5%); P value &lt; 0.05. Similar findings were seen for the second trial (N = 32) (<LINK REF="STD-Belcaro-2007" TYPE="STUDY">Belcaro 2007</LINK>). At 10 days, the reduction in ulcer area was significantly greater for the group receiving hydrogen peroxide: median decrease 44.8%, range 15% to 57% versus median decrease 32%, range 15% to 44%; P value &lt; 0.005.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary of evidence for peroxide-based preparations</HEADING>
<P>Four RCTs recruiting 72 participants evaluated the effects of peroxide-based topical preparations. Comparator interventions included saline dressing (two RCTs) and placebo (two RCTs). Healing estimates were based on surrogate measures (change in wound area). The data suggested that benzoyl peroxide in both 10% and 20% concentrations was more effective than saline dressing. The 10% preparation was associated with adverse effects (versus none for saline). No adverse effects were reported in either group for the comparison of 20% benzoyl peroxide versus saline. The baseline ulcer infection status was not described for either of the benzoyl peroxide RCTs. Hydrogen peroxide 1% cream resulted in greater wound area reduction when compared with a placebo cream; there were no data on secondary outcomes. For both benzoyl peroxide RCTs, it is likely that participants with infected ulcers were excluded. All of the RCTs were small and had either high or unclear risk of bias.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Honey-based preparations</HEADING>
<P>Two multi-centre RCTs (two comparisons) recruiting 476 participants in total evaluated Manuka honey preparations (<LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Honey-based preparations compared with alternative topical preparations</HEADING>
<P>One RCT comparing honey topical application with hydrogel was at high risk of bias (<LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>). The other, at low risk of bias, compared a honey-impregnated calcium alginate dressing with usual care (dressings applied according to clinician choice - could include iodine or silver dressings) (<LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>). Compression was used as a concurrent therapy in both RCTs. One RCT excluded participants who had clinically infected ulcers at baseline but reported that some participants had wounds colonised with various micro-organisms, including a small proportion (15% overall) with methicillin-resistant <I>Staphylococcus aureus</I> (MRSA) (<LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>). Baseline ulcer infection status was not reported for the other trial (<LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>). In one RCT, the mean time to healing was reported as 63.5 days in the honey group, compared with 65.3 days in the usual care group (trial authors reported P value 0.553 for the difference in means). The unadjusted hazard ratio estimation as reported by the trial authors was 1.1 (95% CI 0.8 to 1.5; P value 0.451); the estimate adjusted for study centre and prognostic index was stated to be similar, although data were not presented. (<LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>). Both RCTs reported complete healing at 12 weeks, and data were pooled (<LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>). Overall, 128/241 (53%) participants were healed on honey, compared with 108/235 (46%) on the alternative regimens. No evidence of a difference between groups was found: RR 1.15 (95% CI 0.96 to 1.38) (<LINK REF="CMP-017.01" TYPE="ANALYSIS">Analysis 17.1</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<P>In terms of secondary outcomes, pooled data suggested no between-group differences in the incidence of ulcer infection during the 12-week trial period: RR 0.71 (95% CI 0.49 to 1.04) (<LINK REF="CMP-017.02" TYPE="ANALYSIS">Analysis 17.2</LINK>) (<LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>). One RCT additionally reported that 37 episodes of infection occurred in the group receiving honey compared with 49 in the group allocated usual care (trial authors reported P value 0.449 for the between-group difference) (<LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>). One RCT reported that, in both groups, fewer participants had at least one bacterial species isolated at week four relative to baseline; however, the four-week data were reported for the whole group, not just for those with isolates identified at baseline. The same finding applied to those with more than one isolate. Data from the same RCT indicated no evidence of a difference between groups for the proportions of participants with MRSA eradication at four weeks: RR 4.2 (95% CI 0.67 to 26.30) (<LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>) (<LINK REF="CMP-017.03" TYPE="ANALYSIS">Analysis 17.3</LINK>).</P>
<P>Both RCTs reported adverse events (<LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>), one asserting that no observed adverse events were considered to be attributable to either of the trial treatments (<LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>). Data from the other RCT suggested that more adverse events were detected in the group receiving the honey dressing: RR 1.28 (95% CI 1.05 to 1.56) (<LINK REF="CMP-017.04" TYPE="ANALYSIS">Analysis 17.4</LINK>) (<LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>). The most frequently reported local adverse event in both groups was pain; the trial authors reported that the between-group difference was statistically significant in favour of usual care (P value 0.001). Other local adverse events, reported by the trial authors as not statistically significant in incidence between groups, included bleeding, dermatitis, erythema, oedema, increased exudate, deterioration of the ulcer or peri-ulcer skin and new ulceration (<LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>).</P>
<P>One RCT reported similar outcomes between treatment groups for the SF-36 physical component summary score, the SF-36 mental component summary score, the EQ-5D and the Charing Cross Venous Ulcer Questionnaire, all of which were assessed at 12 weeks (not stated whether any of the measurements were adjusted for baseline values) (<LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>). The same RCT conducted a cost-effectiveness analysis in parallel with the RCT and reported that estimates from the base case analysis of mean total health service costs per participant were NZD 917.00 for the group receiving honey and NZD 972.68 for those allocated usual care (price year not stated) (<LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>). The incremental cost-effectiveness ratio (ICER) was NZD -9.45 (95% CI NZD -39.63 to NZD 16.07) in favour of honey when all costs were considered. Exclusion of hospitalisation costs (based on six participants receiving usual care hospitalised for a total of 40 days and three hospitalised for a total of 10 days allocated the honey dressing) reversed the ICER to NZD 11.34 (95% CI NZD -2.24 to NZD 26.25) in favour of usual care (<LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary of evidence for honey-based preparations</HEADING>
<P>Two RCTs recruiting 476 participants evaluated honey-based preparations. One RCT compared a honey-based topical application with hydrogel (high risk of bias) and the other compared a honey-impregnated dressing with non-honey dressings applied according to the clinician's choice (low risk of bias). Pooled data suggested no difference between groups for the outcomes of complete healing at 12 weeks and incidence of ulcer infection during the trial period. The RCT evaluating topical applications excluded participants with clinically infected wounds at baseline, but reported that some wounds were colonised with MRSA; no difference was detected between groups for eradication of MRSA at four weeks. The RCT comparing honey-impregnated dressing with non-honey dressings reported no difference between groups for time to healing and change in health-related quality of life scores. However, use of honey was associated with more adverse events. The same trial conducted a rigorous cost-effectiveness analysis in parallel with the RCT and concluded that honey was unlikely to be cost effective. This trial did not provide information about baseline ulcer infection status.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Silver-based preparations</HEADING>
<P>Twelve RCTs (13 comparisons) recruiting 1514 participants evaluated the effect of silver-based preparations.</P>
<SUBSECTION>
<HEADING LEVEL="4">Silver sulphadiazine cream compared with non-antimicrobial dressings and topical applications</HEADING>
<P>Three RCTs reporting four comparisons were identified (<LINK REF="STD-Blair-1988" TYPE="STUDY">Blair 1988</LINK>; <LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>; <LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK>); all had an unclear risk of bias overall. Two excluded participants with clinically infected wounds (<LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>; <LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK>); in the third trial, baseline ulcer infection status was not explained (<LINK REF="STD-Blair-1988" TYPE="STUDY">Blair 1988</LINK>).</P>
<P>One RCT recruited 17 participants, each with two leg ulcers; these participants acted as their own controls, the ulcer being the unit of randomisation (<LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK>). Application of 1% silver sulphadiazine cream in addition to usual care was compared with usual care alone (hydrocolloid dressing and a 'compressive bandage'&#8212;no further details were provided). Treatment duration was six weeks. Median time to healing derived from Kaplan-Meier survival analysis was reported as 15 weeks (range seven to 23 weeks) for the group receiving silver plus usual care, and 16 weeks (range nine to 22 weeks) for those allocated usual care alone. The trial authors described the between-group difference as not statistically significant, but the P value was not presented.</P>
<P>A three-armed trial (N = 93 participants) compared three different topical agents: 1% silver sulphadiazine cream; 0.4% tripeptide copper complex cream (described elsewhere as a growth factor <LINK REF="REF-Maquart-1993" TYPE="REFERENCE">Maquart 1993</LINK>); and a placebo cream (<LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>). All participants received a non-adherent dressing and compression (not described further). The respective numbers of participants healed per group at four weeks were as follows: 6/31 (19%); 0/32 (0%); and 1/30 (3%). No statistically significant difference was detected between groups for the comparisons of 1% silver sulphadiazine versus placebo: RR 5.81 (95% CI 0.74 to 45.40) (<LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK>); and 1% silver sulphadiazine versus 0.4% tripeptide copper complex cream: RR 13.41 (95% CI 0.79 to 228.32) (<LINK REF="CMP-019.01" TYPE="ANALYSIS">Analysis 19.1</LINK>). .</P>
<P>Another RCT (N = 60 ulcers) compared 1% silver sulphadiazine cream with a non-adherent dressing; all participants received four-layer compression bandaging (<LINK REF="STD-Blair-1988" TYPE="STUDY">Blair 1988</LINK>). At 12 weeks, 19/30 (63%) ulcers were healed on 1% silver sulphadiazine cream compared with 24/30 (80%) receiving the non-adherent dressing. The RR estimate did not suggest a difference between groups: RR 0.79 (95% CI 0.57 to 1.10) (<LINK REF="CMP-020.01" TYPE="ANALYSIS">Analysis 20.1</LINK>). In the same RCT, four participants receiving 1% silver sulphadiazine cream withdrew from treatment because of erythema and pruritis; two participants in the same group developed cellulitis compared with one allocated to the non-adherent dressing (but not stated whether these participants withdrew) (<LINK REF="STD-Blair-1988" TYPE="STUDY">Blair 1988</LINK>). The review authors did not estimate measures of effect from these data because the denominators for participants were unclear. All ulcers were contaminated at baseline, and the most common isolate was <I>Staphylococcus aureus</I>. However, it was not stated whether wounds were clinically infected. The trial authors stated that bacterial contamination continued throughout the trial in both groups, with only three ulcers having no bacterial growth at any stage (group not stated) (<LINK REF="STD-Blair-1988" TYPE="STUDY">Blair 1988</LINK>). Other trials did not report secondary outcomes. Healing data were not pooled because of differences in comparators, treatment duration and follow-up periods between trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Silver-impregnated dressings compared with alternative silver-impregnated dressings</HEADING>
<P>One RCT, with an unclear risk of bias, compared different proprietary brands of silver-impregnated dressings: a silver-impregnated polyurethane foam dressing (Avance); and a five-layer silver-impregnated dressing comprising absorbent and polyethylene net layers (Acticoat 7) (<LINK REF="STD-Chaloner-2004" TYPE="STUDY">Chaloner 2004</LINK>). All participants received a four-layer compression bandage. All participants had bacterial colonisation of ulcers at baseline, but it was not stated whether any were clinically infected. At 12 weeks, 7/20 (35%) in the Avance group had healed compared with 10/20 (50%) in the Acticoat 7 group, with no between-group difference detected: RR 1.43 (95% CI 0.68 to 3.00) (<LINK REF="CMP-021.01" TYPE="ANALYSIS">Analysis 21.1</LINK>). Some secondary outcomes were mentioned but meaningful data were not provided.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Silver-impregnated dressings compared with non-antimicrobial dressings</HEADING>
<P>Eight RCTs were identified (<LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>; <LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>). Two had low risk of bias overall (<LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>), one was high risk (<LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>), and five were unclear (<LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>; <LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>). Ulcer infection status at baseline varied across the trials. One RCT excluded participants with infected ulcers (<LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>), and another excluded participants taking antibiotics (<LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>); we assumed that the latter meant that those with clinical infection of any type would have been excluded. Three RCTs included participants with critical colonisation of the wound but excluded those with a clinically infected ulcer (<LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>). Another RCT permitted those with critical colonisation or clinical infection, or both, to enter the trial (<LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>). One RCT included only those with infected ulcers (<LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>), and one reported no information at all on wound infection status at baseline (<LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>).</P>
<P>Four RCTs provided data on complete healing at four to 12 weeks (<LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>; <LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>). One multi-centre, pragmatic RCT (N = 213 participants) compared silver-impregnated dressings (different proprietary brands selected according to clinician judgement) with non-antimicrobial low-adherent dressings (<LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>). Two RCTs compared silver-impregnated dressings with the same dressing fabric in a non-antimicrobial version (<LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>), and the other compared a silver-impregnated charcoal dressing with various topical agents used according to different stages of healing (<LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>). Three trials provided compression as concurrent treatment (<LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>), but the use of compression was not mentioned in the RCT by <LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>. Data from all four RCTs were pooled, indicating that 90/213 (42%) participants healed on silver and 76/211 (36%) healed on non-antimicrobial dressings. The RR estimate did not suggest a difference between groups: RR 1.17 (95% CI 0.95 to 1.45) (<LINK REF="CMP-022.01" TYPE="ANALYSIS">Analysis 22.1</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
<P>One RCT reported additional healing-related outcomes relating to longer term follow-up, time to healing and ulcer recurrence, all of which indicated no difference between treatment groups (<LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>). The respective estimates for complete healing at six and 12 months were: RR 1.10 (95% CI 0.96 to 1.28) (<LINK REF="CMP-022.02" TYPE="ANALYSIS">Analysis 22.2</LINK>); and RR 1.05 (95% CI 0.94 to 1.16) (<LINK REF="CMP-022.03" TYPE="ANALYSIS">Analysis 22.3</LINK>). Median time to healing estimates were: 67 days (95% CI 54 to 80 days) for silver dressings, and 58 days (95% CI 43 to 73 days) for non-antimicrobial dressings (P value 0.408 reported by trial authors). The trial authors' reported hazard ratio was: 1.13 (95% CI 0.85 to 1.15), and the estimate for ulcer recurrence within the first year was: RR 0.80 (95% CI 0.38 to 1.70) (<LINK REF="CMP-022.04" TYPE="ANALYSIS">Analysis 22.4</LINK>).</P>
<P>The other four RCTs provided outcome data on change in wound surface area (<LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>). Three RCTs compared silver-impregnated dressings with the same dressing fabric in a non-antimicrobial version (<LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>), whilst the fourth used local best practice as the control group; this could include various types of dressings, including silver dressings as given to 17% of participants in that group (<LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>). All participants in all of these trials received compression therapy. Data from two RCTs were pooled for absolute change in ulcer surface area at four weeks, indicating a between-group difference in favour of silver: difference in means -4.7 cm squared (95% CI -8.46 to -0.94) (<LINK REF="CMP-022.05" TYPE="ANALYSIS">Analysis 22.5</LINK>) (<LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>). The data for percentage change in ulcer area were not pooled because statistically significant heterogeneity was detected (Chi<SUP>2</SUP> test for heterogeneity P value 0.05 and I<SUP>2</SUP> estimation = 75%). In terms of estimates of treatment effect from the individual trials, one suggested a difference in favour of silver: difference in means -19.5% (95% CI -37.94 to -1.06) (<LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>), whilst the other showed no difference between groups: difference in means 7.5% (95% CI -11.68 to 26.68) (<LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>). The pooled data on healing rate also suggested no difference between groups: pooled difference in means -0.12 cm squared per day (95% CI -0.28 to 0.03) (<LINK REF="CMP-022.07" TYPE="ANALYSIS">Analysis 22.7</LINK>). The other two RCTs provided only limited data (<LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>). One reported the median (range) change in ulcer area in cm squared at four weeks as -4.5 (-30.9 to 22.5) for silver and -3.5 (-53.3 to 18.5) for non-antimicrobial dressings; the respective values for percentage change in ulcer area were -35.6 (-100.0 to 182.1) and -40.9 (-100.0 to 308.3) (P value for between-group difference not reported for either outcome) (<LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>). The other reported the median percentage change in ulcer area at four weeks as -45.5 for silver and -28.8 for usual care (reported P value was 0.0001 for the between-group difference) (<LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>).</P>
<P>Six RCTs reported adverse events (<LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>). Two stated that no observed adverse events were deemed related to treatment but provided no further information (<LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>). Four presented the numbers of participants reporting various types of adverse events (<LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>). Pooling of data did not suggest a difference between treatment groups: RR 0.69 (95% CI 0.36 to 1.33) (<LINK REF="CMP-022.08" TYPE="ANALYSIS">Analysis 22.8</LINK>). The most commonly reported adverse events in both groups included maceration and other indications of worsening of the peri-ulcer skin. In terms of change in bacterial colonisation, one RCT (recruiting participants with critical colonisation but not clinical infection of the ulcer), reported that 39% of those receiving the silver dressing and 17% of the non-antimicrobial dressing group had no remaining signs of bacterial colonisation at four weeks (further data and P value not provided) (<LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>). A second RCT, which did not describe details of ulcer infection status at baseline, reported a non-significant reduction in colonisation over the whole study period for the group receiving the silver dressing, and a reduction starting only at week two in the group allocated other topical agents according to the stage of wound healing (follow-up duration was six weeks) (<LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>).</P>
<P>Three RCTs reported change in health-related quality of life (<LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>). Findings from one trial indicated that no statistically significant between-group differences were observed at any of the follow-up times (one, three, six and 12 months) for either of the instruments used (EQ-5D and SF-6D) (estimates adjusted for baseline scores) (<LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>). Available data from the other two RCTs were more limited but suggested that overall EQ-5D scores were similar between treatment groups (<LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>). One RCT reported estimates from a rigorous cost-effectiveness analysis and concluded that silver dressings were unlikely to be cost-effective (incremental cost-effectiveness ratio for silver dressings was GBP 489,250 per quality-adjusted life year gained, price year 2007) (<LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary of evidence for silver-based preparations</HEADING>
<P>Twelve RCTs recruiting 1514 participants evaluated the effect of silver-based preparations. Silver sulphadiazine cream was compared with: usual care (one RCT); placebo (one RCT); growth factor (one RCT); and non-adherent dressing (one RCT). Silver-impregnated dressings were compared with alternative silver dressings (one RCT) and non-antimicrobial dressings (eight RCTs). There was no difference between treatment groups for most healing outcomes; some short-term surrogate measures of healing suggested benefit of silver dressing compared with non-antimicrobial dressings, whilst others suggested no between-group difference. Data on secondary outcomes suggested no difference between silver-impregnated dressing and non-antimicrobial dressings for adverse effects and changes in health-related quality of life scores. A rigorous cost-effectiveness analysis conducted alongside one RCT concluded that silver-impregnated dressings were unlikely to be cost-effective when compared with non-antimicrobial dressings. Two RCTs were large; one had low risk of bias and the other was unclear. The remainder were small with mostly unclear risk of bias. The ulcer infection status at baseline varied across trials.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Miscellaneous topical preparations</HEADING>
<P>Five RCTs (seven comparisons) recruiting 590 participants overall were identified that did not easily fit into any of the groups described above (<LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>; <LINK REF="STD-Cameron-1991" TYPE="STUDY">Cameron 1991</LINK>; <LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>; <LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>; <LINK REF="STD-Bini_x0107_-2010" TYPE="STUDY">Bini&#263; 2010</LINK>). Three RCTs evaluated topical antibiotics (<LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>; <LINK REF="STD-Cameron-1991" TYPE="STUDY">Cameron 1991</LINK>; <LINK REF="STD-Bini_x0107_-2010" TYPE="STUDY">Bini&#263; 2010</LINK>), and the other two assessed the effects of topical antiseptics (<LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>; <LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Chloramphenicol-containing ointment versus enzymatic wound cleansing preparation</HEADING>
<P>One multi-centre RCT recruited 258 participants and comprised three study arms (<LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>). Trial interventions were: an ointment containing an antibiotic (chloramphenicol) combined with an enzyme (clostridiopeptidase); an ointment containing an alternative antibiotic (framycetin sulphate) combined with the enzyme trypsin; and an enzymatic wound cleansing preparation (proprietary name Fibrolan) without added antibiotics. This generated three comparisons, all of which were relevant to the review. All participants received compression bandaging, according to usual care in each study centre. The overall risk of bias was unclear. There was no information about baseline ulcer infection status. The data suggested that more participants were healed at four weeks when receiving the non-antibiotic enzymatic cleanser compared with the chloramphenicol-containing ointment: RR 0.13 (95% CI 0.02 to 0.99) (<LINK REF="CMP-023.01" TYPE="ANALYSIS">Analysis 23.1</LINK>). Adverse events were reported as the number of participants who withdrew from treatment because of ineffectiveness (not defined further) or allergy. The data indicated no difference between groups: RR 2.02 (95% CI 0.52 to 7.84) (<LINK REF="CMP-023.02" TYPE="ANALYSIS">Analysis 23.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Framycetin sulphate&#8211;containing ointment versus enzymatic wound cleansing preparation</HEADING>
<P>Data from the RCT described in the comparison above suggested no difference between groups in healing at four weeks: RR 0.69 (95% CI 0.23 to 2.01) (<LINK REF="CMP-024.01" TYPE="ANALYSIS">Analysis 24.1</LINK>) (<LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>). Adverse events were assessed as described in the comparison above. No evidence was found of a between-group difference: RR 2.93 (95% CI 0.80 to 10.67) (<LINK REF="CMP-024.02" TYPE="ANALYSIS">Analysis 24.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Chloramphenicol-containing ointment versus framycetin sulphate&#8211;containing ointment</HEADING>
<P>Data from the RCT described in the two comparisons above suggested no difference between groups in healing at four weeks: RR 0.18 (95% CI 0.02 to 1.54) (<LINK REF="CMP-025.01" TYPE="ANALYSIS">Analysis 25.1</LINK>) (<LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>). Adverse events were assessed as for the two comparisons above. No evidence was found of a between-group difference: RR 0.69 (95% CI 0.25 to 1.90) (<LINK REF="CMP-025.02" TYPE="ANALYSIS">Analysis 25.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mupirocin compared with vehicle</HEADING>
<P>One RCT with overall unclear risk of bias was identified which compared the application of 2% mupirocin in a white soft paraffin tulle gras, with vehicle (N = 30 participants) (<LINK REF="STD-Cameron-1991" TYPE="STUDY">Cameron 1991</LINK>). Both study groups received compression therapy. The setting of treatment was not stated. At 12 weeks, 8/15 (53%) participants healed on mupirocin and 7/15 (47%) healed on vehicle, with the RR estimate suggesting no difference between groups: RR 1.14 (95% CI 0.56 to 2.35) (<LINK REF="CMP-026.01" TYPE="ANALYSIS">Analysis 26.1</LINK>). Baseline wound infection was not reported, but five participants in each group had colonisation of the ulcer with Gram-positive bacteria. Eradication of Gram-positive bacteria from ulcers was observed in all participants receiving mupirocin compared with none allocated the vehicle preparation. The numbers analysed were very small and did not suggest a difference between groups: RR 11.00 (95% CI 0.77 to 158.01) (<LINK REF="CMP-026.02" TYPE="ANALYSIS">Analysis 26.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Topical antibiotics versus herbal ointment</HEADING>
<P>One RCT (N = 32 participants) at overall unclear risk of bias compared topical antibiotics with an herbal ointment (<LINK REF="STD-Bini_x0107_-2010" TYPE="STUDY">Bini&#263; 2010</LINK>). The topical antibiotics were given according to cultures and sensitivities and included gentamicin, chloramphenicol 5%, enbecin, povidone-iodine 2%, metronidazole and fusidic acid. The herbal ointment (Plantoderm) was described as having antimicrobial properties. All participants received ulcer cleansing, debridement, dressings and bandages (but not compression therapy); dressings were changed twice daily. All ulcers showed signs of contamination or colonisation at baseline, with no signs of ulcer infection or systemic infection. The frequency of complete healing at week seven was 2/17 (12%) in the herbal ointment group compared with none in the topical antibiotics group: RR 4.44 (95% CI 0.23 to 85.83) (<LINK REF="CMP-027.01" TYPE="ANALYSIS">Analysis 27.1</LINK>). The data suggested no differences between groups in terms of eradication of bacteria from ulcers at seven weeks: RR 8.00 (95% CI 0.47 to 137.35) (<LINK REF="CMP-027.02" TYPE="ANALYSIS">Analysis 27.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Chlorhexidine plus usual care versus usual care alone</HEADING>
<P>One RCT was identified, which recruited 17 participants, each with two leg ulcers, who acted as his or her own controls; the ulcer was the unit of randomisation (<LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>). Application of 5% chlorhexidine digluconate solution in addition to usual care was compared with usual care alone (defined as hydrocolloid dressing and a 'compressive bandage'&#8212;no further details were provided). Treatment duration was six weeks. Ulcers were not clinically infected at baseline. The overall risk of bias was unclear. Median time to healing as derived from Kaplan-Meier survival analysis was reported as 14 weeks (range 7 to 17 weeks) for the group receiving chlorhexidine plus usual care, and 15 weeks (range 7 to 19 weeks) for those allocated usual care alone. The trial authors described the between-group difference as not statistically significant, but the P value was not presented.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ethacridine lactate ointment compared with placebo ointment</HEADING>
<P>One multi-centre RCT (N = 253 participants) with unclear risk of bias was identified (<LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>). Participants were assigned to ethacridine lactate ointment 0.1% or placebo ointment, both applied twice daily for 28 days (<LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>). All participants received compression therapy. Treatment was provided in an outpatient setting. Baseline ulcer infection status was not reported. The number of responsive ulcers (defined as &gt; 20% reduction in ulcer surface area) was greater in the group treated with ethacridine compared with the placebo group (RR 1.45, 95% CI 1.21 to 1.73; estimate based on all randomised participants) (<LINK REF="CMP-028.01" TYPE="ANALYSIS">Analysis 28.1</LINK>). In addition, the trial authors reported that the mean reduction in ulcer surface area was 34.1% for the group receiving ethacridine lactate ointment and 24.7% for those allocated the placebo ointment (no further data or P value for the between-group difference was provided).</P>
<P>The proportion of participants reporting at least one adverse event was similar between groups: RR 1.06 (95% CI 0.50 to 2.22; estimate based on those who completed the trial) (<LINK REF="CMP-028.02" TYPE="ANALYSIS">Analysis 28.2</LINK>) (<LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>). In terms of the types of adverse events observed, these were mainly headaches, migraines and pruritis in the group receiving ethacridine, and aches, back pain and nausea in those allocated placebo. The trial authors considered that all adverse events were unlikely to be related to trial treatments. When asked about their satisfaction with the intervention, a significantly larger proportion of participants rated their experience as 'excellent' in the ethacridine group when compared with placebo: 50% versus 17.9% (RR 2.83, 95% CI 1.85 to 4.34; estimate based on those completing the trial) (<LINK REF="CMP-028.03" TYPE="ANALYSIS">Analysis 28.3</LINK>) (<LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>). The trial authors assessed quality of life using the Freiburg Quality of Life Questionnaire at baseline and at endpoint. The group receiving ethacridine achieved a median reduction in score of 0.75 points (reduction indicating improvement), whilst those treated with placebo had a median reduction of 0.3 points (statistical significance of difference not reported by trial authors and not evaluable by review authors) (<LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary of evidence for miscellaneous topical preparations</HEADING>
<P>Five RCTs recruiting 590 participants evaluated the effect of topical applications: topical antibiotics (three RCTs) and topical antiseptics (two RCTs). All had unclear risk of bias.</P>
<P>The comparisons involving topical antibiotics were: chloramphenicol-containing ointment versus enzymatic wound cleanser (one RCT); framycetin sulphate-containing ointment versus enzymatic wound cleanser (one RCT); chloramphenicol-containing ointment versus framycetin sulphate&#8211;containing ointment (one RCT); mupirocin versus vehicle (one RCT); and topical antibiotics according to cultures and sensitivities versus herbal ointment (one RCT). More participants healed at four weeks using an enzymatic wound cleanser when compared with a chloramphenicol-containing ointment. No other between-group differences were found in terms of healing, or for secondary outcomes (adverse effects and bacterial eradication). Two RCTs were small. One trial excluded participants with baseline ulcer infection, but in the other two there was no information about baseline ulcer infection status.</P>
<P>No difference was found in terms of time to healing for chlorhexidine added to usual care versus usual care alone (one small RCT); participants with infected ulcers were excluded. Another trial reported that the number of responsive ulcers (defined as &gt; 20% reduction in ulcer surface area) was greater, and also that participant-reported satisfaction was greater, with ethacridine lactate treatment when compared with placebo. For the same trial, adverse effects were reported as similar between groups. There was no information about baseline ulcer infection.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-12-15 18:50:31 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<SUMMARY_OF_RESULTS MODIFIED="2013-12-15 17:57:24 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Summary of main results for systemic antibiotics</HEADING>
<P>Five RCTs reported eight comparisons involving various systemic antibiotics (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>; <LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>; <LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>; <LINK REF="STD-Daroczy-2006" TYPE="STUDY">Daroczy 2006</LINK>). The only comparison in which a statistically significant between-group difference was detected in terms of healing was that in favour of levamisole (a product normally used to treat roundworm infection) when compared with placebo. This trial, in common with the other evaluations of systemic antibiotics, was small, and so the observed effect could have occurred by chance (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>). In terms of secondary outcomes, data from two RCTs revealed no difference between antibiotics and usual care for rates of bacterial eradication; those with clinically infected ulcers were excluded at baseline in one RCT (<LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>), whilst in the other, this variable was not reported (<LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>). A separate analysis suggested that those receiving placebo were less likely to develop antibiotic-resistant strains of bacteria compared with those given ciprofloxacin (<LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>). Otherwise, few data were reported for secondary outcomes. The overall risk of bias for all RCTs in this comparison was unclear (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>; <LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>; <LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>; <LINK REF="STD-Daroczy-2006" TYPE="STUDY">Daroczy 2006</LINK>). One RCT restricted participant selection to those with non-infected ulcers at baseline (<LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>), whilst the others did not clearly report the baseline ulcer infection status. Therefore it cannot be determined from current evidence whether systemic antibiotics can promote healing in patients with clinically infected ulcers.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary of main results for topical antibiotics and antiseptics</HEADING>
<P>The evidence for the effects of a variety of topical preparations was reviewed; this update extended the range of eligible comparisons to include evaluations of silver- and honey-based products.</P>
<P>Data from four RCTs pooled suggests that more participants healed at four to 12 weeks on cadexomer iodine compared with standard care: RR 2.17 (95% CI 1.30 to 3.60) (<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) (<LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>). No between-group differences in complete healing were detected when cadexomer iodine was compared with the following: hydrocolloid dressing; paraffin gauze dressing; dextranomer; and silver-impregnated dressings. Cadexomer iodine may be associated with decreased bacterial load compared with usual care in participants with infected ulcers at baseline (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>). The available data suggest that more participants reported adverse events for cadexomer iodine relative to standard care (<LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>).</P>
<P>No between-group differences were detected in terms of complete healing when povidone-iodine was compared with paraffin gauze, moist or foam dressings given according to wound status, or growth factor (<LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK>; <LINK REF="STD-Ishibashi-1996" TYPE="STUDY">Ishibashi 1996</LINK>; <LINK REF="STD-Casoni-2002" TYPE="STUDY">Casoni 2002</LINK>; <LINK REF="STD-Kuznetsov-2009" TYPE="STUDY">Kuznetsov 2009</LINK>). Other estimates of healing were of unknown validity (<LINK REF="STD-Groenewald-1981" TYPE="STUDY">Groenewald 1981</LINK>; <LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK>). Few data on secondary outcomes were provided.</P>
<P>Four RCTs presented findings in favour of peroxide-based preparations when compared with usual care for surrogate healing outcomes (change in ulcer area) (<LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>; <LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>; <LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>; <LINK REF="STD-Belcaro-2007" TYPE="STUDY">Belcaro 2007</LINK>). No report described complete healing or time to healing. In two RCTs, all cases of clinical infection were resolved before randomisation (<LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>; <LINK REF="STD-Belcaro-2007" TYPE="STUDY">Belcaro 2007</LINK>); the other two RCTs did not report ulcer infection status at baseline (<LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>; <LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>). All four RCTs were very small, and so findings should be viewed with caution.</P>
<P>Pooled data from two RCTs suggested no difference between honey-based products and usual care for complete healing at 12 weeks (<LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>). One RCT was at low risk of bias overall and reported additional outcomes suggesting no difference in groups in terms of time to healing or health-related quality of life, however, more frequent adverse effects associated with honey. In addition, a cost-effectiveness analysis was conducted in parallel with the clinical trial and found that whilst the incremental cost-effectiveness ratio favoured honey when all costs were considered, the finding was reversed when a small number of hospitalised participants across both groups were excluded (<LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>). In terms of other secondary outcomes, no differences between groups were detected for incidence of ulcer infection (<LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>) or eradication of MRSA (<LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>).</P>
<P>In terms of silver-based preparations, no between-group differences in complete healing were detected when 1% silver sulphadiazine ointment was compared with standard care/placebo and tripeptide copper complex; or when different brands of silver-impregnated dressings were compared; or when silver-impregnated dressings were compared with non-antimicrobial dressings. When estimates of time to healing were available, these also did not indicate a difference between groups (<LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>). However, some shorter-term reports of surrogate healing outcomes (change in ulcer area at four weeks) favoured silver-impregnated dressings. The overall evidence suggested no difference between silver-impregnated dressings and non-antimicrobial dressings for incidence of adverse events, ulcer recurrence and changes in health-related quality of life. One RCT, at overall low risk of bias, included a rigorously conducted cost-effectiveness analysis and concluded that silver-impregnated dressings were unlikely to be cost-effective (<LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>).</P>
<P>In terms of other topical antibiotics, data from one RCT suggested that more participants healed at four weeks when treated with a non-antibiotic enzymatic cleanser compared with a chloramphenicol-containing ointment (additional active ingredients were included in the ointment): RR 0.13 (95% CI 0.02 to 0.99) (<LINK REF="CMP-023.01" TYPE="ANALYSIS">Analysis 23.1</LINK>) (<LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>). No between-group differences were detected in complete healing for the following comparisons: framycetin sulphate&#8211;containing ointment versus enzymatic cleanser; chloramphenicol-containing ointment versus framycetin sulphate&#8211;containing ointment; mupirocin ointment versus vehicle; and topical antibiotics given according to antibiogram versus an herbal ointment. In terms of secondary outcomes, no between-group differences were detected for adverse events (chloramphenicol versus framycetin versus enzymatic cleanser - three-arm RCT); bacterial eradication (mupirocin versus vehicle); or changes in bacterial flora (various topical antibiotics versus herbal ointment).</P>
<P>Two RCTs evaluated topical antiseptics (<LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>; <LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>). A large German study (N = 253) found that ethacridine lotion was better than placebo in achieving greater than 20% ulcer area reduction at 28 days. Although the sample size is larger than many of the other included trials, the period of follow-up is too short for exploration of clinically meaningful outcomes (i.e. frequency of complete healing or time to complete healing), and the validity of this intermediate variable is unknown. Secondary outcomes reported for the same trial indicated that whilst no difference was noted between groups for adverse events, patient satisfaction with treatment was better for ethacridine (<LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>). No between-group difference was detected between chlorhexidine solution and usual care in terms of time to healing (<LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>).</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-12-15 18:50:31 +0000" MODIFIED_BY="[Empty name]">
<P>The role of systemic and topical antibiotics and topical antiseptics in managing venous leg ulcers remains poorly understood. Evidence suggests that these agents are widely used to manage chronic wounds, regardless of whether ulcers are clinically infected at the outset of treatment (<LINK REF="REF-Lorimer-2003b" TYPE="REFERENCE">Lorimer 2003b</LINK>; <LINK REF="STD-Howell_x002d_Jones-2005" TYPE="STUDY">Howell-Jones 2005</LINK>; <LINK REF="REF-_x00d6_ien-2013" TYPE="REFERENCE">Öien 2013</LINK>). Clinical and prescribing guidelines state that antimicrobial therapy should only used in cases of confirmed clinical infection (<LINK REF="REF-AAWC-2010" TYPE="REFERENCE">AAWC 2010</LINK>; <LINK REF="REF-SIGN-2010" TYPE="REFERENCE">SIGN 2010</LINK>; <LINK REF="REF-BNF-2013" TYPE="REFERENCE">BNF 2013</LINK>). There was considerable variation across included RCTs in reporting of baseline ulcer infection status. Of 45 RCTs included, only three provided clear statements that all included participants had clinically infected ulcers at the start of treatment (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Daroczy-2006" TYPE="STUDY">Daroczy 2006</LINK>; <LINK REF="STD-Dimakakos-2009" TYPE="STUDY">Dimakakos 2009</LINK>). Information provided in another eight trials suggested that participants with ulcer infection would have been eligible for inclusion, but in each case the proportion with clinical infection was not described (<LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Harcup-1986" TYPE="STUDY">Harcup 1986</LINK>; <LINK REF="STD-Lindsay-1986" TYPE="STUDY">Lindsay 1986</LINK>; <LINK REF="STD-Steele-1986" TYPE="STUDY">Steele 1986</LINK>; <LINK REF="STD-Laudanska-1988" TYPE="STUDY">Laudanska 1988</LINK>; <LINK REF="STD-Holloway-1989" TYPE="STUDY">Holloway 1989</LINK>; <LINK REF="STD-Ishibashi-1996" TYPE="STUDY">Ishibashi 1996</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>). A further four RCTs (all evaluating silver-impregnated dressings) stipulated that participants had to present with signs of critical colonisation in order to be included (<LINK REF="STD-J_x00f8_rgensen-2005" TYPE="STUDY">Jørgensen 2005</LINK>; <LINK REF="STD-Meaume-2005" TYPE="STUDY">Meaume 2005</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>; <LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>). Signs and symptoms of critical colonisation have been proposed as an alternative to the classic signs and symptoms of wound infection for assessing infection in chronic wounds (<LINK REF="REF-Gardner-2001" TYPE="REFERENCE">Gardner 2001</LINK>; <LINK REF="REF-Cutting-2004" TYPE="REFERENCE">Cutting 2004</LINK>). Only two RCTs mentioned assessing resolution of relevant signs and symptoms as an outcome variable, and neither provided full details (<LINK REF="STD-Ormiston-1985" TYPE="STUDY">Ormiston 1985</LINK>; <LINK REF="STD-Lazareth-2008" TYPE="STUDY">Lazareth 2008</LINK>).</P>
<P>A further 13 included RCTs either excluded participants with clinically infected ulcers or treated existing infections prior to randomisation (<LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>; <LINK REF="STD-Hansson-1998" TYPE="STUDY">Hansson 1998</LINK>; <LINK REF="STD-Smith-1992" TYPE="STUDY">Smith 1992</LINK>; <LINK REF="STD-Casoni-2002" TYPE="STUDY">Casoni 2002</LINK>; <LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK>; <LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK>; <LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>; <LINK REF="STD-Belcaro-2003" TYPE="STUDY">Belcaro 2003</LINK>; <LINK REF="STD-Belcaro-2007" TYPE="STUDY">Belcaro 2007</LINK>; <LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Bini_x0107_-2010" TYPE="STUDY">Bini&#263; 2010</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>). The remaining RCTs provided either no details, or unclear information about participants' baseline ulcer infection status (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>; <LINK REF="STD-Groenewald-1981" TYPE="STUDY">Groenewald 1981</LINK>; <LINK REF="STD-Fischer-1984" TYPE="STUDY">Fischer 1984</LINK>; <LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>; <LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>; <LINK REF="STD-Kero-1987" TYPE="STUDY">Kero 1987</LINK>; <LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>; <LINK REF="STD-Blair-1988" TYPE="STUDY">Blair 1988</LINK>; <LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>; <LINK REF="STD-Cameron-1991" TYPE="STUDY">Cameron 1991</LINK>; <LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK> ;<LINK REF="STD-Bishop-1992" TYPE="STUDY">Bishop 1992</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>; <LINK REF="STD-Chaloner-2004" TYPE="STUDY">Chaloner 2004</LINK>; <LINK REF="STD-Geske-2005" TYPE="STUDY">Geske 2005</LINK>; <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>; <LINK REF="STD-Kuznetsov-2009" TYPE="STUDY">Kuznetsov 2009</LINK>).</P>
<P>There is widespread global concern with regard to the development of antibiotic resistance, and the misuse of both systemic and topical agents (<LINK REF="REF-Bisht-2009" TYPE="REFERENCE">Bisht 2009</LINK>; <LINK REF="REF-Boucher-2009" TYPE="REFERENCE">Boucher 2009</LINK>; <LINK REF="REF-Lazarus-2011" TYPE="REFERENCE">Lazarus 2011</LINK>). Prescribing guidelines in the UK state that such agents should not be used with chronic wounds, such as leg ulcers, except in cases of demonstrable clinical infection, and that their prescription for bacterial colonisation is inappropriate (<LINK REF="REF-BNF-2013" TYPE="REFERENCE">BNF 2013</LINK>). In this review, data from two trials suggested that the emergence of antibiotic-resistant strains of bacteria occurred more often in groups receiving systemic antibiotics (ciprofloxacin) when compared with standard care or placebo (<LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). However, no difference was noted when trimethoprim was compared with placebo, or when ciprofloxacin was compared with trimethoprim, in a small, single RCT (<LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>).</P>
<P>The relationship between ulcer infection and wound healing is unclear. Two RCTs of systemic antibiotics included subgroup analyses to assess the impact of wound infection or bacterial colonisation on healing (<LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>). For bacterial colonisation, one study showed a statistically significant association between positive post-treatment wound cultures and lower healing rates (<LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>), whilst the other suggested that bacterial contamination of ulcers with <I>Staphylococcus aureus</I> did not appear to delay healing (<LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>). In addition, three RCTs assessing cadexomer iodine provided an assessment of the association between bacterial colonisation and healing (<LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK>; <LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK>; <LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>). One RCT reported no difference in healing rates between silver-impregnated dressing and cadexomer iodine when bacterial growth during the first two weeks of the trial (assessed by wound swab) was classified as moderate or heavy. However, when bacterial growth was classified as nil, scant or low, those receiving silver had a significantly faster healing rate compared with those allocated cadexomer iodine in relation to leucocytes (P value &lt; 0.01), Gram-positive bacilli (P value &lt; 0.05), Gram-positive cocci (P value &lt; 0.01) and Gram-negative cocci (P value &lt; 0.05) (<LINK REF="STD-Miller-2010" TYPE="STUDY">Miller 2010</LINK>). <LINK REF="STD-Moss-1987" TYPE="STUDY">Moss 1987</LINK> reported that eradication of <I>Pseudomonas</I> species was significantly associated with a greater reduction in mean ulcer size in both treatment groups (cadexomer iodine and dextranomer) (P value &lt; 0.05); and <LINK REF="STD-Skog-1983" TYPE="STUDY">Skog 1983</LINK> reported a statistically significant association between eradication of <I>Staphylococcus aureus</I> and a faster healing rate (P value &lt; 0.002). It should be noted that the numbers used for analysis in most of these cases were small, and therefore these findings should be interpreted with caution.</P>
<P>In summary, the sparse evidence from RCTs recruiting participants with infected wounds, the variation in outcome assessment and the lack of clarity concerning the prognostic ability of wound infection in relation to healing, means that it is difficult to interpret the effects of antibiotics and antiseptics on both healing and infection.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-12-03 11:42:03 +0000" MODIFIED_BY="[Empty name]">
<P>The methods of this review have now been updated to assign each included RCT an overall rating of risk of bias. Three RCTs had a low risk of bias overall (<LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>; <LINK REF="STD-Michaels-2009" TYPE="STUDY">Michaels 2009</LINK>; <LINK REF="STD-Kerihuel-2010" TYPE="STUDY">Kerihuel 2010</LINK>). Of the remainder, 12 were at high risk of bias, and 27 were unclear. All five RCTs evaluating systemic antibiotics had an unclear risk of bias (<LINK REF="STD-Morias-1979" TYPE="STUDY">Morias 1979</LINK>; <LINK REF="STD-Alinovi-1986" TYPE="STUDY">Alinovi 1986</LINK>; <LINK REF="STD-Valtonen-1989" TYPE="STUDY">Valtonen 1989</LINK>; <LINK REF="STD-Huovinen-1994" TYPE="STUDY">Huovinen 1994</LINK>; <LINK REF="STD-Daroczy-2006" TYPE="STUDY">Daroczy 2006</LINK>). Many RCTS were small and there were not many opportunities for pooling data because of clinical heterogeneity across trials. Whislt most RCTs reported complete healing during the trial period, the most meaningful outcome, time to healing (with appropriate methods of estimation) was conducted in few trials and we were unable to plot, or consider pooling, hazard ratio estimates. We were also unable to carry out our planned sub-group analyses and so were unable to explore differential treatment effect in: participants with, on average, larger or smaller ulcers at baseline; those with and without ulcer infection or colonisation at baseline; and those using different levels of compression as a concurrent therapy. These factors, together with short follow-up periods (mainly four to 12 weeks), hinder interpretation of much of the available evidence.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-12-01 16:28:34 +0000" MODIFIED_BY="[Empty name]">
<P>We were not able to generate funnel plots as planned because of the small number of RCTs in each meta-analysis. Although the search strategy was comprehensive, the effect of publication bias cannot be discounted. However, given the poor quality of most of the published evidence and the absence of treatment effects in the majority of published studies, it may be the case that inclusion of unpublished data would not add further useful information to this body of evidence.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-12-06 13:28:44 +0000" MODIFIED_BY="[Empty name]">
<P>Several systematic reviews evaluating antimicrobial interventions used in patients with venous leg ulcers have been published during the last 10 years (<LINK REF="REF-Chambers-2007" TYPE="REFERENCE">Chambers 2007</LINK>; <LINK REF="REF-Vermeulen-2007" TYPE="REFERENCE">Vermeulen 2007</LINK>; <LINK REF="REF-Lo-2009" TYPE="REFERENCE">Lo 2009</LINK>; <LINK REF="REF-Carter-2010" TYPE="REFERENCE">Carter 2010</LINK>; <LINK REF="REF-Jull-2013" TYPE="REFERENCE">Jull 2013</LINK>). Four of these reviews focused on silver-based products (<LINK REF="REF-Chambers-2007" TYPE="REFERENCE">Chambers 2007</LINK>; <LINK REF="REF-Vermeulen-2007" TYPE="REFERENCE">Vermeulen 2007</LINK>; <LINK REF="REF-Lo-2009" TYPE="REFERENCE">Lo 2009</LINK>; <LINK REF="REF-Carter-2010" TYPE="REFERENCE">Carter 2010</LINK>). One concluded that the evidence was too limited to derive firm conclusions (<LINK REF="REF-Chambers-2007" TYPE="REFERENCE">Chambers 2007</LINK>). Another noted similar findings to our review, namely that although there was some evidence in favour of silver when shorter-term, surrogate measures of healing were considered, benefits were not maintained in terms of complete healing in the longer term (<LINK REF="REF-Carter-2010" TYPE="REFERENCE">Carter 2010</LINK>). A third review reported benefit of silver in relation to several outcomes (healing, reduced odour, pain, reduced exudate and dressing wear time), however, trials recruiting participants with a range of wound aetiologies were pooled, and so findings should be regarded with caution (<LINK REF="REF-Lo-2009" TYPE="REFERENCE">Lo 2009</LINK>). The fourth review only included RCTs of topical silver used with contaminated or infected acute or chronic wounds (including leg ulcers) and concluded that benefit of silver was not demonstrated (<LINK REF="REF-Vermeulen-2007" TYPE="REFERENCE">Vermeulen 2007</LINK>). These findings are broadly in agreement with our review. UK-based clinical guidelines for venous leg ulcers do not recommend the use of silver (<LINK REF="REF-SIGN-2010" TYPE="REFERENCE">SIGN 2010</LINK>), however, this is contrary to US guidelines, where use of silver is endorsed (<LINK REF="REF-AAWC-2010" TYPE="REFERENCE">AAWC 2010</LINK>). One systematic review of honey was identified (<LINK REF="REF-Jull-2013" TYPE="REFERENCE">Jull 2013</LINK>), which included the same two RCTs included in this review (<LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>; <LINK REF="STD-Jull-2008" TYPE="STUDY">Jull 2008</LINK>), and reached similar conclusions to us (i.e. that current evidence does not show a beneficial effect of honey-based products for venous leg ulcers). We were not able to identify recent systematic reviews focusing on participants with venous leg ulcers that evaluated systemic antibiotics, topical antibiotics, or antiseptics such as iodine- or peroxide-based products.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-12-06 13:29:45 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-12-03 14:19:59 +0000" MODIFIED_BY="[Empty name]">
<P>At present, the evidence does not support the routine use of systemic antibiotics to promote healing in venous leg ulcers. However, the lack of reliable evidence means that it is not possible to recommend the discontinuation of any of the agents reviewed. There was some evidence to suggest that systemic antibiotics were associated with emergence of antibiotic-resistant micro-organisms compared with non-antibiotic treatment. Few data were available on adverse effects. Levamisole (an oral antimicrobial product normally used to treat roundworm infection) was the only systemic agent where data showed a benefit in terms of healing. Levamisole is unlicensed in the UK, and is only available from 'special order' suppliers for use in treating roundworm infection (<LINK REF="REF-BNF-2013" TYPE="REFERENCE">BNF 2013</LINK>). It was withdrawn from the US market in 1999. In terms of topical preparations, some evidence supports the use of cadexomer iodine. However, cadexomer iodine is associated with more frequent adverse effects than standard care. Current evidence does not support the routine use of honey- and silver-based preparations. Further good quality research is required before definitive conclusions can be made about the effectiveness of systemic antibiotics and topical preparations such as povidone-iodine, peroxide-based preparations, chloramphenicol, framycetin sulphate, mupirocin, topical antibiotics given according to antibiogram, ethacridine lactate and chlorhexidine in healing venous leg ulceration. Honey-based products and silver-impregnated dressings may not be cost-effective; otherwise, there were few reliable data on cost-effectiveness. In light of the increasing problem of bacterial resistance to antibiotics, current prescribing guidelines recommend that antibacterial preparations should be used only in cases of clinical infection, not for bacterial colonisation (<LINK REF="REF-BNF-2013" TYPE="REFERENCE">BNF 2013</LINK>).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-12-06 13:29:45 +0000" MODIFIED_BY="[Empty name]">
<P>Most of the trials were small, and most of the evidence was of high or unclear risk of bias. Much of the research requires replication in larger, well-designed studies. Future research should pay attention to the following: clearly defined participant selection criteria, particularly with reference to baseline infection and colonisation of wounds, sample size with sufficient power to detect true treatment effects, use of true randomisation with allocation concealment, measures to help ensure comparability of treatment arms at baseline (e.g. stratification for ulcer size and ulcer duration), blinded outcome assessment, use of objective outcome measurement and appropriate methods for data analysis (e.g. complete healing rates and survival analysis using appropriate methods of estimation) and use of the intention-to-treat protocol. </P>
<P>Further research is required to clarify the relationship between healing and infection, colonisation, and critical colonisation of ulcers and to clarify these definitions in terms of chronic wounds. Attention should also be paid to the potential development of resistance to antimicrobial agents, and follow-up should include an assessment of this. The cost-effectiveness of both systemic and topical antimicrobials needs to be established, taking into account the patterns of healing and recurrence that can occur with chronic wounds.</P>
<P>Future studies should make inclusion and exclusion criteria clear with reference to infection and colonisation of wounds. In trials in which the presence of infection does not exclude patients, numbers of participants with and without the clinical signs of infection should be reported at baseline, and groups should be comparable for infection rates and types.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-12-16 15:21:55 +0000" MODIFIED_BY="Sue O'Meara">
<P>We are very grateful to the following peer referees who provided valuable feedback on drafts of the review: Anne-Marie Bagnall, Nicky Cullum and Carmel Hughes (initial review); Julie Bruce, Jane Burch and Zena Moore (this update); and Gill Worthy (both versions of the review). Thanks are also due to Kirsty Benn-Harris, Mario Cruciani, Pawel Kanturski, Angela Lai, Gero Langer, Jesús López Alcalde, Ichiro M. Omori, Elena Shek and Joanna Zakrzewska for assistance with translation; and to Dolores Matthews who copy edited this review update and to Elizabeth Royle for additional copy editing. Finally, we should like to thank the Cochrane Wounds Group - Ruth Foxlee for advising on the search strategy and running the database searches, Sally Bell-Syer for helpful advice and assistance with preparing the draft review and both updates, and Andrea Nelson for approving the final review prior to submission.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-12-02 14:22:05 +0000" MODIFIED_BY="[Empty name]">
<P>Susan O'Meara receives funding from the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research funding scheme (RP-PG-0407-10428). The views expressed in this review are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.</P>
<P>Liza G Ovington is an employee of Ethicon, USA. This company does not have any commercial products that are considered in this review.</P>
<P>Deyaa Al-Kurdi, Yemisi Ologun, Marrissa Martyn-St James, Rachel Richardson: none.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-12-16 15:32:01 +0000" MODIFIED_BY="[Empty name]">
<P>Susan O'Meara: drafted the protocol, initial review and both updates; screened studies for inclusion (initial review and both updates); checked data extraction and risk of bias assessment for all studies included in the initial review and both updates; analysed and interpreted data (initial review and both updates).<BR/>Deyaa Al-Kurdi: screened studies for inclusion; extracted data; undertook risk of bias assessment and analyses; drafted the review (all in relation to the initial review).<BR/>Yemisi Ologun: screened studies for inclusion and extracted data for included studies; undertook risk of bias assessment for all studies and contributed to the draft update (all in relation to the first update).<BR/>Liza G Ovington: commented on the protocol and review; screened studies for inclusion (all in relation to the initial review).<BR/>Marrissa Martyn-St James: screened studies for inclusion; extracted data; undertook assessment of risk of bias; analysed data; contributed to drafting the review (all in relation to the second update).<BR/>Rachel Richardson: screened studies for inclusion in the second update, commented on the text of this update and reviewed the peer referee feedback.<BR/>Susan O'Meara is the guarantor for the review.</P>
<SUBSECTION>
<HEADING LEVEL="5">Contribution of editorial base</HEADING>
<P>Nicky Cullum: advised, edited and approved the original review and the first update and approved them for submission.<BR/>Andrea Nelson, Editor: approved the second update for submission.<BR/>Sally Bell-Syer: coordinated the editorial process, advised, commented and edited all versions of the review.<BR/>Ruth Foxlee: designed and ran the searches for the review and the updates.</P>
</SUBSECTION>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-12-16 15:27:13 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-12-16 15:27:13 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-12-15 19:14:19 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alinovi-1986" MODIFIED="2013-12-03 16:45:59 +0000" MODIFIED_BY="[Empty name]" NAME="Alinovi 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-12-03 16:45:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Alinovi A, Bassissi P, Pini M, Talignani G</AU>
<TI>Systemic administration of antibiotics in the management of chronic venous ulcers</TI>
<SO>14th World Congress International Union of Angiology, 6-11 July 1986, Munich, West Germany</SO>
<YR>1986</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-02 14:50:24 +0000" MODIFIED_BY="Dolores Matthews" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alinovi A, Bassissi P, Pini M</AU>
<TI>Systemic administration of antibiotics in the management of venous ulcers: a randomized clinical trial</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1986</YR>
<VL>15</VL>
<NO>2</NO>
<PG>186-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beitner-1985a" MODIFIED="2013-11-28 16:53:04 +0000" MODIFIED_BY="[Empty name]" NAME="Beitner 1985a" YEAR="1985">
<REFERENCE MODIFIED="2013-11-28 16:53:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beitner H</AU>
<TI>Treatment of chronic leg ulcers with topical application of benzoyl peroxide lotion</TI>
<SO>Current Therapeutic Research</SO>
<YR>1985</YR>
<VL>38</VL>
<NO>4</NO>
<PG>657-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beitner-1985b" MODIFIED="2013-11-28 16:54:53 +0000" MODIFIED_BY="[Empty name]" NAME="Beitner 1985b" YEAR="">
<REFERENCE MODIFIED="2013-11-28 16:54:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beitner H</AU>
<TI>Treatment of chronic leg ulcers with topical application of benzoyl peroxide lotion</TI>
<SO>Current Therapeutic Research</SO>
<YR>1985</YR>
<VL>38</VL>
<NO>4</NO>
<PG>657-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belcaro-2003" MODIFIED="2013-12-02 14:51:19 +0000" MODIFIED_BY="Dolores Matthews" NAME="Belcaro 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-12-02 14:51:19 +0000" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belcaro G, Cesarone MR, Nicolaides AN, Geroulakos G, Di Renzo A, Milani M et al</AU>
<TI>Improvement of microcirculation and healing of venous hypertension and ulcers with Crystacide Evaluation of free radicals, laser Doppler flux and PO2: a prospective-randomized-controlled study</TI>
<SO>Angiology</SO>
<YR>2003</YR>
<VL>54</VL>
<NO>4</NO>
<PG>325-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belcaro-2007" MODIFIED="2013-12-02 14:51:38 +0000" MODIFIED_BY="Dolores Matthews" NAME="Belcaro 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-12-02 14:51:38 +0000" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belcaro G, Cesarone MR, Errichi BM, Di Renzo A, Errichi S, Ricci A et al</AU>
<TI>Improvement of microcirculation and healing of venous hypertension and ulcers with Crystacide: evaluation with a microcirculatory model, including free radicals, laser Doppler flux and PO2/PCO2 measurement</TI>
<SO>Angiology</SO>
<YR>2007</YR>
<VL>58</VL>
<NO>3</NO>
<PG>323-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bini_x0107_-2010" MODIFIED="2013-06-11 18:00:24 +0100" MODIFIED_BY="Marrissa Martyn-St James" NAME="Bini&#263; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-06-11 18:00:24 +0100" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bini&#263; I, Jankovi&#263; A, Jankovi&#263; D, Jankovi&#263; I, Vrucini&#263; Z</AU>
<TI>Evaluation of healing and antimicrobiological effects of herbal therapy on venous leg ulcer: pilot study</TI>
<SO>Phytotherapy Research</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>2</NO>
<PG>277-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bishop-1992" MODIFIED="2011-11-14 11:29:25 +0000" MODIFIED_BY="[Empty name]" NAME="Bishop 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-11-14 11:29:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE et al</AU>
<TI>A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1992</YR>
<VL>16</VL>
<NO>2</NO>
<PG>251-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blair-1988" MODIFIED="2013-06-11 18:03:31 +0100" MODIFIED_BY="[Empty name]" NAME="Blair 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-06-11 18:03:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blair SD, Backhouse CM, Wright DDI, Riddle E, McCollum CN</AU>
<TI>Do dressings influence the healing of chronic venous ulcers?</TI>
<SO>Phlebology</SO>
<YR>1988</YR>
<VL>3</VL>
<PG>129-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cameron-1991" MODIFIED="2013-12-03 18:06:04 +0000" MODIFIED_BY="[Empty name]" NAME="Cameron 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-12-03 18:05:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Cameron J, Cherry GW, Poewll S, Ryan TJ</AU>
<TI>The efficacy of mupirocin (pseudomonic acid) in the management of venous leg ulcers (poster presentation)</TI>
<SO>American Academy of Dermatology 50th Annual Meeting, 7-12 December 1991, Dallas, Texas, USA</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 18:06:04 +0000" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cherry GW, Powell SM, Ryan T</AU>
<TI>The efficacy of mupirocin in the management of venous leg ulcers</TI>
<SO>2nd European Conference on Advances in Wound Management, 20-23 October 1992, Harrogate</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Casoni-2002" MODIFIED="2013-12-03 18:06:36 +0000" MODIFIED_BY="Sue O'Meara" NAME="Casoni 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-12-03 18:06:36 +0000" MODIFIED_BY="Sue O'Meara" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Casoni P</AU>
<TI>Randomized trial using new topical colloids and bandages</TI>
<SO>16th Annual Congress of the American College of Phlebology, 7-10 November 2002, Fort Lauderdale, Florida</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Chaloner-2004" MODIFIED="2013-12-03 18:06:49 +0000" MODIFIED_BY="Marrissa Martyn-St James" NAME="Chaloner 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-12-03 18:06:49 +0000" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Chaloner D</AU>
<TI>A comparative study of two silver containing dressings, Acticoat 7 and Avance in the treatment of chronic venous ulcers</TI>
<SO>2nd World Union of Wound Healing Societies Meeting, 8-13 July 2004, Paris</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-11 18:07:21 +0100" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="OTHER">
<AU>Chaloner D</AU>
<TI>A prospective, multi-centre, randomised, comparative study to compare the effects of Acticoat 7 antimicrobial barrier dressing to Avance silver impregnated foam film dressing in the treatment of chronic venous leg ulcers</TI>
<SO>Unpublished report</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daroczy-2006" NAME="Daroczy 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daroczy J</AU>
<TI>Quality control in chronic wound management: the role of local povidone-iodine (Betadine) therapy</TI>
<SO>Dermatology</SO>
<YR>2006</YR>
<VL>212</VL>
<PG>82-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dimakakos-2009" MODIFIED="2013-06-11 18:09:04 +0100" MODIFIED_BY="[Empty name]" NAME="Dimakakos 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-06-11 18:09:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dimakakos E, Katsenis K, Kalemikerakis J, Arkadopoulos N, Mylonas S, Arapoglou V et al</AU>
<TI>Infected venous leg ulcers: management with silver-releasing foam dressing</TI>
<SO>Wounds: A Compendium of Clinical Research and Practice</SO>
<YR>2009</YR>
<VL>21</VL>
<NO>1</NO>
<PG>4-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fischer-1984" MODIFIED="2013-06-11 17:32:39 +0100" MODIFIED_BY="[Empty name]" NAME="Fischer 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-06-11 17:32:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fischer H, Gilliet F, Hornemann M, Leyh F, Lindemayr H, Stegmann W, et al</AU>
<TI>Enzymatic debridement in venous ulcus cruris. Report of a multicenter clinical comparative study with various enzyme preparations</TI>
<TO>Enzymatische wundreinigung beim venösen ulcus cruris. Beritch uber eine multizentrische klinische vergleichsstudie mit verschiedenen enzympräparaten</TO>
<SO>Fortschritte der Medizin</SO>
<YR>1984</YR>
<VL>102</VL>
<NO>10</NO>
<PG>281-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fumal-2002a" MODIFIED="2013-11-27 14:40:11 +0000" MODIFIED_BY="[Empty name]" NAME="Fumal 2002a" YEAR="2002">
<REFERENCE MODIFIED="2013-11-27 14:40:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fumal I, Braham C, Paquet P, Piérard-Franchimont C, Piérard GE</AU>
<TI>The beneficial toxicity paradox of antimicrobials in leg ulcer healing impaired by a polymicrobial flora: a proof-of-concept study</TI>
<SO>Dermatology</SO>
<YR>2002</YR>
<VL>204</VL>
<NO>Suppl 1</NO>
<PG>70-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fumal-2002b" MODIFIED="2013-11-27 14:42:55 +0000" MODIFIED_BY="[Empty name]" NAME="Fumal 2002b" YEAR="">
<REFERENCE MODIFIED="2013-11-27 14:42:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fumal I, Braham C, Paquet P, Piérard-Franchimont C, Piérard GE</AU>
<TI>The beneficial toxicity paradox of antimicrobials in leg ulcer healing impaired by a polymicrobial flora: a proof-of-concept study</TI>
<SO>Dermatology</SO>
<YR>2002</YR>
<VL>204</VL>
<NO>Suppl 1</NO>
<PG>70-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fumal-2002c" MODIFIED="2013-11-27 14:44:32 +0000" MODIFIED_BY="[Empty name]" NAME="Fumal 2002c" YEAR="">
<REFERENCE MODIFIED="2013-11-27 14:44:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fumal I, Braham C, Paquet P, Piérard-Franchimont C, Piérard GE</AU>
<TI>The beneficial toxicity paradox of antimicrobials in leg ulcer healing impaired by a polymicrobial flora: a proof-of-concept study</TI>
<SO>Dermatology</SO>
<YR>2002</YR>
<VL>204</VL>
<NO>Suppl 1</NO>
<PG>70-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geske-2005" MODIFIED="2013-12-02 14:53:11 +0000" MODIFIED_BY="Dolores Matthews" NAME="Geske 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-12-02 14:53:11 +0000" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geske T, Hachmann E, Effendy I</AU>
<TI>Wound treatment with ethacridine lactate in venous leg ulcers: a prospective, randomized, placebo-controlled, single-blind study</TI>
<SO>Vasomed</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>3</NO>
<PG>99-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gethin-2008" MODIFIED="2013-12-03 18:07:34 +0000" MODIFIED_BY="[Empty name]" NAME="Gethin 2008" YEAR="2009">
<REFERENCE MODIFIED="2013-05-14 11:49:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gethin G, Cowman S</AU>
<TI>Bacteriological changes in sloughy venous leg ulcers treated with manuka honey or hydrogel: an RCT</TI>
<SO>Journal of Wound Care</SO>
<YR>2008</YR>
<VL>17</VL>
<NO>6</NO>
<PG>241-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 18:07:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gethin G, Cowman S</AU>
<TI>Manuka honey versus hydrogel to deslough venous leg ulcers: a randomised controlled trial</TI>
<SO>17th Conference of the European Wound Management Association, 2007 May 2-4, Glasgow</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 18:07:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gethin G, Cowman S</AU>
<TI>Manuka honey versus hydrogel to deslough venous ulcers&#8212;a randomised controlled trial</TI>
<SO>3rd Congress of the World Union of Wound Healing Societies Meeting, 2008 June 4-8, Toronto</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 18:07:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gethin G, Cowman S</AU>
<TI>Manuka honey vs. hydrogel - a prospective, open label, multicentre, randomised controlled trial to compare desloughing efficacy and healing outcomes in venous ulcers</TI>
<SO>Journal of Clinical Nursing</SO>
<YR>2008</YR>
<VL>18</VL>
<NO>3</NO>
<PG>466-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groenewald-1981" NAME="Groenewald 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groenewald JH</AU>
<TI>An evaluation of dextranomer as a cleansing agent in the treatment of the post-phlebitic stasis ulcer</TI>
<SO>South African Medical Journal</SO>
<YR>1980</YR>
<VL>57</VL>
<NO>20</NO>
<PG>809-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Groenewald JH</AU>
<TI>The treatment of varicose stasis ulcers: a controlled trail</TI>
<SO>Schweizerische Rundschau fur Medizin Praxis</SO>
<YR>1981</YR>
<VL>70</VL>
<NO>28</NO>
<PG>1273-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansson-1998" MODIFIED="2013-12-03 18:04:18 +0000" MODIFIED_BY="[Empty name]" NAME="Hansson 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hansson C</AU>
<TI>The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing. Cadexomer Iodine Study Group</TI>
<SO>International Journal of Dermatology</SO>
<YR>1998</YR>
<VL>37</VL>
<NO>5</NO>
<PG>390-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 18:04:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Månsson T</AU>
<TI>Effect of Iodosorb dressing, Duoderm E and Jelonet on symptomatic parameters in exudative venous leg ulcers</TI>
<SO>5th European Conference on Advances in Wound Management, November 1995</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harcup-1986" MODIFIED="2013-12-02 14:55:06 +0000" MODIFIED_BY="Dolores Matthews" NAME="Harcup 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-12-02 14:55:06 +0000" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harcup JW, Saul PA</AU>
<TI>A study of the effect of Cadexomer iodine in the treatment of venous leg ulcers</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1986</YR>
<VL>40</VL>
<NO>9</NO>
<PG>360-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holloway-1989" NAME="Holloway 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holloway GA, Johansen KH, Barnes RW, Pierce GE</AU>
<TI>Multicenter trial of cadexomer iodine to treat venous stasis ulcer</TI>
<SO>Western Journal of Medicine</SO>
<YR>1989</YR>
<VL>151</VL>
<NO>1</NO>
<PG>35-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huovinen-1994" NAME="Huovinen 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huovinen S, Kotilainen P, Jarvinen H, Malanin K, Sarna S, Helander I et al</AU>
<TI>Comparison of ciprofloxacin or trimethoprim therapy for venous leg ulcers: results of a pilot study</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1994</YR>
<VL>31</VL>
<NO>2</NO>
<PG>279-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ishibashi-1996" MODIFIED="2013-12-02 14:55:28 +0000" MODIFIED_BY="[Empty name]" NAME="Ishibashi 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-12-02 14:55:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ishibashi Y, Soeda S, Oura T, Nishikawa T, Niimura M, Nakajima H et al</AU>
<TI>Clinical effects of KCB-1, a solution of recombinant human basic fibroblast growth factor, on skin ulcers: a phase III study comparing with sugar and povidone iodine ointment</TI>
<SO>Rinsho Iyaku</SO>
<YR>1996</YR>
<VL>12</VL>
<NO>10</NO>
<PG>2159-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jull-2008" MODIFIED="2013-12-03 18:08:30 +0000" MODIFIED_BY="[Empty name]" NAME="Jull 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-12-03 18:08:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jull A, Walker N, Parag V, Molan P, Arroll B, Waters J et al</AU>
<TI>Honey as adjuvant therapy for leg ulcers (HALT) trial: a randomized controlled trial (ISRCTN 06161544)</TI>
<SO>16th Conference of the European Wound Management Association, 2006 May 18-20, Prague, Czech Republic</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-11 18:21:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jull A, Walker N, Parag V, Molan P, Rodgers A on behalf of the Honey as Adjuvant Leg Ulcer Therapy trial collaborators</AU>
<TI>Randomized clinical trial of honey-impregnated dressings for venous leg ulcers</TI>
<SO>British Journal of Surgery</SO>
<YR>2008</YR>
<VL>95</VL>
<NO>2</NO>
<PG>175-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 18:08:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jull A, Walker N, Rodgers A, Bennett D, Molan P, Arroll B et al</AU>
<TI>Honey for leg ulcers&#8212;The HALT trial</TI>
<SO>2nd World Union of Wound Healing Societies Meeting, 2004 July 8-13, Paris</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-15 12:29:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK">
<AU>Jull A</AU>
<SO>Honey and venous leg ulceration: a systematic review &amp; randomised controlled trial. PhD thesis</SO>
<YR>2007</YR>
<PB>University of Aukland, New Zealand</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-J_x00f8_rgensen-2005" MODIFIED="2013-12-04 15:49:11 +0000" MODIFIED_BY="[Empty name]" NAME="Jørgensen 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-12-04 15:47:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ivins N, Harding KG, Price P, Jurgensen B, Lohmann M, Gottrup F et al</AU>
<TI>Safety and efficacy in long-term use of a sustained silver-releasing foam dressing: a randomized, controlled trial on venous leg ulcers</TI>
<SO>Symposium on Advanced Wound Care (SAWC) &amp; Medical Research Forum on Wound Repair, 2006 April 30 - May 3, San Antonio, Texas</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-04 15:47:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ivins N, Jørgensen B, Lohmann M, Harding KG, Price P, Gottrup F et al</AU>
<TI>Safety and efficacy in long term use of a sustained silver-releasing foam dressing: a randomised, controlled trial on venous leg ulcers</TI>
<SO>15th Conference of the European Wound Management Association, 2005 September 15-17, Stuttgart, Germany</SO>
<YR>2005</YR>
<PG>Poster abstracts P180 284</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-11 18:23:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jørgensen B, Price P,  Andersen KE, Gottrup F, Bech-Thomsen N, Scanlon E et al</AU>
<TI>The silver-releasing foam dressing, Contreet Foam, promotes faster healing of critically colonised venous leg ulcers: a randomised, controlled trial</TI>
<SO>International Wound Journal</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>1</NO>
<PG>64-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-04 15:48:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Price P, CONTREET Study Group</AU>
<TI>Health-related quality of life aspects after treatment with a foam dressing and a silver containing foam dressing in chronic leg ulcers</TI>
<SO>2nd World Union of Wound Healing Societies Meeting, 2004 July 8-13, Paris</SO>
<YR>2004</YR>
<PG>161</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-04 15:49:11 +0000" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sibbald RG, CONTREET Study Group</AU>
<TI>Wound bed preparation properties of a foam dressing and a silver containing foam dressing</TI>
<SO>2nd World Union of Wound Healing Societies Meeting, 2004 July 8-13, Paris</SO>
<YR>2004</YR>
<PG>35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kerihuel-2010" MODIFIED="2013-06-11 18:24:41 +0100" MODIFIED_BY="[Empty name]" NAME="Kerihuel 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-06-11 18:24:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kerihuel JC</AU>
<TI>Effect of activated charcoal dressings on healing outcomes of chronic wounds</TI>
<SO>Journal of Wound Care</SO>
<YR>2010</YR>
<VL>19</VL>
<NO>5</NO>
<PG>208-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kero-1987" MODIFIED="2011-06-28 14:27:47 +0100" MODIFIED_BY="Marrissa Martyn-St James" NAME="Kero 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-06-28 14:27:47 +0100" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kero M, Tarvainen K, Hollmen A, Pekanmaki K</AU>
<TI>A comparison of cadexomer iodine with dextranomer in the treatment of venous leg ulcers</TI>
<SO>Current Therapeutic Research</SO>
<YR>1987</YR>
<VL>42</VL>
<NO>5</NO>
<PG>761-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-17 15:31:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tarvainen K</AU>
<TI>Cadexomer iodine (Iodosorb) compared with dextranomer (Debrisan) in the treatment of chronic leg ulcers</TI>
<SO>Acta Chirurgica Scandinavica (Supplementum)</SO>
<YR>1988</YR>
<VL>544</VL>
<PG>57-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuznetsov-2009" MODIFIED="2013-05-16 15:38:43 +0100" MODIFIED_BY="Marrissa Martyn-St James" NAME="Kuznetsov 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-05-16 15:38:43 +0100" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuznetsov NA, Rodoman GV, Nikitin VG, Karev MA, Shalayeva TI</AU>
<TI>The use of current bandages in the treatment of patients with venous trophic ulcers of the skin: clinical and economic aspects</TI>
<SO>Khirurgiia</SO>
<YR>2009</YR>
<VL>11</VL>
<PG>63-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laudanska-1988" MODIFIED="2013-12-02 14:58:51 +0000" MODIFIED_BY="Dolores Matthews" NAME="Laudanska 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-12-02 14:58:51 +0000" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laudanska H, Gustavson B</AU>
<TI>In-patient treatment of chronic varicose venous ulcers: a randomized trial of cadexomer iodine versus standard dressings</TI>
<SO>Journal of International Medical Research</SO>
<YR>1988</YR>
<VL>16</VL>
<NO>6</NO>
<PG>428-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lazareth-2008" MODIFIED="2013-12-04 15:49:51 +0000" MODIFIED_BY="[Empty name]" NAME="Lazareth 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-12-04 15:49:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lazareth I, Meaume S, Sigal-Grinberg ML, Combemale P, Le Guyadec T, Zagnoli A, et al</AU>
<TI>The role of a silver releasing lipido-colloid contact layer in venous leg ulcers presenting inflammatory signs suggesting heavy bacterial colonization: results of a randomized controlled study</TI>
<SO>Wounds: A Compendium of Clinical Research and Practice</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>6</NO>
<PG>158-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-04 15:49:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sigal-Grinberg M, Senet P, Lazareth I, Sauvadet A, Bohbot S</AU>
<TI>Evaluation of a new contact layer impregnated with silver salts in the management of critically colonized venous leg ulcers. Results of a randomized clinical trial</TI>
<SO>17th Conference of the European Wound Management Association, 2007 May 2-4, Glasgow, Scotland</SO>
<YR>2007</YR>
<PG>31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindsay-1986" NAME="Lindsay 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindsay G, Latta D, Lyons KGB, Livingstone ED, Thomson W</AU>
<TI>A study in general practice of the efficacy of cadexomer iodine in venous leg ulcers treated on alternate days</TI>
<SO>Acta Therapeutica</SO>
<YR>1986</YR>
<VL>12</VL>
<PG>141-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meaume-2005" MODIFIED="2013-05-16 17:55:37 +0100" MODIFIED_BY="[Empty name]" NAME="Meaume 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-05-16 17:55:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meaume S, Vallet D, Morere MN, Téot L</AU>
<TI>Evaluation of a silver-releasing hydroalginate dressing in chronic wounds with signs of local infection</TI>
<TO>Evaluation einer silberionen-freisetzenden hydroalinat-wundauflage bei chronischen wunden mit anzeichen einer lokalen infektion</TO>
<SO>Zeitschrift fur Wundheilung</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>5</NO>
<PG>236-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-16 17:52:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meaume S, Vallet D, Morere MN, Téot L</AU>
<TI>Evaluation of a silver-releasing hydroalginate dressing in chronic wounds with signs of local infection</TI>
<SO>Journal of Wound Care</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>9</NO>
<PG>411-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michaels-2009" MODIFIED="2013-12-15 19:14:19 +0000" MODIFIED_BY="[Empty name]" NAME="Michaels 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-05-17 12:20:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Michaels JA, Campbell B, King B, Palfreyman SJ, Shackley P, Stevenson M</AU>
<TI>Randomized controlled trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers (VULCAN trial)</TI>
<SO>British Journal of Surgery</SO>
<YR>2009</YR>
<VL>96</VL>
<NO>10</NO>
<PG>1147-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-15 19:14:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michaels JA, Campbell WB, King BM, MacIntyre J, Palfreyman SJ, Shackley P et al</AU>
<TI>A prospective randomised controlled trial and economic modelling of antimicrobial silver dressings versus non-adherent control dressings for venous leg ulcers: the VULCAN trial</TI>
<SO>Health Technology Assessment</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>56</NO>
<PG>1-138</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-17 12:29:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palfreyman S, King B, Turner B, Sears N, Carmody SE, Michaels J</AU>
<TI>An update on the progress of the VULCAN trial</TI>
<SO>Wounds UK</SO>
<YR>2006</YR>
<VL>2</VL>
<NO>2</NO>
<PG>35-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-17 12:27:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palfreyman S, Walker N</AU>
<TI>Venous leg ulcers and the VULCAN trial</TI>
<SO>British Journal of Nursing</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>8</NO>
<PG>442-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-2010" MODIFIED="2013-12-04 15:50:33 +0000" MODIFIED_BY="[Empty name]" NAME="Miller 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-12-04 15:50:14 +0000" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Carville K, Kapp S, Newall N, Saflekas S, Lewin G, Gliddon T, et al</AU>
<TI>Predicting covert and overt infection in venous leg ulcers: a randomised controlled trial</TI>
<SO>Australian Wound Management Association 7th National Conference: Dreams, Diversity, Disasters, 2008 May 7-10, Darwin, Australia</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 18:10:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kapp S, Carville K, Saflekas S, Newall N, Lewin G, Flowers C et al</AU>
<TI>The Angior initiative: results of a randomised controlled trial comparing the effectiveness of two antimicrobials</TI>
<SO>3rd Congress of the World Union of Wound Healing Societies Meeting, 2008 June 4-8, Toronto, Canada</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-04 15:50:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kapp S, Carville K, Saflekas S, Newall N, Lewin G, Flowers C, et al</AU>
<TI>The Angior Initiative: results of a randomised controlled trial comparing the effectiveness of two antimicrobials</TI>
<SO>Australian Wound Management Association 7th National Conference: Dreams, Diversity, Disasters, 2008 May 7-10, Darwin, Australia</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-04 15:50:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller C, Kapp S, Newall N, Lewin G, Karimi L, Carville K, et al</AU>
<TI>Predicting concordance with multilayer compression bandaging</TI>
<SO>Journal of Wound Care</SO>
<YR>2011</YR>
<VL>20</VL>
<NO>2</NO>
<PG>101-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-04 15:50:25 +0000" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller C, Karimi L, Kapp S, Newall N, Lewin G, Carville K, et al</AU>
<TI>Client perceptions of two types of antimicrobial dressings and compression bandaging</TI>
<SO>Wound Practice and Research</SO>
<YR>2010</YR>
<VL>18</VL>
<NO>3</NO>
<PG>124-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-04 15:50:29 +0000" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller CN, Carville K, Newall N, Kapp S, Lewin G, Karimi L, et al</AU>
<TI>Assessing bacterial burden in wounds: comparing clinical observation and wound swabs</TI>
<SO>International Wound Journal</SO>
<YR>2011</YR>
<VL>8</VL>
<NO>1</NO>
<PG>45-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-04 15:50:33 +0000" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Miller CN, Newall N, Kapp SE, Lewin G, Karimi L, Carville K, et al</AU>
<TI>A randomized-controlled trial comparing cadexomer iodine and nanocrystalline silver on the healing of leg ulcers</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2010</YR>
<VL>18</VL>
<NO>4</NO>
<PG>359-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morias-1979" NAME="Morias 1979" YEAR="1979">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Morias J, Peremans W, Campaert H, Mertens RL</AU>
<TI>Levamisole treatment in ulcus cruris. A double-blind placebo-controlled</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1979</YR>
<VL>29</VL>
<NO>7</NO>
<PG>1050-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moss-1987" NAME="Moss 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moss C, Taylor A, Shuster S</AU>
<TI>Controlled trial of Iodosorb in chronic venous ulcers</TI>
<SO>BMJ</SO>
<YR>1985</YR>
<VL>297</VL>
<NO>6499</NO>
<PG>902</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moss C, Taylor AEM, Shuster S</AU>
<TI>Comparison of cadexomer iodine and dextranomer for chronic venous ulcers</TI>
<SO>Clinical and Experimental Dermatology</SO>
<YR>1987</YR>
<VL>12</VL>
<NO>6</NO>
<PG>413-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moss C, Taylow A, Shuster S</AU>
<TI>Comparative study of cadexomer iodine and dextranomer in chronic leg ulcers</TI>
<SO>Scottish Medical Journal</SO>
<YR>1984</YR>
<VL>25</VL>
<PG>54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00fc_nter-2006" MODIFIED="2013-12-04 15:52:34 +0000" MODIFIED_BY="[Empty name]" NAME="Münter 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-12-04 15:51:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Münter K-C, Beele H, Russell L, Basse PB, Groechenig E, Crespi A, et al</AU>
<TI>The CONTOP Study: a large-scale, comparative, randomised study in patients treated with a sustained silver-releasing foam dressing</TI>
<SO>European Wound Management Association Conference, 2005 September 15-17, Stuttgart, Germany</SO>
<YR>2005</YR>
<PG>Poster abstracts P193 292</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-04 15:52:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Münter KC, Beele H, Russell L, Basse PB , Groechenig E, Crespi A, et al</AU>
<TI>The CONTOP Study: a large-scale, comparative, randomized study in patients treated with a sustained silver-releasing foam dressing</TI>
<SO>Symposium on Advanced Wound Care &amp; Medical Research Forum on Wound Repair, 2006 April 30 - May 3, San Antonio, Texas</SO>
<YR>2006</YR>
<PG>Poster 11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-04 15:52:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Münter KC, Beele H, Russell L, Basse PB, Gröchenig E, Crespi A, et al</AU>
<TI>The CONTOP Study: improved healing of delayed healing ulcers with sustained silver-releasing foam dressing versus other silver dressings</TI>
<SO>16th Conference of the European Wound Management Association, 2006 May 18-20, Prague, Czech Republic</SO>
<YR>2006</YR>
<PG>210, Abstract No.P068</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-12 17:26:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Münter KC, Beele H,  Russell L, Crespi A, Gröchenig E, Basse P et al</AU>
<TI>Effect of a sustained silver-releasing dressing on ulcers with delayed healing: the CONTOP study</TI>
<SO>Journal of Wound Care</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>5</NO>
<PG>199-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-20 12:27:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russell L (on behalf of the UK investigators)</AU>
<TI>The CONTOP multinational study: preliminary data from the UK arm</TI>
<SO>Wounds UK</SO>
<YR>2005</YR>
<VL>1</VL>
<NO>1</NO>
<PG>44-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 18:10:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Russell L, Nebbioso G, Münter KC, Beele H, Basse PB, Dienst H</AU>
<TI>The CONTOP Study: a hydro-activated silver containing foam dressing versus standard care</TI>
<SO>2nd World Union of Wound Healing Societies Meeting, 2004 July 8-13, Paris, France</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 18:10:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Scalise A, Forma O, Happe M, Hahn TW</AU>
<TI>The CONTOP study: real life experiences from an international study comparing a silver containing hydro-activated foam dressing with standard wound care</TI>
<SO>13th Conference of the European Wound Management Association, 2003 May 22-24, Pisa, Italy</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ormiston-1985" NAME="Ormiston 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Ormiston MC, Seymour MT, Venn GE, Cohen RI, Fox JA</AU>
<TI>A randomised comparison of cadexomer iodine and a standard treatment in out-patients with chronic venous ulcers</TI>
<SO>Cadexomer Iodine</SO>
<YR>1983</YR>
<PG>63-9</PG>
<PB>Schattauer Verlag</PB>
<CY>Stuttgart</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ormiston MC, Seymour MT, Venn GE, Cohen RI, Fox JA</AU>
<TI>Controlled trial of Iodosorb in chronic venous ulcers</TI>
<SO>BMJ</SO>
<YR>1985</YR>
<VL>291</VL>
<NO>6491</NO>
<PG>308-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skog-1983" MODIFIED="2013-05-22 12:11:52 +0100" MODIFIED_BY="[Empty name]" NAME="Skog 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hillstrom L</AU>
<TI>Iodosorb compared to standard treatment in chronic venous leg ulcers--a multicenter study</TI>
<SO>Acta Chirurgica Scandinavica - Supplementum</SO>
<YR>1988</YR>
<VL>544</VL>
<PG>53-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-17 15:32:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Skog E, Arnesjö B, Troëng T, Gjöres JE, Bergljung L, Gundersen J et al</AU>
<TI>A randomized trial comparing cadexomer iodine and standard treatment in the out-patient management of chronic venous ulcers</TI>
<SO>British Journal of Dermatology</SO>
<YR>1983</YR>
<VL>109</VL>
<NO>1</NO>
<PG>77-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-22 12:11:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Troëng T, Skog E, Arnesjö B, Gjöres JE, Bergljung L, Gundersen J et al</AU>
<TI>A randomised multicentre trial to compare the efficacy of cadexomer iodine and standard treatment in the management of chronic venous ulcers in out-patients</TI>
<SO>Unpublished report</SO>
<PG>43-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1992" NAME="Smith 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith JM, Dore CJ, Charlett A, Lewis JD</AU>
<TI>A randomized trial of biofilm dressing for venous leg ulcers</TI>
<SO>Phlebology</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>3</NO>
<PG>108-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steele-1986" NAME="Steele 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Steele K, Irwin G, Dowds N</AU>
<TI>Cadexomer iodine in the management of venous leg ulcers in general practice</TI>
<SO>The Practitioner</SO>
<YR>1986</YR>
<VL>230</VL>
<NO>1411</NO>
<PG>63-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valtonen-1989" NAME="Valtonen 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valtonen V, Karppinen L, Kariniemi AL</AU>
<TI>A comparative study of Ciprofloxacin and conventional therapy in the treatment of patients with chronic lower leg ulcers infected with Pseudomonas aeruginosa or other gram-negative rods</TI>
<SO>Scandinavian Journal of Infectious Diseases Supplement</SO>
<YR>1989</YR>
<VL>60</VL>
<PG>79-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wunderlich-1991" MODIFIED="2013-05-20 15:28:39 +0100" MODIFIED_BY="[Empty name]" NAME="Wunderlich 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-05-20 15:28:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wunderlich U, Orfanos CE</AU>
<TI>Treatment of venous ulcera cruris with dry wound dressings. Phase overlapping use of silver impregnated activated charcoal xero-dressing</TI>
<TO>Bedhandlung der ulcera cruris venosa mit trockenen wundauflagen. Phasenübergreifende anwendung eines silber-imprägnierten aktivkohle-xerodressings</TO>
<SO>Der Hautarzt</SO>
<YR>1991</YR>
<VL>42</VL>
<NO>7</NO>
<PG>446-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-12-16 15:27:13 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-1980" MODIFIED="2013-06-24 16:25:07 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-06-24 16:23:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen S, Cooper J</AU>
<TI>The effect of an antibacterial on pain ulcerated legs</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1980</YR>
<VL>10</VL>
<PG>284-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-1996" MODIFIED="2013-12-03 18:11:39 +0000" MODIFIED_BY="[Empty name]" NAME="Allen 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-12-03 18:11:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Allen RB, Kerstein M, Klassen H, Friedmann PS, Pryce DW, Lawrence JC et al</AU>
<TI>Prospective study of clinical infections in wounds dressed with occlusive versus conventional dressings</TI>
<SO>9th Annual Symposium on Advanced Wound Care and 6th Annual Medical Research Forum on Wound Repair, 20-24 April 1996, Atlanta, Georgia, USA</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 18:11:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hermans M</AU>
<TI>A prospective clinical trial of wound dressings to investigate the rate of infection under occlusion</TI>
<SO>First World Wound Healing Congress, 10-13 September 2000, Melbourne, Australia</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Altman-1976" NAME="Altman 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altman MA, Richter IH, Kaplan LH</AU>
<TI>Use of an aqueous triple iodine solution in the treatment of chronic leg ulcers and gangrene</TI>
<SO>Angiology</SO>
<YR>1976</YR>
<VL>76</VL>
<NO>27</NO>
<PG>181-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1982" MODIFIED="2013-05-22 18:16:06 +0100" MODIFIED_BY="[Empty name]" NAME="Anonymous 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-05-22 18:16:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Does metronidazole help leg ulcers and pressure sores?</TI>
<SO>Drug and Therapeutics Bulletin</SO>
<YR>1982</YR>
<VL>20</VL>
<NO>3</NO>
<PG>9-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bazzigaluppi-1991" MODIFIED="2013-12-02 15:02:13 +0000" MODIFIED_BY="Dolores Matthews" NAME="Bazzigaluppi 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-12-02 15:02:13 +0000" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bazzigaluppi F, Biraghi MG, Fano M, Moschin AM, Toscani P, Cervone C et al</AU>
<TI>Cadexomer iodine in the treatment of cutaneous ulcers: open, multicentric trial</TI>
<SO>Gazetta Medica Italiana - Archivo per le Scienze Mediche</SO>
<YR>1991</YR>
<VL>150</VL>
<NO>11</NO>
<PG>471-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beele-2010" MODIFIED="2013-05-22 16:25:43 +0100" MODIFIED_BY="[Empty name]" NAME="Beele 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-05-22 16:25:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beele H, Meuleneire F, Nahuys M, Percival SL</AU>
<TI>A prospective randomised open label study to evaluate the potential of a new silver alginate/carboxymethylcellulose antimicrobial wound dressing to promote wound healing</TI>
<SO>International Wound Journal</SO>
<YR>2010</YR>
<VL>7</VL>
<NO>4</NO>
<PG>262-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beitner-1985c" MODIFIED="2013-11-28 16:56:46 +0000" MODIFIED_BY="[Empty name]" NAME="Beitner 1985c" YEAR="">
<REFERENCE MODIFIED="2013-11-28 16:56:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beitner H</AU>
<TI>Treatment of chronic leg ulcers with topical application of benzoyl peroxide lotion</TI>
<SO>Current Therapeutic Research</SO>
<YR>1985</YR>
<VL>38</VL>
<NO>4</NO>
<PG>657-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bender-1982" MODIFIED="2013-05-22 16:29:57 +0100" MODIFIED_BY="Marrissa Martyn-St James" NAME="Bender 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-05-22 16:29:57 +0100" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bender E</AU>
<TI>Local treatment of leg ulcers with silver sulfadiazine in ambulatory practice</TI>
<TO>Die lokale behandlung von unterschenkelgeschwüren mit sulfadiazin-silber in der ambulanten praxis</TO>
<SO>Fortschritte der Medizin</SO>
<YR>1982</YR>
<VL>100</VL>
<NO>29</NO>
<PG>1372-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bourgeois-1963" MODIFIED="2013-12-02 15:02:28 +0000" MODIFIED_BY="Dolores Matthews" NAME="Bourgeois 1963" YEAR="1963">
<REFERENCE MODIFIED="2013-12-02 15:02:28 +0000" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bourgeois P</AU>
<TI>Clinical trials of Kitasamycin</TI>
<SO>Gazette Medicale de France</SO>
<YR>1963</YR>
<VL>70</VL>
<PG>22-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brauman-2008" MODIFIED="2013-05-22 16:33:53 +0100" MODIFIED_BY="Marrissa Martyn-St James" NAME="Brauman 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-05-22 16:33:53 +0100" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braumann C, Pirlich M, Menenakos C, Lochs H, Mueller JM</AU>
<TI>Implementation of the clean and close concept for treatment of surgical and chronic wounds in three university centres in Berlin - Germany. Abstract number 44</TI>
<SO>EWMA Journal</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>2 Suppl</NO>
<PG>41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brzeziska-1990" MODIFIED="2013-06-12 17:33:53 +0100" MODIFIED_BY="[Empty name]" NAME="Brzeziska 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-06-12 17:33:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brzezi&#324;ska-Wcis&#322;o L, Krauze E, Suwa&#322;a-Jurczyk B</AU>
<TI>Levamisole in the treatment of crural ulcers</TI>
<TO>Levamisol w leczeniu owrzodzen podudzi</TO>
<SO>Przeglad Dermatologiczny</SO>
<YR>1990</YR>
<VL>77</VL>
<NO>1</NO>
<PG>51-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castellano-2007" MODIFIED="2013-12-04 15:56:42 +0000" MODIFIED_BY="[Empty name]" NAME="Castellano 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-12-04 15:56:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castellano JJ, Shafii SM, Ko F, Donate G, Wright TE, Mannari RJ et al</AU>
<TI>Comparative evaluation of silver-containing antimicrobial dressings and drugs</TI>
<SO>International Wound Journal</SO>
<YR>2007</YR>
<VL>4</VL>
<NO>2</NO>
<PG>114-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaparro-2003" MODIFIED="2013-06-12 17:35:36 +0100" MODIFIED_BY="[Empty name]" NAME="Chaparro 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-06-12 17:35:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaparro M, Alvarez de los Heros F, Novo E, Rodriguez-Alvarez J, Stolle D, Losada A</AU>
<TI>Effectiveness of topical treatment of chronic varicose ulcers with sterile single-dose ciprofloxacin ampoules versus physiologic serum</TI>
<SO>Revista Espanola de Geriatria y Gerontologia</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>3</NO>
<PG>145-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaudhary-2008" MODIFIED="2013-05-22 16:35:44 +0100" MODIFIED_BY="Marrissa Martyn-St James" NAME="Chaudhary 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-05-22 16:35:44 +0100" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaudhary M, Kumar Dwivedi V, Naithani V</AU>
<TI>Clinical trial survey report of ampucare done on patients with different wounds</TI>
<SO>Journal of Ecophysiology and Occupational Health</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>1-2</NO>
<PG>89-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cherry-2003" MODIFIED="2011-11-08 16:27:00 +0000" MODIFIED_BY="Marrissa Martyn-St James" NAME="Cherry 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-11-08 16:27:00 +0000" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="OTHER">
<AU>Cherry GW</AU>
<TI>Comparison of Syerilox with tap water in the treatment of chronic venous ulcers of the leg</TI>
<SO>National Research Register</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chirwa-2010" MODIFIED="2013-06-04 12:50:55 +0100" MODIFIED_BY="[Empty name]" NAME="Chirwa 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-06-04 12:50:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chirwa Z, Bhengu T, Litiane K</AU>
<TI>The cost effectiveness of using calcium alginate silver matrix in the treatment of wounds</TI>
<SO>EWMA Journal</SO>
<YR>2010</YR>
<VL>10</VL>
<NO>2</NO>
<PG>257</PG>
<EN>2</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colombo-1993" MODIFIED="2013-09-06 13:20:57 +0100" MODIFIED_BY="[Empty name]" NAME="Colombo 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-09-06 13:20:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colombo P</AU>
<TI>Topical chloroxidating solution in wounds treatment: a controlled trial</TI>
<SO>Acta Toxicologica Therapeutica</SO>
<YR>1993</YR>
<VL>24</VL>
<PG>65-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colonna-2004" MODIFIED="2013-12-04 15:57:56 +0000" MODIFIED_BY="[Empty name]" NAME="Colonna 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-12-04 15:57:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Colonna MR, Amadeo G, Giofre C, Strano A, Stagno D'Alcontres F</AU>
<TI>Are nanocristalline silver dressings effective in reducing both secretions and bacterial colonization in necrotic infected wounds</TI>
<SO>2nd World Union of Wound Healing Societies Meeting, 8-13 July 2004, Paris</SO>
<YR>2004</YR>
<PG>91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Contretas_x002d_Ruiz-2004" MODIFIED="2013-12-04 15:58:18 +0000" MODIFIED_BY="[Empty name]" NAME="Contretas-Ruiz 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-12-04 15:58:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Contretas-Ruiz J, Fuentes-Suarez S, Arroyo-Escalante S, Sosa-De-Martinez C, Maravilla-Franco E, Dominguez-Cherit J</AU>
<TI>Larval debridement therapy to control infection in venous leg ulcers. A comparative study</TI>
<SO>2nd World Union of Wound Healing Societies Meeting, 8-13 July 2004, Paris</SO>
<YR>2004</YR>
<PG>103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coutts-2005" MODIFIED="2013-12-04 15:58:42 +0000" MODIFIED_BY="[Empty name]" NAME="Coutts 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-12-04 15:58:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coutts P, Sibbald RG</AU>
<TI>The effect of a silver-containing Hydrofibre<SUP>®</SUP> dressing on superficial wound bed and bacterial balance of chronic wounds</TI>
<SO>International Wound Journal</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>4</NO>
<PG>348-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daltrey-1981" NAME="Daltrey 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daltrey DC, Cunliffe WJ</AU>
<TI>A double-blind study of the effects of benzoyl peroxide 20% and eusol and liquid paraffin on the microbial flora of leg ulcers</TI>
<SO>Acta Dermatologica Venereologica</SO>
<YR>1981</YR>
<VL>61</VL>
<NO>6</NO>
<PG>575-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Danielsen-1997" MODIFIED="2013-10-14 07:19:27 +0100" MODIFIED_BY="Dolores Matthews" NAME="Danielsen 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-10-14 07:19:27 +0100" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Danielsen L, Cherry GW, Harding K, Rollman O</AU>
<TI>Cadexomer iodine in ulcers colonised by <I>Pseudomonas aeruginosa</I>
</TI>
<SO>Journal of Wound Care</SO>
<YR>1997</YR>
<VL>6</VL>
<NO>4</NO>
<PG>169-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dharap-2008" MODIFIED="2009-11-04 11:35:55 +0000" MODIFIED_BY="Sue O'Meara" NAME="Dharap 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-11-04 11:35:55 +0000" MODIFIED_BY="Sue O'Meara" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dharap SB, Ghag GS, Kulkarni KP, Venkatesh V</AU>
<TI>Efficacy and safety of oxum in treatment of the venous ulcer</TI>
<SO>Journal of the Indian Medical Association</SO>
<YR>2008</YR>
<VL>106</VL>
<NO>5</NO>
<PG>326-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferra-2007" MODIFIED="2009-09-17 15:42:40 +0100" MODIFIED_BY="[Empty name]" NAME="Ferra 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-09-17 15:42:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferrara F, Meli F, Raimondi F, Amato C, Bonura F, Mulè G</AU>
<TI>The treatment of venous leg ulcers, a new therapeutic use of iloprost</TI>
<SO>Annals of Surgery</SO>
<YR>2007</YR>
<VL>246</VL>
<NO>5</NO>
<PG>860-4</PG>
<IDENTIFIERS MODIFIED="2009-06-10 11:08:46 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-06-10 11:03:26 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fox-1966" NAME="Fox 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fox DB</AU>
<TI>Trial of betamethasone 17-valerate with neomycin tulle in the treatment of gravitational eczema and ulceration of the leg</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1966</YR>
<VL>20</VL>
<PG>183-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friedman-1984" MODIFIED="2009-09-17 15:42:54 +0100" MODIFIED_BY="[Empty name]" NAME="Friedman 1984" YEAR="1984">
<REFERENCE MODIFIED="2009-09-17 15:42:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friedman SJ, Su WP</AU>
<TI>Management of leg ulcers with hydrocolloid occlusive dressing</TI>
<SO>Archives of Dermatology</SO>
<YR>1984</YR>
<VL>120</VL>
<NO>10</NO>
<PG>1329-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia-1984" NAME="Garcia 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia HGG, Cobian RR, Martin JR, Konaizeh S, Rahola JG</AU>
<TI>The effect on the reparation process of dextranomer (Debrisan) in perimalleolar ulcers due to chronic venous insufficiency</TI>
<SO>Clinical Trials Journal</SO>
<YR>1984</YR>
<VL>21</VL>
<NO>3</NO>
<PG>121-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gottrup-2003" MODIFIED="2013-12-03 18:12:22 +0000" MODIFIED_BY="[Empty name]" NAME="Gottrup 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-12-03 18:12:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gottrup F, Aabenhus A, Holt R and the Contreet Study Group</AU>
<TI>Evaluation of clinical results from 4 studies on two new antibacterial silver containing dressings</TI>
<SO>13th Conference of the European Wound Management Association, 22-24 May 2003, Pisa, Italy</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haler-1964" MODIFIED="2013-12-04 15:59:12 +0000" MODIFIED_BY="[Empty name]" NAME="Haler 1964" YEAR="1964">
<REFERENCE MODIFIED="2013-12-04 15:59:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haler D</AU>
<TI>Polynoxylin: a new antiseptic</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1964</YR>
<VL>May 18</VL>
<PG>267-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanft-2006" MODIFIED="2013-12-04 15:53:42 +0000" MODIFIED_BY="[Empty name]" NAME="Hanft 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-12-04 15:53:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hanft J, Serena T, Snyder R</AU>
<TI>Evaluation of the clinical effectiveness of a collagen-orc antimicrobial matrix in venous leg ulcers</TI>
<SO>16th Conference of the European Wound Management Association, 18-20 May 2006, Prague, Czech Republic</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-12 17:39:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hanft JR, Serena T, Snyder R</AU>
<TI>A study to evaluate the clinical effectiveness of a Collagen-ORC Antimicrobial Matrix in venous leg ulcers</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>2</NO>
<PG>A64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heggers-2003" NAME="Heggers 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heggers JP</AU>
<TI>Assessing and controlling wound infection</TI>
<SO>Clinics in Plastic Surgery</SO>
<YR>2003</YR>
<VL>30</VL>
<NO>1</NO>
<PG>25-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Howell_x002d_Jones-2005" NAME="Howell-Jones 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Howell Jones RS, Wilson MJ, Hill KE, Howard AJ, Price PE, Thomas DW</AU>
<TI>A review of the microbiology, antibiotic usage and resistance in chronic skin wounds</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2005</YR>
<VL>55</VL>
<NO>2</NO>
<PG>143-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hutchinson-1993" MODIFIED="2013-12-03 18:12:41 +0000" MODIFIED_BY="[Empty name]" NAME="Hutchinson 1993" YEAR="1994">
<REFERENCE MODIFIED="2013-12-03 18:12:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Hutchinson JJ</AU>
<TI>A prospective clinical trial of wound dressings to investigate the rate of infection under occlusion</TI>
<SO>3rd European Conference on Advances in Wound Management, 19-22 October 1993, Harrogate, UK</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 18:12:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hutchinson JJ</AU>
<TI>Influence of occlusive dressings on wound microbiology&#8212;interim results of a multi-centre clinical trial of an occlusive hydrocolloid dressing</TI>
<SO>1st European Conference on Advances in Wound Management, 4-6 September 1991, Cardiff, UK</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ivins-2006" MODIFIED="2013-12-04 15:59:39 +0000" MODIFIED_BY="[Empty name]" NAME="Ivins 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-12-04 15:59:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Ivins N, Harding KG, Price P, Jørgensen B, Lohmann M, Gottrup F, et al</AU>
<TI>Safety and efficacy in long-term use of a sustained silver-releasing foam dressing: a randomized, controlled trial on venous leg ulcers</TI>
<SO>SAWC 2006, April 30 - May 3, 2006, San Antonio, Texas</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 18:13:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ivins N, Jørgensen B, Lohmann M</AU>
<TI>Safety and efficacy in long term use of a sustained silver-releasing foam dressing: a randomised, controlled trial on venous leg ulcers</TI>
<SO>European Wound Management Association Conference, 15-17 September 2005, Stuttgart, Germany</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karap-2008" MODIFIED="2013-12-03 18:13:59 +0000" MODIFIED_BY="Marrissa Martyn-St James" NAME="Karap 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-12-03 18:13:59 +0000" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Karap Z</AU>
<TI>Significant difference in pain levels of delayed-healing wounds during applying an ionic silver hydrofibre dressing. Poster 281</TI>
<SO>EWMA Journal. Proceedings of the 18th Conference of the European Wound Management Association, 2008, Lisbon, Portugal</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karas-1984" MODIFIED="2013-12-02 15:04:56 +0000" MODIFIED_BY="[Empty name]" NAME="Karas 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-12-02 15:04:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karas Z, Zabel J, Erenski P</AU>
<TI>Treatment of chronic crural ulcers with Pseudomonilia</TI>
<SO>Przeglad Dermatologiczny</SO>
<YR>1984</YR>
<VL>71</VL>
<NO>1</NO>
<PG>78-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katelaris-1987" MODIFIED="2013-06-12 17:40:07 +0100" MODIFIED_BY="Marrissa Martyn-St James" NAME="Katelaris 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-06-12 17:40:07 +0100" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katelaris PM, Fletcher JP, Little JM, McEntyre RJ, Jeffcoate KW</AU>
<TI>Electrical stimulation in the treatment of chronic venous ulceration</TI>
<SO>Australian and New Zealand Journal of Surgery</SO>
<YR>1987</YR>
<VL>57</VL>
<NO>9</NO>
<PG>605-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kordestani-2008" MODIFIED="2013-06-12 17:40:24 +0100" MODIFIED_BY="[Empty name]" NAME="Kordestani 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-06-12 17:40:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kordestani S, Shahrezaee M, Tahmasebi MN, Hajimahmodi H, Haji Ghasemali D, Abyaneh MS</AU>
<TI>A randomised control trial on the effectiveness of an advanced wound dressing used in Iran</TI>
<SO>Journal of wound care</SO>
<YR>July 2008</YR>
<VL>17</VL>
<NO>7</NO>
<PG>323-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosicek-2004" MODIFIED="2013-12-03 18:14:22 +0000" MODIFIED_BY="[Empty name]" NAME="Kosicek 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-12-03 18:14:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kosicek M, Planinsek Rucigaj T</AU>
<TI>A comparative clinical trial: microbial colonisation of venous leg ulcers treated with hydrofibre dressings or with ointments</TI>
<SO>2nd World Union of Wound Healing Societies Meeting, 8-13 July 2004, Paris</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lanzara-2008" MODIFIED="2013-12-04 16:00:14 +0000" MODIFIED_BY="[Empty name]" NAME="Lanzara 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-12-04 16:00:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lanzara S, Tacconi G, Gianesini S, Menegatti E, Federici F, Liboni A, et al</AU>
<TI>A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers</TI>
<SO>EWMA Journal</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>2 Suppl</NO>
<PG>76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lischka-1980" MODIFIED="2013-12-02 15:05:43 +0000" MODIFIED_BY="Dolores Matthews" NAME="Lischka 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-12-02 15:05:43 +0000" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lischka G, Wolff HH</AU>
<TI>Benzoyl peroxide for the treatment of badly healing leg ulcers: a double-blind study</TI>
<SO>Munchener Medizinische Wochenschrift</SO>
<YR>1980</YR>
<VL>122</VL>
<NO>49</NO>
<PG>1781-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locati-1994" NAME="Locati 1994" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locati F, Rozzoni M, Reseghetti A, Sena P</AU>
<TI>Evaluation of the efficacy and tolerability of a new cutaneous antiseptic combination</TI>
<SO>Giornale Italiano di Dermatologia e Venereologia</SO>
<YR>1994</YR>
<VL>129</VL>
<NO>5</NO>
<PG>XXVII-XXX</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magana-Lozano-1980" MODIFIED="2013-12-02 15:05:54 +0000" MODIFIED_BY="Dolores Matthews" NAME="Magana Lozano 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-12-02 15:05:54 +0000" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magana Lozano M</AU>
<TI>Ulcer leg complex: double blind study of bromelins alone or associated to tetracyclines</TI>
<SO>Compendium de Investigaciones Clinicas Latinoamericanas</SO>
<YR>1980</YR>
<VL>1</VL>
<NO>2</NO>
<PG>6-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maiques-Nadal-1976" MODIFIED="2009-09-17 15:52:42 +0100" MODIFIED_BY="[Empty name]" NAME="Maiques Nadal 1976" YEAR="1976">
<REFERENCE MODIFIED="2009-09-17 15:52:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maiques Nadal V, Zambrano Zambrano A</AU>
<TI>Trial of an enzymatic preparation in the treatment of various ulcerative processes</TI>
<SO>Revista Clinica Espanola</SO>
<YR>1976</YR>
<VL>141</VL>
<NO>1</NO>
<PG>67-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mancuso-1994" MODIFIED="2013-10-14 07:27:23 +0100" MODIFIED_BY="Dolores Matthews" NAME="Mancuso 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-10-14 07:27:23 +0100" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mancuso G, Staffa M, Errani A</AU>
<TI>Acetic acid in the treatment of superficial dermic burns and venous leg ulcers infected by <I>Pseudomonas aeruginosa</I>
</TI>
<SO>Chronica Dermatologica</SO>
<YR>1994</YR>
<VL>4</VL>
<NO>3</NO>
<PG>473-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Markoishvili-2002" NAME="Markoishvili 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Markoishvili K, Tsitlanadze G, Katsarava R, Morris JG Jr, Sulakvelidze A</AU>
<TI>A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds</TI>
<SO>International Journal of Dermatology</SO>
<YR>2002</YR>
<VL>41</VL>
<NO>7</NO>
<PG>453-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marzin-1982" NAME="Marzin 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marzin L, Rouveix B</AU>
<TI>An evaluation of collagen gel in chronic leg ulcers</TI>
<SO>Schweizerische Rundschau fur Medizin Praxis</SO>
<YR>1982</YR>
<VL>71</VL>
<NO>36</NO>
<PG>1373-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McKnight-1965" MODIFIED="2013-12-02 15:06:09 +0000" MODIFIED_BY="Dolores Matthews" NAME="McKnight 1965" YEAR="1965">
<REFERENCE MODIFIED="2013-12-02 15:06:09 +0000" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McKnight AG</AU>
<TI>A clinical trial of povidone-iodine in the treatment of chronic leg ulcers</TI>
<SO>Practitioner</SO>
<YR>1965</YR>
<VL>195</VL>
<PG>230-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mehtar-S-1988" NAME="Mehtar S 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mehtar S, Fox D</AU>
<TI>A double-blind comparative study with Mupirocin vs placebo base in the treatment of chronic leg ulcers</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1988</YR>
<VL>42</VL>
<NO>8</NO>
<PG>324-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mogabgab-1984" MODIFIED="2009-09-17 15:54:23 +0100" MODIFIED_BY="[Empty name]" NAME="Mogabgab 1984" YEAR="1984">
<REFERENCE MODIFIED="2009-09-17 15:54:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mogabgab WJ</AU>
<TI>Treatment of skin and soft-tissue infections with cefsulodin</TI>
<SO>Reviews of Infectious Diseases </SO>
<YR>1984</YR>
<VL>6</VL>
<NO>Suppl 3</NO>
<PG>S721-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morely-de-Benzaquen-1990" MODIFIED="2013-06-12 17:41:18 +0100" MODIFIED_BY="Marrissa Martyn-St James" NAME="Morely de Benzaquen 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-06-12 17:41:18 +0100" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morely de Benzaquen S, Cirelli N, Halmai O, Sanjuan E, Piquero Martín J, Arbona J, et al</AU>
<TI>Argentic sulfadiazine in lower limbs ulcers: double-blinded study</TI>
<SO>Archivos Venezolanos de Farmacología y Terapéutica</SO>
<YR>1990</YR>
<VL>9</VL>
<NO>2</NO>
<PG>116-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Motta-2004" MODIFIED="2009-09-17 15:54:36 +0100" MODIFIED_BY="[Empty name]" NAME="Motta 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-09-17 15:54:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Motta GJ, Milne CT, Corbett LQ</AU>
<TI>Impact of antimicrobial gauze on bacterial colonies in wounds that require packing</TI>
<SO>Ostomy/Wound Management</SO>
<YR>2004</YR>
<VL>50</VL>
<NO>8</NO>
<PG>48-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakagawa-1997" NAME="Nakagawa 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakagawa K, Kobayashi H, Kono T, Hayashi A, Tsuruta D, Ishii M</AU>
<TI>Evaluation of the effects of cadexomer iodine ointment (Decrat(TM) ointment) in the treatment of skin Ulcer</TI>
<SO>Skin Research</SO>
<YR>1997</YR>
<VL>39</VL>
<NO>3</NO>
<PG>364-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ouvry-1989" MODIFIED="2013-06-12 17:44:14 +0100" MODIFIED_BY="Marrissa Martyn-St James" NAME="Ouvry 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-06-12 17:44:14 +0100" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ouvry PA</AU>
<TI>A trial of silver sulfadiazine in the local treatment of venous ulcer</TI>
<TO>Essai de la sulfadiazine argentique dans le traitement local de l'ulc&#1104;re veineux</TO>
<SO>Phlebologie</SO>
<YR>1989</YR>
<VL>42</VL>
<NO>4</NO>
<PG>673-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pardes-1993" NAME="Pardes 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pardes JB, Carson PA, Eaglstein WH, Falanga V</AU>
<TI>Mupirocin treatment of exudative venous ulcers</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1993</YR>
<VL>29</VL>
<NO>3</NO>
<PG>497-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paul-1990" NAME="Paul 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paul E</AU>
<TI>Wound healing with Iruxol. Results of a multicenter study</TI>
<SO>Fortschritte der Medizin</SO>
<YR>1990</YR>
<VL>108</VL>
<NO>35</NO>
<PG>679-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pegum-1968" MODIFIED="2013-12-02 15:06:36 +0000" MODIFIED_BY="Dolores Matthews" NAME="Pegum 1968" YEAR="1968">
<REFERENCE MODIFIED="2013-12-02 15:06:36 +0000" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pegum JM, Fegan WG</AU>
<TI>Polynoxylin in the treatment of varicose ulcers</TI>
<SO>Irish Journal of Medical Science</SO>
<YR>1968</YR>
<VL>7</VL>
<NO>7</NO>
<PG>299-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pereira-2004" MODIFIED="2013-12-03 18:15:02 +0000" MODIFIED_BY="[Empty name]" NAME="Pereira 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-12-03 18:15:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pereira M, Baudrier T, Cotta F, Mota A, Fonseca C</AU>
<TI>Influence of 0.5% sodium hypochlorite solution on bacterial countings in leg ulcers</TI>
<SO>2nd World Union of Wound Healing Societies Meeting, 8-13 July 2004, Paris</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pierard_x002d_Franchimont-1997" MODIFIED="2009-09-17 15:56:20 +0100" MODIFIED_BY="[Empty name]" NAME="Pierard-Franchimont 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pierard-Franchimont C, Paquet P, Arrese JE, Pierard GE</AU>
<TI>Healing rate and bacterial necrotizing vasculitis in venous leg ulcers</TI>
<SO>Dermatology</SO>
<YR>1997</YR>
<VL>194</VL>
<NO>4</NO>
<PG>383-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Planinsek-2006" MODIFIED="2013-12-04 16:01:44 +0000" MODIFIED_BY="[Empty name]" NAME="Planinsek 2006" YEAR="2007">
<REFERENCE MODIFIED="2013-12-04 16:01:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Planinsek TR</AU>
<TI>Treatment of venous leg ulcers with different alginate dressings: their effects on healing rate and pain</TI>
<SO>16th Conference of the European Wound Management Association, 18-20 May 2006, Prague, Czech Republic</SO>
<YR>2006</YR>
<PG>154</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pollice-1989" MODIFIED="2013-12-16 15:27:13 +0000" MODIFIED_BY="[Empty name]" NAME="Pollice 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-12-16 15:27:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pollice F, D'Agostino D, Mirizzi F</AU>
<TI>Treatment of varicose ulcer with iodine cadexomere in powder form</TI>
<SO>Phlebologie</SO>
<YR>1989</YR>
<PG>1184-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Privat-1979" NAME="Privat 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Privat Y</AU>
<TI>Clinical trial of Pulvo 47 Neomycin in the treatment of leg ulcer</TI>
<SO>Semaine des Hopitaux</SO>
<YR>1979</YR>
<VL>55</VL>
<NO>13-14</NO>
<PG>711-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robson-2009" MODIFIED="2013-06-10 18:12:57 +0100" MODIFIED_BY="[Empty name]" NAME="Robson 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-06-10 18:12:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robson V, Dodd S, Thomas S</AU>
<TI>Standardized antibacterial honey (Medihoney<SUP>TM</SUP>) with standard therapy in wound care: randomized clinical trial</TI>
<SO>Journal of Advanced Nursing</SO>
<YR>2009</YR>
<VL>65</VL>
<NO>3</NO>
<PG>565-75 doi: 10.1111/j.1365-2648.2008.04923.x</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rogers-2000" MODIFIED="2013-12-04 16:02:59 +0000" MODIFIED_BY="[Empty name]" NAME="Rogers 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-12-04 16:02:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rogers RR, Alvarez OM, Patel M</AU>
<TI>Effect of a silver ion-containing wound dressing on the bacterial burden of chronic venous ulcers</TI>
<SO>13th Annual Symposium on Advanced Wound Care and 10th Annual Medical Research Forum on Wound Repair, 1-4 April 2000, Dallas, Texas</SO>
<YR>2000</YR>
<PG>D35-D36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romanelli-2010" MODIFIED="2013-12-04 16:02:29 +0000" MODIFIED_BY="Sue O'Meara" NAME="Romanelli 2010" YEAR="">
<REFERENCE MODIFIED="2013-12-04 16:02:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Romanelli M, Dini V, Barbanera S, Bertone MS</AU>
<TI>Evaluation of the efficacy and tolerability of a solution containing propyl betaine and polihexanide for wound irrigation</TI>
<SO>Skin Pharmacology and Physiology</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>Suppl 1</NO>
<PG>41-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 18:16:01 +0000" MODIFIED_BY="Sue O'Meara" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Romanelli M, Dini V, Bertone MS</AU>
<TI>Evaluation of the efficacy and tolerability of a cleansing solution with propil betaine and polyhexanide in reducing the bacterial load of venous wounds in lower limbs (poster presentation)</TI>
<SO>17th Conference of the European Wound Management Association, 2-4 May 2007, Glasgow, Scotland</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rubisz-Brzeziska-87" MODIFIED="2013-06-12 17:50:36 +0100" MODIFIED_BY="[Empty name]" NAME="Rubisz Brzeziska 87" YEAR="1987">
<REFERENCE MODIFIED="2013-06-12 17:50:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubisz-Brzezi&#324;ska J, Szarmach H, Filipiuk J, Brzezi&#324;ska-Wcis&#322;o L, Wilkowska A</AU>
<TI>Benzoyl peroxide in the treatment of crural ulcerations</TI>
<TO>Nadtlenek benzoilu w leczeniu owrzodze&#324; podudzi</TO>
<SO>Przeglad Dermatologiczny</SO>
<YR>1987</YR>
<VL>74</VL>
<NO>4-5</NO>
<PG>363-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rucigaj-2007a" MODIFIED="2013-12-03 18:16:13 +0000" MODIFIED_BY="[Empty name]" NAME="Rucigaj 2007a" YEAR="2007">
<REFERENCE MODIFIED="2013-12-03 18:16:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rucigaj TP</AU>
<TI>Comparative effects of honey based and silver/charcoal based dressings on the healing of venous leg ulcers: a randomized clinical study</TI>
<SO>17th Conference of the European Wound Management Association, 2-4 May 2007, Glasgow, Scotland</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rucigaj-2007b" MODIFIED="2013-12-02 15:07:54 +0000" MODIFIED_BY="[Empty name]" NAME="Rucigaj 2007b" YEAR="2007">
<REFERENCE MODIFIED="2013-12-02 15:07:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rucigaj TP</AU>
<TI>Effectiveness of non alcohol film forming skin protector on skins isles inside the ulcers and the healing rate of venous leg ulcers</TI>
<SO>EWMA Journal</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>1</NO>
<PG>23-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salim-1991" MODIFIED="2009-09-17 15:58:09 +0100" MODIFIED_BY="[Empty name]" NAME="Salim 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-09-17 15:58:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salim AS</AU>
<TI>The role of oxygen-derived free radicals in the management of venous (varicose) ulceration: a new approach</TI>
<SO>World Journal of Surgery</SO>
<YR>1991</YR>
<VL>15</VL>
<NO>2</NO>
<PG>264-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez_x002d_Vasquez-2008" MODIFIED="2013-12-02 15:08:08 +0000" MODIFIED_BY="[Empty name]" NAME="Sanchez-Vasquez 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-12-02 15:08:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sánchez-Vázquez R, Briseño-Rodríguez G, Cardona-Muñoz EG, Gálvez-Gastélum FJ, Totsuka-Sutto SE, Garcia-Benavides L</AU>
<TI>Isosorbide dinitrate spray as therapeutic strategy for treatment of chronic venous ulcers</TI>
<SO>Angiology</SO>
<YR>2008</YR>
<VL>59</VL>
<NO>1</NO>
<PG>64-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serra-2005" MODIFIED="2013-12-04 16:03:21 +0000" MODIFIED_BY="[Empty name]" NAME="Serra 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-12-04 16:03:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serra N, Torres OG, Romo MI, Llovera JM, Vigil-Escalera LJ, Soto MA, et al</AU>
<TI>Hydro-colloidal dressings which liberate hydro-active silver</TI>
<TO>Apósitos hidrocoloides liberadores de plata hidroactiva: estudio clínico comparativo en el tratamiento de úlceras crónicas</TO>
<SO>Revista de Enfermeria</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>2</NO>
<PG>13-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sibbald-2007" MODIFIED="2009-05-21 17:03:20 +0100" MODIFIED_BY="[Empty name]" NAME="Sibbald 2007" YEAR="">
<REFERENCE MODIFIED="2009-05-21 17:03:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sibbald RG, Coutts P, Fierheller M, Woo K</AU>
<TI>A pilot (real-life) randomised clinical evaluation of a pain-relieving foam dressing: (Ibuprofen-foam versus local best practice)</TI>
<SO>International Wound Journal</SO>
<YR>2007</YR>
<VL>4</VL>
<NO>Suppl 1</NO>
<PG>16-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sibbald-2011" MODIFIED="2013-12-04 16:04:50 +0000" MODIFIED_BY="[Empty name]" NAME="Sibbald 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-06-10 18:55:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sibbald RG, Coutts P, Woo KY</AU>
<TI>Reduction of bacterial burden and pain in chronic wounds using a new polyhexamethylene biguanide antimicrobial foam dressing-clinical trial results</TI>
<SO>Advances in Skin and Wound Care</SO>
<YR>2011</YR>
<VL>24</VL>
<NO>2</NO>
<PG>78-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-04 16:04:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woo K, Sibbald G, Coutts P</AU>
<TI>Reduction of infection and pain in chronic wounds using a new antimicrobial foam dressing</TI>
<SO>EWMA Journal</SO>
<YR>2010</YR>
<VL>10</VL>
<NO>2</NO>
<PG>59, Abstract 78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steenvoorde-2007" MODIFIED="2013-06-24 16:31:25 +0100" MODIFIED_BY="[Empty name]" NAME="Steenvoorde 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-06-24 16:27:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steenvoorde P, van Doorn LP, Jacobi CE, Oskam J</AU>
<TI>An unexpected effect of Dermacyn on infected leg ulcers</TI>
<SO>Journal of Wound Care</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>2</NO>
<PG>60-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Subrahmanyam-1993" MODIFIED="2013-06-12 18:01:49 +0100" MODIFIED_BY="Marrissa Martyn-St James" NAME="Subrahmanyam 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-06-12 18:01:49 +0100" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Subrahmanyam M</AU>
<TI>Honey as a surgical dressing for burns and ulcers</TI>
<SO>Indian Journal of Surgery</SO>
<YR>1993</YR>
<VL>55</VL>
<NO>9</NO>
<PG>468-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thebbe-1996" MODIFIED="2013-12-02 15:08:55 +0000" MODIFIED_BY="Dolores Matthews" NAME="Thebbe 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-12-02 15:08:55 +0000" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thebbe B, Orfanos CE</AU>
<TI>Therapy of leg ulcers and decubitus ulcers with a xerodressing: modern wound dressing with anti-bacterial activity</TI>
<SO>Zeitschrift fur Hautkrankheiten</SO>
<YR>1996</YR>
<VL>71</VL>
<NO>9</NO>
<PG>697-702</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thorne-1965" MODIFIED="2009-11-04 11:40:10 +0000" MODIFIED_BY="Sue O'Meara" NAME="Thorne 1965" YEAR="1965">
<REFERENCE MODIFIED="2009-11-04 11:40:10 +0000" MODIFIED_BY="Sue O'Meara" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thorne N, Fox D</AU>
<TI>A trial of povidone-iodine ointment in the treatment of leg ulcers</TI>
<SO>The Practitioner</SO>
<YR>1965</YR>
<VL>Feb</VL>
<PG>250-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wuite-1974" MODIFIED="2013-12-02 15:09:07 +0000" MODIFIED_BY="Marrissa Martyn-St James" NAME="Wuite 1974" YEAR="1974">
<REFERENCE MODIFIED="2013-12-02 15:09:07 +0000" MODIFIED_BY="Marrissa Martyn-St James" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wuite J, van der Meer BJ</AU>
<TI>Local silver nitrate therapy in leg ulcer associated with a<I> Pseudomonas aeruginosa</I> super infection</TI>
<TO>Silbernitrat-lokaltherapie bei ulcus cruris mit pseudomonas aeruginosa-superinfektion</TO>
<SO>Der Hautarzt</SO>
<YR>1974</YR>
<VL>25</VL>
<NO>8</NO>
<PG>388-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-06-11 17:14:53 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2009-07-08 16:23:44 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-12-15 19:22:36 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<ADDITIONAL_REFERENCES MODIFIED="2013-12-15 19:22:36 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<REFERENCE ID="REF-AAWC-2010" MODIFIED="2013-12-15 19:06:39 +0000" MODIFIED_BY="[Empty name]" NAME="AAWC 2010" TYPE="OTHER">
<AU>Association for the Advancement of Wound Care (AAWC)</AU>
<TI>Association for the Advancement of Wound Care (AAWC) venous ulcer guideline</TI>
<SO>Malvern (PA)</SO>
<YR>2010</YR>
<PG>Available from http://www.guideline.gov/content.aspx?id=36081</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1997" NAME="Altman 1997" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Statistics notes: units of analysis</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>314</VL>
<NO>7098</NO>
<PG>1874</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Augustin-2012" MODIFIED="2013-12-15 19:11:35 +0000" MODIFIED_BY="[Empty name]" NAME="Augustin 2012" TYPE="JOURNAL_ARTICLE">
<AU>Augustin M, Brocatti LK, Rustenbach SJ, Schäfer I, Herberger K</AU>
<TI>Cost-of-illness of leg ulcers in the community</TI>
<SO>International Wound Journal</SO>
<YR>2012</YR>
<VL>9</VL>
<PG>doi: 10.1111/j.1742-481X.2012.01089.x</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ayton-1985" MODIFIED="2009-09-17 16:11:27 +0100" MODIFIED_BY="[Empty name]" NAME="Ayton 1985" TYPE="JOURNAL_ARTICLE">
<AU>Ayton M</AU>
<TI>Wounds that won't heal</TI>
<SO>Nursing Times</SO>
<YR>1985</YR>
<VL>81</VL>
<NO>46</NO>
<PG>386-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aziz-2013" MODIFIED="2013-12-03 16:49:36 +0000" MODIFIED_BY="[Empty name]" NAME="Aziz 2013" TYPE="COCHRANE_REVIEW">
<AU>Aziz Z, Cullum N, Flemming K</AU>
<TI>Electromagnetic therapy for treating venous leg ulcers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-12-03 16:49:30 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-03 16:49:30 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002933.pub5"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bisht-2009" MODIFIED="2013-12-01 18:32:56 +0000" MODIFIED_BY="[Empty name]" NAME="Bisht 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bisht R, Katiyar A, Singh R, Mittal P</AU>
<TI>Antibiotic resistance - a global issue of concern</TI>
<SO>Asian Journal of Pharmaceutical and Clinical Research</SO>
<YR>2009</YR>
<VL>2</VL>
<NO>2</NO>
<PG>34-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BNF-2013" MODIFIED="2013-11-22 16:42:56 +0000" MODIFIED_BY="Sue O'Meara" NAME="BNF 2013" TYPE="BOOK">
<AU>British National Formulary, British Medical Association, British Royal Pharmaceutical Society of Great Britain</AU>
<SO>British National Formulary November 2013</SO>
<YR>2013</YR>
<PB>British Medical Association</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boucher-2009" MODIFIED="2013-12-04 16:08:05 +0000" MODIFIED_BY="[Empty name]" NAME="Boucher 2009" TYPE="JOURNAL_ARTICLE">
<AU>Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al</AU>
<TI>Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2009</YR>
<VL>48</VL>
<NO>1</NO>
<PG>1-12. doi: 10.1086/595011</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bowler-2003" MODIFIED="2013-12-04 16:08:16 +0000" MODIFIED_BY="[Empty name]" NAME="Bowler 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bowler PG</AU>
<TI>The 105 bacterial growth guideline: reassessing its clinical relevance in wound healing</TI>
<SO>Ostomy/Wound Management</SO>
<YR>2003</YR>
<VL>49</VL>
<NO>1</NO>
<PG>44-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brook-1998" NAME="Brook 1998" TYPE="JOURNAL_ARTICLE">
<AU>Brook I, Frazier EH</AU>
<TI>Aerobic and anaerobic microbiology of chronic venous ulcers</TI>
<SO>International Journal of Dermatology</SO>
<YR>1998</YR>
<VL>37</VL>
<PG>426-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cardinal-2009" MODIFIED="2013-12-04 16:08:28 +0000" MODIFIED_BY="[Empty name]" NAME="Cardinal 2009" TYPE="JOURNAL_ARTICLE">
<AU>Cardinal M, Eisenbud DE, Armstrong DG, Zelen C, Driver V, Attinger C, et al</AU>
<TI>Serial surgical debridement: a retrospective study on clinical outcomes in chronic lower extremity wounds</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2009</YR>
<VL>17</VL>
<PG>306-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carter-2010" MODIFIED="2013-12-01 15:49:30 +0000" MODIFIED_BY="[Empty name]" NAME="Carter 2010" TYPE="JOURNAL_ARTICLE">
<AU>Carter MJ, Tingley-Kelley K, Warriner RA</AU>
<TI>Silver treatments and silver-impregnated dressings for the healing of leg wounds and ulcers: a systematic review and meta-analysis</TI>
<SO>Journal of the American Adademy of Dermatology</SO>
<YR>2010</YR>
<VL>63</VL>
<NO>4</NO>
<PG>668-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chambers-2007" MODIFIED="2013-12-04 16:08:47 +0000" MODIFIED_BY="[Empty name]" NAME="Chambers 2007" TYPE="JOURNAL_ARTICLE">
<AU>Chambers H, Dumville JC, Cullum N</AU>
<TI>Silver treatments for leg ulcers: a systematic review</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>2</NO>
<PG>165-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-2010" MODIFIED="2013-12-04 16:08:58 +0000" MODIFIED_BY="[Empty name]" NAME="Chang 2010" TYPE="JOURNAL_ARTICLE">
<AU>Chang A, Osterloh J, Thomas J</AU>
<TI>Levamisole: a dangerous new cocaine adulterant</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2010</YR>
<VL>88</VL>
<NO>3</NO>
<PG>408-11 doi:10.1038/clpt.2010.156</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cullum-2010" MODIFIED="2013-12-03 18:22:09 +0000" MODIFIED_BY="[Empty name]" NAME="Cullum 2010" TYPE="COCHRANE_REVIEW">
<AU>Cullum N, Al-Kurdi D, Bell-Syer SEM</AU>
<TI>Therapeutic ultrasound for venous leg ulcers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2013-12-03 18:22:02 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-03 18:22:02 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001180.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cutting-2004" MODIFIED="2013-12-04 16:09:26 +0000" MODIFIED_BY="[Empty name]" NAME="Cutting 2004" TYPE="JOURNAL_ARTICLE">
<AU>Cutting KF, White R</AU>
<TI>Defined and refined: criteria for identifying wound infection revisited</TI>
<SO>British Journal of Community Nursing</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>3</NO>
<PG>S6-S15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davies-2005" NAME="Davies 2005" TYPE="JOURNAL_ARTICLE">
<AU>Davies CE, Turton G, Woolfrey G, Elley R, Taylor M</AU>
<TI>Exploring debridement options for chronic venous leg ulcers</TI>
<SO>British Journal of Nursing</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>7</NO>
<PG>393-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davies-2007" MODIFIED="2013-12-04 16:09:45 +0000" MODIFIED_BY="[Empty name]" NAME="Davies 2007" TYPE="JOURNAL_ARTICLE">
<AU>Davies CE, Hill KE, Newcombe RG, Stephens P, Wilson MJ, Harding KG, et al</AU>
<TI>A prospective study of the microbiology of chronic venous leg ulcers to reevaluate the clinical predictive value of tissue biopsies and swabs</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>1</NO>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2013-12-15 19:00:16 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG on behalf of the Cochrane Statistical Methods Group</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses</TI>
<SO>Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doughty-2007" MODIFIED="2011-11-09 12:12:52 +0000" MODIFIED_BY="Marrissa Martyn-St James" NAME="Doughty 2007" TYPE="BOOK_SECTION">
<AU>Doughty DB, Sparks-DeFriese B</AU>
<TI>Wound healing physiology</TI>
<SO>Acute and chronic wounds: current management concepts</SO>
<YR>2007</YR>
<EN>3rd</EN>
<ED>Bryant RA, Nix DP</ED>
<PB>Mosby</PB>
<CY>St Louis, Missouri, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dow-1999" NAME="Dow 1999" TYPE="JOURNAL_ARTICLE">
<AU>Dow G, Browne A, Sibbald RG</AU>
<TI>Infection in chronic wounds: controversies in diagnosis and treatment</TI>
<SO>Ostomy/Wound Management</SO>
<YR>1999</YR>
<VL>45</VL>
<NO>8</NO>
<PG>23-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farid-2011" MODIFIED="2013-06-15 16:14:28 +0100" MODIFIED_BY="[Empty name]" NAME="Farid 2011" TYPE="JOURNAL_ARTICLE">
<AU>Farid KJ, Kelly K, Roshlin S</AU>
<TI>Gentian violet 1% solution in the treatment of wounds in the geriatric patient: a retrospective study</TI>
<SO>Geriatric Nursing</SO>
<YR>2011</YR>
<VL>32</VL>
<NO>2</NO>
<PG>85-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Flemming-1999" MODIFIED="2013-12-03 16:53:42 +0000" MODIFIED_BY="[Empty name]" NAME="Flemming 1999" TYPE="COCHRANE_REVIEW">
<AU>Flemming K, Cullum NA</AU>
<TI>Laser therapy for venous leg ulcers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-12-03 16:53:37 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-03 16:53:37 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001182"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gardner-2001" MODIFIED="2013-12-01 13:47:36 +0000" MODIFIED_BY="[Empty name]" NAME="Gardner 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gardner SE, Frantz RA, Doebbeling BN</AU>
<TI>The validity of the clinical signs and symptoms used to identify localized chronic wound infection</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2001</YR>
<VL>9</VL>
<NO>3</NO>
<PG>178-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gohel-2005" MODIFIED="2013-12-03 18:17:29 +0000" MODIFIED_BY="[Empty name]" NAME="Gohel 2005" TYPE="JOURNAL_ARTICLE">
<AU>Gohel MS, Taylor M, Earnshaw JJ, Heather BP, Poskitt KR, Whyman MR</AU>
<TI>Risk factors for delayed healing and recurrence of chronic venous leg ulcers - an analysis of 1324 legs</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2005</YR>
<VL>29</VL>
<NO>1</NO>
<PG>74-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Graham-2003" MODIFIED="2013-06-14 15:06:56 +0100" MODIFIED_BY="[Empty name]" NAME="Graham 2003" TYPE="JOURNAL_ARTICLE">
<AU>Graham ID, Harrison MB, Nelson EA, Lorimer K, Fisher A</AU>
<TI>Prevalence of lower-limb ulceration: a systematic review of prevalence studies</TI>
<SO>Advances in Skin and Wound Care</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>6</NO>
<PG>305-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Halbert-1992" NAME="Halbert 1992" TYPE="JOURNAL_ARTICLE">
<AU>Halbert AR, Stacey MC, Rohr JB, Jopp-McKay A</AU>
<TI>The effect of bacterial colonization on venous ulcer healing</TI>
<SO>Australasian Journal of Dermatology</SO>
<YR>1992</YR>
<VL>33</VL>
<PG>75-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hansson-1995" MODIFIED="2009-09-17 16:24:35 +0100" MODIFIED_BY="[Empty name]" NAME="Hansson 1995" TYPE="JOURNAL_ARTICLE">
<AU>Hansson C, Hoborn J, Moller A, Swanbeck G</AU>
<TI>The microbial flora in venous leg ulcers without clinical signs of infection</TI>
<SO>Acta Dermato-venereologica</SO>
<YR>1995</YR>
<VL>75</VL>
<NO>1</NO>
<PG>24-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harker-2001" NAME="Harker 2001" TYPE="JOURNAL_ARTICLE">
<AU>Harker J</AU>
<TI>The effect of bacteria on leg ulcer healing</TI>
<SO>British Journal of Community Nursing</SO>
<YR>2001</YR>
<VL>6</VL>
<NO>3</NO>
<PG>126-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herber-2007" MODIFIED="2013-12-15 18:59:01 +0000" MODIFIED_BY="[Empty name]" NAME="Herber 2007" TYPE="JOURNAL_ARTICLE">
<AU>Herber OR, Schnepp W, Rieger MA</AU>
<TI>A systematic review on the impact of leg ulceration on patients' quality of life</TI>
<SO>Health and Quality of Life Outcomes</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>44</NO>
<PG>DOI:10.1186/1477-7525-5-44. Available from http://www.hqlo.com/content/5/1/44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2011-11-09 12:07:58 +0000" MODIFIED_BY="Marrissa Martyn-St James" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2013-12-04 16:10:19 +0000" MODIFIED_BY="Marrissa Martyn-St James" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2013-12-04 16:21:32 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2013-12-04 16:21:41 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ</AU>
<TI>Chapter 7: Selecting studies and collecting data</TI>
<SO>Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Iglesias-2004" MODIFIED="2013-12-15 18:47:52 +0000" MODIFIED_BY="[Empty name]" NAME="Iglesias 2004" TYPE="JOURNAL_ARTICLE">
<AU>Iglesias C, Nelson EA, Cullum NA, Torgerson DJ on behalf of the VenUS Team</AU>
<TI>VenUS I: a randomised controlled trial of two types of bandage for treating venous leg ulcers</TI>
<SO>Health Technology Assessment</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>29</NO>
<PG>1-120</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jull-2013" MODIFIED="2013-12-15 18:45:37 +0000" MODIFIED_BY="[Empty name]" NAME="Jull 2013" TYPE="COCHRANE_REVIEW">
<AU>Jull AB, Walker N, Deshpande S</AU>
<TI>Honey as a topical treatment for wounds</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-12-15 18:45:37 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-15 18:45:37 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005083.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kontiainen-1988" MODIFIED="2013-12-02 15:10:55 +0000" MODIFIED_BY="Dolores Matthews" NAME="Kontiainen 1988" TYPE="JOURNAL_ARTICLE">
<AU>Kontiainen S, Rinne E</AU>
<TI>Bacteria in ulcera crurum</TI>
<SO>Acta Dermato-Venereologica</SO>
<YR>1988</YR>
<VL>68</VL>
<NO>3</NO>
<PG>240-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lansdown-2002" MODIFIED="2013-06-17 14:50:30 +0100" MODIFIED_BY="[Empty name]" NAME="Lansdown 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lansdown ABG</AU>
<TI>Silver I: its antibacterial properties and mechanism of action</TI>
<SO>Journal of Wound Care</SO>
<YR>2002</YR>
<VL>11</VL>
<NO>4</NO>
<PG>125-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lazarus-2011" MODIFIED="2013-12-01 18:34:57 +0000" MODIFIED_BY="[Empty name]" NAME="Lazarus 2011" TYPE="JOURNAL_ARTICLE">
<AU>Lazarus GS, Zenilman JM</AU>
<TI>Wound microbiology: tabula rosa, a blank slate</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2011</YR>
<VL>19</VL>
<PG>531</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2013-12-02 15:11:06 +0000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J, on behalf of the Cochrane Information Retrieval Methods Group</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liberati-2009" MODIFIED="2013-06-17 19:40:50 +0100" MODIFIED_BY="[Empty name]" NAME="Liberati 2009" TYPE="JOURNAL_ARTICLE">
<AU>Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA et al</AU>
<TI>The PRISMA Statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration</TI>
<SO>PLoS Medicine</SO>
<YR>2009</YR>
<VL>6</VL>
<NO>7</NO>
<PG>e1000100. doi:10.1371/journal.pmed.1000100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lo-2009" MODIFIED="2013-12-04 16:12:00 +0000" MODIFIED_BY="[Empty name]" NAME="Lo 2009" TYPE="JOURNAL_ARTICLE">
<AU>Lo S-F, Chang C-J, Hu W-Y, Hayter M, Chang Y-T</AU>
<TI>The effectiveness of silver-releasing dressings in the management of non-healing chronic wounds: a meta-analysis</TI>
<SO>Journal of Clinical Nursing</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>5</NO>
<PG>716-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lorimer-2003a" MODIFIED="2013-12-04 16:12:05 +0000" MODIFIED_BY="[Empty name]" NAME="Lorimer 2003a" TYPE="JOURNAL_ARTICLE">
<AU>Lorimer K, Harrison MB, Graham ID, Friedberg E, Davies B</AU>
<TI>Assessing venous ulcer population characteristics and practices in a home care community</TI>
<SO>Ostomy/Wound Management</SO>
<YR>2003</YR>
<VL>49</VL>
<NO>5</NO>
<PG>32-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lorimer-2003b" MODIFIED="2013-11-30 19:50:59 +0000" MODIFIED_BY="[Empty name]" NAME="Lorimer 2003b" TYPE="JOURNAL_ARTICLE">
<AU>Lorimer KR, Harrison MB, Graham ID, Friedberg E, Davies B</AU>
<TI>Venous leg ulcer care: how evidence-based is nursing practice?</TI>
<SO>Journal of Wound Ostomy and Continence Nursing</SO>
<YR>2003</YR>
<VL>30</VL>
<PG>132-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Macpherson-2004" MODIFIED="2013-06-15 15:50:13 +0100" MODIFIED_BY="[Empty name]" NAME="Macpherson 2004" TYPE="BOOK">
<AU>Macpherson G (ed)</AU>
<SO>Black's Student Medical Dictionary</SO>
<YR>2004</YR>
<PB>A &amp; C Black Publishers Limited</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Madsen-1996" NAME="Madsen 1996" TYPE="JOURNAL_ARTICLE">
<AU>Madsen SM, Westh H, Danielsen L, Rosdahl VT</AU>
<TI>Bacterial colonisation and healing of venous leg ulcers</TI>
<SO>APMIS</SO>
<YR>1996</YR>
<VL>104</VL>
<NO>12</NO>
<PG>895-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maquart-1993" MODIFIED="2013-12-04 16:12:20 +0000" MODIFIED_BY="[Empty name]" NAME="Maquart 1993" TYPE="JOURNAL_ARTICLE">
<AU>Maquart F-X, Bellon G, Chaquor B, Wegrowski J, Patt LM, Trachy RE, et al</AU>
<TI>In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L- lysine-Cu<SUP>2+</SUP> in rat experimental wounds</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1993</YR>
<VL>92</VL>
<PG>2368-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Margolis-2000" MODIFIED="2013-12-02 15:11:26 +0000" MODIFIED_BY="Sue O'Meara" NAME="Margolis 2000" TYPE="JOURNAL_ARTICLE">
<AU>Margolis DJ, Berlin JA, Strom BL</AU>
<TI>Which venous leg ulcers will heal with limb compression bandages?</TI>
<SO>American Journal of Medicine</SO>
<YR>2000</YR>
<VL>109</VL>
<PG>15-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Margolis-2002" MODIFIED="2013-06-14 15:01:13 +0100" MODIFIED_BY="[Empty name]" NAME="Margolis 2002" TYPE="JOURNAL_ARTICLE">
<AU>Margolis DJ, Bilker W, Santanna J, Baumgarten M</AU>
<TI>Venous leg ulcer: the incidence and prevalence in the elderly</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>3</NO>
<PG>381-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Margolis-2004" MODIFIED="2011-11-09 12:12:05 +0000" MODIFIED_BY="Sue O'Meara" NAME="Margolis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA</AU>
<TI>The accuracy of venous leg ulcer prognostic models in a wound care system</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2004</YR>
<VL>12</VL>
<PG>163-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moffatt-1995" MODIFIED="2013-06-14 11:49:03 +0100" MODIFIED_BY="[Empty name]" NAME="Moffatt 1995" TYPE="JOURNAL_ARTICLE">
<AU>Moffatt CJ, Dorman MC</AU>
<TI>Recurrence of leg ulcers within a community ulcer service</TI>
<SO>Journal of Wound Care</SO>
<YR>1995</YR>
<VL>4</VL>
<NO>2</NO>
<PG>57-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moffatt-2004" MODIFIED="2013-06-14 14:51:16 +0100" MODIFIED_BY="[Empty name]" NAME="Moffatt 2004" TYPE="JOURNAL_ARTICLE">
<AU>Moffatt CJ, Franks PJ, Doherty DC, Martin R, Blewett R, Ross F</AU>
<TI>Prevalence of leg ulceration in a London population</TI>
<SO>QJM: monthly journal of the Association of Physicians</SO>
<YR>2004</YR>
<VL>97</VL>
<NO>7</NO>
<PG>431-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moffatt-2007" MODIFIED="2013-06-14 15:32:33 +0100" MODIFIED_BY="[Empty name]" NAME="Moffatt 2007" TYPE="BOOK">
<AU>Moffatt C</AU>
<SO>Compression therapy in practice</SO>
<YR>2007</YR>
<PB>Wounds UK Publishing</PB>
<CY>Aberdeen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2010" MODIFIED="2013-06-14 18:21:02 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 2010" TYPE="JOURNAL_ARTICLE">
<AU>Moore K, Hall V, Paull A, Morris T, Brown S, McCulloch D et al</AU>
<TI>Surface bacteriology of venous leg ulcers and healing outcome</TI>
<SO>Journal of Clinical Pathology</SO>
<YR>2010</YR>
<VL>63</VL>
<PG>830-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelzen-2008" MODIFIED="2013-06-14 14:48:08 +0100" MODIFIED_BY="[Empty name]" NAME="Nelzen 2008" TYPE="JOURNAL_ARTICLE">
<AU>Nelzen O</AU>
<TI>Prevalence of venous leg ulcer: the importance of the data collection method</TI>
<SO>Phlebolymphology</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>4</NO>
<PG>143-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Meara-2001" MODIFIED="2013-12-04 16:16:21 +0000" MODIFIED_BY="[Empty name]" NAME="O'Meara 2001" TYPE="JOURNAL_ARTICLE">
<AU>O'Meara SM, Cullum NA, Majid M, Sheldon TA</AU>
<TI>Systematic review of antimicrobial agents used for chronic wounds</TI>
<SO>British Journal of Surgery</SO>
<YR>2001</YR>
<VL>88</VL>
<NO>1</NO>
<PG>4-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Meara-2012" MODIFIED="2013-12-15 19:07:21 +0000" MODIFIED_BY="[Empty name]" NAME="O'Meara 2012" TYPE="COCHRANE_REVIEW">
<AU>O'Meara S, Cullum N, Nelson EA, Dumville JC</AU>
<TI>Compression for venous leg ulcers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2013-12-15 19:07:21 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-15 19:07:21 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000265.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" MODIFIED="2013-12-04 16:17:09 +0000" MODIFIED_BY="[Empty name]" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MKB, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>24</NO>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Persoon-2004" MODIFIED="2013-06-14 15:42:42 +0100" MODIFIED_BY="[Empty name]" NAME="Persoon 2004" TYPE="JOURNAL_ARTICLE">
<AU>Persoon A, Heinen MA, van der Vleuten CJM, de Rooij MG, van de Kerkhof PCM, van Achterberg T</AU>
<TI>Leg ulcers: a review of their impact on daily life</TI>
<SO>Journal of Clinical Nursing</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>3</NO>
<PG>341-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ragnarson-Tennvall-2005" MODIFIED="2013-06-14 15:51:47 +0100" MODIFIED_BY="[Empty name]" NAME="Ragnarson Tennvall 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ragnarson Tennvall G, Hjelmgren J</AU>
<TI>Annual costs of treatment for venous leg ulcers in Sweden and the United Kingdom</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>1</NO>
<PG>13-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RCN-2006" MODIFIED="2013-12-03 18:18:50 +0000" MODIFIED_BY="[Empty name]" NAME="RCN 2006" TYPE="COMPUTER_PROGRAM">
<TI>Clinical practice guidelines. The nursing management of patients with venous leg ulcers, 2006. http://www.rcn.org.uk/development/practice/clinicalguidelines/venous_leg_ulcers (accessed 14 June 2013)</TI>
<YR>2006</YR>
<PB>Royal College of Nursing</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-12-06 12:26:52 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robson-2006" MODIFIED="2013-06-12 18:07:59 +0100" MODIFIED_BY="[Empty name]" NAME="Robson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Robson MC, Cooper DM, Aslam R, Gould LJ, Harding KG, Margolis DJ et al</AU>
<TI>Guidelines for the treatment of venous ulcers</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>6</NO>
<PG>649-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ruckley-1998" MODIFIED="2013-06-14 11:51:30 +0100" MODIFIED_BY="[Empty name]" NAME="Ruckley 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ruckley CV</AU>
<TI>Caring for patients with chronic leg ulcer</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<NO>7129</NO>
<PG>407-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Siah-2011" MODIFIED="2013-06-17 15:38:36 +0100" MODIFIED_BY="[Empty name]" NAME="Siah 2011" TYPE="JOURNAL_ARTICLE">
<AU>Siah CJ, Yatim J</AU>
<TI>Efficacy of a total occlusive ionic silver-containing dressing combination in decreasing risk of surgical site infection: an RCT</TI>
<SO>Journal of Wound Care</SO>
<YR>2011</YR>
<VL>20</VL>
<NO>12</NO>
<PG>561-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SIGN-2010" MODIFIED="2013-12-04 16:18:17 +0000" MODIFIED_BY="[Empty name]" NAME="SIGN 2010" TYPE="OTHER">
<AU>Scottish Intercollegiate Guidelines Network (SIGN)</AU>
<TI>SIGN Guildeline 120. Management of chronic venous leg ulcers</TI>
<SO>http://www.sign.ac.uk/guidelines/fulltext/120/index.html</SO>
<YR>2010 (accessed 29 November 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SIGN-2013" MODIFIED="2013-06-17 19:18:15 +0100" MODIFIED_BY="[Empty name]" NAME="SIGN 2013" TYPE="OTHER">
<AU>Scottish Intercollegiate Guidelines Network (SIGN)</AU>
<TI>Search filters</TI>
<SO>http://www.sign.ac.uk/methodology/filters.html</SO>
<YR>(accessed 17 May 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Srinivasaiah-2007" MODIFIED="2013-06-14 14:57:03 +0100" MODIFIED_BY="[Empty name]" NAME="Srinivasaiah 2007" TYPE="JOURNAL_ARTICLE">
<AU>Srinivasaiah N, Dugdall H, Barrett S, Drew PJ</AU>
<TI>A point prevalence survey of wounds in north-east England</TI>
<SO>Journal of Wound Care</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>10</NO>
<PG>413-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2013-12-15 19:02:01 +0000" MODIFIED_BY="[Empty name]" NAME="Sterne 2011" TYPE="OTHER">
<AU>Sterne JAC, Egger M, Moher D on behalf of the Cochrane Bias Methods Group</AU>
<TI>Chapter 10: Addressing reporting biases</TI>
<SO>Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trengove-1996" NAME="Trengove 1996" TYPE="JOURNAL_ARTICLE">
<AU>Trengove NJ, Stacey MC, McGechie DF, Stingemore NF, Mata S</AU>
<TI>Qualitative bacteriology and leg ulcer healing</TI>
<SO>Journal of Wound Care</SO>
<YR>1996</YR>
<VL>5</VL>
<PG>277-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vermeulen-2007" MODIFIED="2013-12-15 19:22:36 +0000" MODIFIED_BY="[Empty name]" NAME="Vermeulen 2007" TYPE="COCHRANE_REVIEW">
<AU>Vermeulen H, van Hattem JM, Storm-Versloot MN, Ubbink DT, Westerbos SJ</AU>
<TI>Topical silver for treating infected wounds</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-12-15 19:22:28 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-15 19:22:28 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005486.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vowden-2009a" MODIFIED="2013-06-14 11:55:20 +0100" MODIFIED_BY="[Empty name]" NAME="Vowden 2009a" TYPE="JOURNAL_ARTICLE">
<AU>Vowden KR, Vowden P</AU>
<TI>The prevalence, management and outcome for patients with lower limb ulceration identified in a wound care survey within one English health care district</TI>
<SO>Journal of Tissue Viability</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>1</NO>
<PG>13-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vowden-2009b" MODIFIED="2013-06-14 11:56:54 +0100" MODIFIED_BY="[Empty name]" NAME="Vowden 2009b" TYPE="JOURNAL_ARTICLE">
<AU>Vowden KR, Vowden P</AU>
<TI>A survey of wound care provision within one English health care district</TI>
<SO>Journal of Tissue Viability</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>1</NO>
<PG>2-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vowden-2009c" MODIFIED="2013-06-14 11:58:30 +0100" MODIFIED_BY="[Empty name]" NAME="Vowden 2009c" TYPE="JOURNAL_ARTICLE">
<AU>Vowden K, Vowden P</AU>
<TI>The resource costs of wound care in Bradford and Airedale primary care trust in the UK</TI>
<SO>Journal of Wound Care</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>3</NO>
<PG>93-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-2001" MODIFIED="2013-06-15 16:16:21 +0100" MODIFIED_BY="[Empty name]" NAME="White 2001" TYPE="JOURNAL_ARTICLE">
<AU>White RJ, Cooper R, Kingsley A</AU>
<TI>Wound colonization and infection: the role of topical antimicrobials</TI>
<SO>British Journal of Nursing</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>9</NO>
<PG>563-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilton-1978" MODIFIED="2013-12-04 16:19:13 +0000" MODIFIED_BY="Sue O'Meara" NAME="Wilton 1978" TYPE="JOURNAL_ARTICLE">
<AU>Wilton JMA</AU>
<TI>Levamisole in chronic inflammatory diseases</TI>
<SO>Journal of Rheumatology. Supplement</SO>
<YR>1978</YR>
<VL>4</VL>
<PG>101-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-_x00d6_ien-2013" MODIFIED="2013-11-30 19:48:44 +0000" MODIFIED_BY="[Empty name]" NAME="Öien 2013" TYPE="JOURNAL_ARTICLE">
<AU>Öien RF, Forssell HW</AU>
<TI>Ulcer healing time and antibiotic treatment before and after the introduction of the Registry of Ulcer Treatment: an improvement project in a national quality registry in Sweden</TI>
<SO>BMJ Open</SO>
<YR>2013</YR>
<VL>3</VL>
<PG>e003091. doi:10.1136/bmjopen-2013-003091</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2011-07-12 09:55:22 +0100" MODIFIED_BY="Marrissa Martyn-St James"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-12-15 17:59:42 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-12-15 17:59:42 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-12-06 12:49:11 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Alinovi-1986">
<CHAR_METHODS MODIFIED="2013-12-02 14:22:41 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial conducted in Italy. Some details of sample size estimation described but unclear whether this was a priori</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:22:41 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>48 people with 56 venous leg ulcers randomly assigned:<BR/>Group 1: 24 people/26 legs<BR/>Group 2: 24 people/30 legs<BR/>Mean ± SD baseline ulcer size, cm<SUP>2</SUP>:</P>
<P>Group 1 completers (24 people/26 legs): 12.5 ± 14.4</P>
<P>Group 2 completers (23 people/29 legs): 14.1 ± 15.9<BR/>Mean ± SD baseline ulcer duration (months):</P>
<P>Group 1 completers: 11.7 ± 12.6</P>
<P>Group 2 completers: 10.4 ± 8.9<BR/>Patients with clinically infected ulcers were excluded from the trial, but all included patients had wounds with positive bacterial cultures</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:22:41 +0000" MODIFIED_BY="Sue O'Meara">
<P>1. Bed rest, and standard treatment of merbromin 2% solution applied to ulcer surface. Betamethasone dipropionate 0.05% cream applied to rest of leg, zinc oxide and ichthammol&#8211;impregnated gauze bandage wrapped around the leg and elastic support bandage applied from toes to knee. The bandage remained in place for 20 days<BR/>2. Bed rest with standard treatment and a 10-day course of systemic antibiotics (co-trimoxazole, gentamicin or amikacin according to sensitivity)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:49:11 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>After 20 days:<BR/>Complete healing:<BR/>1. 7/26 (27%)<BR/>2. 5/30 (17%)</P>
<P>Following the 20-day treatment period, participants whose ulcers had not healed were treated with bandages alone (further details of bandages not provided). Eventual rates of complete healing reported as follows (assessment point not stated):</P>
<P>1. 20/26 (77%)</P>
<P>2. 21/30 (70%)</P>
<P>Mean percentage decrease in ulcer area:<BR/>1. 57.2 ± 29.3<BR/>2. 61.6 ± 25.8</P>
<P>The trial authors reported the between-group difference as not statistically significant (P value 0.56)</P>
<P>Secondary outcomes:<BR/>Bacterial eradication<BR/>1. 5/24<BR/>2. 8/24</P>
<P>Relationship between ulcer healing and bacteriological results in people with positive pretreatment culture, excluding healed ulcers:<BR/>mean percentage decrease in ulcer area (persistent bacterial colonisation)<BR/>1. 44.8 ± 31.8 (n = 19)<BR/>2. 42.1 ± 11.9 (n = 24)</P>
<P>Mean percentage decrease in ulcer area (eradicated bacterial colonisation)<BR/>1. 70.8 ± 19.4 (n = 19)<BR/>2. 76.6 ± 13.6 (n = 24)</P>
<P>The trial authors reported that within-group differences for change in ulcer area between those with persistent bacterial colonisation and eradication were statistically significant (P value 0.04 for Group 1; and P value 0.00003 for Group 2)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:23:09 +0000" MODIFIED_BY="[Empty name]">
<P>Bacterial culture:<BR/>
<I>Staphylococcus aureus:</I> 25.4%; <I>Pseudomonas aeruginosa:</I> 18.2%; B-haemolytic strep: 14.5%</P>
<P>Withdrawals:<BR/>Group 1: 0<BR/>Group 2: intolerant of compression bandage (1)<BR/>Total = 1</P>
<P>Unit of analysis:</P>
<P>Some participants had multiple leg ulcers studied, but this did not appear to have been accounted for in the trialists' analyses<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-02 15:45:14 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Beitner-1985a">
<CHAR_METHODS MODIFIED="2013-11-28 17:04:11 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Randomised controlled trial conducted in Sweden. Each participant had 2 leg ulcers each and acted as his or her own control. Ulcers were the unit of randomisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-28 17:05:15 +0000" MODIFIED_BY="[Empty name]">
<P>10 participants (20 ulcers) were recruited. There were no details of baseline characteristics, including ulcer infection status</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-28 17:21:27 +0000" MODIFIED_BY="[Empty name]">
<P>Interventions were applied to 10 participants with 2 leg ulcers each, acting as his or her own control. For each participant, one ulcer was treated with 10% benzoyl peroxide lotion and the other with normal saline solution. For both ulcers, treatment was applied by moistening a sterile sponge compress, cut to the exact shape of the ulcer, with the respective solution. The sponge dressings were then covered with a thick pad and kept in place with a gauze stocking. The ulcer margins were protected with zinc ointment, and a supporting elastic bandage was applied. Dressings were changed 3 times a week for 42 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-02 15:45:14 +0000" MODIFIED_BY="Sue O'Meara">
<P>Mean ± SD percentage ulcer area remaining at 42 days:<BR/>Normal saline solution 94.7% ± 12.7%</P>
<P>10% benzoyl peroxide lotion 64.3% ± 14.0%<BR/>
</P>
<P>Adverse effects:</P>
<P>3 participants reported severe irritation from use of 10% benzoyl peroxide lotion. No information about adverse effects for ulcers treated with the normal saline solution</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-28 17:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>3 participants withdrew; it was not stated whether withdrawal was related to adverse effects (severe irritation from use of 10% benzoyl peroxide lotion). </P>
<P>This trial report described 3 separate RCTs recruiting 31 participants in total. All participants had 2 leg ulcers each and acted as his or her own control. One other RCT was included (<LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>) and the other was excluded (<LINK REF="STD-Beitner-1985c" TYPE="STUDY">Beitner 1985c</LINK>). </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-28 17:38:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beitner-1985b">
<CHAR_METHODS MODIFIED="2013-11-28 17:04:22 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial conducted in Sweden. Each participant had 2 leg ulcers each and acted as his or her own control. Ulcers were the unit of randomisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-28 17:06:32 +0000" MODIFIED_BY="[Empty name]">
<P>10 participants (20 ulcers) were recruited. There were no details of baseline characteristics, including ulcer infection status</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-28 17:22:14 +0000" MODIFIED_BY="[Empty name]">
<P>Interventions were applied to 10 participants with 2 leg ulcers each, acting as his or her own control. For each participant, one ulcer was treated with 20% benzoyl peroxide lotion and the other with normal saline solution. For both ulcers, treatment was applied by moistening a sterile sponge compress, cut to the exact shape of the ulcer, with the respective solution. The sponge dressings were then covered with a thick pad and kept in place with a gauze stocking. The ulcer margins were protected with zinc ointment, and a supporting elastic bandage was applied. Dressings were changed 3 times a week for 42 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-28 17:30:30 +0000" MODIFIED_BY="[Empty name]">
<P>Mean ± SD percentage ulcer area remaining at 42 days:<BR/>Normal saline solution 93.7% ± 15.2%</P>
<P>20% benzoyl peroxide lotion 59.6% ± 12.3%<BR/>
</P>
<P>Adverse effects:</P>
<P>No information provided for either treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-28 17:38:46 +0000" MODIFIED_BY="[Empty name]">
<P>There were no withdrawals.</P>
<P>This trial report described 3 separate RCTs recruiting 31 participants in total. All participants had 2 leg ulcers each and acted as his or her own control. One other RCT was included (<LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>) and the other was excluded (<LINK REF="STD-Beitner-1985c" TYPE="STUDY">Beitner 1985c</LINK>).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:43:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Belcaro-2003">
<CHAR_METHODS MODIFIED="2013-12-02 14:23:55 +0000" MODIFIED_BY="Sue O'Meara">
<P>Randomised controlled trial conducted in Italy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-01 19:54:50 +0000" MODIFIED_BY="Sue O'Meara">
<P>20 people with venous ulceration with minimum and maximum ulcer diameters &gt; 2 cm and &lt; 5 cm<BR/>Group 1: 10<BR/>Group 2: 10</P>
<P>Mean ± SD baseline ulcer area (cm<SUP>2</SUP>): Group 1: 3.98 ± 0.4; Group 2: 3.76 ± 0.4<BR/>Mean ± SD baseline ulcer duration (months): Group 1: 2.9 ± 2.0; Group 2: 2.5 ± 1.0</P>
<P>All participants were treated with systemic antibiotics for 15 to 20 days before the start of trial treatment to resolve clinical infection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-01 19:54:50 +0000" MODIFIED_BY="[Empty name]">
<P>1. The lower limb and the area of ulceration were cleaned with water and neutral soap; skin was dried with tissue paper; 2 g of placebo cream was applied to the ulcerated area and surrounding skin, and compression below-knee stockings were applied<BR/>2. 2 g hydrogen peroxide cream 1% was used instead of placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:43:25 +0000" MODIFIED_BY="[Empty name]">
<P>After 10 days, median decrease in ulcerated area:<BR/>1. 11%<BR/>2. 35%<BR/>(P value &lt; 0.05)</P>
<P>Mean percentage ulcer area remaining:<BR/>1. 89%<BR/>2. 65%<BR/>(P value &lt; 0.05)</P>
<P>Improvement in microcirculatory parameters was significant in Group 2<BR/>No adverse effects reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-05 11:43:10 +0000" MODIFIED_BY="[Empty name]">
<P>No information given about withdrawals<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:43:25 +0000" MODIFIED_BY="Sue O'Meara" STUDY_ID="STD-Belcaro-2007">
<CHAR_METHODS MODIFIED="2013-12-02 14:24:22 +0000" MODIFIED_BY="Sue O'Meara">
<P>Randomised controlled trial conducted in Italy<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:24:22 +0000" MODIFIED_BY="Sue O'Meara">
<P>32 people with venous ulceration with ulcer diameter &gt; 2 cm and &lt; 4 cm<BR/>Group 1: 14<BR/>Group 2: 18</P>
<P>Mean ± SD baseline ulcer area (cm<SUP>2</SUP>): Group 1: 3.5 ± 0.8; Group 2: 3.3 ± 0.6<BR/>Mean ± SD baseline ulcer duration (months): Group 1: 1.2 ± 0.3; Group 2: 1.1 ± 0.2</P>
<P>All participants were treated with systemic antibiotics for 2 weeks before the start of trial treatment to resolve clinical infection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:24:22 +0000" MODIFIED_BY="[Empty name]">
<P>1. The lower limb and the area of ulceration were cleaned with water and neutral soap; skin was dried with tissue paper; 2 g of placebo cream was applied to the ulcerated area and surrounding skin and compression below-knee stockings were applied<BR/>2. 2 g hydrogen peroxide cream 1% was used instead of placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:43:25 +0000" MODIFIED_BY="[Empty name]">
<P>After 10 days, median decrease in ulcerated area:<BR/>1.32%<BR/>2. 44.8%<BR/>P value &lt; 0.005</P>
<P>Improvements in microcirculatory parameters were significant in Group 2</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-08 12:55:05 +0100" MODIFIED_BY="[Empty name]">
<P>No information given about withdrawals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-02 14:24:57 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Bini_x0107_-2010">
<CHAR_METHODS MODIFIED="2013-12-02 14:24:48 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Randomised controlled trial (pilot study) conducted in Serbia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:24:48 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>32 people with venous leg ulcers &#8804; 10 cm<SUP>2</SUP> of not longer than 2 months' duration</P>
<P>Group 1: 15 people</P>
<P>Group 2: 17 people</P>
<P>Information given by the trial authors suggested that some people had more than one ulcer, but full details not provided</P>
<P>Mean ± SD baseline ulcer size (cm<SUP>2</SUP>): Group 1: 6.7 ± 1.09; Group 2: 7.04 ± 1.37</P>
<P>Mean ± SD (range) baseline ulcer duration (weeks): Group 1: 5.80 ± 2.66 (2.3 to 8); Group 2: 5.53 ± 1.95 (1.8 to 8)</P>
<P>Those with ulcers with signs of clinical infection at baseline were excluded. All ulcers of included patients showed signs of contamination or colonisation from swab, without signs of ulcer infection or systemic infection. All participants had at least one micro-organism identified at baseline, the most frequent isolates being <I>Staphylococcus aureus</I> and <I>Pseudomonas aeruginosa</I>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:24:48 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>1. Topical antibiotics applied to ulcers, selected according to antibiogram results and including gentamicin, chloramphenicol 5%, enbecin, povidone-iodine 2%, metronidazole and fusidic acid. Antiexudative, anti-inflammatory and disinfectant wet dressing bandages applied (further details of these interventions not provided)</P>
<P>2. Plantoderm ointment applied to ulcers and Fitoven gel applied to skin on lower leg and peri-ulcer area</P>
<P>Plantoderm ointment contains extracts of <I>Calendula officinalis</I> (marigold),<I> Symphytum officinale </I>(comfrey),<I> Achillea millefolium</I> (yarrow) and <I>Salvia officinalis</I> (sage),<I> </I>and is described by the trial authors as having antimicrobial properties. Fitoven gel contains extracts of <I>Aesculus hippocastanum</I> (horse chestnut),<I> Melilotus officinalis</I> (yellow sweet clover),<I> Rosmarinus</I> (rosemary) and <I>Lavandula</I> (lavender)</P>
<P>All participants received the following: ulcer cleansing with sterile saline solution or sterile boric acid 3%; debridement using scissors and tweezers; routine dressings (not specified further, but excluding hydrocolloid, foam, alginate and hydrogel dressings); and routine bandages (no further details provided). Compression was not used in any participant (confirmed through correspondence with trial authors). All participants were treated twice daily, with dressings removed and reapplied each time to reapply the study treatments. The treatment duration was 7 weeks</P>
<P>Some information about intervention regimens was confirmed through contact with the trial authors</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-02 14:24:57 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>At 7 weeks:</P>
<P>Number of participants with healed ulcers (data confirmed by trial authors):</P>
<P>1. 0/15 (0%)</P>
<P>2. 2/17 (12%)</P>
<P>Mean % change in ulcer surface area:</P>
<P>1. -35.65%</P>
<P>2. -42.68%</P>
<P>Secondary outcomes at 7 weeks:</P>
<P>Number of participants with bacterial eradication of ulcer:</P>
<P>1. 0/15 (0%)</P>
<P>2. 4/17 (24%)</P>
<P>Number of participants with at least one bacterial isolate:</P>
<P>1. 15/15 (100%)</P>
<P>2. 13/17 (76%)</P>
<P>Number of participants with more than 1 bacterial isolate:</P>
<P>Group 1: 6/15 (40%)</P>
<P>Group 2: 3/17 (18%)</P>
<P>Most of the isolates in both groups were<I> Staphylococcus aureus </I>and/or<I> Pseudomonas aeruginosa</I>
</P>
<P>Adverse effects:</P>
<P>1. 1/15 (7%) (small increment of the ulcerated area).</P>
<P>2. 0/17 (0%)</P>
<P>No details were provided defining what adverse effects were monitored, nor methods of monitoring used</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:24:57 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>No information about withdrawals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:59:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bishop-1992">
<CHAR_METHODS MODIFIED="2013-12-02 14:25:44 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial (2 centres) conducted in the USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:25:44 +0000" MODIFIED_BY="[Empty name]">
<P>93 participants randomly assigned, with venous stasis ulcers 3 cm<SUP>2</SUP> to 50 cm<SUP>2</SUP> in size, of at least 3 months' duration</P>
<P>Group 1: 30 participants</P>
<P>Group 2: 31 participants</P>
<P>Group 3: 32 participants</P>
<P>Mean baseline ulcer size of completers, cm<SUP>2 </SUP>± SD (median):</P>
<P>Group 1: 9.6 ± 8.1 (6.2)</P>
<P>Group 2: 11.9 ± 11.2 (6.9)</P>
<P>Group 3: 9.9 ± 8.5 (6.5)</P>
<P>Mean baseline ulcer duration of completers, months ± SD (median):</P>
<P>Group 1: n = 29, 38.0 ± 88.7 (12.0)</P>
<P>Group 2: n = 28, 44.1 ± 58.0 (19.0)</P>
<P>Group 3: n = 29, 57.1 ± 94.9 (11.0)</P>
<P>Patients with &gt; 10<SUP>5</SUP> bacteria/gram ulcer tissue (confirmed by tissue biopsy) were excluded, as were those with systemic sepsis or bone infection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:25:44 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: Placebo (topical preparation comprising petroleum-based cream, vehicle of preparation used for Group 3)</P>
<P>Group 2: Topical preparation comprising 1% silver sulphadiazine cream</P>
<P>Group 3: Topical preparation comprising 0.4% tripeptide copper complex cream</P>
<P>All participants received ulcer cleansing with normal saline and compression; and were instructed to apply treatment daily followed by nonadherent dressing and elastic wrap, and to keep the affected limb elevated when sitting. The treatment duration was 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:59:31 +0000" MODIFIED_BY="[Empty name]">
<P>Numbers (%) of participants with ulcers healed at week 4:</P>
<P>Group 1: 1/30 (3)</P>
<P>Group 2: 6/31 (19)</P>
<P>Group 3: 0/32 (0)</P>
<P>Numbers (%) of participants whose ulcers remained healed after 1 year, having received no further topical treatment, just elastic support:</P>
<P>Group 1: 1/1 (100)</P>
<P>Group 2: 5/6 (83)</P>
<P>Group 3: 0/0 (0)</P>
<P>Mean percentage change in ulcer size % ± SE at week 4:</P>
<P>Group 1: -22.5 ± 10.2</P>
<P>Group 2: -44.0 ± 8.21</P>
<P>Group 3; -18.7 ± 9.07</P>
<P>Secondary outcomes:</P>
<P>No microbiological outcomes reported</P>
<P>Adverse events:</P>
<P>The trial authors reported no statistically significant between-group differences for burning, itching, pain or oedema observed (numbers of participants and P values not provided). Only placebo group complained of pain, itching or burning after 15 days. On a scale of 0 to 3+, all mean scores were less than 1+ (direction and administration of scale not explained)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:25:59 +0000" MODIFIED_BY="[Empty name]">
<P>Withdrawals</P>
<P>Group 1: 1/30 (3%)</P>
<P>Group 2: 3/31 (10%) (2 were immediate withdrawals)</P>
<P>Group 3: 3/32 (9%) (1 was an immediate withdrawal)</P>
<P>Apart from the information about immediate withdrawals, other information, including reasons for withdrawal, was not provided</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-02 14:26:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blair-1988">
<CHAR_METHODS MODIFIED="2013-12-02 14:26:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, controlled trial conducted in the UK. 2 separate trials are reported in the paper; only 1 is relevant to this review</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:26:38 +0000" MODIFIED_BY="[Empty name]">
<P>60 ulcers, with surface area up to 10 cm<SUP>2</SUP> were randomly assigned:</P>
<P>Group 1: 30 ulcers</P>
<P>Group 2: 30 ulcers</P>
<P>Initial mean ulcer surface area cm<SUP>2 </SUP>± SEM: Group 1: 3.8 ± 0.6; Group 2: 3.4 ± 0.5</P>
<P>Ulcer duration (described as time since ulcer last healed), mean months ± SEM: Group 1: 27.8 ± 3.4; Group 2: 33.4 ± 4.1</P>
<P>All ulcers were initially contaminated, with 80% of wounds growing more than one organism. Most common organisms were <I>Staphylococcus aureus</I> (73% of ulcers) and beta-haemolytic <I>Streptococcus </I>(35% of ulcers). Data not presented by group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:26:38 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: non-adherent dressing</P>
<P>Group 2: silver sulphadiazine cream (Flamazine, Smith &amp; Nephew)</P>
<P>All participants received ulcer cleansing with saline; four-layer compression bandaging designed to provide 42 mmHg initial ankle pressure; weekly change of dressings and bandages at outpatient venous leg ulcer clinic. The treatment duration was 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-02 14:26:50 +0000" MODIFIED_BY="[Empty name]">
<P>Numbers (%) of ulcers healed at 12 weeks:</P>
<P>Group 1: 24/30 (80)</P>
<P>Group 2: 19/30 (63)</P>
<P>Mean % healing rate per week first 6 weeks:</P>
<P>Group 1: -12.8%</P>
<P>Group 2: -11.0%</P>
<P>Mean % healing rate per week last 6 weeks:</P>
<P>Group 1: -2.5%</P>
<P>Group 2: -1.7%</P>
<P>Secondary outcomes:</P>
<P>Adverse effects:</P>
<P>Group 1: 1 participant developed cellulitis (not stated whether treatment was stopped)</P>
<P>Group 2: 4 participants&#8212;treatment stopped because of erythema and pruritis. 2 participants developed cellulitis (not stated whether treatment stopped)</P>
<P>In participants with cellulitis from both groups, the predominant organism was beta-haemolytic <I>Streptococcus</I>, Lancefield group G</P>
<P>Microbial outcomes:</P>
<P>In both groups, bacterial contaminants were continued throughout the study (monitored by fortnightly swabs), with only 3 ulcers having no bacterial growth at any stage during the trial (group not stated)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:26:50 +0000" MODIFIED_BY="[Empty name]">
<P>The units of randomisation and analysis are not clear (whether ulcers or participants)</P>
<P>Apart from the 4 participants in Group 2 who stopped treatment because of adverse effects, no information was presented about withdrawals; it is not clear whether these participants were included in all analyses</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:46:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cameron-1991">
<CHAR_METHODS MODIFIED="2013-12-02 14:27:15 +0000" MODIFIED_BY="Sue O'Meara">
<P>Randomised controlled trial conducted in the UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:27:15 +0000" MODIFIED_BY="[Empty name]">
<P>30 people with venous leg ulcers:<BR/>Group 1: 15<BR/>Group 2: 15</P>
<P>Mean baseline ulcer area (cm<SUP>2</SUP>&#8212;variability data not reported): Group 1: 17.3. Group 2: 16.3<BR/>Mean (range) baseline ulcer duration: Group 1: 6 years (1 month to 36 years); Group 2: 2.7 years (6 months to 9 years)</P>
<P>5 participants in each group had Gram-positive bacteria present in their wounds at baseline. There was no report of signs and symptoms of clinical infection.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:27:15 +0000" MODIFIED_BY="Dolores Matthews">
<P>1. White soft paraffin tulle gras and compression therapy<BR/>2. Mupirocin-impregnated tulle gras and compression therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:46:57 +0000" MODIFIED_BY="[Empty name]">
<P>After 12 weeks complete healing:<BR/>1. 46%<BR/>2. 53%</P>
<P>Mean percentage change in ulcer area:<BR/>1. 68%<BR/>2. 50%</P>
<P>Eradication of Gram-positive bacteria<BR/>1. 0/5<BR/>2. 5/5<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-05 11:10:51 +0000" MODIFIED_BY="[Empty name]">
<P>No withdrawals reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-02 14:27:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casoni-2002">
<CHAR_METHODS MODIFIED="2013-12-02 14:27:48 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial conducted in Italy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:27:48 +0000" MODIFIED_BY="Sue O'Meara">
<P>74 participants with vascular leg ulcers (information from author: ABPI had to be at least 0.6 for patient to be included; some patients had leg ulcers of mixed arterial/venous aetiology):<BR/>Group 1: 22 participants<BR/>Group 2: 26 participants<BR/>Group 3: 26 participants</P>
<P>Mean ± SD [range] baseline ulcer area (mm<SUP>2</SUP>): Group 1: 162 ± 167 [40 to 810]; Group 2: 202 ± 140 [40 to 650]; Group 3: 180 ± 117 [60 to 560]<BR/>Median (interquartile range) baseline ulcer area (mm<SUP>2</SUP>&#8212;read from box plot): Group 1: 125 (90, 170); Group 2: 170 (90, 300); Group 3: 150 (125, 220)</P>
<P>Median (interquartile range) baseline ulcer duration (months&#8212;read from box plot): Group 1: 10.5 (6, 24); Group 2: 7 (4, 12.5); Group 3: 7 (3, 8)</P>
<P>Participants in all groups received systemic antibiotics as necessary before trial treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:27:48 +0000" MODIFIED_BY="[Empty name]">
<P>All participants received the following interventions 2 weeks before trial treatment: compression, local antiseptics and systemic antibiotics in cases of proven infection</P>
<P>Trial treatments:<BR/>Group 1: non-adherent, paraffin gauze (Vaseline) dressing plus compression<BR/>Group 2: hyaluronic acid and povidone-iodine dressing plus compression<BR/>Group 3: hydrocolloid dressing plus compression</P>
<P>Trial dressings and bandages were changed weekly. Compression could be in the form of Unna's boot; multilayer bandages; or stockings plus elastic bandage (removed at night)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-02 14:27:48 +0000" MODIFIED_BY="[Empty name]">
<P>At 3 months&#8212;median percentage area reduction/25th percentile (read from box plot):<BR/>Group 1: 90%/65%<BR/>Group 2: 100%/90%<BR/>Group 3: 100%/80%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:27:48 +0000" MODIFIED_BY="[Empty name]">
<P>In terms of the median percentage area reduction&#8212;no data are available on those whose ulcers enlarged during the trial, the box plot shows only those with area reduction; full interquartile ranges are not shown</P>
<P>No information given about withdrawals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-02 14:28:18 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Chaloner-2004">
<CHAR_METHODS MODIFIED="2013-12-02 14:28:17 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Randomised controlled trial conducted in the UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:28:18 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>40 patients with chronic venous leg ulcers recruited from 3 centres within primary care setting:</P>
<P>Group 1: 20 participants</P>
<P>Group 2: 20 participants</P>
<P>Median ulcer duration, weeks (range): 52 (6 weeks to 20 years), breakdown per group not provided</P>
<P>Median ulcer area, cm<SUP>2</SUP> (range): 4.9 (0.9 to 196.1), breakdown per group not provided</P>
<P>The available information suggests that all participants had bacterial colonisation of ulcers at baseline, but not stated whether any were clinically infected</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:28:18 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Group 1: silver-impregnated polyurethane foam dressing (Avance)</P>
<P>Group 2: 5-layer silver impregnated dressing comprising two layers of an absorbent inner core sandwiched between three layers of silver-coated, low-adherent polyethylene net (Acticoat 7)</P>
<P>All participants received four-layer compression bandage (Profore), providing 40 mmHg at the ankle</P>
<P>Duration of treatment was 12 weeks unless the ulcer healed before this time</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-02 14:28:17 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Number (%) of ulcers healed at 12 weeks:</P>
<P>Group 1: 7/20 (35)</P>
<P>Group 2: 10/20 (50)</P>
<P>Median percentage (%) change in ulcer area at 12 weeks:</P>
<P>Group 1: -80.4%</P>
<P>Group 2: -95.1%</P>
<P>The trial authors reported that the between-group difference was not statistically significant but did not provide the P value</P>
<P>Seondary outcomes:</P>
<P>The trial authors reported that there was a greater reduction in the total number of bacteria (colony forming units per cm<SUP>2</SUP>) in Group 2 compared with Group 1, but the between-group difference was not statistically significant (data and P value not provided)</P>
<P>The trial authors reported that more pathogenic bacterial groups were eliminated in Group 2 compared with Group 1, including <I>Staphylococcus aureus, </I>beta-haemolytic streptococci, anaerobes and coliforms. No further data or P values were provided</P>
<P>Adverse events at 12 weeks:</P>
<P>The trial authors reported that a higher proportion of participants in Group 2 reported no pain from the study ulcer and a healthy condition of the peri-ulcer skin compared with Group 1</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:28:18 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Data were extracted from a conference poster and abstract, and further details were confirmed through correspondence with the study author. A full report was not available</P>
<P>Microbiological analysis (bacterial counts and bacterial identification) was by wound swabs taken at 0, 2, 4, 8 and 12 weeks. No details of techniques used were provided</P>
<P>The median baseline value in ulcer duration as recorded above was taken from the conference abstract (52 weeks); the conference poster reported a different value (34.7 weeks)</P>
<P>In the conference abstract, the trial authors reported: "the rate of healing was on average 16.8% faster" in Group 2 compared with Group 1, but did not explain how this statistic was estimated; also, contradictory information was given in the poster, which suggested that participants in Group 1 healed faster, on average</P>
<P>Withdrawals (available from a brief interim report only):</P>
<P>Group 1: 2 participants withdrew because of adverse events (further details not provided)</P>
<P>Group 2: no information provided</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-02 14:28:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daroczy-2006">
<CHAR_METHODS MODIFIED="2013-12-02 14:28:46 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial conducted in Hungary</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:28:46 +0000" MODIFIED_BY="[Empty name]">
<P>63 people with ulcerated stasis dermatitis due to deep venous reflux, of &lt; 5 cm 'size'<BR/>Group 1: 21<BR/>Group 2: 21<BR/>Group 3: 21</P>
<P>No information provided on baseline characteristics such as ulcer area and ulcer duration. Ulcers were described as infected, but no further details provided, and not clear if this referred to baseline status or incidence during the trial treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:28:46 +0000" MODIFIED_BY="[Empty name]">
<P>1. Povidone-iodine with compression<BR/>2. Amoxicillin (dose, route and frequency of administration not stated) with compression<BR/>3. Povidone-iodine without compression</P>
<P>The treatment duration was 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-02 14:28:46 +0000" MODIFIED_BY="[Empty name]">
<P>After 12 weeks complete healing:<BR/>1. 82%<BR/>2. 85%<BR/>3. 62%</P>
<P>5 months after conclusion of trial: relapse of superficial bacterial infection:<BR/>1. 11%<BR/>2. 32%<BR/>3. 11%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-05 11:11:21 +0000" MODIFIED_BY="[Empty name]">
<P>No withdrawals mentioned</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-02 14:29:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dimakakos-2009">
<CHAR_METHODS MODIFIED="2013-12-02 14:29:04 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial conducted in Greece</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:29:05 +0000" MODIFIED_BY="[Empty name]">
<P>42 participants with venous leg ulcers that were classified as exclusively infected:</P>
<P>Group 1: 21 participants</P>
<P>Group 2: 21 participants</P>
<P>Initial ulcer diameter:</P>
<P>Group 1: &lt; 1 cm, n = 3; 1 to 2 cm, n = 4; 2 to 3 cm, n = 5; 3 to 4 cm, n = 5; &gt; 4 cm, n = 4</P>
<P>Group 2: &lt; 1 cm, n = 2; 1 to 2 cm, n = 5; 2 to 3 cm, n = 4; 3 to 4 cm, n = 7; &gt; 4 cm, n = 3</P>
<P>Initial ulcer depth:</P>
<P>Group 1: &lt; 0.5 cm, n = 16; &gt; 0.5 cm, n = 5</P>
<P>Group 2: &lt; 0.5 cm, n = 14; &gt; 0.5 cm, n = 7</P>
<P>Number of (%) participants with ulcer duration &gt; 1 month:</P>
<P>Group 1: 14/21 (67)</P>
<P>Group 2: 12/21 (57)</P>
<P>Number of participants with initial ulcer pain (assessed with VAS where 0 = no pain, &lt; 4 = mild pain, 4 to 7 = moderate pain, &gt; 7 = severe pain, and 10 = worst imaginable pain):</P>
<P>Group 1: severe, n = 5; moderate, n = 8; none/mild, n = 8</P>
<P>Group 2: severe, n = 5; moderate, n = 11; none/mild, n = 5</P>
<P>Number of participants with <I>Staphylococcus aureus</I> identified from swab:</P>
<P>Group 1: 4/21</P>
<P>Group 2: 9/21</P>
<P>Number of participants with <I>Pseudomonas aeruginosa</I> identified from swab:</P>
<P>Group 1: 5/21</P>
<P>Group 2: 7/21</P>
<P>
<I>Escherichia coli, Staphylococcus capitis, Enterococcus </I>species and other bacteria were also present in some participants in both groups</P>
<P>Number of participants with &gt;1 wound isolate:</P>
<P>Group 1: 13/21</P>
<P>Group 2: 11/21</P>
<P>All ulcers were infected and had clinical signs of inflammation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:29:12 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: non-adhesive foam (Biatain)</P>
<P>Group 2: non-adhesive silver-releasing foam (Contreet Ag)</P>
<P>All participants received wound cleansing using sterile water and a 10% povidone-iodine solution; short stretch bandage as compression therapy; twice-weekly dressing changes; and antibiotics if wound cultures were positive</P>
<P>Treatment duration was 9 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-02 14:29:21 +0000" MODIFIED_BY="[Empty name]">
<P>Numbers (%) of ulcers healed at 9 weeks:</P>
<P>Group 1: 10/21 (48)</P>
<P>Group 2: 17/21 (81)</P>
<P>Number of ulcers healed at 3/4/5/6/7/8/9 weeks:</P>
<P>Group 1: 2/1/1/1/0/2/3</P>
<P>Group 2: 2/3/3/2/1/2/4</P>
<P>Secondary outcomes:</P>
<P>Adverse events:</P>
<P>The trial authors reported that none of the participants experienced systemic or local side effects that could be attributed to the treatments, but no further details were provided</P>
<P>Pain:</P>
<P>Group 1: 1/5 participants with severe pain and 3/8 participants with moderate pain were pain-free at 4 weeks. Moderate pain persisted in 4 participants until the end of the nine weeks. 13/21 participants were pain-free by the end of the study</P>
<P>Group 2: 2/5 participants with severe pain and 8/11 participants with moderate pain were pain-free at 3 weeks. 21/21 participants were pain-free by week 8.</P>
<P>No microbiological outcomes were reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:29:05 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-15 17:59:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fischer-1984">
<CHAR_METHODS MODIFIED="2013-12-02 14:29:50 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial (multi-centre, involving 6 hospitals in Germany, 1 hospital in Austria and 1 phlebology practice in Switzerland)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:29:50 +0000" MODIFIED_BY="[Empty name]">
<P>258 participants randomly assigned, with venous leg ulcers 3 cm to 10 cm in diameter</P>
<P>Group 1: 89 participants</P>
<P>Group 2: 88 participants</P>
<P>Group 3: 81 participants</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-15 17:59:42 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: non-antibiotic enzymatic cleanser - topical preparation comprising 1 unit bovine fibrinolysin to 666 units desoxyribonuclease in a water-free basic ointment (Fribolan)</P>
<P>Group 2: enzymatic cleanser with added antibiotic - topical preparation comprising 0.6 units clostridiopeptidase A to 10 mg chloramphenicol in a lipophilic water-free basic ointment (no proprietary name provided)</P>
<P>Group 3: enzymatic cleanser with added antibiotic - topical preparation comprising 20 units trypsin to 20 mg framycetin sulphate in water-soluble basic ointment (no proprietary name provided)</P>
<P>All participants received compression bandages, according to the standard practice of each hospital. Wound cleansing was standardised across study groups (but not specified). No information regarding the frequency of dressing changes was reported</P>
<P>Treatment was discontinued in the following instances: after complete ulcer healing; if there were complications or allergies ('complications' not defined); or if no improvement was noted after 7 days ('no improvement' not defined)</P>
<P>Although not specifically reported, treatment duration appears to be 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-02 14:29:50 +0000" MODIFIED_BY="[Empty name]">
<P>Numbers (%) of participants healed (translated as treatment discontinued because of rapid healing; assessment point not clear but could be 28 days):</P>
<P>Group 1: 8/89 (9)</P>
<P>Group 2: 1/88 (1)</P>
<P>Group 3: 5/81 (6)</P>
<P>Secondary outcomes:</P>
<P>Adverse events:</P>
<P>Numbers (%) of participants who discontinued treatment because of ineffectiveness (not defined) or allergy:</P>
<P>Group 1: 3/89 (3)</P>
<P>Group 2: 6/88 (7)</P>
<P>Group 3: 8/81 (10)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:29:50 +0000" MODIFIED_BY="[Empty name]">
<P>Paper translated from German</P>
<P>Clinical examinations were undertaken at baseline and at days 4, 7, 14 and 28</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:43:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fumal-2002a">
<CHAR_METHODS MODIFIED="2013-11-27 15:01:23 +0000" MODIFIED_BY="Sue O'Meara">
<P>Randomised controlled trial conducted in Belgium. Each participant had 2 leg ulcers each and acted as his or her own control. Ulcers were the unit of randomisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-28 17:05:27 +0000" MODIFIED_BY="Sue O'Meara">
<P>17 participants (34 ulcers) were recruited. The minimum ulcer size was 16 cm<SUP>2</SUP>. Other information about baseline ulcer area and ulcer duration was not presented. Wounds were not clinically infected at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-27 15:03:39 +0000" MODIFIED_BY="[Empty name]">
<P>Interventions were applied to 17 participants with 2 leg ulcers each, acting as his or her own control. One ulcer was managed with usual treatment consisting of hydrocolloid dressing and compression (described as a 'compressive bandage' - no further details provided). The other ulcer was treated with 10% povidone-iodine solution applied underneath usual treatment. All dressings and bandages were changed three times per week.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:43:33 +0000" MODIFIED_BY="[Empty name]">
<P>Median (range) time to healing in weeks, estimated from Kaplan-Meier survival curves:</P>
<P>Usual treatment alone 18 (11 to 24)</P>
<P>10% povidone-iodine and usual treatment 11 (9 to 17)</P>
<P>The trial authors reported P value &lt; 0.01 (log rank test) for the difference between treatments</P>
<P>Median (range) healing rate at 6 weeks (assessed using a healing index, see notes below for method of calculation - higher value means better outcome):<BR/>Usual treatment alone 6.8 (3.9 to 13.2)</P>
<P>10% povidone-iodine and usual treatment 10.2 (4.4 to 16.0)</P>
<P>The trial authors reported P value &lt; 0.01 for the difference between treatments</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-28 17:39:10 +0000" MODIFIED_BY="Sue O'Meara">
<P>There was no information about withdrawals.</P>
<P>Healing index = DA[P(t0)]<SUP>-1</SUP> where: A = Area; P = Perimeter; DA = Differential Area = equal to baseline area minus follow-up area; t0 = baseline.</P>
<P>This trial report described 3 separate RCTs recruiting 51 participants in total. All participants had 2 leg ulcers each and acted as his or her own control. The other 2 RCTs are included in the review and described under <LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK> and <LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:59:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fumal-2002b">
<CHAR_METHODS MODIFIED="2013-11-27 14:50:56 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial conducted in Belgium. Each participant had two leg ulcers and acted as his or her own control. Ulcers were the unit of randomisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-28 17:05:36 +0000" MODIFIED_BY="[Empty name]">
<P>17 participants (34 ulcers) were recruited. The minimum ulcer size was 16 cm<SUP>2</SUP>. Other information about baseline ulcer area and ulcer duration was not presented. Wounds were not clinically infected at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-27 16:10:45 +0000" MODIFIED_BY="[Empty name]">
<P>Interventions were applied to 17 participants with 2 leg ulcers each, acting as his or her own control. One ulcer was managed with usual treatment consisting of hydrocolloid dressing and compression (described as a 'compressive bandage' - no further details provided). The other ulcer was treated with 1% silver sulphadiazine cream applied underneath usual treatment. All dressings and bandages were changed three times per week.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:59:41 +0000" MODIFIED_BY="[Empty name]">
<P>Median (range) time to healing in weeks, estimated from Kaplan-Meier survival curves:</P>
<P>Usual treatment alone 16 (9 to 22)</P>
<P>1% silver sulphadiazine and usual treatment 15 (7 to 23)</P>
<P>The trial authors reported that the difference between treatments was not statistically significant, but no P value was presented</P>
<P>Median (range) healing rate at 6 weeks (assessed using a healing index, see notes below for method of calculation - higher value means better outcome):<BR/>Usual treatment alone 7.2 (3.4 to 13.6)</P>
<P>1% silver sulphadiazine &amp;and usual treatment 7.5 (3.6 to 14.3)</P>
<P>The trial authors reported that the difference between treatments was not statistically significant, but no P value was presented</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-28 17:39:35 +0000" MODIFIED_BY="[Empty name]">
<P>There was no information about withdrawals.</P>
<P>Healing index = DA[P(t0)]<SUP>-1</SUP> where: A = Area; P = Perimeter; DA = Differential Area = equal to baseline area minus follow-up area; t0 = baseline.</P>
<P>This trial report described 3 separate RCTs recruiting 51 participants in total. All participants had 2 leg ulcers each and acted as his or her own control. The other 2 RCTs are included in the review and described under <LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK> and <LINK REF="STD-Fumal-2002c" TYPE="STUDY">Fumal 2002c</LINK>.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 13:00:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fumal-2002c">
<CHAR_METHODS MODIFIED="2013-11-27 14:51:00 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial conducted in Belgium. Each participant had two leg ulcers and acted as his or her own control. Ulcers were the unit of randomisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-28 17:05:43 +0000" MODIFIED_BY="[Empty name]">
<P>17 participants (34 ulcers) were recruited. The minimum ulcer size was 16 cm<SUP>2</SUP>. Other information about baseline ulcer area and ulcer duration was not presented. Wounds were not clinically infected at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-27 16:12:15 +0000" MODIFIED_BY="[Empty name]">
<P>Interventions were applied to 17 participants with 2 leg ulcers each, acting as his or her own control. One ulcer was managed with usual treatment consisting of hydrocolloid dressing and compression (described as a 'compressive bandage' - no further details provided). The other ulcer was treated with 5% chlorhexidine digluconate solution applied underneath usual treatment. All dressings and bandages were changed three times per week.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 13:00:01 +0000" MODIFIED_BY="[Empty name]">
<P>Median (range) time to healing in weeks, estimated from Kaplan-Meier survival curves:</P>
<P>Usual treatment alone 15 (7 to 19)</P>
<P>5% chlorhexidine digluconate solution and usual treatment 14 (7 to 17)</P>
<P>The trial authors reported that the difference between treatments was not statistically significant, but no P value was presented</P>
<P>Median (range) healing rate at 6 weeks (assessed using a healing index, see notes below for method of calculation - higher value means better outcome):<BR/>Usual treatment alone 7.3 (4.0 to 11.9)</P>
<P>5% chlorhexidine digluconate solution and usual treatment 7.6 (4.1 to 12.4)</P>
<P>The trial authors reported that the difference between treatments was not statistically significant, but no P value was presented</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-28 17:39:52 +0000" MODIFIED_BY="[Empty name]">
<P>There was no information about withdrawals.</P>
<P>Healing index = DA[P(t0)]<SUP>-1</SUP> where: A = Area; P = Perimeter; DA = Differential Area = equal to baseline area minus follow-up area; t0 = baseline.</P>
<P>This trial report described 3 separate RCTs recruiting 51 participants in total. All participants had 2 leg ulcers each and acted as his or her own control. The other 2 RCTs are included in the review and described under <LINK REF="STD-Fumal-2002a" TYPE="STUDY">Fumal 2002a</LINK> and <LINK REF="STD-Fumal-2002b" TYPE="STUDY">Fumal 2002b</LINK>.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-02 14:30:54 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Geske-2005">
<CHAR_METHODS MODIFIED="2013-12-02 14:30:34 +0000" MODIFIED_BY="Sue O'Meara">
<P>Randomised controlled trial conducted in Germany</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:30:34 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>253 people with venous leg ulcers were randomly assigned (241 completed the trial and were analysed per protocol)<BR/>1. 124 randomly assigned, 119 completed<BR/>2. 129 randomly assigned, 122 completed</P>
<P>Median baseline ulcer area (cm<SUP>2</SUP>): Group 1: 7.28; Group 2: 9.3 (ranges not reported)<BR/>Median baseline ulcer duration (months): Group 1: 6.12; Group 2: 6.73 (ranges not reported)<BR/>Patients with ulcers infected with MRSA were excluded from the trial, but otherwise it was unclear whether wounds were clinically infected at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:30:34 +0000" MODIFIED_BY="Dolores Matthews">
<P>1. Ulcer treated with placebo preparation in the same fashion, plus compression therapy<BR/>2. Ulcer treated with 0.1% ethacridine lactate ointment for 30 minutes twice daily for 28 days, plus compression therapy<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-02 14:30:46 +0000" MODIFIED_BY="[Empty name]">
<P>After 28 days&#8212;response indicated by &gt; 20% decrease in ulcer surface area<BR/>Number of responders<BR/>1. 69/124 (56%)<BR/>2. 104/129 (81%)</P>
<P>Median decrease in ulcer surface area<BR/>1. 7.2 ± 18.17 points<BR/>2. 12.7 ± 17.43 points</P>
<P>NB: It is unclear what the 'points' refer to; also unclear whether the variance data refer to standard deviation or a different statistic</P>
<P>Mean decrease in ulcer surface area<BR/>1. 24.7%<BR/>2. 34.1%</P>
<P>Subjective outcomes:<BR/>Effectiveness of treatment rated as 'excellent' by physician<BR/>1. 13.6%<BR/>2. 55.7%</P>
<P>Effectiveness of treatment rated as 'excellent' by participant<BR/>1. 17.9%<BR/>2. 50%</P>
<P>Secondary outcomes:<BR/>Quality of life according to the Freiburg Quality of Life Questionnaire<BR/>Mean points reduced (reduction = improved quality)<BR/>1. 0.3 points<BR/>2. 0.75 points</P>
<P>Numbers (%) of participants experiencing at least one adverse event (total number of adverse events and description):<BR/>1. 12/119 (10.1%) (12 participants reported a total of 16 adverse events, mostly aches/back pain and nausea)<BR/>2. 13/122 (10.7%) (13 participants reported a total of 21 adverse events, classed as mild to moderate&#8212;headaches/migraines and pruritis)</P>
<P>The trial authors reported that all adverse events were unlikely to be related to treatment. Two cases of serious adverse events were noted (hip operation and erysipelas), both considered unrelated to treatment (unclear which treatment group these related to)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:30:54 +0000" MODIFIED_BY="[Empty name]">
<P>Withdrawals:</P>
<P>1. 5/124 (4%)</P>
<P>2. 7/129 (5%)<BR/>Reasons for withdrawal (unclear which group these relate to): discontinued therapy (5); beyond inclusion criteria (6); serious adverse event (unrelated to treatment) (1)<BR/>Total = 12</P>
<P>Paper was published in German; data were extracted by a translator</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:43:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gethin-2008">
<CHAR_METHODS MODIFIED="2013-12-02 14:31:15 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial conducted in Ireland (pragmatic, multicentre involving 10 study centres). A priori sample size estimation determined that 156 participants were required to show a 20% difference between treatments for the primary outcomes (healing and desloughing) at a 5% two-sided significance level, but only 108 participants were recruited because of slower than expected recruitment rates</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:31:15 +0000" MODIFIED_BY="[Empty name]">
<P>108 participants with venous leg ulcers &lt; 100 cm<SUP>2 </SUP>with &#8805; 50% wound area covered in slough</P>
<P>Group 1: 54 participants</P>
<P>Group 2: 54 participants</P>
<P>Mean wound duration weeks ± SD:</P>
<P>Group 1: 29.93 ± 35.20</P>
<P>Group 2: 39.46 ± 40.50</P>
<P>Mean wound area cm<SUP>2</SUP>± SD (median):</P>
<P>Group 1: 9.87 ± 12.90 (4.2)</P>
<P>Group 2: 10.52 ± 12.30 (5.4)</P>
<P>Patients with clinical diagnosis of wound infection or taking antibiotics for any reason were excluded. None of the ulcers or surrounding skin showed signs of inflammation at baseline</P>
<P>Coliforms, <I>Staphylococcus</I> <I>aureus</I> and <I>Proteus</I> species were the most common isolates at baseline and were found in 25%, 23% and 19% of all wounds, respectively (assessed with wound swab)</P>
<P>Numbers (%) of participants with at least one isolate:</P>
<P>Group 1: 44/54 (81)</P>
<P>Group 2: 51/54 (94)</P>
<P>Numbers (%) of participants with &gt; 1 isolate:</P>
<P>Group 1: 22/54 (41)</P>
<P>Group 2: 29/54 (54)</P>
<P>Numbers (%) of participants with methicillin-resistant <I>Staphylococcus aureus </I>(MRSA):</P>
<P>Group 1: 6/54 (11)</P>
<P>Group 2: 10/54 (19)</P>
<P>Mean pain scores ± SD (assessed using 5-point visual analogue scale, where 0 = no pain and 5 = worst pain ever):</P>
<P>Group 1: 1.39 ± 1.15</P>
<P>Group 2: 1.41 ± 1.05</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:31:33 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: Hydrogel therapy (IntraSite Gel, Smith &amp; Nephew, Hull, UK) 3 g/20 cm<SUP>2</SUP> applied weekly</P>
<P>Group 2: Manuka honey (topical agent) (Woundcare 18+, Comvita, Te Puke, New Zealand) 5 g/20 cm<SUP>2 </SUP>applied weekly</P>
<P>All participants received wound cleansing with warm tap water; secondary foam dressings (Allevyn); and compression therapy, usually four-layer bandage. Treatment period was four weeks. After four weeks, all participants received follow-up treatment based on clinicians' judgement; this varied between participants. The final follow-up assessment was conducted at week 12. Participants requiring antibiotics or immunosuppressants during the trial were withdrawn</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:43:38 +0000" MODIFIED_BY="[Empty name]">
<P>Percentage change in wound size at week 12 (unclear whether mean or median):</P>
<P>Group 1: -13%</P>
<P>Group 2: -34%</P>
<P>Trial authors report P value &lt; 0.001 for between-group difference</P>
<P>Numbers (%) of ulcers healed at week 12:</P>
<P>Group 1: 18/54 (33)</P>
<P>Group 2: 24/54 (44)</P>
<P>Secondary outcomes:</P>
<P>Adverse events:</P>
<P>The trial authors reported no adverse events directly attributable to either wound agent (see information below on withdrawals for further details)</P>
<P>Bacterial changes during 4 weeks of treatment (detected by wound swab):</P>
<P>Numbers (%) of participants with at least one isolate at week 4:</P>
<P>Group 1: 29/54 (54)</P>
<P>Group 2: 35/54 (65)</P>
<P>Numbers (%) of participants with &gt; 1 isolate at week 4:</P>
<P>Group 1: 15/54 (28)</P>
<P>Group 2: 22/54 (41)</P>
<P>Numbers of participants (%) with MRSA eradication at week 4:</P>
<P>Group 1: 1/6 (16)</P>
<P>Group 2: 7/10 (70)</P>
<P>Coliforms, coagulase-negative <I>Staphylococcus</I> and <I>Staphylococcus</I> <I>aureus</I> were the most common isolates at four weeks and were found in 16%, 15% and 13% of all wounds, respectively</P>
<P>The authors reported no statistically significant differences between groups in pain outcome as assessed by visual analogue scale score at any follow-up point<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-06 12:43:39 +0000" MODIFIED_BY="[Empty name]">
<P>Unit of analysis was the participant. For participants with multiple ulcers, the uppermost or largest ulcer was selected for study</P>
<P>Procedure for taking wound swabs at baseline, 1 week and 4 weeks: 2 swabs taken after wound cleansed with warm tap water to safeguard against loss/damage; cotton-tipped swab rotated 360 degrees in the wound bed; then swabs placed in transport media and transported immediately to the laboratory for routine qualitative culture</P>
<P>Numbers (%) of participant withdrawals (reasons&#8212;wound infection diagnosed on clinical presentation):</P>
<P>Group 1: 17/54 (31%) (infection in reference wound 12; infection elsewhere 1; participant request 3; did not attend follow-up 1)</P>
<P>Group 2: 9/54 (17%) (infection in reference wound 6; infection elsewhere 1; non-compliance with treatment 1; did not attend follow-up 1)</P>
<P>The trial authors reported that the between-group difference for time to withdrawal because of infection was not statistically significant (P value &lt; 0.07, log rank test)</P>
<P>Note: A discrepancy is evident between text and table for numbers of participants with MRSA eradication; data have been extracted from the main text (relates to secondary reference of <LINK REF="STD-Gethin-2008" TYPE="STUDY">Gethin 2008</LINK>)</P>
<P>The main primary outcome for the RCT was reduction in slough; the trial authors reported no statistically significant differences between groups in percentage reduction of slough at four weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:43:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Groenewald-1981">
<CHAR_METHODS MODIFIED="2013-12-02 14:32:28 +0000" MODIFIED_BY="Sue O'Meara">
<P>Randomised controlled trial conducted in South Africa</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:32:29 +0000" MODIFIED_BY="Sue O'Meara">
<P>100 people with varicose stasis ulcers<BR/>Group 1: 50<BR/>Group 2: 50</P>
<P>Scant data on baseline characteristics such as ulcer area and ulcer duration. Unclear whether wounds clinically infected at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:32:29 +0000" MODIFIED_BY="[Empty name]">
<P>1. Existing dressing removed, ulcer and surrounding area washed with a soft brush in povidone-iodine solution; appropriate treatment for frequently occurring fungal infections then applied; povidone-iodine swabbed on the ulcer surface; 2.5 cm thick foam rubber pad placed directly on ulcer; whole foot and lower leg covered with zinc oxide&#8211;impregnated gauze bandage and covered by an elastic bandage<BR/>2. Treated similarly in all respects, except that dextranomer beadlets applied to the ulcer surface to form a 2 to 3 mm layer instead of the final application of povidone-iodine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:43:40 +0000" MODIFIED_BY="[Empty name]">
<P>Objective outcome:<BR/>Average healing time (no information about methods of estimation):<BR/>1. 5.3 weeks<BR/>2. 4.4 weeks<BR/>(significant at 95% CI)</P>
<P>Secondary outcome:<BR/>Average eradication time:<BR/>for <I>Staph aureus</I>:<BR/>1. 18.7 days<BR/>2. 14.7 days<BR/>(significant at 99.5% CI)</P>
<P>Mean cleansing time:<BR/>1. 15.4 ± 6.4 days<BR/>2. 5.9 ± 2.8 days<BR/>(P value &lt; 0.001)</P>
<P>People with painful ulcers:<BR/>1. 35<BR/>2. 30</P>
<P>Immediate improvement of pain<BR/>1. 7 /35 (20%)<BR/>2. 20/30 (66.6%)</P>
<P>Worsened pain:<BR/>1. 4/35 (11.4%)<BR/>2. 0/30</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:32:41 +0000" MODIFIED_BY="[Empty name]">
<P>Withdrawal total = 5<BR/>People withdrawn from the trial were replaced to keep population size N = 100</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:53:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hansson-1998">
<CHAR_METHODS MODIFIED="2013-12-02 14:33:10 +0000" MODIFIED_BY="Sue O'Meara">
<P>Randomised controlled trial conducted in Sweden<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:33:10 +0000" MODIFIED_BY="[Empty name]">
<P>153 people with non-infected venous leg ulcers randomly assigned, only withdrawals judged to be unrelated to treatment efficacy were excluded from the analysis<BR/>Group 1: 49<BR/>Group 2: 56<BR/>Group 3: 48</P>
<P>Mean ± SD baseline ulcer area (cm<SUP>2</SUP>): Group 1: 7.1 ± 7.1; Group 2: 8.8 ± 11.9; Group 3: 10.7 ± 20.6<BR/>Data on baseline ulcer duration not reported. Patients with clinically infected ulcers excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:33:10 +0000" MODIFIED_BY="[Empty name]">
<P>1. Paraffin gauze dressing, which was changed when saturated or leaking</P>
<P>2. Cadexomer iodine paste, which was changed when moisture saturated, indicated by a colour change</P>
<P>3. Hydrocolloid dressing, which was changed when saturated or leaking</P>
<P>All participants received a short-stretch compression bandage (Comprilan). Treatment duration was 12 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:53:17 +0000" MODIFIED_BY="[Empty name]">
<P>At 12 weeks:<BR/>Ulcers completely healed:<BR/>1. 7/49<BR/>2. 8/56<BR/>5. 5/48</P>
<P>Mean percentage reduction in ulcer area:<BR/>1. 23.9 ± 97.4%<BR/>2. 61.6 ± 36.9%<BR/>3. 40.7 ± 56.5%</P>
<P>Mean ulcer area reduction per week (%/wk)<BR/>1. 3 ± 14<BR/>2. 8 ± 10<BR/>3. 9 ± 8</P>
<P>Secondary outcomes:<BR/>No statistically significant difference in the time to cease exudation between groups of the study</P>
<P>Adverse effects:</P>
<P>Total number of adverse events per group (group denominators unclear):</P>
<P>1. 26</P>
<P>2. 19</P>
<P>3. 33</P>
<P>Erosions around ulcer:<BR/>1. 15<BR/>2. 0<BR/>3. 10</P>
<P>Pain<BR/>1. 1<BR/>2. 8<BR/>3. 2</P>
<P>Allergy<BR/>1. 1<BR/>2. 2<BR/>3. 6</P>
<P>Cost of treatment in 38 people (staff time, materials, and transport) USD/ percentage ulcer area reduction<BR/>1. 12.9<BR/>2. 8.8<BR/>3. 32.5</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:33:34 +0000" MODIFIED_BY="[Empty name]">
<P>Withdrawals (NB 1 to 2 reasons per participant)</P>
<P>Group 1:<BR/>Allergy (1); increased size (8); pain (1); infection (4); adverse effects (2); not related A/Es (6); refused to continue (2)<BR/>Total = 24</P>
<P>Group 2:<BR/>Pain (6); infection (1); not related A/Es (4); poor compliance (1); protocol violation (1)<BR/>Total = 13</P>
<P>Group 3:<BR/>Allergy (5); increased size (3); infection (5); use of systemic Abx (2); not related A/Es (1); refused to continue (1)<BR/>Total = 17<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:43:41 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Harcup-1986">
<CHAR_METHODS MODIFIED="2013-11-26 15:50:05 +0000" MODIFIED_BY="Sue O'Meara">
<P>Randomised controlled trial conducted in the UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 15:45:51 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>72 people over 30 years of age with venous leg ulcers<BR/>1. 31<BR/>2. 41<BR/>Statistics for baseline ulcer area in cm<SUP>2</SUP> (presume mean ± SD, but not stated): Group 1: 7.74 ± 1.04; Group 2: 9.08 ± 1.37</P>
<P>Mean (range) baseline ulcer duration for all participants was 16.9 (1 to 256) months (breakdown per group not provided)</P>
<P>Unclear whether wounds were clinically infected at baseline (but it appeared that those with infected ulcers might have been allowed into the trial).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:34:04 +0000" MODIFIED_BY="[Empty name]">
<P>1. Support bandaging or stocking with a dry dressing. Multiple treatment modalities used<BR/>2. Ulcer was cleaned with sterile saline swabs; cadexomer iodine applied to the surface; sterile dressing used and secured in place with bandaging or stocking. Cadexomer iodine removed daily</P>
<P>All patients were treated by general practitioners, in a community setting.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:43:41 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>At 4 weeks:<BR/>Ulcers completely healed:<BR/>1. 1/31 (3.2%)<BR/>2. 13/41 (31.7%)</P>
<P>Percentage reduction in ulcer size at 4 weeks (72 participants analysed)<BR/>1. 10%<BR/>2. 36%<BR/>P value &lt; 0.01</P>
<P>Secondary outcome:<BR/>Significantly improved pain, erythema, exudation, oedema, pus/debris and granulation in the group treated with cadexomer iodine<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:34:04 +0000" MODIFIED_BY="[Empty name]">
<P>Withdrawals:<BR/>Group 1:<BR/>2 participants withdrew at 6 weeks because of insufficient effect of treatment and failure to attend</P>
<P>Group 2:<BR/>3 participants withdrew at 2 weeks because of diarrhoea, erythema, oedema, ulcer irritation and unhappiness with treatment<BR/>3 participants withdrew at 4 weeks because of burning sensation (1) and insufficient effect (2)<BR/>
</P>
<P>2 participants withdrew at 6 weeks because of development of multiple ulcers, dry skin, itching and pain</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:49:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Holloway-1989">
<CHAR_METHODS MODIFIED="2013-12-02 14:34:38 +0000" MODIFIED_BY="Sue O'Meara">
<P>Randomised controlled trial conducted in the USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:34:38 +0000" MODIFIED_BY="[Empty name]">
<P>75 people with venous leg ulcers were recruited:<BR/>Group 1: 37<BR/>Group 2: 38</P>
<P>Median (range) baseline ulcer area in cm<SUP>2</SUP>: Group 1: 9.8 (3.0 to 37.0); Group 2: 10.7 (0.6 to 136.0)<BR/>Median (range) baseline ulcer duration in months: Group 1: 4.5 (3 to 130); Group 2: 7.5 (3 to 240)</P>
<P>Unclear whether ulcers were infected at baseline (but it appeared that those with infected ulcers might have been allowed into the trial).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:34:38 +0000" MODIFIED_BY="Dolores Matthews">
<P>1. Wet-to-dry dressings with saline-soaked gauze pads changed by the participant daily plus toe-to-knee elastic compression bandage<BR/>2. Ulcer irrigated with saline, cadexomer iodine sprinkled onto the surface, then covered with a dry gauze dressing; done daily plus toe-to-knee elastic compression bandage</P>
<P>Information provided suggests that all participants were treated in a community setting.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:49:12 +0000" MODIFIED_BY="[Empty name]">
<P>Outcomes were assessed at 24 weeks, with analyses based on 54 participants overall (breakdown of completers per group not stated)<BR/>
</P>
<P>Mean (standard error of the mean) rate of ulcer healing (cm²/wk):<BR/>1. 0.41 (0.13)<BR/>2. 0.95 (0.12)</P>
<P>The trial authors reported a statistically significant between-group difference (P value 0.0025)</P>
<P>Mean (standard error of the mean) rate of ulcer healing versus baseline circumference (cm²/wk/cm)<BR/>1. 0.03 (0.01)<BR/>2. 0.04 (0.01)<BR/>The trial authors reported that the between-group difference was not statistically significant (P value 0.072)</P>
<P>Secondary outcomes:<BR/>Bacterial eradication</P>
<P>The trial authors reported: "Neither treatment was superior in causing a reduction in bacterial numbers on a semiquantitative (categorized as profuse, moderate or sparse) basis." No further information or data were provided</P>
<P>Adverse effects: burning, itching or pain<BR/>1. 0<BR/>2. 6</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:34:43 +0000" MODIFIED_BY="[Empty name]">
<P>Withdrawals from both groups (breakdown per group not provided):<BR/>Death (2); dropped out or failed to return (9); failed to respond to trial treatment (4)</P>
<P>Excluded from statistical analysis: do not satisfy inclusion criteria (2); lost to follow-up (4)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:53:35 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Huovinen-1994">
<CHAR_METHODS MODIFIED="2013-12-02 14:35:14 +0000" MODIFIED_BY="Sue O'Meara">
<P>Randomised controlled trial conducted in Finland</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:35:14 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>36 people initially recruited, 5 people withdrawn and excluded from analysis<BR/>Group 1: 11 randomly assigned, 10 completed<BR/>Group 2: 13 randomly assigned and 12 completed<BR/>Group 3: 12 randomly assigned, 9 completed</P>
<P>Average&#8212;unclear if this is the mean value (range) baseline ulcer area (cm<SUP>2</SUP>): Group 1: 27 (1 to 154); Group 2: 53 (1 to 475); Group 3: 31 (1 to 145)</P>
<P>Average (range) baseline ulcer duration (months): Group 1: 29 (3 to 96); Group 2: 72 (3 to 126); Group 3: 67 (4 to 252)</P>
<P>The trial authors stated that 26/31 (84%) ulcers had <I>Staphylococcus aureus</I> at baseline, but it was not clear whether wounds were colonised or clinically infected<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:35:14 +0000" MODIFIED_BY="[Empty name]">
<P>1. Placebo tablet twice daily plus local treatment with 0.2 g zinc in 1 g petroleum-paraffin ointment and Comprilan elastic bandage<BR/>2. Ciprofloxacin 750 mg twice daily plus the above local treatment<BR/>3. Trimethoprim 160 mg twice daily plus the above local treatment</P>
<P>Treatment duration was 12 weeks in all groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:53:35 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>At 16 weeks:<BR/>Complete healing:<BR/>1. 3/11 (27%)<BR/>2. 5/13 (38%)<BR/>3. 3/12 (25%)</P>
<P>Average (range) change in ulcer size, calculated as % of original size (estimated from graph):</P>
<P>1. Excluding outlier -70% (+35 to -100), including outlier -20% (+200 to -100)</P>
<P>2. -75% (+15 to -100)</P>
<P>3. -35% (+70 to -100)</P>
<P>The trial authors did not report P values for between-group differences for change in ulcer size</P>
<P>Secondary outcomes:<BR/>Emergence of antibiotic-resistant flora during treatment period (30 participants included in analysis overall):<BR/>1. 1/10<BR/>2. 8/12<BR/>3. 6/9</P>
<P>The trial authors reported that the difference between Group 1 and the other groups was statistically significant (P value 0.02, appears to apply to Group 1 vs Group 2, and also to Group 1 vs Group 3)</P>
<P>Proportion of bacterial species isolated from ulcers resistant to ciprofloxacin/trimethoprim at the end of the study (16 weeks):</P>
<P>1. 4%/8%</P>
<P>2. 94%/63%</P>
<P>3. 12%/65%</P>
<P>The trial authors reported P value &lt; 0.0001 in relation to the difference between groups for ciprofloxacin resistance; it was not stated which comparison(s) this applied to. For trimethoprim resistance, the trial authors reported the following between-group differences: P value 0.004 for Group 1 versus Group 2; and P value 0.0003 for Group 1 versus Group 3</P>
<P>Persistence of presence of <I>Staph. aureus</I> in open ulcers at 16 weeks (denominators as reported by trial authors):</P>
<P>1. 7/7<BR/>2. 1/7<BR/>3. 5/6</P>
<P>Cost of treatment in Finland, in USD:<BR/>1. not reported<BR/>2. 600<BR/>3. 120</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:35:56 +0000" MODIFIED_BY="[Empty name]">
<P>Withdrawals:<BR/>Group 1: osteitis (1)<BR/>Group 2: personal reasons (1)<BR/>Group 3: adverse effects (3&#8212;rash, mild vertigo and nausea, chest pain)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-02 14:36:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ishibashi-1996">
<CHAR_METHODS MODIFIED="2013-12-02 14:36:24 +0000" MODIFIED_BY="Sue O'Meara">
<P>Randomised controlled trial conducted in Japan</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:36:24 +0000" MODIFIED_BY="[Empty name]">
<P>Setting: Japan (inpatients and outpatients)</P>
<P>Inclusion criteria: ulcer size 2 cm to 12 cm (unclear whether this is diameter or surface area); ulcer aetiology decubitus, burn injury or chronic venous insufficiency; participant aged 16 years or over</P>
<P>218 participants recruited in total (109 participants allocated per group)</P>
<P>Numbers of participants according to ulcer aetiology of 207 participants analysed (decubitus, burn injury, venous insufficiency): Group 1: 31, 41, 32; Group 2: 32, 40, 31</P>
<P>Numbers of participants with baseline ulcer area (in mm<SUP>2</SUP> &lt; 250, 250 to &lt; 500, 500 to &lt; 1000, 1000 to &lt; 2500, &#8805; 2500): Group 1: 4, 27, 24, 29, 20; Group 2: 8, 24, 29, 22, 20</P>
<P>Mean ± SE baseline ulcer area (mm<SUP>2</SUP>): Group 1: 1716.4 ± 217.8; Group 2: 1440.4 ± 153.5</P>
<P>Numbers of participants with baseline ulcer duration (in months, &lt; 1, 1 to &lt; 3, 3 to &lt; 6, 6 to &lt; 12, &#8805; 12, unknown): Group 1: 18, 45, 15, 10, 16, 0; Group 2: 21, 42, 16, 10, 13, 1</P>
<P>Mean ± SD baseline ulcer duration (days): Group 1: 270.4 ± 63.4; Group 2: 300.9 ± 87.4</P>
<P>Numbers of participants with infected ulcer at baseline (category assessed by clinical examination&#8212;much, moderate, slight, none): Group 1: 4, 8, 32, 60; Group 2: 1, 9, 26, 67</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:36:24 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: spray solution containing recombinant human basic fibroblast growth factor (KCB-1 0.01% solution 0.3 mL) to ulcer once a day after the ulcer was cleansed with antiseptic solution (unspecified). Three minutes after spraying, gauze pad was applied and secured with tape</P>
<P>Group 2: sugar and povidone-iodine ointment applied to ulcer once or twice daily after cleansing with antiseptic solution (unspecified), then gauze pad applied and secured with tape</P>
<P>No details of co-interventions such as compression</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-02 14:36:24 +0000" MODIFIED_BY="[Empty name]">
<P>Analysis based on 207 participants in total: Group 1: 104 participants; Group 2: 103 participants</P>
<P>Numbers (%) of venous leg ulcer participants with complete healing at 4 weeks: Group 1: 9/32 (28%); Group 2: 5/31 (16%)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:36:24 +0000" MODIFIED_BY="Sue O'Meara">
<P>If participants had multiple ulcers, one was selected for study (method of selection not stated)</P>
<P>Withdrawals due to protocol violation (excluded from analysis):</P>
<P>Group 1: 5/109 (4.6%) (1 took disallowed medication before trial, 1 had traumatic ulcer, 2 previously used sugar and povidone-iodine ointment, 1 nutritionally depleted)</P>
<P>Group 2: 6/109 (5.5%) (1 had hypothyroidism and did not use study medication, 1 had previously used sugar and povidone-iodine ointment and did not use study medication, 1 had positive patch test for povidone-iodine and did not use study medication, 1 general condition deteriorated because of sepsis and participant did not use study medication, 1 had traumatic ulcer, 1 had ulcer smaller than 2 cm)</P>
<P>Further withdrawals during the trial (included in analysis):</P>
<P>Group 1: 4 withdrawals (1 worsening condition, 1 concomitant disease, 2 other reasons); Group 2: 9 withdrawals (3 adverse events, 1 worsening condition, 2 no effect of trial treatment, 1 discharged, 1 died, 1 other reason)</P>
<P>Withdrawal data were not broken down by wound aetiology</P>
<P>Sponsor of study not stated; KCB-1 provided by Kaken Pharmaceutical Company Ltd, and sugar and povidone-iodine ointment provided by Kowa Company Ltd</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:54:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jull-2008">
<CHAR_METHODS MODIFIED="2013-12-02 14:36:56 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial (multi-centre, involving 4 community-based district nursing services in New Zealand). A sample size of 400 people was estimated as required to detect a 30% between-group difference in the proportion of healed ulcers at 12 weeks, with 90% power and 5% significance level, and allowing for 10% loss to follow-up. Recruitment achieved 92% of planned target; this was deemed to retain 90% power, as the anticipated loss to follow-up did not occur</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:36:56 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>368 participants with venous ulceration (ABPI &gt; 0.8) or mixed venous and arterial ulceration (ABPI &gt; 0.7), able to tolerate compression, were randomly assigned:</P>
<P>Group 1: 181 participants</P>
<P>Group 2: 187 participants</P>
<P>Ulcer duration at baseline, weeks, median (range) [mean ± SD]:</P>
<P>Group 1: 16 (2 to 999) [47.9 ± 118.1]</P>
<P>Group 2: 20 (3 to 688) [38.7 ± 76.3]</P>
<P>Baseline ulcer area, cm<SUP>2</SUP>, median (range) [mean ± SD]:</P>
<P>Group 1: 2.6 (0.2 to 81.0) [6.4 ± 9.8]</P>
<P>Group 2: 2.7 (0.1 to 193.0) [7.4 ± 18.2]</P>
<P>Numbers (%) of participants with mixed venous and arterial ulceration (ABPI &gt; 0.7 but &lt; 0.8):</P>
<P>Group 1: 5/181 (2.8)</P>
<P>Group 2: 2/187 (1.1)</P>
<P>Baseline SF-36 physical component summary score, mean ± SD:</P>
<P>Group 1: 34.0 (9.8)</P>
<P>Group 2: 36.7 (10.1)</P>
<P>Baseline SF-36 mental component summary score, mean ± SD:</P>
<P>Group 1: 50.5 (12.4)</P>
<P>Group 2: 48.7 (11.6)</P>
<P>The number of participants with signs and symptoms of infected ulcers at baseline is not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:37:07 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Group 1: usual care, with dressings applied according to district nurse choice (alginate, hydrofibre, hydrocolloid, foam, hydrogel, non-adherent, iodine or silver dressings)</P>
<P>Group 2: calcium alginate dressing impregnated with Manuka honey (ApiNate, Comvita, Te Puke, New Zealand) .</P>
<P>All participants received compression bandaging in accordance with usual practice in the study centres and dressing changes when compression bandaging was changed, with frequency determined by district nurses</P>
<P>Numbers (%) of participants with baseline compression system:</P>
<P>Group 1: short stretch 5 (3); long stretch 5 (3); three layer 65 (36); four layer 106 (59)</P>
<P>Group 2: short stretch 2 (1); long stretch 5 (3); three layer 74 (40); four layer 106 (57)</P>
<P>Treatment duration was 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:54:06 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Primary outcomes:</P>
<P>Numbers (%) of participants with ulcers completely healed at 12 weeks:</P>
<P>Group 1: 90/181 (50)</P>
<P>Group 2: 104/187 (56)</P>
<P>The trial authors reported a 5.9% (95% CI -4.3% to 15.7%) absolute increase in healing in Group 2, P value 0.258, and stated that findings were similar with adjustment for study centre and prognostic index (statistics not provided)</P>
<P>Mean time to healing, days at 12 weeks:</P>
<P>Group 1: 65.3</P>
<P>Group 2: 63.5</P>
<P>The trial authors reported a difference in means of -1.8 days (95% CI -7.7 days to 4.1 days), P value 0.553</P>
<P>The trial authors reported a hazard ratio estimation of 1.1 (95% CI 0.8 to 1.5), P value 0.451, and stated that findings were similar with adjustment for study centre and prognostic index (statistics not provided)</P>
<P>Mean percentage change in ulcer area at 12 weeks:</P>
<P>Group 1: -65.5%</P>
<P>Group 2: -74.1%</P>
<P>The trial authors reported a difference in means of 8.6% (95% CI 23.9% to -4.7%), P value 0.186, and stated that findings were similar with adjustment for study centre and prognostic index (statistics not provided)</P>
<P>Secondary outcomes:</P>
<P>Numbers (%) of participants with incident ulcer infection, diagnosed by clinical assessment or wound swab:</P>
<P>Group 1: 40/181 (22)</P>
<P>Group 2: 32/187 (17)</P>
<P>The trial authors reported an absolute difference of 5% (95% CI -3.1% to 13.1%), P value 0.228</P>
<P>Number of episodes of infection:</P>
<P>Group 1: 49</P>
<P>Group 2: 37</P>
<P>The trial authors reported P value 0.449 for the between-group difference</P>
<P>Numbers (%) of participants reporting one or more adverse events:</P>
<P>Group 1: 84/181 (46)</P>
<P>Group 2: 111/187 (59)</P>
<P>The trial authors reported a risk ratio of 1.3 (95% CI 1.1 to 1.6), P value 0.013</P>
<P>Numbers (%) of participants reporting local adverse events:</P>
<P>Group 1: pain 18 (10); bleeding 3 (2); dermatitis 8 (4); deterioration of ulcer 9 (5); erythema 4 (2); oedema 1 (&lt; 1); increased exudate 1 (&lt; 1); deterioration of surrounding skin 3 (2); new ulceration 15 (8); other 3 (2)</P>
<P>Group 2: pain 47 (25); bleeding 3 (2); dermatitis 8 (4); deterioration of ulcer 19 (10); erythema 6 (3); oedema 4 (2); increased exudate 5 (3); deterioration of surrounding skin 5 (3); new ulceration 16 (9); other 6 (3)</P>
<P>The trial authors reported that the between-group difference in pain was statistically significant, P value 0.001. All other between-group differences were not statistically significant (reported P values all &gt; 0.06)</P>
<P>Numbers (%) of participants reporting systemic adverse events:</P>
<P>Group 1: cardiovascular 3 (2); cancer 2 (1); neurological 1 (&lt; 1); gastrointestinal 2 (1); injury 9 (5); musculoskeletal 9 (5); respiratory 3 (2); other 7 (4)</P>
<P>Group 2: cardiovascular 4 (2); cancer 2 (1); neurological 4 (2); gastrointestinal 4 (2); injury 10 (5); musculoskeletal 13 (7); respiratory 6 (3); other 3 (2)</P>
<P>All between-group differences were not statistically significant (reported P values all &gt; 0.18)</P>
<P>Health-related quality of life assessed with SF-36 (8 domains scored on a scale of 1 to 100, with higher scores representing better perceived health, 100 being the best possible score):</P>
<P>SF-36 physical component mean summary score at 12 weeks:</P>
<P>Group 1: 37.9 (n = 174)</P>
<P>Group 2: 39.0 (n = 186)</P>
<P>The trial authors reported a difference in means of 1.1 (95% CI -0.8 to 3.0), P value 0.256 (not stated whether adjusted for baseline values)</P>
<P>SF-36 mental component mean summary score at 12 weeks:</P>
<P>Group 1: 50.4 (n = 174)</P>
<P>Group 2: 51.1 (n = 186)</P>
<P>The trial authors reported a difference in means of 0.7 (95% CI -1.1 to 2.4), P value 0.437 (not stated whether adjusted for baseline values)</P>
<P>Health-related quality of life assessed with CXVUQ (Charing Cross Venous Ulcer Questionnaire comprising four domains scored from 0 to 100, higher scores reflecting greater affliction, 100 being the worst possible score):</P>
<P>CXVUQ mean overall score at 12 weeks:</P>
<P>Group 1: 35.1 (n = 174)</P>
<P>Group 2: 33.5 (n = 186)</P>
<P>The trial authors reported a difference in means of -1.6 (95% CI -4.2 to 0.9), P value 0.204 (not stated whether adjusted for baseline values)</P>
<P>Health-related quality of life assessed with EQ-5D visual analogue scale (scale from 0 to 100, 0 = worst imaginable health state to 100 = best imaginable health state):</P>
<P>EQ-5D VAS mean score at 12 weeks:</P>
<P>Group 1: 73.5 (n = 174)</P>
<P>Group 2: 75.1 (n = 186)</P>
<P>The trial authors reported a difference in means of 1.6 (95% CI -1.5 to 4.7), P value 0.313 (not stated whether adjusted for baseline values)</P>
<P>Cost-effectiveness analysis, base case analysis of mean total health service costs per participant:</P>
<P>Group 1: NZD 972.68</P>
<P>Group 2: NZD 917.00</P>
<P>The trial authors reported that the ICER (incremental cost-effectiveness ratio) was -NZD 9.45 (95% CI -NZD 39.63 to NZD 16.07) favouring Group 2. Exclusion of hospitalisation costs (six participants hospitalised for a total of 40 days in Group 1 and three participants hospitalised for a total of 10 days in Group 2) reversed the ICER to NZD 11.34 (95% CI -NZD 2.24 to NZD 26.25) in favour of Group 1</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:37:57 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>This is the HALT Trial (ISRCTN 06161544)</P>
<P>In participants with multiple ulcers, the largest was used as the reference ulcer, and all ulcers for that participant were treated with the allocated intervention</P>
<P>Numbers (%) of participants lost to follow-up (reasons):</P>
<P>Group 1: 6/181 (3) (2 died, 3 moved, 1 uncontactable)</P>
<P>Group 2: 0/187 (0)</P>
<P>Numbers (%) of participants withdrawing from treatment (reasons):</P>
<P>Group 1: 0/181 (0)</P>
<P>Group 2: 31/187 (17) (8 deterioration of ulcer or surrounding skin, 7 healthcare professional's advice, 7 ulcer infection, 4 ulcer pain, 3 participant's choice, 1 ulcer bleeding, 1 dressing not available)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:49:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-J_x00f8_rgensen-2005">
<CHAR_METHODS MODIFIED="2013-12-02 14:38:17 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial (multi-centre, 15 centres in 7 countries, including Canada, Denmark, Germany, Italy, Netherlands, UK and USA)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:38:17 +0000" MODIFIED_BY="[Empty name]">
<P>129 participants with chronic venous or mixed venous/arterial leg ulcers (ABPI &#8805; 0.65) were recruited with the following characteristics: moderately or highly exuding ulcer; minimum ulcer size of 2 cm<SUP>2 </SUP>and maximum size not exceeding the 10 × 10-cm dressing; delayed healing (defined as area reduction 0.5 cm<SUP>2</SUP> or less during the previous 4 weeks); at least 1 clinical sign of critical colonisation (including increased exudate during previous 4 weeks, increased wound pain during previous 4 weeks, discolouration of granulation tissue or foul odour as assessed by study staff); use of compression therapy for 4 weeks before randomisation</P>
<P>Patients who had the following were excluded: clinical infection (including erysipelas and cellulitis of peri-ulcer skin); concomitant treatment with antibiotics or antiseptics during the week before randomisation; concomitant treatment with systemic corticosteroids exceeding 10 mg/d or other immunosuppressants from 4 weeks before randomisation; uncontrolled diabetes (HbA<SUB>1c</SUB> &gt; 10%); and diseases that may interfere with ulcer healing (e.g. vasculitis, rheumatoid arthritis, severe kidney or heart disease)</P>
<P>Group 1: 64 participants</P>
<P>Group 2: 65 participants</P>
<P>Baseline ulcer area, median cm<SUP>2 </SUP>(range):</P>
<P>Group 1: 6.7 (1.3 to 50.6)</P>
<P>Group 2: 6.1 (1.1 to 53.4)</P>
<P>Duration of ulcer at baseline, median years (range):</P>
<P>Group 1: 1.0 (0.1 to 10.0)</P>
<P>Group 2: 1.1 (0.1 to 32.0)</P>
<P>Numbers (%) of participants with ulcer infections during the previous year:</P>
<P>Group 1: 40/64 (62)</P>
<P>Group 2: 44/65 (67)</P>
<P>Health-related quality of life baseline score, assessed with EQ-5D (EUROQoL):</P>
<P>Group 1: median 0.71</P>
<P>Group 2: median 0.69</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:39:06 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: hydrocellular foam dressing 10 × 10 cm (Allevyn)</P>
<P>Group 2: silver foam dressing 10 × 10 cm (Contreet Ag)</P>
<P>All participants received wound cleansing with saline or tap water; securing of dressings with gauze or adhesive tape; treatment of peri-ulcer skin, as necessary, with a mild zinc cream or a topical steroid ointment; compression therapy according to the clinical practice of the centre, with the system unchanged throughout the trial period; dressings left in place for as long as clinically possible, to a maximum of 7 days; and weekly evaluation. Participants were treated for 4 weeks unless complete wound healing or withdrawal occurred sooner. Participants were withdrawn if treated with antibiotics or antiseptics during the trial</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:49:36 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<P>Numbers (%) of ulcers healed at 4 weeks:</P>
<P>Group 1: 5/64 (8)</P>
<P>Group 2: 5/65 (8)</P>
<P>Mean ulcer area remaining relative to baseline at 4 weeks % ± SD (median, range):</P>
<P>Group 1: 71.0 ± 38.9 (74.6, 100 to 148)</P>
<P>Group 2: 53.3 ± 34.6 (54.8, 100 to 126)</P>
<P>Median % change in ulcer area at 4 weeks:</P>
<P>Group 1: -25</P>
<P>Group 2: -45</P>
<P>Weekly % wound reduction rate median (mean):</P>
<P>Group 1: not reported</P>
<P>Group 2: 11.3 (11.2)</P>
<P>Secondary outcomes:</P>
<P>Health-related quality of life scores - EQ-5D (EUROQoL) at week 4 (1 = perfect health, 0 = death):</P>
<P>Group 1: median 0.79<BR/>Group 2: median 0.79</P>
<P>Numbers (%) of participants reporting adverse events and type of events:</P>
<P>Group 1: 3/64 (5) device-related skin reactions: maceration, eczema and satellite ulcer</P>
<P>Group 2: 4/65 (6) device-related skin reactions: satellite ulcer and deterioration of peri-ulcer skin</P>
<P>Proportion of participants developing peri-ulcer maceration after 1 week/4 weeks of treatment:</P>
<P>Group 1: 55%/48%</P>
<P>Group 2: 34%/37%</P>
<P>The trial authors reported the between-group difference at 1 week as statistically significant (P value 0.008) but did not report a test of statistical significance for the 4-week data</P>
<P>The trial authors reported that participants in both groups indicated a decrease in pain during the treatment period, but no data are presented</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:39:14 +0000" MODIFIED_BY="[Empty name]">
<P>Numbers (%) of participants withdrawing (reasons):</P>
<P>Group 1: 7 (11) (5 protocol violation, e.g. ulcer did not meet defined size limits; 1 treated with antibiotics unrelated to study ulcer; 1 other protocol violation, not defined)</P>
<P>Group 2: 13 (20) (7 protocol violation, e.g. ulcer did not meet defined size limits; 3 treated with antibiotics unrelated to study ulcer; 2 treated with antibiotics for study ulcer infection; 1 other protocol violation, not defined)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-02 14:39:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kerihuel-2010">
<CHAR_METHODS MODIFIED="2013-12-02 14:39:45 +0000" MODIFIED_BY="[Empty name]">
<P>Two separate randomised controlled trials, 1 in venous leg ulcer patients with 7 participating hospitals in France, the other in pressure ulcers. The trial authors stated that no a priori power calculation was undertaken</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:39:45 +0000" MODIFIED_BY="[Empty name]">
<P>Leg ulcer study: 60 participants were randomly assigned, with ulcers of primarily venous origin (ABPI &gt; 0.7), of &#8804; 12 months' duration, area 5 to 100 cm<SUP>2</SUP> and necrotic tissue covering &#8805; 50% of wound bed, not contraindicated to compression bandaging. Participants with diabetes were eligible for inclusion. Participants with infected ulcers requiring systemic antibiotics were excluded:</P>
<P>Group 1: 30 (9 had some arterial disease)</P>
<P>Group 2: 30 (8 had some arterial disease)</P>
<P>Numbers (%) of participants with wound duration &gt; 1 month:</P>
<P>Group 1: 11 (37)</P>
<P>Group 2: 10 (33)</P>
<P>Numbers (%) of participants with wound duration &gt; 3 months:</P>
<P>Group 1: 1 (3)</P>
<P>Group 2: 9 (30)</P>
<P>Wound area cm<SUP>2 </SUP>mean ± SD (median):</P>
<P>Group 1: 17.5 ± 24.4 (8.2)</P>
<P>Group 2: 18.1 ± 18.2 (12.1)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:39:56 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: hydrocolloid dressing (Duoderm)</P>
<P>Group 2: charcoal dressing impregnated with silver (Actisorb 220 silver)</P>
<P>All participants received sharp debridement of necrotic tissue; wound cleansing with sterile saline; dressing changes 2 to 3 times per week or more frequently in cases of abundant exudate; recommendation to wear elastic compression bandage (Biflex 16) daily; and weekly assessment</P>
<P>Numbers (%) of participants complying with use of compression:</P>
<P>Group 1: 15/30 (50)</P>
<P>Group 2: 12/30 (40)</P>
<P>Treatment duration was 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-02 14:39:56 +0000" MODIFIED_BY="[Empty name]">
<P>Change in wound area, cm<SUP>2 </SUP>median (range) at week 4:</P>
<P>Group 1: -3.5 (-53.3 to 18.5)</P>
<P>Group 2: -4.5 (-30.9 to 22.5)</P>
<P>P value for between-group difference at 4 weeks not provided</P>
<P>Percentage change at week 4, median (range):</P>
<P>Group 1: -40.9 (-100.0 to 308.3)</P>
<P>Group 2: -35.6 (-100.0 to 182.1)</P>
<P>P value for between-group difference at 4 weeks not provided</P>
<P>Numbers (%) of participants reporting adverse events (reasons):</P>
<P>Group 1: 20/30 (67) (9 maceration/high exudation, 1 wound infection, 5 eczema, 1 pain, 3 skin irritation, 1 bleeding at dressing removal)</P>
<P>Group 2: 5/30 (17) (1 wound infection, 2 wound aggravation, 1 pain, 1 skin irritation)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:39:56 +0000" MODIFIED_BY="[Empty name]">
<P>One ulcer per participant was included in the study; it was not reported how the reference wound was selected in participants with multiple wounds</P>
<P>Numbers (%) of participants withdrawing (reasons):</P>
<P>Group 1: 6/30 (20) (2 local adverse event&#8212;eczema; 1 died; 2 withdrew consent; 1 was discharged home)</P>
<P>Group 2: 1/30 (3) (hospitalisation for heart failure)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 13:00:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kero-1987">
<CHAR_METHODS MODIFIED="2013-12-02 14:40:43 +0000" MODIFIED_BY="Sue O'Meara">
<P>Randomised controlled trial conducted in Finland<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:40:43 +0000" MODIFIED_BY="[Empty name]">
<P>27 people over 18 years of age with venous leg ulcers recruited<BR/>Group 1: 13 people<BR/>Group 2: 14 people</P>
<P>Mean ± SD (range) baseline ulcer duration in months: Group 1: 12.2 ± 23.0 (1 to 72); Group 2: 54.8 ± 108.7 (1 to 360)</P>
<P>Baseline ulcer area and infection status were not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:40:43 +0000" MODIFIED_BY="Dolores Matthews">
<P>1. Ulcer surface cleansed with normal saline, mechanical wound cleansing procedure carried out, dextranomer applied to ulcer surface, dry compress cover applied, and conventional compression bandage applied<BR/>2. Same as above but cadexomer iodine used</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 13:00:25 +0000" MODIFIED_BY="[Empty name]">
<P>Complete healing at 8 weeks:<BR/>1. 5/13 (38%)<BR/>2. 7/14 (50%)</P>
<P>Trial authors did not report a P value for this comparison</P>
<P>Mean reduction in ulcer area at 8 weeks:<BR/>1. 35%<BR/>2. 81%<BR/>Between-group difference reported as non-significant but P value not presented</P>
<P>Secondary outcomes:<BR/>Adverse events:<BR/>Group 1: pain (1)<BR/>Group 2: erythema (1); pain (1); stinging sensation (1)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:40:43 +0000" MODIFIED_BY="[Empty name]">
<P>Withdrawals:<BR/>Group 1:<BR/>Drug-related S/Es (1); infection (2)</P>
<P>Group 2:<BR/>Drug-related S/Es (1); infection (2)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 13:09:30 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Kuznetsov-2009">
<CHAR_METHODS MODIFIED="2013-12-02 14:41:22 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Randomised controlled trial conducted in Russia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:41:22 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>30 participants with venous leg ulcers recruited from surgical outpatient clinic in Moscow, Russia</P>
<P>Group 1: 15 participants</P>
<P>Group 2: 15 participants</P>
<P>Numbers (%) of participants with aetiological factors for VLUs:</P>
<P>Group 1: 11 (73) participants with varicose vein disease; 4 (27) participants post thrombophlebitis</P>
<P>Group 2: 12 (80) participants with varicose vein disease; 3 (20) participants post thrombophlebitis</P>
<P>Mean size of ulcer at baseline cm<SUP>2 </SUP>± SD (range):</P>
<P>Group 1: 14.8 ± 3.4 (2.5 to 50.3)</P>
<P>Group 2: 17.4 ± 6.4 (2.2 to 99.5)</P>
<P>Numbers (%) of participants with ulcers &gt; 20cm<SUP>2</SUP>:</P>
<P>Group 1: 5 (33)</P>
<P>Group 2: 4 (27)</P>
<P>Numbers (%) of participants with microbiological isolates:</P>
<P>Group 1: <I>Staphylococcus aureus</I> 10 (67);<I> Pseudomonas aeruginosa </I>1 (6.7);<I> Escherichia coli </I>1 (6.7)</P>
<P>Group 2: <I>Staphylococcus aureus</I> 9 (60);<I> Pseudomonas aeruginosa </I>4 (27);<I> Proteus </I>species<I> </I>1 (6.7)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:41:22 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Group 1: 10% povidone-iodine dressing (Betadine), changed daily</P>
<P>Group 2: different dressings used according to ulcer status. If necrotic tissue present, a moist wound dressing was used (TenderWet 24). This is a wound dressing pad used in combination with Ringer's solution to continuously irrigate the wound bed for 24 hours, changed daily. Once the necrotic tissue was cleared, a foam dressing (PermaFoam) was applied and was changed every 5th day or sooner. In the case of resistant infection, the foam dressing was combined with tulle dressing containing silver (Atrauman Ag)</P>
<P>Both groups received short-stretch compression bandaging (Pütter-Verband, Hartmann). No participants underwent surgery</P>
<P>Biological and cytological assessment was undertaken at baseline and on days 7, 14 and 21</P>
<P>The duration of treatment was 28 days or until complete healing (whichever came first)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 13:09:30 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Primary outcomes:</P>
<P>Numbers (%) of participants with complete healing at 21 days:</P>
<P>Group 1: 1/15 (7)</P>
<P>Group 2: 4/15 (27)</P>
<P>Numbers (%) of participants with complete healing at 28 days:</P>
<P>Group 1: 2/15 (13)</P>
<P>Group 2: 5/15 (33)</P>
<P>Mean change in ulcer size in cm<SUP>2 </SUP>at 7 days:</P>
<P>Group 1: -0.35</P>
<P>Group 2: -2.09</P>
<P>Mean change in ulcer size in cm<SUP>2 </SUP>at 21 days:</P>
<P>Group 1: -1.27</P>
<P>Group 2: -5.03</P>
<P>Mean rate of healing in cm<SUP>2</SUP>/d:</P>
<P>Group 1: -0.06</P>
<P>Group 2: -0.24</P>
<P>The study authors reported that the between-group difference was statistically significant (P value &lt; 0.05)</P>
<P>Secondary outcomes:</P>
<P>Numbers (%) of participants with microbiological isolates at 21 days:</P>
<P>Group 1: <I>Staphylococcus aureus</I> 7 (47)<I>, Pseudomonas aeruginosa </I>1 (6.7)<I>, Escherichia coli </I>1 (6.7)</P>
<P>Group 2: <I>Staphylococcus aureus</I> 5 (33)<I>, Pseudomonas aeruginosa 3</I> (20)<I>, Proteus </I>species<I> </I>1 (6.7)</P>
<P>Mean cost of complete course of treatment per group (RUB):</P>
<P>Group 1: 6,669.84</P>
<P>Group 2: 14,360.15</P>
<P>Mean cost of treatment per participant, per day (RUB):</P>
<P>Group 1: 16.47</P>
<P>Group 2: 36.82</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:41:43 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Article translated from Russian</P>
<P>Unit of randomisation and analysis was the participant</P>
<P>Withdrawals not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:44:19 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Laudanska-1988">
<CHAR_METHODS MODIFIED="2013-12-02 14:48:45 +0000" MODIFIED_BY="Sue O'Meara">
<P>Randomised controlled trial conducted in Poland</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:48:45 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>67 people with venous leg ulcers who failed to respond to outpatient treatment (dressings and compression bandages) were recruited; data from 60 people were analysed by the trial authors. Those with ulcers of diameter &lt; 2 cm were excluded:<BR/>1. 33 people<BR/>2. 33 people</P>
<P>1 patient was excluded from the trial authors' analyses, for whom the treatment group was not specified</P>
<P>Mean ± SE baseline ulcer area, cm<SUP>2</SUP>: Group 1: 35.2 ± 8.1; Group 2: 27.5 ± 7.0<BR/>Mean ± SE baseline ulcer duration, months: Group 1: 15.0 ± 3.1; Group 2: 19.1 ± 4.3<BR/>No information about ulcer infection status at baseline (but it appeared that those with infected ulcers might have been allowed into the trial).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:48:45 +0000" MODIFIED_BY="[Empty name]">
<P>1. Ulcers cleansed with dilute hydrogen peroxide and covered with zinc paste dressing. The following were also used if deemed necessary by the clinician: saline dressing; dilute potassium permanganate solution; and gentian violet solution</P>
<P>2. Cadexomer iodine applied in a 3 to 4 mm layer</P>
<P>All participants were treated in a hospital inpatient setting and received daily dressing changes; a light elastic bandage to keep the dressing in place; and bed rest for the 6 weeks' duration of the trial; allowed out of bed for meals and toileting</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:44:19 +0000" MODIFIED_BY="Sue O'Meara">
<P>Primary outcomes:</P>
<P>Complete healing or very superficial wound remaining at 6 weeks:<BR/>1. 7/33<BR/>2. 16/33</P>
<P>Mean ulcer area reduction at 6 weeks:<BR/>1. 54%<BR/>2. 71%<BR/>P value &lt; 0.01 (reported by trial authors)</P>
<P>Secondary outcomes:<BR/>Pain assessed using 100=cm visual analogue scale: Figure presented in paper indicates reduction in pain at 6 weeks in both groups relative to baseline, but figure not detailed enough for values to be read. The trial authors reported that pain reduction occurred more rapidly in Group 2, and that relative to Group 1, significantly less pain was reported within 1 week of commencement of treatment (P value &lt; 0.01)</P>
<P>Numbers (%) of participants reporting adverse events (description):<BR/>1. 1/30 (3%) (stinging sensation in the ulcer when dressing applied)<BR/>2. 6/30 (20%) (1 peri-ulcer erythema; 5 stinging sensation in the ulcer when dressing applied)</P>
<P>Elevation of serum concentrations of protein-bound iodine occurred after treatment with cadexomer iodine in participants with large ulcers, but tests of thyroid function showed no changes associated with the use of cadexomer iodine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:48:45 +0000" MODIFIED_BY="[Empty name]">
<P>Overall, 7/67 (10%) participants withdrew. 4 participants (2 per group) withdrew before the first assessment (social reasons 3 and heart failure 1; reasons not presented per group)</P>
<P>A further 3 participants completed the trial but were excluded from analysis, 2 because of difficulty in measuring the ulcer because of large size (1 per group) and 1 because of having an ulcer associated with severe rheumatoid arthritis, which interfered with assessment (group not stated)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:49:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lazareth-2008">
<CHAR_METHODS MODIFIED="2013-12-02 14:48:46 +0000" MODIFIED_BY="[Empty name]">
<P>Multi-centre randomised controlled trial (24 centres in France, including hospital dermatology and vascular medicine outpatient clinics). A minimum sample size of 96 participants was determined a priori<I> </I>to have 80% power to detect, at 8 weeks, 15% superiority of the silver dressing if relative wound area regression in the non-silver group was within a 20% to 25% range, with an expected standard deviation of 26% and a two-tailed 5% significance level</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:48:46 +0000" MODIFIED_BY="[Empty name]">
<P>102 participants with venous leg ulcers (ABPI &gt; 0.8), ulcer duration &lt; 24 months, wound area 5 to 40 cm<SUP>2</SUP> and presence of at least 3 of 5 clinical signs of heavy bacterial load (pain at dressing change, peri-ulcer erythema, oedema, foul odour, and heavy exudate). Patients with diabetes were eligible for inclusion. Patients with the following were excluded: current (or within previous week) usage of local or systemic antibiotics; clinically infected wound; erysipelas; malignant wound; recent deep vein thrombosis or venous surgery; neoplastic lesion treated by radiotherapy or chemotherapy; and ongoing treatment with immunosuppressive agents or high dose corticosteroids</P>
<P>Group 1: 50 participants</P>
<P>Group 2: 52 participants</P>
<P>Mean duration of ulcer months ± SD (median)</P>
<P>Group 1: 10 ± 8 (9.0)</P>
<P>Group 2: 11 ± 8 (9.5)</P>
<P>Mean ulcer area, cm<SUP>2</SUP> ± SD (median)</P>
<P>Group 1: 17.5 ± 14.4 (12.6)</P>
<P>Group 2: 22.3 ± 20.4 (16.3)</P>
<P>71% of patients were outpatients at recruitment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:48:46 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: contact layer dressing (Restore)&#8212;similar to test dressing, the only difference being the absence of silver</P>
<P>Group 2: contact layer silver dressing (Restore Silver)&#8212;non-adhesive, non-occlusive, polyester mesh impregnated with hydrocolloid particles and Vaseline. Silver incorporated as silver sulphate that releases over 7 days. 10 × 10-cm dressing</P>
<P>All participants received wound cleansing with normal saline; mechanical debridement, where necessary, to remove slough and necrotic tissue; secondary foam dressings (Ultrasorb); compression therapy selected by the investigators; and dressing changes every other day or less frequently, depending on the clinical condition of the wound and the volume of exudate. Local use of antiseptics (but not antibiotics) was permitted</P>
<P>Investigators withdrew participants from the study if dressing-related adverse events occurred, or if they considered that a different treatment was warranted (e.g. systemic antibiotics)</P>
<P>Treatment duration was 4 weeks, after which all participants received the non-silver dressing for a further 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:49:37 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<P>Mean change in ulcer area at 4 weeks, cm<SUP>2</SUP> ± SD (median):</P>
<P>Group 1: -1.3 ± 9.0 (-1.1), n = 48</P>
<P>Group 2: -6.5 ± 13.4 (-4.2), n = 51</P>
<P>The trial authors reported that the between-group difference was statistically significant (P value 0.023)</P>
<P>Mean relative change in ulcer size at 4 weeks % ± SD (median):</P>
<P>Group 1: -8.6 ± 54.6 (-9.5), n = 48</P>
<P>Group 2: -28.1 ± 36.7 (-29.1), n = 51</P>
<P>No P value reported for between-group difference</P>
<P>Mean healing rate, cm<SUP>2</SUP>/day ± SD (median) at 4 weeks:</P>
<P>Group 1: -0.08 ± 0.56 (-0.04), n = 48</P>
<P>Group 2: -0.20 ± 0.42 (-0.15), n = 51</P>
<P>The trial authors reported that the between-group difference was statistically significant (P value 0.009)</P>
<P>Secondary outcomes:</P>
<P>Numbers (%) of participants with no clinical signs of bacterial colonisation at 4 weeks:</P>
<P>Group 1: 8/50 (17)</P>
<P>Group 2: 20/52 (39)</P>
<P>Numbers (%) of participants with adverse events at 4 weeks (event type):</P>
<P>Group 1: 11/50 (22) (2 erythema/oedema, 1 infection, 4 peri-ulcer skin irritation, 1 pain, 1 over granulation, 2 other). 5 participants withdrew because of adverse events (types not specified)</P>
<P>Group 2: 11/52 (21) (1 erythema/oedema, 2 infection, 4 peri-ulcer skin irritation, 2 pain, 2 other). 4 participants withdrew because of adverse events (types not specified)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:48:46 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Numbers (%) of participants withdrawing up to week 4 (reasons):</P>
<P>Group 1: 14 (28) (4 ulcer aggravation, 9 local adverse event, 1 other event)</P>
<P>Group 2: 3 (6) (1 consent withdrawal, 2 ulcer aggravation)</P>
<P>Further follow-up data were reported at 8 weeks, but data here were only recorded at 4 weeks to reflect the period of the controlled study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:44:25 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Lindsay-1986">
<CHAR_METHODS MODIFIED="2013-12-02 14:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial conducted in the UK. Trial was of cross-over design with cross-over point at 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:48:47 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>28 females over 30 years of age with exuding venous leg ulcers were recruited. Patients with insulin-dependent diabetes were excluded<BR/>Group 1: 14 randomly assigned, 13 completed<BR/>Group 2: 14 randomly assigned, 12 completed</P>
<P>Mean ulcer area, mm<SUP>2</SUP> (read from graph):</P>
<P>Group 1: 1300</P>
<P>Group 2: 1250</P>
<P>Mean baseline ulcer duration: 20.1 months (breakdown per group not reported)<BR/>Not stated whether wounds were clinically infected at baseline (but it appeared that those with infected ulcers might have been allowed into the trial).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>1. Standard treatment consisting of sterile, non-adherent dressing plus support bandaging or stocking changed on alternate days. Other treatments were also allowed, including topical antimicrobials<BR/>
</P>
<P>2. Ulcer cleansed with sterile saline swabs or water or saline irrigation; cadexomer iodine applied to ulcer surface in a 3-mm layer; dry sterile dressing applied and secured with support bandaging or stocking. The dressing was changed on alternate days</P>
<P>All participants had ulcers managed in the community by general practitioners. After 4 weeks, participants were switched to the alternative treatment or were withdrawn from the trial according to the clinician's judgement</P>
<P>The duration of the trial was 10 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:44:25 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Primary outcomes:</P>
<P>Complete healing at 4 weeks:<BR/>1. 1/14<BR/>2. 4/14</P>
<P>Mean reduction in ulcer area at 4 weeks:<BR/>1. 4.2%<BR/>2. 33.6%<BR/>P value &lt; 0.005 (reported by trial authors)</P>
<P>Secondary outcomes:<BR/>Ulcer pain assessed with 10-cm visual analogue scale. The trial authors reported that Group 2 had significantly better results for pain after 4 weeks (P value &lt; 0.002) but no further information presented</P>
<P>Infection assessed using swab taken before ulcer cleansing: the trial authors reported that the most frequently isolated organisms during the trial were Enterobacteriaceae, usually polymicrobial infections. The second most frequently occurring group was <I>Staphylococcus aureus,</I> and 4 participants were colonised by <I>Pseudomonas</I> species. Streptococci groups C and G were also isolated but were quickly eliminated. Cadeomer iodine treatment resulted in elimination or decrease of organisms in most cases. These data appear to relate to the first 4 weeks of the trial, but further information and breakdown by group not provided<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>Numbers of participants who withdrew, with reasons:<BR/>Group 1: peripheral vascular disease (1)<BR/>Group 2: allergy (1); itching and irritation (1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:49:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meaume-2005">
<CHAR_METHODS MODIFIED="2013-12-02 14:48:48 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial (multi-centre, involving 13 study centres in France). Sample size estimation was described, although not in relation to healing outcomes (it was in relation to a risk of wound infection score&#8212;mASEPSIS)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:48:48 +0000" MODIFIED_BY="[Empty name]">
<P>99 patients with venous leg ulcers (ABPI &gt; 0.7) or pressure ulcers were recruited who were hospitalised or who could be seen daily for 14 days. To be eligible, wounds had to be 2 to 20 cm in one dimension; have at least one of the following signs&#8212;covered with &gt; 50% yellow slough, discoloured or friable granulation tissue, pocketing or undermining at the base of the wound, or foul odour; have at least two of the following signs of critical colonisation present&#8212;continuous pain, erythema, oedema, heat and moderate to high levels of exudate. Patients with diabetes were eligible for inclusion</P>
<P>Patients with the following were excluded: clear signs of ulcer infection requiring antibiotics, or lymphangitis and/or fever; poor life expectancy; clinical condition that might interfere with wound healing; receiving systemic antibiotics during previous 5 days; or receiving a topical chemical debridement agent during previous 7 days</P>
<P>Group 1: 48 participants (33 had VLU)</P>
<P>Group 2: 51 participants (38 had VLU)</P>
<P>Mean ulcer duration of VLU participants, months ± SD (median):</P>
<P>Group 1: 25.0 ± 37.2 (7.0)</P>
<P>Group 2: 42.5 ± 96.0 (12.0)</P>
<P>Mean ulcer area of VLU participants, cm<SUP>2</SUP> ± SD (median):</P>
<P>Group 1: 24.5 ± 21.3 (16.1)</P>
<P>Group 2: 44.8 ± 46.3 (25.7)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-03 16:06:21 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: pure calcium alginate dressing (Algosteril)</P>
<P>Group 2: silver-releasing hydro alginate dressing (Silvercel)</P>
<P>All participants received wound cleansing with sterile saline; debridement as necessary, using surgical or mechanical methods; sterile pads as secondary dressings secured with hypoallergenic adhesives; systemic antibiotic therapy in cases of wound infection; at least 5 dressing changes per week during the first 2 weeks, and at least every 2 to 3 days thereafter. All participants with venous leg ulcers were treated with compression bandaging designed to provide 15 to 35 mmHg initial ankle pressure (French classification II to III). Wound cultures were taken at the investigators' discretion, but methods used were not reported</P>
<P>Treatment duration was two weeks. Participants were followed up whenever possible for an additional two weeks to evaluate change in wound surface area and to continue monitoring dressing acceptability and tolerability</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:49:38 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<P>Mean ± SD change in ulcer area (cm<SUP>2</SUP>, VLU participants only) at week 4:</P>
<P>Group 1: -6.0 ± 11.7</P>
<P>Group 2: -9.5 ± 17.9</P>
<P>The trial authors did not report a P value for the between-group difference</P>
<P>Mean ± SD percentage change in ulcer area (VLU participants only) at week 4:</P>
<P>Group 1: -28.5 ± 37.0</P>
<P>Group 2: -21.0 ± 45.4</P>
<P>The trial authors did not report a P value for the between-group difference</P>
<P>Mean ± SD healing rate over 4 weeks (cm<SUP>2</SUP>/d, VLU participants only):</P>
<P>Group 1: 0.21 ± 0.42</P>
<P>Group 2: 0.34 ± 0.64</P>
<P>The trial authors did not report a P value for the between-group difference</P>
<P>Secondary outcomes:</P>
<P>Mean ± SD mASEPSIS index (ITT population, VLU participants only), follow-up point unclear:</P>
<P>Group 1: 86.3 ± 51.0 (n = 33)</P>
<P>Group 2: 111.8 ± 79.1 (n = 38)</P>
<P>Note: The mASEPSIS index is an evaluation of the risk of wound infection, with higher scores indicating higher risk of infection. The trial authors reported that the between-group difference was not statistically significant (P value not provided) and that findings were similar for VLU participants between ITT and per protocol populations</P>
<P>NB: The following findings apply to all participants, separate data not available for VLU participants:</P>
<P>Numbers (%) of wounds in all participants who developed a clinical infection during the 4-week follow-up:</P>
<P>Group 1; 23/51 (46)</P>
<P>Group 2: 16/48 (33)</P>
<P>The trial authors reported that the between-group difference was not statistically significant (P value 0.223)</P>
<P>Numbers (%) of all participants requiring systemic antibiotics during the 4-week follow-up:</P>
<P>Group 1: 4/51 (8)</P>
<P>Group 2: 5/48 (10)</P>
<P>The trial authors reported that the between-group difference was not statistically significant (P value 0.736)</P>
<P>Numbers (%) of all participants with adverse events (event type):</P>
<P>Group 1: 5/48 (10)&#8212;all were VLU participants (1 pain during dressing change; 1 peri-ulcer eczema; 1 burning sensation following dressing change; 1 increased wound size and pain; 1 erythema and pain)</P>
<P>Group 2: 5/51 (8)&#8212;4 were VLU participants (1 peri-ulcer eczema; 1 peri-wound irritation due to maceration; 1 extension of slough and dry wound; 1 pruritis and pain; 1 pain during dressing change, peri-ulcer erythema and pruritus)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:48:48 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Numbers (%) of all participants withdrawing (reasons):</P>
<P>Group 1: 9/48 (19) (1 alginate dressing no longer indicated, as wound had become dry; 1 intercurrent event; 1 wound grafting; 2 wound infection; 4 wound aggravation)</P>
<P>Group 2: 10/51 (20) (1 alginate dressing no longer indicated, as wound had become dry; 1 consent withdrawal; 4 intercurrent event; 1 wound grafting; 1 wound infection; 2 wound aggravation)</P>
<P>Numbers (%) of VLU participants withdrawing:</P>
<P>Group 1: 6/33 (18)</P>
<P>Group 2: 9/38 (24)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 13:04:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Michaels-2009">
<CHAR_METHODS MODIFIED="2013-12-02 14:48:49 +0000" MODIFIED_BY="[Empty name]">
<P>Multi-centre pragmatic randomised controlled trial conducted in the UK. Initial sample size requirement was for 300 participants, including loss to follow-up and withdrawal; this was revised to 212 participants after slow recruitment resulting in an extension to the trial's duration, and information from an interim analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:48:49 +0000" MODIFIED_BY="[Empty name]">
<P>Patients with active ulceration of the lower leg &#8805; 1 cm in diameter that had been present for longer than 6 weeks were included. Patients with the following were excluded: ABPI &lt; 0.8 in the affected leg; systemic antibiotic use; and insulin-controlled diabetes mellitus</P>
<P>Group 1: 106 participants</P>
<P>Group 2: 107 participants</P>
<P>Numbers (%) of participants with ulcer size &#8804; 3 cm in diameter:</P>
<P>Group 1: 76 (72)</P>
<P>Group 2: 77 (72)</P>
<P>Numbers (%) of participants with ulcer size &gt; 3 cm in diameter:</P>
<P>Group 1: 30 (28)</P>
<P>Group 2: 30 (28)</P>
<P>Numbers (%) of participants with previous ulcer in either leg:</P>
<P>Group 1: 52 (49)</P>
<P>Group 2: 61 (57)</P>
<P>Median baseline ulcer size, cm<SUP>2</SUP> (from figure):</P>
<P>Group 1: 2.5</P>
<P>Group 2: 2.5</P>
<P>Numbers (%) of participants with ulcer present &gt; 12 weeks:</P>
<P>Group 1: 43 (40)</P>
<P>Group 2: 39 (36)</P>
<P>Mean EQ-5D health state scores:</P>
<P>Group 1: 0.6536 (n = 94)</P>
<P>Group 2: 0.6446 (n = 98)</P>
<P>Mean SF-6D health state scores:</P>
<P>Group 1: 0.6792 (n = 83)</P>
<P>Group 2: 0.6544 (n = 89)</P>
<P>No information on signs of ulcer infection or colonisation reported, but patients were excluded if using antibiotics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:48:49 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: non-antimicrobial low-adherent dressing from any manufacturer (most were knitted viscose dressings)</P>
<P>Group 2: approved silver-donating dressings including silver-impregnated foam, alginate, hydrocolloid, low-adherent and non-adherent dressings (Aquacel Ag, Acticoat, Acticoat 7, Acticoat Absorbant, Contreet Ag or Urgotel SSD). The most commonly used dressings were Urgotel SSD, Acticoat 7 and Aquacel Ag. Most participants remained on the same dressing during the treatment period</P>
<P>The choice of the specific silver-donating or non-silver dressing was the responsibility of the clinician. In both groups, the allocated dressing was placed beneath multi-layer compression, applied by a nurse trained in the technique. Dressings were changed and bandages reapplied on a weekly basis unless clinicians believed that more frequent changes were necessary. The choice of compression was based on local practice. After healing, a compression stocking was recommended. Other interventions such as debridement were used if needed</P>
<P>Treatment duration was until the ulcers were fully healed, or for the 12-week treatment period of the trial. Follow-up was at 1, 3, 6 and 12 months. If active ulceration was still present after 12 weeks, the decision regarding continuation or change of the dressing was made by the clinician</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 13:04:35 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<P>Median time to healing, days (95% CI):</P>
<P>Group 1: 58 (43 to 73)</P>
<P>Group 2: 67 (54 to 80)</P>
<P>The trial authors reported that the between-group difference was not statistically significant (P value 0.408, Cox proportional hazards model)</P>
<P>The trial authors reported the following hazard ratio estimate for silver versus control dressings: 1.13 (95% CI 0.85 to 1.15)</P>
<P>Numbers (%) of participants with complete ulcer healing at 12 weeks:</P>
<P>Group 1: 59/106 (56)</P>
<P>Group 2: 62/107 (58)</P>
<P>Numbers (%) of participants with complete ulcer healing at 6 months:</P>
<P>Group 1: 78/106 (74)</P>
<P>Group 2: 87/107 (81)</P>
<P>Numbers (%) of participants with complete ulcer healing at 12 months:</P>
<P>Group 1: 90/106 (85)</P>
<P>Group 2: 95/107 (89)</P>
<P>Secondary outcomes:</P>
<P>Recurrence rates within first year.:</P>
<P>Group 1: 13 (14%) of 90 participants who were healed within the first year</P>
<P>Group 2: 11 (12%) of 95 participants who were healed within the first year</P>
<P>
<BR/>Health-related quality of life:</P>
<P>Mean EQ-5D health state scores at 12 weeks/1 year (adjusted for baseline EQ-5D score):</P>
<P>Group 1: 0.7004 (n = 76)/0.6752 (n = 58)</P>
<P>Group 2: 0.7255 (n = 81)/0.7526 (n = 61)</P>
<P>Mean SF-6D health state scores at 12 weeks/1 year (adjusted for baseline SF-6D score):</P>
<P>Group 1: 0.7029 (n = 68)/0.662 (n = 53)</P>
<P>Group 2: 0.6864 (n = 73)/0.7092 (n = 55)</P>
<P>The trial authors reported no significant between-group differences at any of the follow-up times (baseline, 1, 3, 6 and 12 months) in the EQ-5D and SF-6D mean utility scores. No significant difference between groups was noted with respect to mean follow-up after adjustment for age. This was also true when the mean scores for the eight SF-36 dimensions were compared.</P>
<P>
<BR/>Adverse events:</P>
<P>The trial authors reported no adverse events identified as being related to the dressings, although 1 participant in Group 2 stopped treatment at week 4 because of skin irritation. Also, 4 participants in each group died during the 1-year follow-up period, but after the 12-week treatment period</P>
<P>Costs and resource use, price year 2007:</P>
<P>Mean cost of clinic visits GBP (95% CI):</P>
<P>Group 1: 196.06 (156.95 to 235.18) (n = 67)</P>
<P>Group 2: 275.39 (236.83 to 313.95) (n = 74)</P>
<P>Mean cost per dressing GBP (95% CI):</P>
<P>Group 1: 5.73 (2.96 to 8.49) (n = 67)</P>
<P>Group 2: 30.62 (25.47 to 35.78) (n = 74)</P>
<P>Mean total cost per participant based on cost of clinic visits, home visits, dressings, bandages, GP and chiropody contacts, compression hosiery, antibiotics and other medicines GBP (95% CI):</P>
<P>Group 1: 320.12 (277.42 to 362.82) (n = 67)</P>
<P>Group 2: 417.97 (375.01 to 460.93) (n = 74)</P>
<P>Cost-effectiveness:</P>
<P>Silver dressings were associated with an incremental cost in GBP of 97·85 and an incremental QALY (quality-adjusted life-year) gain of 0·0002 compared with control dressings. The ICER for silver dressings was GBP 489,250 per QALY gained. Based on these data and additional sensitivity analyses, the trial authors concluded that silver dressings were unlikely to be cost-effective</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:48:49 +0000" MODIFIED_BY="[Empty name]">
<P>In participants with bilateral ulceration, the leg with the greatest total ulcer area was the study limb, but the allocated treatment was used for both legs</P>
<P>Numbers (%) of participants withdrawing (reasons):</P>
<P>Group 1: 5 (5) (2 lost to follow-up; 3 received silver dressing; 1 was by participant request and 2 by nurses' choice)</P>
<P>Group 2: 8 (7) (3 lost to follow-up; 4 did not receive a silver dressing; 1 case was due to non-availability of dressing and 3 were unexplained; 1 case of skin irritation)</P>
<P>Numbers (%) of participants who did not receive the allocated dressing:</P>
<P>Group 1: 3/106 (3)&#8212;treated with silver-donating dressings</P>
<P>Group 2: 4/107 (4)&#8212;1 healed before dressing became available, 3 unexplained breach of protocol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:49:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-2010">
<CHAR_METHODS MODIFIED="2013-12-02 14:48:50 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial (multi-centre involving 2 not-for-profit community nursing services in Australia). Sample size calculation estimation was reported, but the number of patients recruited was less than the estimated number (281 vs 360)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:48:50 +0000" MODIFIED_BY="[Empty name]">
<P>281 participants with venous or mixed venous/arterial aetiology leg ulcers (ABPI &#8805; 0.6) and &#8804; 15 cm in diameter were randomly assigned. Ulcers had to present at least one of the following signs of infection or critical colonisation: cellulitis, suppuration, lymphangitis, sepsis, bacteraemia, changes in granulation tissue, increased or malodorous exudate, new areas of slough or wound breakdown, impaired healing, increased or new pain. Patients with/receiving the following were excluded: diabetes; malignant leg ulcer; topical antiseptics within 1 week of recruitment; antibiotics within 48 hours of recruitment; systemic steroids; or palliative care</P>
<P>74% of recruited participants had venous leg ulceration; the remainder had mixed disease (data per group not provided):</P>
<P>Group 1: 140 participants</P>
<P>Group 2: 141 participants</P>
<P>Mean baseline ulcer area reported for participants included in final analysis (cm<SUP>2</SUP> ± SD):</P>
<P>Group 1: 59.7 ± 63.2 (n = 133)</P>
<P>Group 2: 81.2 ± 107.0 (n = 133)</P>
<P>Mean baseline ulcer duration reported for participants included in final analysis (weeks ± SD):</P>
<P>Group 1: 58.1 ± 260.6 (n = 133)</P>
<P>Group 2: 49.4 ± 165.9 (n = 133)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:48:50 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Group 1: silver-donating dressings (Acticoat, Acticoat Absorbant or Acticoat 7)</P>
<P>Group 2: cadexomer iodine dressings (Iodosorb ointment or Iodosor powder)</P>
<P>All participants received dressing choice determined by clinician, according to individual wound characteristics such as moisture levels; and four-layer compression bandaging (Profore or Profore Lite). Dressings in both groups were provided until all signs of critical colonisation and infection had been absent for 1 week, after which a non-antimicrobial dressing was applied according to the clinician's judgement. If signs of critical colonisation or infection recurred, the original randomised dressing was reinstated</P>
<P>Fifty-five participants received antibiotic treatment during the 12-week study period. Breakdown by group not reported</P>
<P>Duration of treatment was 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:49:39 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Primary outcomes:</P>
<P>Time to healing:</P>
<P>Estimates not provided; the trial authors reported that the between-group difference was not statistically significant (P value 0.70, log rank test; and P value 0.80 Wilcoxon test)</P>
<P>Numbers (%) of ulcers healed at week 12:</P>
<P>Group 1: 85/140 (61)</P>
<P>Group 2: 84/141 (60)</P>
<P>Mean percentage daily healing rate ± SD:</P>
<P>Group 1: -2.10 ± 1.89 (n = 133)</P>
<P>Group 2: -1.69 ± 2.46 (n = 133)</P>
<P>Secondary outcomes:</P>
<P>Numbers of adverse events reported:</P>
<P>Group 1: 13</P>
<P>Group 2: 8</P>
<P>Details of the adverse events not provided; unclear whether the numbers provided refer to the numbers of participants reporting adverse events, or the number of adverse events in the group.</P>
<P>Bacterial profile of wounds obtained by swab, using a rotating, 10-point zigzag technique while avoiding necrotic tissue, across wound bed, which had been cleansed with sterile water before specimen collection. Gram stain and semi-quantitative analyses were conducted to identify the species and level of bacteria present. The bacterial burden was classified as nil/scant, low, moderate or heavy. In assessing the semi-quantitative bacteriology results for each swab, the highest level of growth for bacilli positive, bacilli negative, cocci positive or cocci negative was used, regardless of which organism was isolated from the wound culture. Swab data obtained from 278 participants, breakdown per group not provided</P>
<P>Numbers (%) of participants with nil/scant/low and mod/high degree of bacterial growth during the first 2 weeks of treatment:</P>
<P>Leucocytes:</P>
<P>Group 1: 116 nil/scant/ low; 16 mod/high</P>
<P>Group 2: 110 nil/scant/ low; 17 mod/high</P>
<P>Gram-postive bacilli:</P>
<P>Group 1: 90 nil/scant/ low; 5 mod/high</P>
<P>Group 2: 90 nil/scant/ low; 1 mod/high</P>
<P>Gram-negative bacilli:</P>
<P>Group 1: 62 nil/scant/ low; 43 mod/high</P>
<P>Group 2: 64 nil/scant/ low; 32 mod/high</P>
<P>Gram-positive cocci:</P>
<P>Group 1: 72 nil/scant/ low; 41 mod/high</P>
<P>Group 2: 73 nil/scant/ low; 35 mod/high</P>
<P>Gram-negative cocci:</P>
<P>Group 1: 87 nil/scant/ low; 0 mod/high</P>
<P>Group 2: 83 nil/scant/ low; 0 mod/high</P>
<P>
<I>Staphylococcus aureus</I> was the most commonly isolated organism overall (isolated from around 90% of ulcers, further data and breakdown per group not provided). 16 swabs were identified with methicillin-resistant <I>Staphylococcus aureus</I> (not explained how many participants this relates to, nor which treatment groups)</P>
<P>The trial authors reported that when moderate to heavy growth was identified, no differences in healing rates were noted between treatment groups. When nil/scant or low bacterial growth was identified, Group 1 had a significantly faster healing rate compared with Group 2 in relation to leucocytes (P value &lt; 0.01), Gram-positive bacilli (P value &lt; 0.05), Gram-positive cocci (P value &lt; 0.01) and Gram-negative cocci (P value &lt; 0.05) within the first 2 weeks</P>
<P>Healing rates in light of bacterial colony and degree of bacterial burden were not examined for the entire 12-week study period because of variations in the timing of swabs; the baseline swab was the only consistent time when all study participants were swabbed</P>
<P>Dressing acceptability as rated by participants with a 4-point questionnaire&#8212;completely agree, moderately agree, moderately disagree, completely disagree that the dressing was acceptable</P>
<P>Proportion of participants who completely or moderately agreed that the dressing was acceptable overall:</P>
<P>Group 1: 91.6% (n = 107)</P>
<P>Group 2: 88.9% (n = 100)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:48:50 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>The trial authors reported that baseline differences in wound size were adjusted for in the analysis.</P>
<P>Numbers (%) of participants withdrawing (reasons):</P>
<P>Group 1: 7 (5) (1 lost to follow-up, 5 withdrawn and insufficient data for analysis, 1 died)</P>
<P>Group 2: 8 (6) (3 lost to follow-up, 5 withdrawn and insufficient data for analysis)</P>
<P>When participants had multiple wounds, the wound with the most signs of critical colonisation or infection was studied, but the same randomly assigned treatment was applied to all wounds for that participant</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-02 14:48:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morias-1979">
<CHAR_METHODS MODIFIED="2013-12-02 14:48:51 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial conducted in Belgium<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:48:51 +0000" MODIFIED_BY="[Empty name]">
<P>59 people with chronic leg ulcers, 45/59 (76%) of venous aetiology, were recruited<BR/>Group 1: 29 people<BR/>Group 2: 30 people</P>
<P>Median (range) baseline ulcer area (mm<SUP>2</SUP>): Group 1: 100 (4 to 3300); Group 2: 100 (3 to 4400)<BR/>No information about baseline ulcer duration or infection status of wounds<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:48:51 +0000" MODIFIED_BY="[Empty name]">
<P>1. Placebo tablet identical in appearance to levamisole<BR/>2. Levamisole dosed according to body weight ranging from 100 to 250 mg, given on 2 consecutive days every week until cure or failure or for 20 weeks</P>
<P>Previously used topical treatment was continued for all participants; no information about whether this included compression<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-01 19:16:08 +0000" MODIFIED_BY="[Empty name]">
<P>At 20 weeks<BR/>Number of ulcers cured<BR/>1. 22/29 (76%)<BR/>2. 30/30 (100%)</P>
<P>Secondary outcomes:<BR/>Adverse effects<BR/>1. Group 1: 0/29 (0%)<BR/>2. Group 2: 3/30 (10%) - all were gastric complaints </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:48:51 +0000" MODIFIED_BY="Sue O'Meara">
<P>Group 1: evident failure (8)<BR/>Group 2: evident failure (2)</P>
<P>The trial authors state that double-blind treatment was stopped before the end of the trial in eight participants in Group 1 and two participants in Group 2 because of "evident failure" (defined as no improvement). However, other information in the trial report suggests that all 59 participants were followed up for 20 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 13:00:26 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Moss-1987">
<CHAR_METHODS MODIFIED="2013-12-02 14:48:52 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial conducted in the UK, cross-over design (with cross-over point at 6 weeks)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:48:52 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>43 outpatients with venous leg ulcers of &gt; 3 months' duration, unresponsive to topical treatment, were randomly assigned. Some participants also had arterial disease, and no further information was provided. Data reported on 42 participants:<BR/>Group 1: 21 completers<BR/>Group 2: 21 completers</P>
<P>Median ± SD baseline ulcer area (cm<SUP>2</SUP>): Group 1: 25.5 ± 29.5; Group 2: 19.7 ± 19.8<BR/>Median ± SD baseline ulcer duration (months): Group 1: 61.0 ± 68.0; Group 2: 75.0 ± 127.0<BR/>No information about whether wounds were clinically infected at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:48:52 +0000" MODIFIED_BY="[Empty name]">
<P>1. Ulcers cleansed with normal saline, filled with dextranomer powder, non-adhesive pad, cotton wool wadding, stockinet and a firm elastic bandage applied</P>
<P>2. As above, but cadexomer iodine powder used instead</P>
<P>All participants were allowed to receive a 2-week course of oral antibiotics during the trial for clinical infection of ulcers</P>
<P>After 6 weeks of randomly assigned treatment, those not improving could be changed to the other treatment for the remaining 20 weeks of the trial</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 13:00:26 +0000" MODIFIED_BY="Sue O'Meara">
<P>Primary outcomes:</P>
<P>At 6 weeks:<BR/>Mean percentage area change: Group 1: -2%; Group 2: -3% (values read from graph)<BR/>No significant difference between groups (P value not reported)</P>
<P>
<BR/>Secondary outcomes:<BR/>Numbers (%) of participants requiring antibiotics up to week 6:</P>
<P>1. 5/21 (24); 3 for infection in trial ulcer and 2 for infection in another ulcer</P>
<P>2. 5/21 (24); 4 for infection in trial ulcer; 1 for chest infection</P>
<P>Proportion of participants acquiring organisms during 6 weeks of treatment (values read from graph):</P>
<P>1. Beta-haemolytic <I>Streptococcus</I> 35%;<I> Staphylococcus aureus</I> 18%; <I>Pseudomonas</I> species 10%; <I>Proteus</I> species 10%</P>
<P>2. Beta-haemolytic <I>Streptococcus</I> 20%;<I> Staphylococcus aureus</I> 15%; <I>Pseudomonas</I> species 0%; <I>Proteus</I> species 0%</P>
<P>Proportions of participants eradicating organisms during 6 weeks of treatment (values read from graph):</P>
<P>1. Beta-haemolytic <I>Streptococcus</I> 0%;<I> Staphylococcus aureus</I> 42%; <I>Pseudomonas</I> species 10%; <I>Proteus</I> species 25%</P>
<P>2. Beta-haemolytic <I>Streptococcus</I> 40%;<I> Staphylococcus aureus</I> 0%; <I>Pseudomonas</I> species 35%; <I>Proteus</I> species 50%</P>
<P>Link between bacteriology and wound healing:</P>
<P>Complete eradication of bacteria during the 6-week trial was associated with a reduction in mean ulcer size in both treatment groups. In terms of specific isolates, this association was statistically significant for <I>Pseudomonas</I> species (P value &lt; 0.05)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:48:52 +0000" MODIFIED_BY="Sue O'Meara">
<P>1 participant was withdrawn because of poor compliance (group allocation not stated)</P>
<P>Bacterial profile assessed by wound swab</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:49:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-M_x00fc_nter-2006">
<CHAR_METHODS MODIFIED="2013-12-02 14:48:53 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial. Multi-centre&#8212;80 study centres, 9 countries (Belgium, Brazil, Canada, Denmark, Germany, Italy, Slovenia, Switzerland, UK). From an interim analysis, a sample of 272 participants per treatment group was estimated as required to detect a difference in means of 17.1 relative surface area with standard deviation 71.0, at 80% power and 5% significance level. To ensure adequate recruitment, while allowing for a withdrawal rate of 15%, a target of "over 600" was set</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:48:53 +0000" MODIFIED_BY="[Empty name]">
<P>619 participants with chronic wounds exhibiting delayed healing and producing moderate to high levels of exudate were recruited. Ulcers had to be &lt; 0.5 cm in depth and characterised by at least one of the following: delayed healing due to bacteria (&lt; 0.5 cm ulcer reduction or no change or increase in wound volume or surface area over past 4 weeks); being at risk of infection (such as diabetic wounds or sacral pressure ulcers); discolouration of granulation tissue; malodour; or clinical infection requiring treatment with systemic antibiotics</P>
<P>Group 1: 293 participants</P>
<P>Group 2: 326 participants</P>
<P>Breakdown of proportions of participants according to wound type:</P>
<P>Group 1: venous leg ulcers 50%; mixed venous/arterial leg ulcers 17%; pressure ulcers 7%; diabetic foot ulcers 8%; other wounds 18%</P>
<P>Group 2: venous leg ulcers 46%; mixed venous/arterial leg ulcers 21%; pressure ulcers 8%; diabetic foot ulcers 8%; other wounds 17%</P>
<P>Numbers of participants with leg ulcers, with breakdown according to aetiology:</P>
<P>Group 1: 197&#8212;venous 147/197 (75%); venous/arterial 50/197 (25%)</P>
<P>Group 2: 218&#8212;venous 150/218 (69%); venous/arterial 68/218 (31%)</P>
<P>Mean baseline ulcer size in cm<SUP>2</SUP> ± SD (median, range) for all wound types (separate data not presented for participants with leg ulcers):</P>
<P>Group 1: 36.6 ± 64.4 (12.0, 0.1 to 400)</P>
<P>Group 2: 52.9 ± 90.0 (20.0, 0.1 to 700)</P>
<P>No data on baseline wound duration were provided</P>
<P>Participants with clinically infected wounds, or wounds deemed at risk of infection, were eligible for inclusion, but no data related to prevalence of infection at baseline were presented</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:48:53 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: local best practice, including the following dressings&#8212;foams/alginates (53%), hydrocolloids (12%), gauze (3%), silver dressings (17%), other antimicrobial dressings (9%), other active dressings (6%)</P>
<P>Group 2: silver-donating foam dressing (Contreet Ag). Both adhesive and non-adhesive versions of the dressing were used</P>
<P>Wound management for all participants (including compression therapy) was performed in line with local protocols, guidelines and dressing manufacturers&#8217; instructions. All dressings were changed between weekly assessments when judged necessary by the wound care practitioners</P>
<P>Duration of treatment was 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:49:40 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<P>Median percentage change in ulcer area at 4 weeks for venous and venous/arterial leg ulcer participants:</P>
<P>Group 1: -28.8 (n = 197)</P>
<P>Group 2: -45.5 (n = 218)</P>
<P>The trial authors reported that the between-group difference was statistically significant (P value 0.0001)</P>
<P>Median percentage change in ulcer area at 4 weeks for venous leg ulcer participants:</P>
<P>Group 1: -26.9 (n = 147)</P>
<P>Group 2: -46.2 (n = 150)</P>
<P>The trial authors reported that the between-group difference was statistically significant (P value 0.0001)</P>
<P>Secondary outcomes:</P>
<P>Numbers (%) of participants with pain at dressing change for venous and venous/arterial leg ulcers:</P>
<P>Group 1: 2/197 (1%)</P>
<P>Group 2: 1/218 (&lt; 1%)</P>
<P>The trial authors reported that the between-group difference was statistically significant (P value &lt; 0.0001)</P>
<P>Numbers (%) of participants with ulcer pain between dressing changes for venous and venous/arterial leg ulcers:</P>
<P>Group 1: 2/197 (1%)</P>
<P>Group 2: 1/218 (&lt; 1%)</P>
<P>The trial authors reported that the between-group difference was statistically significant (P value 0.0003)</P>
<P>Adverse events&#8212;numbers (%) of participants with macerated peri-ulcer skin at 4 weeks for venous and venous/arterial leg ulcer participants:</P>
<P>Group 1: 27/197 (13.7%) (22.1% at baseline)</P>
<P>Group 2. 26/218 (12.0%) (28.6% at baseline)</P>
<P>The trial authors reported that the between-group difference at week 4 was not statistically significant, but no P value was provided</P>
<P>Health-related quality of life (EQ-5D) for venous leg ulcer participants:</P>
<P>The trial authors reported that the between-group difference for the overall EQ-5D score at 4 weeks was not statistically significant, but no data were provided apart from the P value (P value 0.0878) When analysed separately, significantly less pain/discomfort was reported in Group 2 compared with Group 1; again, no data shown other than the P value (P value 0.0426). Not stated whether values were adjusted for baseline scores (and no baseline scores were presented)</P>
<P>Cost-effectiveness parameters&#8212;mean wear time of dressing for venous and venous/arterial leg ulcer participants:</P>
<P>Group 1: 2.1 days</P>
<P>Group 2: 3.5 days</P>
<P>The trial authors reported that the between-group difference was statistically significant (P value &lt; 0.0001)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:48:53 +0000" MODIFIED_BY="[Empty name]">
<P>No outcome data on infection-related or microbiological outcomes were presented </P>
<P>No information about withdrawals was provided</P>
<P>Note: 17% of participants in the control group received silver dressings</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:49:42 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Ormiston-1985">
<CHAR_METHODS MODIFIED="2013-12-02 14:48:54 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial conducted in the UK with optional cross-over point at 12 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:48:54 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>61 participants with chronic venous ulcers (ABPI &#8805; 0.7) were recruited; the trial authors presented data on 60 participants<BR/>Group 1: 30 participants<BR/>Group 2: 31 participants</P>
<P>Mean ± SD baseline ulcer area (cm<SUP>2</SUP>): Group 1: 10.2 ± 8.7; Group 2: 12.1 ± 13.9<BR/>Median [10th to 90th percentile] (range) baseline duration of ulcer (months): Group 1: 6.0 [4 to 36] (3 to 96); Group 2: 8.5 [3 to 144] (3 to 517)<BR/>No information about ulcer infection status at baseline (but it appeared that those with infected ulcers might have been allowed into the trial).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:48:54 +0000" MODIFIED_BY="[Empty name]">
<P>1. Ulcers cleansed with saline; polymyxin and bacitracin ointment (Polyfax) and gentian violet applied; ulcer covered with non-adherent dressing (Melolin)</P>
<P>2. Ulcers cleansed with saline; cadexomer iodine powder sprinkled in a layer 3 to 5 mm deep; ulcer covered with gauze pad</P>
<P>All participants were treated at home; were trained by study nurses how to dress and bandage their ulcers; changed dressings and bandages daily; and received below-knee bandaging with a crepe bandage followed by a cotton crepe compression bandage</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:49:42 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Primary outcomes:</P>
<P>At 12 weeks:<BR/>Complete healing:<BR/>1. 7/30<BR/>2. 12/31</P>
<P>Mean ± SEM healing rate (cm²/wk):<BR/>1. 0.46 ± 0.1<BR/>2. 0.89 ± 0.1</P>
<P>P value 0.0001 (reported by trial authors)</P>
<P>Mean healing rate (cm²/wk/cm circumference)<BR/>1. 0.03 ± 0.004<BR/>2. 0.06 ± 0.005<BR/>P value 0.0001 (reported by trial authors)</P>
<P>Secondary outcomes:</P>
<P>No significant difference in improvement in pain, erythema, exudate, oedema, pus/debris and granulation between both groups of the study</P>
<P>The trial authors reported no significant effect of treatment on bacterial colonisation, but no data were presented</P>
<P>Numbers of participants reporting adverse events:<BR/>1. Eczema, pruritus, rashes (2)<BR/>2. Difficulty in removing cadexomer iodine from ulcer (2&#8212;not stated whether 1 of these participants was the one who withdrew); stinging or itching on application of cadexomer iodine (3); eczema, pruritis, rashes (5)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:48:54 +0000" MODIFIED_BY="[Empty name]">
<P>Withdrawals:<BR/>Group 1: none<BR/>Group 2:<BR/>Death (1, included in analysis)<BR/>Difficulty in removing cadexomer iodine from ulcer (1, included in analysis)<BR/>Admitted to hospital for routine surgery and received inappropriate dressing (1, excluded from analysis)<BR/>Total = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:45:19 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Skog-1983">
<CHAR_METHODS MODIFIED="2013-12-02 14:48:55 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Randomised controlled trial conducted in Sweden (multi-centre, 10 study centres), with optional cross-over point at 6 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:48:55 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>95 participants with chronic infected venous ulcers of &#8805; 3 months' duration, &#8805; 2 cm diameter and &#8805; 3 cm<SUP>2</SUP> surface area were recruited, of whom 21 were excluded from analyses. Some included participants had mixed venous/arterial aetiology leg ulcers</P>
<P>Group 1: 45 randomly assigned, 36 analysed<BR/>Group 2: 50 randomly assigned, 38 analysed</P>
<P>Numbers (%) of participants with venous/mixed venous/arterial leg ulcers:</P>
<P>Group 1: 30/36 (83)/6/36 (17)</P>
<P>Group 2: 37/38 (97)/1 (3)</P>
<P>Mean ± SEM baseline ulcer area, cm<SUP>2</SUP>:</P>
<P>Group 1: 34.0 ± 5.7 (n = 36)</P>
<P>Group 2: 20.1 ± 4.4 (n = 38)<BR/>Mean ± SEM baseline ulcer duration, months:</P>
<P>Group 1: 22.2 ± 14.3 (n = 36)</P>
<P>Group 2: 26.5 ± 18.3 (n = 38)</P>
<P>Mean ± SEM baseline pain score (assessed by 100-point visual analogue scale divided into increments of 10, where 0 = no pain and 100 = severe pain):</P>
<P>Group 1: 33.0 ± 4.3 (n = 36)</P>
<P>Group 2: 32.0 ± 4.7 (n = 38)</P>
<P>All participants had infected ulcers at baseline (infection was defined as a colony count of +++ using a standard plating technique).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:48:55 +0000" MODIFIED_BY="[Empty name]">
<P>1. Ulcers cleansed daily with dilute hydrogen peroxide or dilute potassium permanganate baths, then non-adherent dressing applied (most commonly paraffin-impregnated dressings, also saline dressings and bland ointments used). Other treatments were allowed, including systemic antibiotics</P>
<P>2. Ulcers cleansed with running water, then cadexomer iodine powder applied to a depth of 3 mm followed by application of a dry dressing</P>
<P>All participants received care at home or at a hospital clinic; compression bandages (system unspecified, applied by nurse or participant); twice-daily dressing changes, if necessary, during the first few days of the trial, thereafter once-daily changes. If no improvement in the ulcer was noted at 6 weeks, the participant was switched to the other treatment for a further 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:45:19 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<P>At 6 weeks:<BR/>Mean (SEM) percentage change in ulcer area (SEM values read from figure):<BR/>Group 1: increase of 5% (SEM 15) (n = 36)<BR/>Group 2: reduction of 34% (SEM 5) (n = 38)<BR/>The trial authors reported that the between-group difference was statistically significant (P value &lt; 0.02)</P>
<P>Secondary outcomes:<BR/>Numbers of participants with eradication or reduction of staphylococcal infection/infection persisted or new infection during treatment:</P>
<P>Group 1: 0/18</P>
<P>Group 2: 16/7</P>
<P>The trial authors reported that the between-group difference was statistically significant (P value &lt; 0.001)</P>
<P>Numbers of participants with eradication or improvement of <I>Pseudomonas aeruginosa</I> infection/infection persisted or new infection during treatment:</P>
<P>Group 1: 1/6</P>
<P>Group 2: 3/0</P>
<P>The trial authors reported that the between-group difference was statistically significant (P value &lt; 0.05)</P>
<P>Numbers of participants with eradication or improvement of infection from other pathogenic organisms <I>(Streptococcus, Proteus, Enterococcus, Enterobacteria</I> and <I>Klebsiella</I>)/infection persisted or new infection during treatment:</P>
<P>Group 1: 3/17</P>
<P>Group 2: 15/5</P>
<P>The trial authors reported that the between-group difference was statistically significant (P value &lt; 0.01)</P>
<P>Relationship between ulcer healing and bacteriological response to treatment: The trial authors reported that a statistically significant association was evident between eradication of <I>Staphylococcus aureus</I> and a more rapid rate of healing (P value &lt; 0.002). Figure presented in a secondary reference, but no detailed description of methods or outcomes was provided to allow assessment of this association</P>
<P>Mean ± SEM pain score at 6 weeks (assessed by 100-point visual analogue scale divided into increments of 10, where 0 = no pain and 100 = severe pain) [change in means relative to baseline, calculated by review authors]:</P>
<P>Group 1: 23.0 ± 3.7 [-10] (n = 36)</P>
<P>Group 2: 10.0 ± 2.5 [-22] (n = 38)</P>
<P>The trial authors reported that the between-group difference was statistically significant (P value &lt; 0.01)</P>
<P>Numbers of participants (%) with adverse events with description:<BR/>1. 1/36 (3%) pain following application of dressing<BR/>2. 4/38 (11%) pain following application of dressing; 1/38 (3%) itching in the peri-ulcer area; 1/38 (3%) rash resulting in withdrawal</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:48:56 +0000" MODIFIED_BY="[Empty name]">
<P>Bacteriological outcomes assessed by wound swab (further details of specimen acquisition not provided)</P>
<P>Numbers of participants who withdrew:</P>
<P>Group 1:<BR/>Ineligible (3); beta-haemolytic strep. infection (4); squamous cell cancer (1); dramatic increase in ulcer size (1) total = 9</P>
<P>Group 2:<BR/>Ineligible (4); beta-haemolytic strep. infection (2); rash (1); holiday (2); missing information (2); recurrence of pain (1) total = 12</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 13:05:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-1992">
<CHAR_METHODS MODIFIED="2013-12-02 14:48:56 +0000" MODIFIED_BY="Sue O'Meara">
<P>Randomised controlled trial conducted in the UK<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:48:56 +0000" MODIFIED_BY="[Empty name]">
<P>200 people with venous leg ulcers (ABPI &#8805; 0.75) &#8805; 2 cm in diameter were recruited. Those with the following were excluded: diabetes; rheumatoid arthritis; infected ulcers requiring treatment that precluded dressings being left in situ; infection requiring immediate antibiotics; known intolerance to iodine; and neurological disease causing tropic impairment<BR/>Group 1: 99<BR/>Group 2: 101</P>
<P>Participants with smaller baseline ulcer diameter (2 to 4 cm)<BR/>Group 1a: 64<BR/>Group 2a: 62</P>
<P>Participants with larger baseline ulcer diameter &gt; 4 cm<BR/>Group 1b: 35<BR/>Group 2b: 39</P>
<P>Median (interquartile range) baseline ulcer area (cm<SUP>2</SUP>) in participants with smaller/larger ulcers: Group 1: 3.1 (2.0 to 5.0)/13.3 (9.0 to 27.0); Group 2: 2.6 (2.0 to 4.0)/17.6 (9.0 to 38.0)</P>
<P>Median (interquartile range) baseline ulcer duration (months) in participants with smaller/larger ulcers: Group 1: 5 (3 to 9)/14 (2 to 45); Group 2: 3 (2 to 10)/17 (6 to 58)</P>
<P>Ulcers were not clinically infected at baseline. Most had bacteria present at initial assessment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:48:56 +0000" MODIFIED_BY="[Empty name]">
<P>1. Ulcers cleansed with sterile isotonic saline and ulcers filled with hydrocolloid powder (Biofilm powder) until level with the ulcer margins, before a hydrocolloid dressing (Biofilm dressing) was applied. Participants were allowed to remove their compression bandages and bathe or shower with the dressing in place</P>
<P>2. Ulcers cleansed with sterile isotonic saline, then povidone-iodine dressing applied (Betadine), cut to fit exactly the shape of the ulcer, and an absorbent pad placed over. Participants could not bathe or shower with the dressing in place</P>
<P>All participants were treated in a community setting and received graduated compression in the form of an elasticated tubular bandage (2 layers of shaped Tubigrip) or a stocking (Venosan 2002)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 13:05:11 +0000" MODIFIED_BY="Sue O'Meara">
<P>Frequency of complete healing at 4 months:<BR/>
</P>
<P>1a: 38/64 (59%)<BR/>2a: 43/62 (69%)<BR/>P value 0.27</P>
<P>1b: 12/35 (34%)<BR/>2b: 4/39 (10%)<BR/>P value 0.02 (reported by trial authors)</P>
<P>Cox proportional hazards model found that the following 4 variables were significant independent predictors of time to healing (P value &lt; 0.01): baseline ulcer area, ulcer duration, age, deep vein involvement. No significant interaction was detected between treatment and baseline ulcer area. Hazard ratio estimate of treatment effect not reported</P>
<P>Median (interquartile range) healing rate (cm²/d) at 1 month (analysis based on 151 participants):<BR/>1a(50 participants analysed): 0.056 (0.027 to 0.085)<BR/>2a (52 participants analysed): 0.062 (0.039 to 0.086)<BR/>P value 0.40 Mann-Whitney U-test</P>
<P>1b (25 participants analysed): 0.184 (0.115 to 0.338)<BR/>2b (24 participants analysed): 0.017 (0.001 to 0.267)<BR/>P value 0.09 Mann-Whitney U-test</P>
<P>Numbers (%) of participants reporting moderate or severe ulcer pain, assessed using 5-point scale (1 = no pain and 5 = worst pain) at 1 month (analysis based on 123 participants):</P>
<P>1a: 6/34 (18%)<BR/>2a: 16/36 (44%)<BR/>P value 0.02</P>
<P>1b: 12/27 (44%)<BR/>2b: 14/26 (54%)<BR/>P value 0.02</P>
<P>Estimated cost of dressings and nursing time over 4 months (GBP, price year not stated, analysis based on all 200 participants):</P>
<P>Participants with smaller wounds, defined as baseline diameter &lt; 6 cm:<BR/>1a: 48.96<BR/>2a: 38.95</P>
<P>Participants with large wounds, defined as baseline diameter &#8805; 6 cm:<BR/>1b: 526.63<BR/>2b: 183.75<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:48:57 +0000" MODIFIED_BY="[Empty name]">
<P>In participants with bilateral ulceration, the right leg was included as the study limb</P>
<P>Numbers of participants (%) who withdrew, with reasons:<BR/>Group 1: total = 27/99 (27%)<BR/>Refused treatment (12); acute infection (1); admission (7); allergy (6); moved (1)<BR/>Group 2: total = 33/101 (33%)<BR/>Refused treatment (11); acute infection (12); admission (5); allergy (2); died (2); moved (1)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-06 12:49:46 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Steele-1986">
<CHAR_METHODS MODIFIED="2013-12-02 14:48:57 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial conducted in the UK (Northern Ireland)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:48:57 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>60 participants with active venous leg ulcers for at least 3 months and at least 2 cm<SUP>2</SUP> surface area were recruited; data on 57 participants are presented:<BR/>Group 1: 29 (completers)<BR/>Group 2: 28 (completers)</P>
<P>Mean ± standard error baseline ulcer area, mm<SUP>2</SUP>: Group 1: 1759 ± 397; Group 2: 1264 ± 291<BR/>Mean ± standard error baseline ulcer duration, months: Group 1: 16.3 ± 2.5; Group 2: 16.6 ± 2.7</P>
<P>Day-to-day ulcer pain reported as none/mild/moderate/severe at baseline:</P>
<P>Group 1: 12/5/3/9 (n = 29)</P>
<P>Group 2: 9/8/4/7 (n = 28)</P>
<P>Unclear whether wounds were clinically infected at baseline (but it appeared that those with infected ulcers might have been allowed into the trial).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:48:57 +0000" MODIFIED_BY="[Empty name]">
<P>1. Various topical agents including antibiotics, antiseptics, hydrophilic agents, topical steroids and bland agents. Compression bandage applied to the whole leg, and changes occurred 3 times a week<BR/>2. Ulcer cleaned with normal saline, sprinkled with cadexomer iodine and dressed with gauze. Compression bandage applied to whole leg, and changes occurred 3 times a week</P>
<P>All patients were treated in a community setting</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-06 12:49:46 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<P>Complete healing at 6 weeks:<BR/>1: 1/29<BR/>2: 3/28<BR/>
</P>
<P>Mean percentage change in ulcer area at 6 weeks (values read from figure):</P>
<P>1. -18% (n = 29)</P>
<P>2. -22% (n = 28)</P>
<P>The trial authors reported that the between-group difference was not statistically significant (P value 0.31)</P>
<P>Secondary outcomes:</P>
<P>Numbers of participants reporting pain after treatment at 2/4/6 weeks:</P>
<P>1. 2/2/4</P>
<P>2. 14/11/11</P>
<P>The trial authors reported that between-group differences were statistically significant at 2 weeks (P value 0.001), 4 weeks (P value 0.008) and 6 weeks (P value 0.032)</P>
<P>Day-to-day ulcer pain reported as none/mild/moderate/severe at 2 weeks:</P>
<P>Group 1: 7/4/9/9 (n = 29)</P>
<P>Group 2: 10/13/1/4 (n = 28)</P>
<P>The trial authors reported that the between-group difference was statistically significant (P value 0.03)</P>
<P>Day-to-day ulcer pain reported as none/mild/moderate/severe at 4 weeks:</P>
<P>Group 1: 8/7/8/6 (n = 29)</P>
<P>Group 2: 15/7/3/3 (n = 28)</P>
<P>The trial authors reported that the between-group difference was not statistically significant (P value 0.17)</P>
<P>Day-to-day ulcer pain reported as none/mild/moderate/severe at 6 weeks:</P>
<P>Group 1: 9/8/6/6 (n = 29)</P>
<P>Group 2: 16/4/3/5 (n = 28)</P>
<P>The trial authors reported that the between-group difference was not statistically significant (P value 0.31)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:48:57 +0000" MODIFIED_BY="[Empty name]">
<P>Three withdrawals were reported overall. Reasons for withdrawal were given as hospital admission and lack of cooperation, but breakdown of numbers/reasons per group was not provided</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-02 14:48:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Valtonen-1989">
<CHAR_METHODS MODIFIED="2013-12-02 14:48:58 +0000" MODIFIED_BY="Sue O'Meara">
<P>Randomised controlled trial conducted in Finland<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:48:58 +0000" MODIFIED_BY="[Empty name]">
<P>27 participants with <I>Pseudomonas aeruginosa</I> or other Gram-negative rod colonised chronic leg ulcers of &#8805; 2 months' duration were recruited. Patients with diabetes were eligible for inclusion. Those with ulcer flora resistant to ciprofloxacin were excluded:<BR/>Group 1: 8 participants<BR/>Group 2: 18 participants</P>
<P>Numbers (%) of participants with venous/arterial insufficiency:</P>
<P>Group 1: 6/8 (75%); 8/8 (100%)</P>
<P>Group 2: 16/18 (89%); 13/18 (72%)</P>
<P>Mean ± SD sum of maximum length plus width of ulcer (cm) at baseline: Group 1: 16.9 ± 11.4; Group 2: 16.7 ± 8.2</P>
<P>Range for baseline ulcer duration, months: Group 1: 29 to 35; Group 2: 60 to 71</P>
<P>Proportions of participants with isolation of <I>Pseudomonas aeruginosa</I> at baseline: Group 1: 63%; Group 2: 61%</P>
<P>Unclear whether wounds had signs and symptoms of clinical infection at baseline or whether just colonised</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:48:58 +0000" MODIFIED_BY="[Empty name]">
<P>1. Standard care consisting of: daily ulcer cleansing with warm water and disinfectants (chlorhexidine or potassium permanganate); mechanical or enzymatic debridement; coverage with dextranomer paste or hydrocolloid (DuoDerm) dressing. Topical antibiotic creams were not used<BR/>
</P>
<P>2. Oral ciprofloxacin 750 mg twice daily for 3 months in addition to standard care as above. Some participants received a lower dose as the study progressed (250 or 500 mg twice daily) to achieve a maximum serum level of 2 to 4 mg/L.</P>
<P>
<BR/>All participants were treated as inpatients or outpatients according to clinical status; additional systemic antibiotics based on clinical features of infection, and the resistance pattern of the bacteria isolated. Use of compression not mentioned</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-02 14:48:58 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<P>Numbers (%) of participants with complete healing at 3 months:<BR/>1. 0/8 (0)<BR/>2. 3/18 (17)</P>
<P>Numbers (%) of participants with clinical improvement (defined as those with complete healing plus those with reduction of at least 10% of sum of maximum length and width of ulcer) at 3 months:<BR/>1. 1/8 (13)<BR/>2. 12/18 (67)</P>
<P>Secondary outcomes:<BR/>Numbers of participants with adverse events:<BR/>Group 1: (0)<BR/>Group 2: mild, transient nausea that did not result in discontinuation of treatment (3)</P>
<P>Numbers (%) of participants who needed extra antimicrobial treatment during the trial:<BR/>1. 6/8 (75)<BR/>2. 3/18 (17)</P>
<P>Numbers (%) of participants with bacterial eradication or no bacteriological growth during trial:<BR/>1. 1/8 (13)<BR/>2. 6/18 (33)</P>
<P>Numbers (%) of participants with eradication of original strain during trial:</P>
<P>1. 2/8 (25)</P>
<P>2. 15/18 (83)</P>
<P>Numbers (%) of participants with ciprofloxacin-resistant strain in ulcer during trial:<BR/>1. 0/8 (0)<BR/>2. 12/18 (67)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:48:58 +0000" MODIFIED_BY="[Empty name]">
<P>One participant excluded from analysis because of malignant tumour in leg ulcer (group allocation not stated)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-02 14:48:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wunderlich-1991">
<CHAR_METHODS MODIFIED="2013-12-02 14:48:59 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial conducted in Germany</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 14:48:59 +0000" MODIFIED_BY="[Empty name]">
<P>40 participants with venous leg ulcers were recruited:</P>
<P>Group 1: 20 participants</P>
<P>Group 2: 20 participants</P>
<P>Mean ulcer duration in years:</P>
<P>Group 1: 7.9</P>
<P>Group 2: 7.6</P>
<P>Mean ulcer area in mm<SUP>2</SUP> (values taken from graph):</P>
<P>Group 1: 2000</P>
<P>Group 2: 3000</P>
<P>No information about ulcer infection/colonisation status at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 14:48:59 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: various topical agents used for different stages of wound healing, including mineral oil or mixture of sea salt and povidone-iodine paste for granulation phase; and paraffin-impregnated gauze or oil-and-water emulsion with panthenol for epithelialisation phase</P>
<P>Group 2: silver-impregnated activated charcoal dressing (Actisorb plus, Johnson &amp; Johnson) used for all stages of wound healing</P>
<P>All participants received initial debridement (mechanical or enzymatic) for 5 days; intermittent debridement as necessary during the trial (up to 4 times in 6 weeks) for large ulcers; and daily dressing changes. No mention was made of using compression therapy</P>
<P>Treatment duration was 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-02 14:48:59 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<P>Numbers (%) ulcers healed at 6 weeks:</P>
<P>Group 1: 2/20 (10)</P>
<P>Group 2: 6/20 (30)</P>
<P>Median percentage change in ulcer area at 6 weeks (from graph):</P>
<P>Group 1: -60%</P>
<P>Group 2: -75%</P>
<P>The trial authors did not report P values for between-group differences</P>
<P>Secondary outcomes:</P>
<P>Semi-quantitive bacterial colony growth was assessed at weeks 2, 4 and 6 (details of method not reported). Assessment was reported on a scale: 0 = no growth, 1 = low growth, 2 = medium growth, 3 = high growth. The trial authors reported a non-significant reduction in colonisation over the whole study period in Group 2 and a reduction only at week 2 in Group 1. No data were presented</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-02 14:48:59 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Translated from German</P>
<P>One withdrawal per group (reasons not reported)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-12-06 13:34:27 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:31:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allen-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:31:09 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:31:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allen-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:31:10 +0000" MODIFIED_BY="[Empty name]">
<P>No healing outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:31:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Altman-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:31:11 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:31:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:31:19 +0000" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:31:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bazzigaluppi-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:31:12 +0000" MODIFIED_BY="[Empty name]">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:31:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beele-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:31:13 +0000" MODIFIED_BY="[Empty name]">
<P>Patients with various wound types recruited. Results not available for VLU patients only (communication with study author)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:31:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beitner-1985c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:31:28 +0000" MODIFIED_BY="[Empty name]">
<P>No antimicrobial intervention evaluated (comparison was vehicle of benzoyl peroxide lotion versus saline solution). Two other RCTs were reported in the same paper, and are included in this review (<LINK REF="STD-Beitner-1985a" TYPE="STUDY">Beitner 1985a</LINK>; <LINK REF="STD-Beitner-1985b" TYPE="STUDY">Beitner 1985b</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:31:29 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Bender-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:31:29 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Not RCT (confirmed by translator)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:31:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bourgeois-1963">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:31:32 +0000" MODIFIED_BY="[Empty name]">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:31:33 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Brauman-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:31:33 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Not RCT (confirmed by study author)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:31:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brzeziska-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:31:41 +0000" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:31:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Castellano-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:31:45 +0000" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:31:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chaparro-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:31:49 +0000" MODIFIED_BY="[Empty name]">
<P>CCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:31:51 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Chaudhary-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:31:51 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:31:56 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Cherry-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:31:56 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Not an RCT - single arm study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chirwa-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:00 +0000" MODIFIED_BY="[Empty name]">
<P>Mixed wound aetiologies, 20% of patients had venous leg ulcers. Conference abstract with no further details available (unable to establish contact with trial authors)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:11 +0000" MODIFIED_BY="Sue O'Meara" STUDY_ID="STD-Colombo-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:11 +0000" MODIFIED_BY="Sue O'Meara">
<P>Participants with various wound types recruited, unclear if venous leg ulcers included. No objective healing outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colonna-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:03 +0000" MODIFIED_BY="[Empty name]">
<P>Mixed wound aetiologies, 28% of patients had venous leg ulcers. Conference abstract with no further details available following contact with trial authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Contretas_x002d_Ruiz-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:06 +0000" MODIFIED_BY="[Empty name]">
<P>Antimicrobial intervention is not the only systematic difference between treatment groups; different methods of debridement are used (confirmed through contact with trial authors)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coutts-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:19 +0000" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daltrey-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:21 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Danielsen-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:22 +0000" MODIFIED_BY="[Empty name]">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dharap-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:24 +0000" MODIFIED_BY="[Empty name]">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferra-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:26 +0000" MODIFIED_BY="[Empty name]">
<P>Interventions evaluated do not include antimicrobials</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fox-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:27 +0000" MODIFIED_BY="[Empty name]">
<P>CCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Friedman-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:28 +0000" MODIFIED_BY="[Empty name]">
<P>Mixed aetiologies, minority venous, CCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garcia-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:32 +0000" MODIFIED_BY="[Empty name]">
<P>Antimicrobial intervention not clearly defined</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-22 16:39:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gottrup-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-22 16:39:50 +0100" MODIFIED_BY="[Empty name]">
<P>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haler-1964">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:36 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomised, no objective outcomes of healing reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hanft-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:37 +0000" MODIFIED_BY="[Empty name]">
<P>Available only as conference abstracts with no outcome data. Unable to establish contact with the trial authors in order to request further information</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heggers-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:39 +0000" MODIFIED_BY="[Empty name]">
<P>Not a controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Howell_x002d_Jones-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:39 +0000" MODIFIED_BY="[Empty name]">
<P>Not a controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hutchinson-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:41 +0000" MODIFIED_BY="[Empty name]">
<P>No healing outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ivins-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:52 +0000" MODIFIED_BY="[Empty name]">
<P>Not an RCT (random allocation of only some patients from one treatment group of a previously reported trial to receive either the treatment or comparator for a further 4 weeks)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:57 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Karap-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:57 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Not an RCT (confirmed by study author)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:32:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karas-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:32:58 +0000" MODIFIED_BY="[Empty name]">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:00 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Katelaris-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:00 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>CCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kordestani-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:01 +0000" MODIFIED_BY="[Empty name]">
<P>Quasi randomised, intervention not antimicrobial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kosicek-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:02 +0000" MODIFIED_BY="[Empty name]">
<P>CCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lanzara-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:03 +0000" MODIFIED_BY="[Empty name]">
<P>Available only as a conference abstract. Unable to establish contact with the trial authors in order to request further information</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lischka-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:05 +0000" MODIFIED_BY="[Empty name]">
<P>CCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Locati-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:06 +0000" MODIFIED_BY="[Empty name]">
<P>No control group, mixed aetiology</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Magana-Lozano-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:07 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maiques-Nadal-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:08 +0000" MODIFIED_BY="[Empty name]">
<P>Case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mancuso-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:11 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Markoishvili-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:12 +0000" MODIFIED_BY="[Empty name]">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marzin-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:12 +0000" MODIFIED_BY="[Empty name]">
<P>CCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McKnight-1965">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:13 +0000" MODIFIED_BY="[Empty name]">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mehtar-S-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:15 +0000" MODIFIED_BY="[Empty name]">
<P>Mixed aetiology</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mogabgab-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:16 +0000" MODIFIED_BY="[Empty name]">
<P>Soft tissue infections, not venous leg ulcers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:32 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Morely-de-Benzaquen-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:32 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>From abstract, appears to be RCT evaluating silver sulphadiazine versus placebo in participants with lower limb ulcers. Not clear if venous leg ulcers included or if healing reported. Full study report unavailable from overseas and unable to locate contact details for study authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Motta-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:33 +0000" MODIFIED_BY="[Empty name]">
<P>Not venous leg ulcers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nakagawa-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:33 +0000" MODIFIED_BY="[Empty name]">
<P>Mixed aetiology, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:39 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Ouvry-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:39 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pardes-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:45 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paul-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:43 +0000" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pegum-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:47 +0000" MODIFIED_BY="[Empty name]">
<P>CCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pereira-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:48 +0000" MODIFIED_BY="[Empty name]">
<P>Mixed aetiology, primary outcome not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pierard_x002d_Franchimont-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:49 +0000" MODIFIED_BY="[Empty name]">
<P>CCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Planinsek-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:50 +0000" MODIFIED_BY="[Empty name]">
<P>Available only as a conference abstract. Unable to establish contact with the trial authors in order to request further information</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pollice-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:53 +0000" MODIFIED_BY="[Empty name]">
<P>CCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Privat-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:54 +0000" MODIFIED_BY="[Empty name]">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Robson-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:55 +0000" MODIFIED_BY="[Empty name]">
<P>Patients with various types of wounds recruited. Less than 75% had leg ulcers, and aetiology of leg ulcers not explained. Unable to obtain further information from trial authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rogers-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:56 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-10 18:31:59 +0100" MODIFIED_BY="Sue O'Meara" STUDY_ID="STD-Romanelli-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-10 18:31:59 +0100" MODIFIED_BY="Sue O'Meara">
<P>Insufficient report of outcomes and unable to obtain further information from trial authors.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-22 17:55:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rubisz-Brzeziska-87">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-22 17:55:50 +0100" MODIFIED_BY="[Empty name]">
<P>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rucigaj-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:58 +0000" MODIFIED_BY="[Empty name]">
<P>Available only as a conference abstract. Unable to establish contact with the trial authors in order to request further information</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:33:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rucigaj-2007b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:33:59 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention has no microbial properties</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:34:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salim-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:34:00 +0000" MODIFIED_BY="[Empty name]">
<P>No antibacterial or antiseptic intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:34:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanchez_x002d_Vasquez-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:34:01 +0000" MODIFIED_BY="[Empty name]">
<P>Isosorbide dinitrate spray, not antibiotic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:34:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Serra-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:34:03 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomised (confirmed by translator - paper published in Spanish)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:34:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sibbald-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:34:04 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention not antimicrobial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:34:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sibbald-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:34:13 +0000" MODIFIED_BY="[Empty name]">
<P>Partcicipants with various types of wounds recruited. Less than 75% had leg ulcers, and aetiology of leg ulcers not explained. Unable to obtain further information from trial authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:34:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steenvoorde-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:34:20 +0000" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:34:22 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Subrahmanyam-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:34:22 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>Unable to obtain data for VLU patients only. Confirmed by study author (email communication)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:34:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thebbe-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:34:24 +0000" MODIFIED_BY="[Empty name]">
<P>Mixed aetiology, silver used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:34:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thorne-1965">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:34:26 +0000" MODIFIED_BY="[Empty name]">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-06 13:34:27 +0000" MODIFIED_BY="Marrissa Martyn-St James" STUDY_ID="STD-Wuite-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-06 13:34:27 +0000" MODIFIED_BY="Marrissa Martyn-St James">
<P>No healing outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-06-11 17:14:53 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-07-08 16:23:44 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-12-06 13:29:28 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-12-03 15:04:07 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:23:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alinovi-1986">
<DESCRIPTION>
<P>Reported that "patients were.....randomly allocated." It was not reported how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-28 17:41:05 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Beitner-1985a">
<DESCRIPTION>
<P>Quote: "The ulcer chosen for BPO treatment was randomised according to left or right leg and most distal or proximal location. When ulcers were situated at the same level, medial or lateral localization was randomised"</P>
<P>Comment: the sequence generation method was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-28 17:41:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beitner-1985b">
<DESCRIPTION>
<P>Quote: "The ulcer chosen for BPO treatment was randomised according to left or right leg and most distal or proximal location. When ulcers were situated at the same level, medial or lateral localization was randomised"</P>
<P>Comment: the sequence generation method was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:24:06 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2003">
<DESCRIPTION>
<P>"the effects of a new compound (Crystacide) were assessed in a randomised controlled study"; it was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:24:32 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2007">
<DESCRIPTION>
<P>Information from author suggested randomised sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:25:20 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Bini_x0107_-2010">
<DESCRIPTION>
<P>"The study was opened, randomised and controlled". Report contains no statement regarding generation of random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-01 17:48:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bishop-1992">
<DESCRIPTION>
<P>"Patients...were stratified by lesion size and randomly assigned to one of three treatment groups". No information regarding sequence generation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-01 18:49:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blair-1988">
<DESCRIPTION>
<P>"Ulcers were cleaned with saline and the dressing applied according to randomization using a sequential system of sealed envelopes with treatment allocation by random number table"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-03 14:46:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cameron-1991">
<DESCRIPTION>
<P>Quote: "patients were randomised into 2 treatment groups"</P>
<P>Comment: It was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-03 14:52:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casoni-2002">
<DESCRIPTION>
<P>Quote: Patients were "randomised in three groups"</P>
<P>Comment: no information about methods for generating sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:28:30 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="YES" STUDY_ID="STD-Chaloner-2004">
<DESCRIPTION>
<P>Random sequence generation achieved using computer-generated programme (confirmed through email communication with trial author)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:28:56 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Daroczy-2006">
<DESCRIPTION>
<P>"A total of 63 patients were enrolled in this prospective randomised controlled study." It was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:29:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dimakakos-2009">
<DESCRIPTION>
<P>"Forty-two patients were included in the study and were randomised into two groups"</P>
<P>Comment: No information was reported on the method of random sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:30:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fischer-1984">
<DESCRIPTION>
<P>"The allocation of preparations was carried out with a random criteria" (translated from German)</P>
<P>Comment: no statement on methods used to generate the randomisation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-27 16:48:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002a">
<DESCRIPTION>
<P>Quote: "At entry in the study the two target ulcers in each patient were randomly assigned to receive one of the two treatment modalities"</P>
<P>Comment: It was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-27 16:49:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002b">
<DESCRIPTION>
<P>Quote: "At entry in the study the two target ulcers in each patient were randomly assigned to receive one of the two treatment modalities"</P>
<P>Comment: It was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-27 16:49:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002c">
<DESCRIPTION>
<P>Quote: "At entry in the study the two target ulcers in each patient were randomly assigned to receive one of the two treatment modalities"</P>
<P>Comment: It was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:31:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geske-2005">
<DESCRIPTION>
<P>"We carried out a randomised placebo controlled clinical study"; it was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:31:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gethin-2008">
<DESCRIPTION>
<P>"Following screening, and when consent was provided, patients were randomised via remote phone allocation to either treatment group"</P>
<P>Comment: This was judged to be a satisfactory method of random sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:32:55 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Groenewald-1981">
<DESCRIPTION>
<P>"...a single-blind study of 100 patients randomised into two equal groups..." It was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:33:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hansson-1998">
<DESCRIPTION>
<P>"patients were randomised to receive one of three treatments"; it was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:34:17 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Harcup-1986">
<DESCRIPTION>
<P>"patients were randomised to receive either standard dressing or Cadexomer iodine"; it was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:34:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Holloway-1989">
<DESCRIPTION>
<P>"patients were randomly assigned to either the standard or cadexomer iodine group"; it was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:36:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huovinen-1994">
<DESCRIPTION>
<P>"patients randomly assigned to groups"; it was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:36:46 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Ishibashi-1996">
<DESCRIPTION>
<P>Described as "randomised controlled trial", but no further information provided as to how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-03 15:04:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jull-2008">
<DESCRIPTION>
<P>Quote: "Participants were randomly assigned to one of two groups by an independent central telephone service. The allocation sequence was stratified by study centre and the Margolis Index using minimisation"</P>
<P>Comment: the method of random sequence generation was deemed satisfactory</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:39:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-J_x00f8_rgensen-2005">
<DESCRIPTION>
<P>Quote: "Patients were randomised to treatment with either Contreet Foam or Allevyn Hydrocellular by computer generated randomisation"</P>
<P>Comment: This was judged to be a satisfactory method of random sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:40:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kerihuel-2010">
<DESCRIPTION>
<P>Quote: "Randomisation was by blocks of four: identical sealed boxes containing the allocated dressings, gauze and saline were randomly allocated to each patient. The box reference number indicated which study arm the patient had been allocated to, although this was unknown to the patient and investigator. The box reference numbers were verified by a co-ordinating centre before allocation"</P>
<P>Comment: Although the method of random sequence generation is not specifically stated, the details provided suggest that a satisfactory method was likely to have been used and that the trial is likely to be at low risk of bias for this domain</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:41:08 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Kero-1987">
<DESCRIPTION>
<P>"The trial was conducted under open design using random allocation to treatment with either cadexomer iodine or dextranomer"</P>
<P>"Each patient was allocated to the treatment by using a sealed enclosure envelope containing the treatment code of the individual patient"</P>
<P>Information taken from secondary publication (Tarvainen 1988)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:41:55 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Kuznetsov-2009">
<DESCRIPTION>
<P>Comment: Translation indicates that participants were randomly assigned to groups, but no details of randomisation methods were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laudanska-1988">
<DESCRIPTION>
<P>Quote: "Patients were randomly allocated to treatment with either cadexomer iodine or the standard local dressing regime"</P>
<P>Comment: It was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lazareth-2008">
<DESCRIPTION>
<P>Quote: "A random list balanced by blocks of 4 patients was used"</P>
<P>Comment: no statement on how randomisation sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindsay-1986">
<DESCRIPTION>
<P>"patients were randomised to receive either standard dressing or cadexomer iodine"; it was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meaume-2005">
<DESCRIPTION>
<P>Quote: "Two <I>a priori </I>randomisation lists were prepared and balanced by blocks of six"</P>
<P>Comment: no statement on how the randomisation sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Michaels-2009">
<DESCRIPTION>
<P>Quote: "Treatment allocation was carried out using a computer program to generate stratified block randomisation with variable block size"</P>
<P>Comment: The details provided suggested a satisfactory method of random sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:51 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="YES" STUDY_ID="STD-Miller-2010">
<DESCRIPTION>
<P>Quote: "The randomization lists were generated using the random number function generator in Microsoft Excel"</P>
<P>Comment: The details provided suggested a satisfactory method of random sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:52 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Morias-1979">
<DESCRIPTION>
<P>"All patients were sequentially numbered and received a bottle bearing their individual sequence number and containing double-blind tablets. These tablets randomly contained either 50 mg of levamisole (30 patients) or a placebo (29 patients) and were identical in appearance." It was not stated how the randomisation sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moss-1987">
<DESCRIPTION>
<P>"n=42 were randomly allocated to treatment"; it was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-M_x00fc_nter-2006">
<DESCRIPTION>
<P>Quote: "Using a computer-generated list in sealed envelopes, patients were randomly assigned to a four-week treatment period of either silver foam or LBP"</P>
<P>Comment: The above information suggested a satisfactory method of random sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ormiston-1985">
<DESCRIPTION>
<P>"subjects were randomised to treatment with cadexomer iodine or standard"; it was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:56 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Skog-1983">
<DESCRIPTION>
<P>"Patients were allocated blindly and at random to the standard treatment or to cadexomer iodine." It was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:57 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1992">
<DESCRIPTION>
<P>"200 patients with VLUs assessed by continuous wave ultrasound and plethysmography were randomly allocated to each treatment group, stratified by initial maximum ulcer diameter 2-4 cm and &gt;4 cm, using a block length of 4 within each strata." It was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steele-1986">
<DESCRIPTION>
<P>"patients were divided into 2 groups using random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:58 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Valtonen-1989">
<DESCRIPTION>
<P>"Patients were randomised to two treatment groups." It was not stated how the sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wunderlich-1991">
<DESCRIPTION>
<P>Quote, from translation: "Randomized in each group were 20 patients treated with SIAX or with conventional control therapy"</P>
<P>Comment: no information regarding the method of random sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-12-03 15:04:30 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:23:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alinovi-1986">
<DESCRIPTION>
<P>"randomisation was by sealed envelope", but it was not reported whether the envelopes were opaque or sequentially numbered</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-28 17:42:23 +0000" MODIFIED_BY="Sue O'Meara" RESULT="NO" STUDY_ID="STD-Beitner-1985a">
<DESCRIPTION>
<P>Quote: "the randomisation and treatment was given in the day care unit by personnel not involved in the evaluation of results"</P>
<P>Comment: the information provided suggests that group allocation was likely to be unconcealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-28 17:42:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Beitner-1985b">
<DESCRIPTION>
<P>Quote: "the randomisation and treatment was given in the day care unit by personnel not involved in the evaluation of results"</P>
<P>Comment: the information provided suggests that group allocation was likely to be unconcealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:24:06 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2003">
<DESCRIPTION>
<P>No information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:24:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2007">
<DESCRIPTION>
<P>No information given about how assignment to treatment groups was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:25:20 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Bini_x0107_-2010">
<DESCRIPTION>
<P>"The study was opened, randomised and controlled". Report contains no statement regarding allocation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-01 17:48:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bishop-1992">
<DESCRIPTION>
<P>"Patients meeting the inclusion criteria and completing an informed consent form were stratified by lesion size and randomly assigned to one of three treatment groups". No information regarding allocation concealment reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:27:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blair-1988">
<DESCRIPTION>
<P>"Ulcers were cleaned with saline and the dressing applied according to randomization using a sequential system of sealed envelopes with treatment allocation by random number table"</P>
<P>No statement whether envelopes were opaque or not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-03 14:47:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cameron-1991">
<DESCRIPTION>
<P>Quote: "patients were randomised into 2 treatment groups"</P>
<P>Comment: allocation concealment was not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-03 14:52:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casoni-2002">
<DESCRIPTION>
<P>Quote: Patients were "randomised in three groups"</P>
<P>Comment: no mention of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:28:30 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Chaloner-2004">
<DESCRIPTION>
<P>"A prospective, multi-centre, randomised, comparative study to compare the effects of Acticoat 7 antimicrobial barrier dressing to Avance silver impregnated foam film dressing in the treatment of chronic venous leg ulcers"</P>
<P>Comment: no details of allocation concealment reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 11:11:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daroczy-2006">
<DESCRIPTION>
<P>No mention of this in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:29:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dimakakos-2009">
<DESCRIPTION>
<P>"Forty-two patients were included in the study and were randomised into two groups"</P>
<P>Comment: No information was reported on the method of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:30:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fischer-1984">
<DESCRIPTION>
<P>"The allocation of preparations was carried out with a random criteria" (translated from German)</P>
<P>Comment: no statement regarding the group allocation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-27 16:50:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002a">
<DESCRIPTION>
<P>Comment: No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-27 16:50:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002b">
<DESCRIPTION>
<P>Comment: No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-27 16:50:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002c">
<DESCRIPTION>
<P>Comment: No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 11:29:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geske-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:31:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gethin-2008">
<DESCRIPTION>
<P>"The allocation sequence was generated using serially numbered, sealed, opaque envelopes, prior to the study by two persons independent of the study"</P>
<P>Comment: This was judged to be a satisfactory method of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 11:30:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Groenewald-1981">
<DESCRIPTION>
<P>No information given about how knowledge of assignment to treatment groups was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 11:31:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hansson-1998">
<DESCRIPTION>
<P>No information about how assignment to treatment groups concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:34:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harcup-1986">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 11:32:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Holloway-1989">
<DESCRIPTION>
<P>No information given about whether/how assignment to treatment groups was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:36:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huovinen-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:36:46 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Ishibashi-1996">
<DESCRIPTION>
<P>Information from the translator suggested that central randomisation was used. From English language abstract: "The study was performed by the telephone or fax registration method." Exact methods not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-03 15:04:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jull-2008">
<DESCRIPTION>
<P>Quote: "Participants were randomly assigned to one of two groups by an independent central telephone service. The allocation sequence was stratified by study centre and the Margolis Index using minimisation"</P>
<P>Comment: the method of allocation concealment was deemed satisfactory</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:39:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-J_x00f8_rgensen-2005">
<DESCRIPTION>
<P>Quote: "Patients were randomised to treatment with either Contreet Foam or Allevyn Hydrocellular by computer generated randomisation"</P>
<P>Comment: No information regarding group allocation was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:40:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kerihuel-2010">
<DESCRIPTION>
<P>Quote: "Randomisation was by blocks of four: identical sealed boxes containing the allocated dressings, gauze and saline were randomly allocated to each patient. The box reference number indicated which study arm the patient had been allocated to, although this was unknown to the patient and investigator. The box reference numbers were verified by a co-ordinating centre before allocation"</P>
<P>Comment: The details provided suggest a satisfactory method of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:41:08 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Kero-1987">
<DESCRIPTION>
<P>"The trial was conducted under open design using random allocation to treatment with either cadexomer iodine or dextranomer"</P>
<P>"Each patient was allocated to the treatment by using a sealed enclosure envelope containing the treatment code of the individual patient"</P>
<P>Information taken from secondary publication (Tarvainen 1988)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:41:55 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Kuznetsov-2009">
<DESCRIPTION>
<P>Comment: The report contained no statement regarding the group allocation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:45 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Laudanska-1988">
<DESCRIPTION>
<P>Quote: "Treatment code not broken until study was completed"</P>
<P>Comment: No measures were described to prevent foreseeing the intervention allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lazareth-2008">
<DESCRIPTION>
<P>Quote: "Each centre received at least 4 sealed envelopes with a number corresponding to the chronological order of patients' inclusion. According to the centre recruitment capacities, more than one block could be provided. No randomization error or deviation was detected by the on-site audits held during the study"</P>
<P>Comment: not stated whether envelopes were opaque</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 11:33:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindsay-1986">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meaume-2005">
<DESCRIPTION>
<P>Quote: "Two <I>a priori</I> randomisation lists were prepared and balanced by blocks of six"</P>
<P>Comment: no information on group allocation concealment provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Michaels-2009">
<DESCRIPTION>
<P>Quote: "Trial numbers and randomisation were allocated through a telephone-based service which recorded details of the patient and which proffered a checklist of questions to confirm eligibility"</P>
<P>Comment: The details provided suggested a satisfactory method of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:51 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Miller-2010">
<DESCRIPTION>
<P>Quote: "Following recruitment, clients were randomized to their treatment group by the nurse opening the next numbered envelope in which the group allocation was concealed"</P>
<P>Comment: not stated whether envelopes were sealed or opaque</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 11:54:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morias-1979">
<DESCRIPTION>
<P>Reports "sequentially numbered drug containers of identical appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 11:33:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moss-1987">
<DESCRIPTION>
<P>Not reported that allocation was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-M_x00fc_nter-2006">
<DESCRIPTION>
<P>Quote: "Using a computer-generated list in sealed envelopes, patients were randomly assigned to a four-week treatment period of either silver foam or LBP"</P>
<P>Comment: No statement was made as to whether envelopes were opaque</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ormiston-1985">
<DESCRIPTION>
<P>"patients were then allocated a code number according to sequence of selection for the trial. for each number there was a double sealed envelope that contained a paper stating which treatment the patient should receive. The sequence of treatments was randomised, and the code of randomisation was not available to the investigators"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:56 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Skog-1983">
<DESCRIPTION>
<P>"Patients were allocated blindly and at random to the standard treatment or to cadexomer iodine." The method of allocation concealment was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 11:34:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steele-1986">
<DESCRIPTION>
<P>No description of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:58 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Valtonen-1989">
<DESCRIPTION>
<P>No information was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wunderlich-1991">
<DESCRIPTION>
<P>Quote, from translation: "Randomized in each group were 20 patients treated with SIAX or with conventional control therapy"</P>
<P>Comment: no information regarding allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-12-03 15:05:11 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Participant blinded to the intervention</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Outcome assessor blinded to the intervention</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:23:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alinovi-1986">
<DESCRIPTION>
<P>Not reported that those allocated to standard treatment only were given placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:23:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alinovi-1986">
<DESCRIPTION>
<P>No details about who performed the outcome assessment or how it was performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-28 17:43:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beitner-1985a">
<DESCRIPTION>
<P>Comment: no information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-11-29 14:35:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beitner-1985a">
<DESCRIPTION>
<P>Quote: "the randomisation and treatment was given in the day care unit by personnel not involved in the evaluation of results"</P>
<P>Comment: no statement that outcome assessors were blind to treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-28 17:43:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beitner-1985b">
<DESCRIPTION>
<P>Comment: no information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-11-29 14:35:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beitner-1985b">
<DESCRIPTION>
<P>Quote: "the randomisation and treatment was given in the day care unit by personnel not involved in the evaluation of results"</P>
<P>Comment: Comment: no statement that outcome assessors were blind to treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:24:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belcaro-2003">
<DESCRIPTION>
<P>The trial authors stated that participants in Group 1 received the same treatment and that: "A placebo cream, comparable in aspect and density to Crystacide, was used. The creams were given to patients in containers without labels"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-11-05 11:43:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2003">
<DESCRIPTION>
<P>No information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:24:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belcaro-2007">
<DESCRIPTION>
<P>A placebo cream comparable in aspect and density with crystacide was used. The creams were given to participants in containers without labels</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:24:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2007">
<DESCRIPTION>
<P>No information given about blinding the outcome assessor to intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:25:20 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Bini_x0107_-2010">
<DESCRIPTION>
<P>Report describes study as "open" with no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:25:13 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Bini_x0107_-2010">
<DESCRIPTION>
<P>Report describes study as "open" with no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-01 17:48:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bishop-1992">
<DESCRIPTION>
<P>No information regarding blinding of participants reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-01 17:48:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bishop-1992">
<DESCRIPTION>
<P>"Before evaluation, all medication was removed and the ulcer cleaned to keep the evaluator blinded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-01 18:49:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blair-1988">
<DESCRIPTION>
<P>No information on blinding of participants reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-01 18:49:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blair-1988">
<DESCRIPTION>
<P>No information on blinding of outcome assessors reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-03 14:47:53 +0000" MODIFIED_BY="Sue O'Meara" RESULT="YES" STUDY_ID="STD-Cameron-1991">
<DESCRIPTION>
<P>Quote: "The study was a randomised double-blind placebo controlled pilot study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-03 14:48:31 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Cameron-1991">
<DESCRIPTION>
<P>Quote: "The study was a randomised double blind placebo controlled pilot study"</P>
<P>Comment: It was not stated that outcome assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-03 14:53:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casoni-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:28:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casoni-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:28:30 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Chaloner-2004">
<DESCRIPTION>
<P>No information on participant blinding reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:28:30 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Chaloner-2004">
<DESCRIPTION>
<P>No information on outcome assessor blinding reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-05 11:11:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daroczy-2006">
<DESCRIPTION>
<P>No information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-11-05 11:11:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daroczy-2006">
<DESCRIPTION>
<P>No information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-13 18:15:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dimakakos-2009">
<DESCRIPTION>
<P>No information reported on participant blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-13 18:15:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dimakakos-2009">
<DESCRIPTION>
<P>No information reported on assessor blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:30:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fischer-1984">
<DESCRIPTION>
<P>Described as "open trial" (translated from German)</P>
<P>Comment: no further information provided about blinding participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:30:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fischer-1984">
<DESCRIPTION>
<P>Described as "open trial" (translated from German)</P>
<P>Comment: no further information provided about blinding outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-27 16:56:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002a">
<DESCRIPTION>
<P>Quote: "51 patients were enrolled in this open study"</P>
<P>Comment: The 51 patients refers to all 3 RCTs reported in this paper, of which 17 were included in this RCT. There was no clear statement about participants being blind to intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-11-27 17:05:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002a">
<DESCRIPTION>
<P>Quote: "51 patients were enrolled in this open study"</P>
<P>Comment: The 51 patients refers to all 3 RCTs reported in this paper, of which 17 were included in this RCT. There was no clear statement about outcome assessors being blind to intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-27 17:04:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002b">
<DESCRIPTION>
<P>Quote: "51 patients were enrolled in this open study"</P>
<P>Comment: The 51 patients refers to all 3 RCTs reported in this paper, of which 17 were included in this RCT. There was no clear statement about participants being blind to intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-11-27 17:05:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002b">
<DESCRIPTION>
<P>Quote: "51 patients were enrolled in this open study"</P>
<P>Comment: The 51 patients refers to all 3 RCTs reported in this paper, of which 17 were included in this RCT. There was no clear statement about outcome assessors being blind to intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-27 17:04:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002c">
<DESCRIPTION>
<P>Quote: "51 patients were enrolled in this open study"</P>
<P>Comment: The 51 patients refers to all 3 RCTs reported in this paper, of which 17 were included in this RCT. There was no clear statement about participants being blind to intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-11-27 17:05:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002c">
<DESCRIPTION>
<P>Quote: "51 patients were enrolled in this open study"</P>
<P>Comment: The 51 patients refers to all 3 RCTs reported in this paper, of which 17 were included in this RCT. There was no clear statement about outcome assessors being blind to intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-05 11:29:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geske-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-11-05 11:30:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geske-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-03 14:57:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gethin-2008">
<DESCRIPTION>
<P>Described as "open label" with no further information about blinding of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:31:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gethin-2008">
<DESCRIPTION>
<P>Quote in relation to healing outcomes: "Blinded outcome assessment was not possible because of obvious differences in the colour and presentation of the products, specifically orange staining of the peri-wound skin when MH was used"</P>
<P>Quote in relation to microbiological outcomes: "The laboratory was blinded to treatment allocation"</P>
<P>Comment: judged as high risk of bias because healing is the primary outcome in the review</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:32:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Groenewald-1981">
<DESCRIPTION>
<P>"patients were incorporated into in a single blind randomised trial"; no other information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:32:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Groenewald-1981">
<DESCRIPTION>
<P>"at each visit the ulcers were evaluated by 2 independent investigators"; no other information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-17 15:45:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hansson-1998">
<DESCRIPTION>
<P>"A 12-week, randomised, open, controlled, multicentre multinational trial...."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-06-17 15:45:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hansson-1998">
<DESCRIPTION>
<P>"A 12-week, randomised, open, controlled, multicentre multinational trial...."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:34:17 +0000" MODIFIED_BY="Sue O'Meara" RESULT="NO" STUDY_ID="STD-Harcup-1986">
<DESCRIPTION>
<P>"the patient, or whoever was to manage the patient, was instructed on how to treat the ulcer"; those in the cadexomer iodine group had to apply CI to the wound before the dressing, while those with standard treatment did not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-11-05 11:31:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harcup-1986">
<DESCRIPTION>
<P>No information mentioned regarding this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:34:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Holloway-1989">
<DESCRIPTION>
<P>Wound care: "treatment was repeated on a daily basis by the patient"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:34:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Holloway-1989">
<DESCRIPTION>
<P>"each ulcer was evaluated serially by the same person as each medical centre"; no further information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-08 11:06:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huovinen-1994">
<DESCRIPTION>
<P>"The patients were.....treated in a double-blind manner...</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:36:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huovinen-1994">
<DESCRIPTION>
<P>No mention of who the outcome assessor was and the adequacy of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-05 11:32:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ishibashi-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-11-05 11:32:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ishibashi-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-03 15:05:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jull-2008">
<DESCRIPTION>
<P>Trial described as "open label" but no further information provided about blinding participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-03 15:05:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jull-2008">
<DESCRIPTION>
<P>Quote: "Outcome assessment could not be blinded. However, re-analysis of the primary outcome using healing state determined from blinded review of ulcer photographs did not affect the study findings"</P>
<P>Comment: The above information suggests low risk of bias in relation to blinding of outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:39:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-J_x00f8_rgensen-2005">
<DESCRIPTION>
<P>Quote: "The study was designed as a multicenter, open, block-randomised and controlled study"</P>
<P>Comment: No mention was made of participants being blind to treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:39:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-J_x00f8_rgensen-2005">
<DESCRIPTION>
<P>Quote: "The study was designed as a multicenter, open, block-randomised and controlled study"</P>
<P>Quote: "The study personnel evaluated the patients weekly at the clinic or hospital throughout the study"</P>
<P>Comment: No mention was made of outcome assessors being blind to treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:40:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kerihuel-2010">
<DESCRIPTION>
<P>Comment: no details provided about blinding of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:40:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kerihuel-2010">
<DESCRIPTION>
<P>Quote: "All wound tracings were measured by two independent, experienced clinicians who were unaware of the treatment allocation"</P>
<P>Comment: The method of blinded outcome assessment was deemed satisfactory</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:41:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kero-1987">
<DESCRIPTION>
<P>"The trial was conducted under open design..."<BR/>Information taken from secondary publication (Tarvainen 1988)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:40:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kero-1987">
<DESCRIPTION>
<P>"The trial was conducted under open design..."<BR/>Information taken from secondary publication (Tarvainen 1988)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:41:55 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Kuznetsov-2009">
<DESCRIPTION>
<P>Comment: The trial was described as "open", but no details of blinding of participants were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:41:55 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Kuznetsov-2009">
<DESCRIPTION>
<P>Comment: The trial was described as "open", but no details of blinding of outcome assessors were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:48:45 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Laudanska-1988">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:48:46 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Laudanska-1988">
<DESCRIPTION>
<P>Quote: "A single observer made all assessments in every patient throughout the trial and treatment code not broken until study completed"</P>
<P>Comment: It was not stated whether this observer was blind to treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:48:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lazareth-2008">
<DESCRIPTION>
<P>Comment: trial described as "open-label". No information about blinding of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:48:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lazareth-2008">
<DESCRIPTION>
<P>Quote: "The wound area tracings were measured by an independent person who was unaware of the test dressings. Furthermore, a blind review of the planimetric and photographic data was performed at the end of the study to validate the investigators&#8217; evaluations, by 2 independent and experienced physicians. These reviewers did not know the received dressings and classified the final target ulcer status according to a 7-point scale (from "leg ulcer strongly improved" or "healed", to leg ulcer "strongly aggravated"). This review detected no difference between investigators and reviewers evaluations and confirmed that the decision rules followed by the investigators when the treatment was prematurely discontinued were no different for patients treated with the silver releasing dressing or the control."</P>
<P>Comment: The details provided were judged as indicating a low risk of bias for this domain</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:48:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lindsay-1986">
<DESCRIPTION>
<P>"The patient or whoever was to manage the patient was instructed how to treat the ulcer"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-11-05 11:33:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindsay-1986">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:48:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meaume-2005">
<DESCRIPTION>
<P>Comment: trial described as "open-label" with no information about participant blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:48:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meaume-2005">
<DESCRIPTION>
<P>Comment: trial described as "open-label" with no information about outcome assessor blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:48:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Michaels-2009">
<DESCRIPTION>
<P>Quote: "It was not possible to blind either the patients or the nurses applying the dressings, because each type of dressing had different physical characteristics"</P>
<P>Comment: It is clear from the details provided that participants were not blind to treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:48:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Michaels-2009">
<DESCRIPTION>
<P>Quote: "The research staff dealing with postal questionnaires, the staff measuring ulcer sizes based upon tracings, and the staff carrying out initial data entry and analysis were all blinded to the treatment allocation of the patient"</P>
<P>Comment: It is clear from the details provided that outcome assessors were blind to treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:48:51 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="NO" STUDY_ID="STD-Miller-2010">
<DESCRIPTION>
<P>Quote: "The design of this trial could have been strengthened by participant and data collector blinding. However, presentation of the two antimicrobial treatments was quite distinctive and might have been discerned by sensation alone"</P>
<P>Comment: It was clear that participants were not blind to treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:48:51 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="NO" STUDY_ID="STD-Miller-2010">
<DESCRIPTION>
<P>Quote: "The design of this trial could have been strengthened by participant and data collector blinding. However, presentation of the two antimicrobial treatments was quite distinctive and might have been discerned by sensation alone"</P>
<P>Comment: It was clear that outcome assessors were not blind to treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-09 16:02:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morias-1979">
<DESCRIPTION>
<P>"these tablets randomly contained either 50mg of levamisole or a placebo and were identical in appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:48:52 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Morias-1979">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-21 16:13:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moss-1987">
<DESCRIPTION>
<P>"...the trial was not blind because the treatments can easily be distinguished by colour..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-21 15:12:38 +0100" MODIFIED_BY="Sue O'Meara" RESULT="NO" STUDY_ID="STD-Moss-1987">
<DESCRIPTION>
<P>"All assessments were performed by CM or AT, but could not be blind because after the dressing were removed differences in colour were still apparent"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:48:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-M_x00fc_nter-2006">
<DESCRIPTION>
<P>Comment: The trial was described as "open", and no mention was made of participant blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:48:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-M_x00fc_nter-2006">
<DESCRIPTION>
<P>Quote: "The study personnel at the participating centres completed the data collection forms"</P>
<P>Comment: The trial was described as "open", and no mention was made of outcome assessor blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-08 12:38:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ormiston-1985">
<DESCRIPTION>
<P>"A nurse specially attached to the study taught the patients how to dress and bandage their ulcers..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:48:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ormiston-1985">
<DESCRIPTION>
<P>"At the 12th week each case was reviewed by a clinician not associated with the routine assessment of the ulcer to see whether it was healing satisfactorily."</P>
<P>Not stated whether clinician was blind to treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:48:56 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Skog-1983">
<DESCRIPTION>
<P>No information was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:48:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Skog-1983">
<DESCRIPTION>
<P>"at each centre the same observer always made these observations"; it was not stated whether observer was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-04 14:25:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smith-1992">
<DESCRIPTION>
<P>"this was not a blind study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:48:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smith-1992">
<DESCRIPTION>
<P>"this was not a blind study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:48:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Steele-1986">
<DESCRIPTION>
<P>"cadexomer iodine did not lend itself to a double blind trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 14:48:58 +0000" MODIFIED_BY="Sue O'Meara" RESULT="NO" STUDY_ID="STD-Steele-1986">
<DESCRIPTION>
<P>"Measurements were recorded on the Proforma at 0, 2, 4 and 6 weeks by each patient's nurse." "Cadexomer iodine did not lend itself to a double blind trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-29 09:14:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Valtonen-1989">
<DESCRIPTION>
<P>"We have studied, using an open, comparative study design, the efficacy of..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-29 09:14:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Valtonen-1989">
<DESCRIPTION>
<P>"We have studied, using an open, comparative study design, the efficacy of..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-02 14:48:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wunderlich-1991">
<DESCRIPTION>
<P>Comment: The trial was described as "an open randomised study", but no participant blinding was described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-12-02 15:47:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wunderlich-1991">
<DESCRIPTION>
<P>Comment: The trial was described as "an open randomised study" but no description of outcome assessor blinding was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-12-06 13:29:28 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.03" NO="3">
<NAME>ITT analysis</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Drop out rate described</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Drop out rate acceptable</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:23:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alinovi-1986">
<DESCRIPTION>
<P>One withdrawal from Group 2 because could not tolerate compression bandage</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:23:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alinovi-1986">
<DESCRIPTION>
<P>No withdrawals from Group 1; 1/24 (4%) withdrew from Group 2</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:23:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alinovi-1986">
<DESCRIPTION>
<P>Participant withdrew from intervention Group 2 because could not tolerate bandage and was "excluded from analysis". It is unlikely that exclusion of one participant from the analysis had an important impact on estimates of treatment effect</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-29 14:36:44 +0000" MODIFIED_BY="Sue O'Meara" RESULT="YES" STUDY_ID="STD-Beitner-1985a">
<DESCRIPTION>
<P>Comment: clearly stated that 3 participants withdrew, and reasons provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-11-29 14:28:12 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Beitner-1985a">
<DESCRIPTION>
<P>Comment: 3/10 (30%) participants withdrew </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-11-29 14:28:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beitner-1985a">
<DESCRIPTION>
<P>Comment: no information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-28 17:48:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beitner-1985b">
<DESCRIPTION>
<P>Comment: it was clear that there were no withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-11-29 14:29:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beitner-1985b">
<DESCRIPTION>
<P>Comment: it was clear that there were no withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-11-29 14:30:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beitner-1985b">
<DESCRIPTION>
<P>Comment: it was clear that there were no withdrawals, and the review authors assume that all randomised participants were included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:24:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2003">
<DESCRIPTION>
<P>No mention of dropouts or withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:24:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2003">
<DESCRIPTION>
<P>No information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2009-11-05 11:10:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2003">
<DESCRIPTION>
<P>No exclusions described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:24:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2007">
<DESCRIPTION>
<P>No mention of withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:24:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2007">
<DESCRIPTION>
<P>No information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:24:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2007">
<DESCRIPTION>
<P>No information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:25:20 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="YES" STUDY_ID="STD-Bini_x0107_-2010">
<DESCRIPTION>
<P>Although no statement, it appears from the report that all randomly assigned participants completed the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:25:20 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="YES" STUDY_ID="STD-Bini_x0107_-2010">
<DESCRIPTION>
<P>Although no statement, it appears from the report that all randomly assigned participants completed the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:25:20 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="YES" STUDY_ID="STD-Bini_x0107_-2010">
<DESCRIPTION>
<P>Although no statement, it appears from the report that all randomly assigned participants completed the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:26:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bishop-1992">
<DESCRIPTION>
<P>Numbers of withdrawals reported per treatment arm but reasons not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:26:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bishop-1992">
<DESCRIPTION>
<P>Withdrawals:</P>
<P>Group 1: 1/30 (3%)</P>
<P>Group 2: 3/31 (10%)</P>
<P>Group 1: 3/32 (9%)</P>
<P>Overall withdrawal rate 8%; 86/93 (92%) completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:26:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bishop-1992">
<DESCRIPTION>
<P>Per protocol, "eighty-six were evaluable for efficacy". It is unclear how these withdrawals might have impacted estimates of treatment effect (this is a small RCT)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:27:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blair-1988">
<DESCRIPTION>
<P>No information on withdrawals reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:27:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blair-1988">
<DESCRIPTION>
<P>No information on withdrawals reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:27:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blair-1988">
<DESCRIPTION>
<P>No information on withdrawals reported. Apart from the 4 participants in Group 2 who stopped treatment because of adverse effects, no information was presented about withdrawals; it is not clear whether these participants were included in all analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-03 14:48:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cameron-1991">
<DESCRIPTION>
<P>30 patients were recruited; no withdrawals were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-03 14:49:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cameron-1991">
<DESCRIPTION>
<P>Withdrawal rate was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-03 14:49:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cameron-1991">
<DESCRIPTION>
<P>Method of analysis not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-03 14:53:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casoni-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-03 14:53:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casoni-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-03 14:53:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casoni-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:28:30 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Chaloner-2004">
<DESCRIPTION>
<P>"In the Avance group.....2 patients had been withdrawn due to adverse reactions"</P>
<P>Comment: The above information was taken from a brief, interim report. No information on withdrawals was provided in relation to the Acticoat 7 group, and no information was available for either group at the final analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:28:30 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Chaloner-2004">
<DESCRIPTION>
<P>"In the Avance group.....2 patients had been withdrawn due to adverse reactions"</P>
<P>Comment: The above information was taken from a brief, interim report. No information on withdrawals was provided in relation to the Acticoat 7 group, and no information was available for either group at the final analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-06 13:29:28 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Chaloner-2004">
<DESCRIPTION>
<P>From conference abstract: "Results from 40 patients have demonstrated"</P>
<P>From conference poster: "The primary analysis could only be conducted on 18 (45%) patients who had a baseline bacteria count and at least one post baseline bacteria count"</P>
<P>Comment: no statement as to whether analysis conducted per protocol or according to intention-to-treat</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:28:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daroczy-2006">
<DESCRIPTION>
<P>No withdrawals or dropouts reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:28:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daroczy-2006">
<DESCRIPTION>
<P>No withdrawals or dropouts reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2009-11-05 11:11:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daroczy-2006">
<DESCRIPTION>
<P>No information given about mode of analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:29:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dimakakos-2009">
<DESCRIPTION>
<P>Comment: It appears that all randomly assigned participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:29:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dimakakos-2009">
<DESCRIPTION>
<P>Comment: It appears that all randomly assigned participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:29:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dimakakos-2009">
<DESCRIPTION>
<P>Comment: It appears that all randomly assigned participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:30:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fischer-1984">
<DESCRIPTION>
<P>Comment: The study reports treatment discontinuation because of ineffectiveness or allergy per group. Unclear if other withdrawals occurred</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:30:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fischer-1984">
<DESCRIPTION>
<P>Comment: The study reports treatment discontinuation because of ineffectiveness or allergy per group. No reporting on other withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:30:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fischer-1984">
<DESCRIPTION>
<P>Comment: no information reported on whether the analyses were conducted on a per-protocol or intention-to-treat basis; however, it appears that all randomly assigned participants were included in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-27 16:57:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002a">
<DESCRIPTION>
<P>Comment: No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-11-27 16:57:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002a">
<DESCRIPTION>
<P>Comment: No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-11-27 16:57:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002a">
<DESCRIPTION>
<P>Comment: No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-27 17:06:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002b">
<DESCRIPTION>
<P>Comment: No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-11-27 17:06:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002b">
<DESCRIPTION>
<P>Comment: No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-11-27 17:06:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002b">
<DESCRIPTION>
<P>Comment: No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-27 17:06:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002c">
<DESCRIPTION>
<P>Comment: No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-11-27 17:06:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002c">
<DESCRIPTION>
<P>Comment: No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-11-27 17:06:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002c">
<DESCRIPTION>
<P>Comment: No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:31:03 +0000" MODIFIED_BY="Sue O'Meara" RESULT="YES" STUDY_ID="STD-Geske-2005">
<DESCRIPTION>
<P>253 participants were randomly assigned, of whom 12 were classed as withdrawals (5 discontinued therapy before trial end, 6 were ineligible, 1 suffered serious adverse event)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:31:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Geske-2005">
<DESCRIPTION>
<P>In Group 1: 5/124 (4%) withdrew; and in Group 2: 7/129 (5%) withdrew</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:31:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geske-2005">
<DESCRIPTION>
<P>241 of 253 randomly assigned participants were analysed per protocol. No mention of ITT analysis. It is unclear how these withdrawals might have impacted estimates of treatment effect</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-03 14:58:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gethin-2008">
<DESCRIPTION>
<P>Withdrawal rate and reasons for withdrawal were reported per group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-03 14:59:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gethin-2008">
<DESCRIPTION>
<P>Group 1: 31% of patients withdrew</P>
<P>Group 2: 17% of patients withdrew</P>
<P>Comment: the withdrawal rate in Group 1 was greater than 20%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-03 14:59:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gethin-2008">
<DESCRIPTION>
<P>Quote: "All patients were included in the final analysis"</P>
<P>Comment: it is clearly shown in the paper that all patients received their allocated treatment and were followed up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:32:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Groenewald-1981">
<DESCRIPTION>
<P>"a total of 100 patients were evaluated with 50 in each group, five dropped out"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 15:45:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Groenewald-1981">
<DESCRIPTION>
<P>5/50 (10%) withdrawals - withdrawal rate is acceptable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:32:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Groenewald-1981">
<DESCRIPTION>
<P>"five dropped out and were replaced to keep the final number at 50/group"; no further information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:33:48 +0000" MODIFIED_BY="Sue O'Meara" RESULT="YES" STUDY_ID="STD-Hansson-1998">
<DESCRIPTION>
<P>153 participants were randomly assigned, of whom 48 withdrew</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:33:48 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hansson-1998">
<DESCRIPTION>
<P>Dropout rate &gt; 20% in all treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:33:48 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hansson-1998">
<DESCRIPTION>
<P>"28 patients (12 in cadexomer iodine, 7 in hydrocolloid, 9 in paraffin gauze group) were withdrawn from the study for reason unrelated to efficacy and were excluded from the analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:34:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harcup-1986">
<DESCRIPTION>
<P>Describes number of people withdrawn at 2, 4, 6 weeks from both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:34:17 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Harcup-1986">
<DESCRIPTION>
<P>Withdrawal rates differed between groups: Group 1 6.5%; Group 2 19.5%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:34:17 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Harcup-1986">
<DESCRIPTION>
<P>"two patients were randomised to standard therapy, but were treated with CI during the trial. The analysis was carried out assigning these patients to the CI group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:34:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Holloway-1989">
<DESCRIPTION>
<P>"Of the 75 patients starting the trial,15 did not complete the study for reasons other than healing of the ulcer. Four failed to respond to one or both treatments and required more aggressive treatment. Two died during the study of causes unrelated to the ulcers, &amp; 9 dropped out or failed to return. An additional 6 patients were excluded from statistical analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:34:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Holloway-1989">
<DESCRIPTION>
<P>dropout rate &gt; 20%; breakdown per group not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:34:58 +0000" MODIFIED_BY="Sue O'Meara" RESULT="NO" STUDY_ID="STD-Holloway-1989">
<DESCRIPTION>
<P>"6 patients were excluded from statistical analysis"</P>
<P>"A total of 12 patients switched treatments during the trial: all 12 crossed over from the control treatment to using cadexomer iodine because of a failure of healing..." It is not clear whether these participants were retained in their original groups for the purposes of data analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-05 11:51:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huovinen-1994">
<DESCRIPTION>
<P>Describes 5 patients excluded and states reasons for exclusion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:36:09 +0000" MODIFIED_BY="Sue O'Meara" RESULT="NO" STUDY_ID="STD-Huovinen-1994">
<DESCRIPTION>
<P>The dropout rate differed between groups: Group 1: 9%; Group 2: 8%; Group 3: 25%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:36:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huovinen-1994">
<DESCRIPTION>
<P>"five were eventually excluded"; no other information provided about analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:36:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ishibashi-1996">
<DESCRIPTION>
<P>Dropout rate of each group described: Group 1: 109 participants randomly assigned, 5 excluded for protocol violation; Group 2: 109 participants randomly assigned, 6 excluded (5 for protocol violation, 1 for worsening clinical condition)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:36:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ishibashi-1996">
<DESCRIPTION>
<P>Dropout rate about 5% in both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:36:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ishibashi-1996">
<DESCRIPTION>
<P>Patients excluded from analysis: Group 1: 109 - 5 = 104 patients analysed; Group 2: 109 - 6= 103 patients analysed&#8212;these values relate to the whole trial population, which consisted of people with various wound types. It is unclear how these withdrawals might have impacted estimates of treatment effect for those with venous leg ulceration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-03 15:05:39 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="YES" STUDY_ID="STD-Jull-2008">
<DESCRIPTION>
<P>Numbers withdrawing, with reasons reported for both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-03 15:06:09 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="YES" STUDY_ID="STD-Jull-2008">
<DESCRIPTION>
<P>Withdrawal rate less then 20% in both groups, with patients discontinuing treatment followed up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-03 15:06:58 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="YES" STUDY_ID="STD-Jull-2008">
<DESCRIPTION>
<P>Quote: "Intention-to-treat analysis was undertaken with the inclusion of all participants randomised"</P>
<P>Comment: all participants were included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:39:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-J_x00f8_rgensen-2005">
<DESCRIPTION>
<P>Comment: Numbers withdrawing and reasons are reported for both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:39:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-J_x00f8_rgensen-2005">
<DESCRIPTION>
<P>Comment: A greater proportion of participants withdrew from the silver dressing group:</P>
<P>Group 1: n = 7 (11%)</P>
<P>Group 2: n = 13 (20%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:39:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-J_x00f8_rgensen-2005">
<DESCRIPTION>
<P>Quote: "Intention-to-treat analyses were performed in connection with the safety parameters, whereas per-protocol analyses were applied for the performance parameters"</P>
<P>Comment: Analysis of healing outcomes was undertaken on a per-protocol basis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:40:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kerihuel-2010">
<DESCRIPTION>
<P>Comment: The numbers of withdrawals and reasons are reported for both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:40:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kerihuel-2010">
<DESCRIPTION>
<P>11.7% withdrew overall, but proportions differed between groups:</P>
<P>Group 1: 6/30 (20%)</P>
<P>Group 2: 1/30 (3%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:40:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kerihuel-2010">
<DESCRIPTION>
<P>"All analyses used data from the intention-to-treat population (defined as all randomised patients whose wounds were traced in at least one assessment during the first four weeks of the study)"</P>
<P>Comment: The presentation of results suggested that all randomly assigned participants had been included in all analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:41:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kero-1987">
<DESCRIPTION>
<P>"Two patients (one in each group) withdrew because of drug related side effects"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:41:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kero-1987">
<DESCRIPTION>
<P>Dropout rate less than 20%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:41:08 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Kero-1987">
<DESCRIPTION>
<P>"Two patients, one in each group were excluded from the evaluation of ulcer size because of infection that made cessation of therapy necessary. Two more patients, one in each group, were also excluded because of adverse reactions"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:41:55 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="YES" STUDY_ID="STD-Kuznetsov-2009">
<DESCRIPTION>
<P>Comment: The trial report indicates that all randomly assigned participants completed treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:41:55 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="YES" STUDY_ID="STD-Kuznetsov-2009">
<DESCRIPTION>
<P>Comment: The trial report indicates that all randomly assigned participants completed treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:41:55 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="YES" STUDY_ID="STD-Kuznetsov-2009">
<DESCRIPTION>
<P>Comment: The trial report indicates that all randomly assigned participants completed treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:48:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laudanska-1988">
<DESCRIPTION>
<P>Quote: "Two patients in each treatment group dropped out of the trial before the first assessment. In three instances this was due to social reasons and in one case because of cardiac failure not due to treatment..."</P>
<P>Quote: "The results obtained from three patients, all of whom responded to treatment, were excluded from the analysis"</P>
<P>Comment: Some information on withdrawals (numbers/reasons) was given in relation to the whole sample, not per treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:48:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laudanska-1988">
<DESCRIPTION>
<P>Comment: Overall withdrawal rate was less than 20%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:48:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laudanska-1988">
<DESCRIPTION>
<P>Quote: "The results obtained from three patients, all of whom responded to treatment, were excluded from the analysis"</P>
<P>Comment: Analysis was based on 60/67 participants. It is unclear how these withdrawals might have impacted estimates of treatment effect (this is a small RCT)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:48:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lazareth-2008">
<DESCRIPTION>
<P>Comment: Numbers withdrawing and reasons are reported for both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:48:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lazareth-2008">
<DESCRIPTION>
<P>Group 1: 14 (28%)</P>
<P>Group 2: 3 (6%)</P>
<P>Comment: Withdrawal rates differed between groups, and Group 1 had withdrawal rate &gt; 20%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:48:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lazareth-2008">
<DESCRIPTION>
<P>Quote: "All analyses were conducted on the intent-to-treat population defined as all randomised patients with at least one follow-up planimetry value"</P>
<P>Quote: "...the efficacy analysis on the ITT population included 99 subjects (51 patients treated with the silver sequential strategy [CLS] and 48 patients with the continuous strategy with the control dressing [CL])"</P>
<P>Comment: Presentation of data in the trial report indicated that analyses had been conducted according to intention-to-treat, as defined above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:48:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lindsay-1986">
<DESCRIPTION>
<P>28 participants were randomly assigned, of whom 3 withdrew, one from Group 1 (because of peripheral vascular disease) and two from Group 2 (allergic reaction, skin irritation/itching)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:48:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lindsay-1986">
<DESCRIPTION>
<P>Dropout rate less than 20% in each group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:48:48 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Lindsay-1986">
<DESCRIPTION>
<P>"Statistical analysis at four weeks was performed on 12 assigned to cadexomer iodine and 13 patient assigned to standard treatment." This suggests that 25 participants were analysed out of 28 recruited to the trial. It is unclear how these withdrawals might have impacted estimates of treatment effect (this is a small RCT)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:48:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meaume-2005">
<DESCRIPTION>
<P>Comment: The numbers withdrawing and the reasons for withdrawal were reported for both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:48:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Meaume-2005">
<DESCRIPTION>
<P>Group 1: 6/33 VLU participants (18%)</P>
<P>Group 2: 9/38 VLU participants (24%)</P>
<P>Comment: A larger proportion of VLU participants in Group 2 withdrew; withdrawal rate of VLU participants in Group 2 was &gt; 20%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:48:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meaume-2005">
<DESCRIPTION>
<P>Quote: "All patients received at least one application of the allocated dressings and had at least one clinical evaluation (ITT population)"</P>
<P>
<BR/>Comment: both ITT and per-protocol analyses presented, and clear that all randomly assigned participants included in the ITT population</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:48:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Michaels-2009">
<DESCRIPTION>
<P>Comment: The numbers of participants withdrawing from each group were reported, along with reasons for withdrawal</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:48:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Michaels-2009">
<DESCRIPTION>
<P>Group 1: 5/106 (5%)</P>
<P>Group 2: 8/107 (7%)</P>
<P>Comment: Withdrawal rates were low and similar between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:48:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Michaels-2009">
<DESCRIPTION>
<P>Quote: "Analysis of all outcomes was on an intention-to-treat basis"</P>
<P>Comment: It is clear from the trial report that an intention-to-treat analysis was conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:48:51 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Miller-2010">
<DESCRIPTION>
<P>Comment: Numbers of participants lost to follow-up, withdrawing or died are given for each group, but reasons for withdrawal are not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:48:51 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="YES" STUDY_ID="STD-Miller-2010">
<DESCRIPTION>
<P>Group 1: 7/140 (5%)</P>
<P>Group 2: 8/141 (6%)</P>
<P>Comment: The withdrawal rates are low and similar between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:48:51 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Miller-2010">
<DESCRIPTION>
<P>Quote: "In accordance with the intention-to-treat principle, once the client was randomized to a treatment, they remained in the study regardless of variations to their treatment and completed all data collection including monitoring the treatment provided"</P>
<P>Quote: "All clients with at least two wound size measurements at any time during the 12-week period, for whom a healing rate could therefore be calculated, were included in the final analysis in the treatment arm to which they were randomized, even if a change in treatment had occurred. With a total of 15 clients excluded from the analysis due to missing data or loss to follow-up (seven from the silver treatment group and eight from the iodine treatment group), 266 clients (95%) were included in the final analysis"</P>
<P>Comment: Some randomly assigned participants were excluded from the analysis. It is unclear how these withdrawals might have impacted estimates of treatment effect</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:48:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morias-1979">
<DESCRIPTION>
<P>Participants complete at analysis; no dropouts or withdrawals reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-11-05 11:33:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morias-1979">
<DESCRIPTION>
<P>No withdrawals reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2009-11-05 11:54:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morias-1979">
<DESCRIPTION>
<P>Participants complete, no exclusions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:48:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moss-1987">
<DESCRIPTION>
<P>Dropout rate described (1 participant from unspecified group, because of "poor compliance")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:48:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moss-1987">
<DESCRIPTION>
<P>Dropout rate &lt; 20%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:48:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moss-1987">
<DESCRIPTION>
<P>One participant dropped out, and it is not clear whether that participant was included in the 6-week analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:48:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-M_x00fc_nter-2006">
<DESCRIPTION>
<P>Comment: Although no explicit statement is made, tabulated outcome data for leg ulcers indicate that analyses were based on all participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:48:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-M_x00fc_nter-2006">
<DESCRIPTION>
<P>Comment: Although no explicit statement is made, tabulated outcome data for leg ulcers indicate that analyses were based on all participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:48:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-M_x00fc_nter-2006">
<DESCRIPTION>
<P>Quote: "Data were analysed on the principle of last observation carried forward"</P>
<P>Quote: "The obtained data were analysed as intention to treat (ITT)"</P>
<P>Comment: Although no explicit statement is made, tabulated outcome data for leg ulcers indicate that analyses were based on all participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:48:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ormiston-1985">
<DESCRIPTION>
<P>"Sixty one patients entered this study. One patient receiving cadexomer iodine was admitted to hospital for routine surgery and his ulcer was dressed inappropriately.He was withdrawn from the trial"</P>
<P>Study further describes 2 participants who failed to complete the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:48:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ormiston-1985">
<DESCRIPTION>
<P>Dropout rate acceptable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:48:55 +0000" MODIFIED_BY="Sue O'Meara" RESULT="YES" STUDY_ID="STD-Ormiston-1985">
<DESCRIPTION>
<P>"Sixty one patients entered this study. One patient receiving cadexomer iodine was admitted to hospital for routine surgery and his ulcer was dressed inappropriately. He was withdrawn from the trial. This left 30 in each group. Two patients, both receiving cadexomer iodine, failed to complete the study. One died of a perforated ulcer and the other had difficulty removing the cadexomer iodine from the ulcer. The data on these two patient were included in the analysis."</P>
<P>It is unlikely that exclusion of one participant from the analysis had an important impact on estimates of treatment effect</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:48:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Skog-1983">
<DESCRIPTION>
<P>Study reported number of dropouts and provided reasons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-11-04 10:32:58 +0000" MODIFIED_BY="Sue O'Meara" RESULT="NO" STUDY_ID="STD-Skog-1983">
<DESCRIPTION>
<P>21/95 withdrew overall (22%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2009-06-09 16:04:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Skog-1983">
<DESCRIPTION>
<P>"ninety five sets of data were received for evaluation, of which 21 were excluded from the statistical analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:48:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1992">
<DESCRIPTION>
<P>Dropout rate described (60/200 participants)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-06-04 14:26:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smith-1992">
<DESCRIPTION>
<P>"70% completed the trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2009-11-04 10:37:46 +0000" MODIFIED_BY="Sue O'Meara" RESULT="NO" STUDY_ID="STD-Smith-1992">
<DESCRIPTION>
<P>"Five patients did not receive their randomly allocated treatment because of clerical errors. Two patients received biofilm instead of Betadine and three patients received Betadine instead of biofilm. Statistical analysis was performed on basis of treatment received"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:48:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steele-1986">
<DESCRIPTION>
<P>"57 of the 60 patients completed the trial"; reasons given for the three withdrawals were hospital admission and lack of cooperation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-11-05 11:57:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steele-1986">
<DESCRIPTION>
<P>Withdrawal rate 5%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:48:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steele-1986">
<DESCRIPTION>
<P>Analyses were based on 57 of 60 randomly assigned participants. It is unclear how these withdrawals might have impacted estimates of treatment effect (this is a small RCT)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:48:58 +0000" MODIFIED_BY="Sue O'Meara" RESULT="YES" STUDY_ID="STD-Valtonen-1989">
<DESCRIPTION>
<P>"Altogether 27 patients enrolled..." One was excluded from analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:48:58 +0000" MODIFIED_BY="Sue O'Meara" RESULT="YES" STUDY_ID="STD-Valtonen-1989">
<DESCRIPTION>
<P>One participant was excluded because of malignancy in ulcer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:48:59 +0000" MODIFIED_BY="Sue O'Meara" RESULT="YES" STUDY_ID="STD-Valtonen-1989">
<DESCRIPTION>
<P>Participants were analysed in the groups into which they were enrolled at the beginning of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 14:48:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wunderlich-1991">
<DESCRIPTION>
<P>Comment: The trial authors report that 19 of the 20 participants in each arm completed the study, but no details of the participants not completing are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-12-02 14:48:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wunderlich-1991">
<DESCRIPTION>
<P>Group 1: 1/20 (5%)</P>
<P>Group 2: 1/20 (5%)</P>
<P>Comment: Withdrawal rates are low in both groups, with identical rates</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-12-02 14:49:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wunderlich-1991">
<DESCRIPTION>
<P>Comment: The trial authors report that the analyses were undertaken on 19/20 participants randomly assigned to each arm, but no analysis methods were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2013-12-03 15:07:25 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Baseline factors comparable</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:23:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alinovi-1986">
<DESCRIPTION>
<P>Mean values reported for ulcer size and ulcer duration (these variables are often skewed), and so difficult to judge comparability</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-29 14:29:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beitner-1985a">
<DESCRIPTION>
<P>Comment: no information provided on baseline characteristics of participants/ulcers in each group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-29 14:30:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beitner-1985b">
<DESCRIPTION>
<P>Comment: no information provided on baseline characteristics of participants/ulcers in each group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:24:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2003">
<DESCRIPTION>
<P>Mean values appear to have been reported for ulcer size and ulcer duration, and so difficult to judge comparability</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:24:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2007">
<DESCRIPTION>
<P>Mean values appear to have been reported for ulcer size and ulcer duration, and so difficult to judge comparability</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:25:21 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="YES" STUDY_ID="STD-Bini_x0107_-2010">
<DESCRIPTION>
<P>Patients with non-infected venous leg ulcers with surface area &#8804; 10 cm<SUP>2</SUP> and ulcer duration not longer than 2 months were recruited. Ulcer area and duration appear comparable between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:26:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bishop-1992">
<DESCRIPTION>
<P>On the basis of median values, Group 2 (1% silver sulphadiazine) included participants with longer ulcer duration, on average, than the other groups. Treatment groups appear comparable in terms of ulcer area</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:27:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blair-1988">
<DESCRIPTION>
<P>Ulcer size and duration at baseline appear comparable between groups (inclusion criteria for ulcer size &lt; 10 cm<SUP>2</SUP>&#8212;this will have restricted variation in size)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-03 14:49:53 +0000" MODIFIED_BY="Sue O'Meara" RESULT="NO" STUDY_ID="STD-Cameron-1991">
<DESCRIPTION>
<P>The ulcers in Group 1 had longer mean duration than those in Group 2 (2.7 years versus 6 years)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-03 14:54:27 +0000" MODIFIED_BY="Sue O'Meara" RESULT="NO" STUDY_ID="STD-Casoni-2002">
<DESCRIPTION>
<P>Ulcers in Group 2 were larger than those in the other groups. Ulcer in Group 1 were of longer during than those in the other groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:28:31 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Chaloner-2004">
<DESCRIPTION>
<P>Baseline participant characteristics were not presented per group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 11:44:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daroczy-2006">
<DESCRIPTION>
<P>Not sufficient information in tables to illustrate baseline characteristics</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:29:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dimakakos-2009">
<DESCRIPTION>
<P>Comment: Categorical data were provided for baseline ulcer diameter and depth, and groups appeared comparable. The only information regarding baseline ulcer duration was the number of participants in each group with ulcers &gt; 1 month duration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:30:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fischer-1984">
<DESCRIPTION>
<P>Comment: Although the study reported specific inclusion criteria for ulcer size (leg ulcers 3 cm to 10 cm diameter), no data per group are reported for baseline ulcer size or duration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-27 17:03:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002a">
<DESCRIPTION>
<P>No clear description of baseline characteristics of participants in each group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-27 17:06:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002b">
<DESCRIPTION>
<P>No clear description of baseline characteristics of participants in each group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-27 17:06:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fumal-2002c">
<DESCRIPTION>
<P>No clear description of baseline characteristics of participants in each group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:31:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geske-2005">
<DESCRIPTION>
<P>Limited data presented on baseline characteristics</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-03 15:00:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gethin-2008">
<DESCRIPTION>
<P>Both wound size and wound duration appear comparable at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:32:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Groenewald-1981">
<DESCRIPTION>
<P>Insufficient information on baseline characteristics provided to allow a judgement to be made</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:33:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hansson-1998">
<DESCRIPTION>
<P>Mean values were presented for baseline ulcer area, making comparability difficult to judge. No data on baseline ulcer duration were presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:34:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harcup-1986">
<DESCRIPTION>
<P>Not clear about all baseline characteristics in each group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:34:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Holloway-1989">
<DESCRIPTION>
<P>Ulcers were larger and of longer duration in Group 2</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:36:09 +0000" MODIFIED_BY="Sue O'Meara" RESULT="NO" STUDY_ID="STD-Huovinen-1994">
<DESCRIPTION>
<P>Ulcer area and duration varied considerably across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:36:46 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Ishibashi-1996">
<DESCRIPTION>
<P>Ulcer area, duration and infection appear similar across all participants, but data were not provided per wound type</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-03 15:07:25 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="YES" STUDY_ID="STD-Jull-2008">
<DESCRIPTION>
<P>The median ulcer size and the median ulcer duration appear comparable at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:39:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-J_x00f8_rgensen-2005">
<DESCRIPTION>
<P>Comment: Baseline ulcer size and duration appear comparable. Similar rates of infection were reported per group during previous year</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:40:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kerihuel-2010">
<DESCRIPTION>
<P>Although between-group wound surface area appears broadly comparable, it is difficult to judge wound duration comparability (categorical data only provided)<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:41:08 +0000" MODIFIED_BY="Sue O'Meara" RESULT="NO" STUDY_ID="STD-Kero-1987">
<DESCRIPTION>
<P>Ulcer duration appeared longer in the group receiving cadexomer iodine. No information about baseline ulcer area or wound infection status</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:41:56 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Kuznetsov-2009">
<DESCRIPTION>
<P>The upper end of the ulcer area range is larger in Group 2. No information was provided about baseline ulcer duration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:46 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Laudanska-1988">
<DESCRIPTION>
<P>Difficult to judge baseline comparability, as mean values, rather than medians, were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lazareth-2008">
<DESCRIPTION>
<P>Baseline ulcer characteristics appear comparable across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindsay-1986">
<DESCRIPTION>
<P>Limited data available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Meaume-2005">
<DESCRIPTION>
<P>Comment: Median baseline ulcer area and duration are comparatively greater in Group 2 than in Group 1</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Michaels-2009">
<DESCRIPTION>
<P>The information provided on baseline ulcer area suggests between-group comparability, but the only information on baseline ulcer duration was the number of participants in each group with ulcers present &gt; 12 weeks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:51 +0000" MODIFIED_BY="Marrissa Martyn-St James" RESULT="UNKNOWN" STUDY_ID="STD-Miller-2010">
<DESCRIPTION>
<P>Difficult to judge between-group baseline comparability of ulcer size or duration, as data are reported only for participants included in the final analysis (not all participants randomly assigned). Values are reported as mean ± SD (medians are not reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:52 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Morias-1979">
<DESCRIPTION>
<P>The two groups appeared comparable for baseline ulcer area. However, no information about baseline ulcer duration was available, and it was not stated whether wounds were clinically infected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moss-1987">
<DESCRIPTION>
<P>Ulcers in Group 1 were of shorter duration but larger area compared with Group 2. It is not clear whether wounds were clinically infected at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-M_x00fc_nter-2006">
<DESCRIPTION>
<P>Baseline ulcer size was reported for all wound types together, not separately for the leg ulcer participants. For the overall group, the baseline ulcer size was larger in Group 2. No information on baseline ulcer duration was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ormiston-1985">
<DESCRIPTION>
<P>Median values indicate that ulcers in Group 2 were of longer duration than those in Group 1. It is difficult to interpret comparability for ulcer area, as mean rather than median values are presented. It is unclear whether ulcers were clinically infected at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:56 +0000" MODIFIED_BY="Sue O'Meara" RESULT="UNKNOWN" STUDY_ID="STD-Skog-1983">
<DESCRIPTION>
<P>Mean values were reported for ulcer area and ulcer duration; therefore it was difficult to assess comparability</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smith-1992">
<DESCRIPTION>
<P>Of those with larger ulcers at baseline (&gt; 4 cm diameter), Group 2 included more participants with larger ulcers and wounds of longer duration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 15:46:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steele-1986">
<DESCRIPTION>
<P>Mean, rather than median, values were reported for baseline ulcer area and ulcer duration and so it is difficult to judge comparability</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:48:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Valtonen-1989">
<DESCRIPTION>
<P>Longer baseline ulcer duration in ciprofloxacin group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 14:49:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wunderlich-1991">
<DESCRIPTION>
<P>Comment: Limited information was presented on baseline ulcer area and duration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" NO="9">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-11-04 11:00:15 +0000" MODIFIED_BY="Sue O'Meara"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-12-15 18:27:59 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-12-02 15:14:08 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Systemic antibiotic given according to sensitivities versus standard care</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7174755886503665" CI_START="0.22312978256050178" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6190476190476191" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.23489057292821974" LOG_CI_START="-0.6514424577823847" LOG_EFFECT_SIZE="-0.20827594242708247" METHOD="MH" MODIFIED="2013-07-01 17:20:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.35698330758478625" Q="0.0" RANDOM="NO" SCALE="245.81350228381214" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="26" WEIGHT="100.0" Z="0.9211285867930261">
<NAME>Complete healing at 3 weeks</NAME>
<GROUP_LABEL_1>Systemic antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antibiotic</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.717475588650367" CI_START="0.22312978256050173" EFFECT_SIZE="0.6190476190476191" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.23489057292821985" LOG_CI_START="-0.6514424577823849" LOG_EFFECT_SIZE="-0.20827594242708247" MODIFIED="2013-07-01 17:19:32 +0100" MODIFIED_BY="[Empty name]" ORDER="3565" O_E="0.0" SE="0.5206364096586706" STUDY_ID="STD-Alinovi-1986" TOTAL_1="30" TOTAL_2="26" VAR="0.2710622710622711" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2468914536627915" CI_START="0.6641315870498787" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.91" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.09582864824428433" LOG_CI_START="-0.1777458636020971" LOG_EFFECT_SIZE="-0.040958607678906384" METHOD="MH" MODIFIED="2013-12-02 15:13:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5572858223741444" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="26" WEIGHT="100.0" Z="0.5868777421241632">
<NAME>Complete healing&#8212;eventual, assessment point not stated</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard care</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antibiotics</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2468914536627913" CI_START="0.6641315870498788" EFFECT_SIZE="0.91" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.09582864824428426" LOG_CI_START="-0.17774586360209702" LOG_EFFECT_SIZE="-0.040958607678906384" MODIFIED="2013-07-01 17:22:32 +0100" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.1606990224742385" STUDY_ID="STD-Alinovi-1986" TOTAL_1="30" TOTAL_2="26" VAR="0.025824175824175816" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.193409653655758" CI_START="0.6104817347783389" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.6225672906487115" LOG_CI_START="-0.21432732533686188" LOG_EFFECT_SIZE="0.2041199826559248" METHOD="MH" MODIFIED="2013-12-02 15:14:08 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.33903338481393896" Q="0.0" RANDOM="NO" SCALE="69.85" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.9560769226825797">
<NAME>Bacterial eradication</NAME>
<GROUP_LABEL_1>Systemic antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antibiotic</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.193409653655758" CI_START="0.6104817347783389" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6225672906487115" LOG_CI_START="-0.21432732533686188" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2013-07-01 17:23:40 +0100" MODIFIED_BY="[Empty name]" ORDER="3567" O_E="0.0" SE="0.4915960401250875" STUDY_ID="STD-Alinovi-1986" TOTAL_1="24" TOTAL_2="24" VAR="0.24166666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-12-02 15:36:17 +0000" MODIFIED_BY="Marrissa Martyn-St James" NO="2">
<NAME>Ciprofloxacin versus standard care/placebo</NAME>
<DICH_OUTCOME CHI2="0.31653914491077473" CI_END="5.303113916713409" CI_START="0.5705122167685599" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7393939393939395" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.7245309563413903" LOG_CI_START="-0.24373505130121823" LOG_EFFECT_SIZE="0.24039795252008606" METHOD="MH" MODIFIED="2013-12-02 15:14:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5736950731241779" P_Q="1.0" P_Z="0.33044048847884966" Q="0.0" RANDOM="NO" SCALE="239.94" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="19" WEIGHT="100.0" Z="0.9732270371520677">
<NAME>Frequency of complete healing</NAME>
<GROUP_LABEL_1>Ciprofloxacin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ciproflox.</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.6121814111841815" CI_START="0.4312109532046061" EFFECT_SIZE="1.4102564102564104" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.6639063810872713" LOG_CI_START="-0.36531021615178205" LOG_EFFECT_SIZE="0.14929808246774467" MODIFIED="2013-09-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="3568" O_E="0.0" SE="0.6045669239225426" STUDY_ID="STD-Huovinen-1994" TOTAL_1="13" TOTAL_2="11" VAR="0.3655011655011655" WEIGHT="82.72727272727272"/>
<DICH_DATA CI_END="57.61443058206967" CI_START="0.19082823040546767" EFFECT_SIZE="3.3157894736842106" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7605312740003058" LOG_CI_START="-0.7193573769988004" LOG_EFFECT_SIZE="0.5205869485007527" ORDER="3569" O_E="0.0" SE="1.4566988692436766" STUDY_ID="STD-Valtonen-1989" TOTAL_1="18" TOTAL_2="8" VAR="2.121971595655806" WEIGHT="17.272727272727273"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.12355215268635368" CI_END="42.60063097806768" CI_START="1.7569295927039916" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="8.65137614678899" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="1.629416031691066" LOG_CI_START="0.24475435790234323" LOG_EFFECT_SIZE="0.9370851947967047" METHOD="MH" MODIFIED="2013-12-02 15:14:51 +0000" MODIFIED_BY="Marrissa Martyn-St James" NO="2" P_CHI2="0.7252134420627092" P_Q="1.0" P_Z="0.007981418001287615" Q="0.0" RANDOM="NO" SCALE="361.46" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="18" WEIGHT="100.0" Z="2.652854869914578">
<NAME>Emergence of antibiotic-resistant strains</NAME>
<GROUP_LABEL_1>Ciprofloxacin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ciproflox.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="44.65916048806281" CI_START="0.9951921164376623" EFFECT_SIZE="6.666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.6499105548565867" LOG_CI_START="-0.002093072967949051" LOG_EFFECT_SIZE="0.8239087409443188" MODIFIED="2013-11-25 15:35:50 +0000" MODIFIED_BY="[Empty name]" ORDER="3571" O_E="0.0" SE="0.9703951085339758" STUDY_ID="STD-Huovinen-1994" TOTAL_1="12" TOTAL_2="10" VAR="0.9416666666666668" WEIGHT="61.651376146788984"/>
<DICH_DATA CI_END="178.5411147508571" CI_START="0.7854518958246777" EFFECT_SIZE="11.842105263157896" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.251738242035437" LOG_CI_START="-0.10488040771836964" LOG_EFFECT_SIZE="1.0734289171585336" ORDER="3572" O_E="0.0" SE="1.3842894603158402" STUDY_ID="STD-Valtonen-1989" TOTAL_1="18" TOTAL_2="8" VAR="1.9162573099415203" WEIGHT="38.34862385321101"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="18.674048617474455" CI_START="0.38080178844863927" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="1.27123848514843" LOG_CI_START="-0.4193010206038677" LOG_EFFECT_SIZE="0.4259687322722811" METHOD="MH" MODIFIED="2013-12-02 15:15:05 +0000" MODIFIED_BY="Marrissa Martyn-St James" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.32329355743448085" Q="0.0" RANDOM="NO" SCALE="517.82" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="8" WEIGHT="100.0" Z="0.9877123497594088">
<NAME>Bacterial eradication</NAME>
<GROUP_LABEL_1>Ciprofloxacin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ciproflox.</GRAPH_LABEL_2>
<DICH_DATA CI_END="18.674048617474455" CI_START="0.3808017884486392" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.27123848514843" LOG_CI_START="-0.41930102060386776" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="3573" O_E="0.0" SE="0.9930312739844155" STUDY_ID="STD-Valtonen-1989" TOTAL_1="18" TOTAL_2="8" VAR="0.9861111111111112" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-12-02 15:19:50 +0000" MODIFIED_BY="Marrissa Martyn-St James" NO="3">
<NAME>Ciprofloxacin versus trimethoprim</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.093317426646381" CI_START="0.4646998620079861" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="100.00000000000001" ID="CMP-003.01" LOG_CI_END="0.7070007431985775" LOG_CI_START="-0.33282745648428863" LOG_EFFECT_SIZE="0.18708664335714445" METHOD="MH" MODIFIED="2013-12-02 15:15:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.4806383230423361" Q="8.259658318196803E-33" RANDOM="NO" SCALE="122.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="12" WEIGHT="100.0" Z="0.7052762813709542">
<NAME>Frequency of complete healing</NAME>
<GROUP_LABEL_1>Ciprofloxacin</GROUP_LABEL_1>
<GROUP_LABEL_2>Trimethoprim</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trimethoprim</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ciproflox.</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.093317426646381" CI_START="0.4646998620079861" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7070007431985775" LOG_CI_START="-0.33282745648428863" LOG_EFFECT_SIZE="0.18708664335714445" MODIFIED="2013-09-05 15:58:45 +0100" MODIFIED_BY="[Empty name]" ORDER="3574" O_E="0.0" SE="0.6108002317263175" STUDY_ID="STD-Huovinen-1994" TOTAL_1="13" TOTAL_2="12" VAR="0.3730769230769231" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8425051558732632" CI_START="0.5427393224992337" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.2654087118169369" LOG_CI_START="-0.265408711816937" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2013-12-02 15:15:29 +0000" MODIFIED_BY="Marrissa Martyn-St James" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="9" WEIGHT="100.0" Z="0.0">
<NAME>Emergence of antibiotic-resistant strains</NAME>
<GROUP_LABEL_1>Ciprofloxacin</GROUP_LABEL_1>
<GROUP_LABEL_2>Trimethoprim</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trimethoprim</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ciproflox.</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8425051558732632" CI_START="0.5427393224992337" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.2654087118169369" LOG_CI_START="-0.265408711816937" LOG_EFFECT_SIZE="0.0" ORDER="3575" O_E="0.0" SE="0.31180478223116176" STUDY_ID="STD-Huovinen-1994" TOTAL_1="12" TOTAL_2="9" VAR="0.09722222222222221" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-12-02 15:15:50 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Trimethoprim versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.626808650055042" CI_START="0.23168516976075515" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.559524642865408" LOG_CI_START="-0.6351017646442076" LOG_EFFECT_SIZE="-0.0377885608893998" METHOD="MH" MODIFIED="2013-12-02 15:15:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9013187465859338" Q="0.0" RANDOM="NO" SCALE="191.41" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="11" WEIGHT="100.0" Z="0.12399561554180084">
<NAME>Frequency of complete healing</NAME>
<GROUP_LABEL_1>Trimethoprim</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours trimethoprim</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.626808650055042" CI_START="0.23168516976075515" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.559524642865408" LOG_CI_START="-0.6351017646442076" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2013-09-05 16:01:24 +0100" MODIFIED_BY="[Empty name]" ORDER="3576" O_E="0.0" SE="0.701729465267237" STUDY_ID="STD-Huovinen-1994" TOTAL_1="12" TOTAL_2="11" VAR="0.4924242424242423" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="45.28764282175335" CI_START="0.9813812703693225" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="6.666666666666667" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="1.655979716661176" LOG_CI_START="-0.008162234772538664" LOG_EFFECT_SIZE="0.8239087409443188" METHOD="MH" MODIFIED="2013-12-02 15:15:50 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.05229010879122853" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0" Z="1.940737636482722">
<NAME>Emergence of antibiotic-resistant strains</NAME>
<GROUP_LABEL_1>Trimethoprim</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trimethoprim</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="45.28764282175337" CI_START="0.9813812703693223" EFFECT_SIZE="6.666666666666667" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6559797166611763" LOG_CI_START="-0.008162234772538763" LOG_EFFECT_SIZE="0.8239087409443188" MODIFIED="2013-11-25 15:37:02 +0000" MODIFIED_BY="[Empty name]" ORDER="3577" O_E="0.0" SE="0.9775252199076787" STUDY_ID="STD-Huovinen-1994" TOTAL_1="9" TOTAL_2="10" VAR="0.9555555555555556" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-12-02 15:20:15 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Amoxicillin plus compression verus povidone-iodine alone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0211213401439827" CI_START="0.9485624268244244" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.3055923876236973" LOG_CI_START="-0.022934082030758755" LOG_EFFECT_SIZE="0.1413291527964693" METHOD="MH" MODIFIED="2013-12-02 15:16:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.09173456609853352" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="1.6863179988996722">
<NAME>Frequency of complete healing</NAME>
<GROUP_LABEL_1>Amox. + compress</GROUP_LABEL_1>
<GROUP_LABEL_2>Povidone iodine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours povidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours amox + compr</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0211213401439827" CI_START="0.9485624268244244" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.3055923876236973" LOG_CI_START="-0.022934082030758755" LOG_EFFECT_SIZE="0.1413291527964693" ORDER="3578" O_E="0.0" SE="0.19297807450727983" STUDY_ID="STD-Daroczy-2006" TOTAL_1="21" TOTAL_2="21" VAR="0.03724053724053725" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2013-12-02 15:20:31 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Amoxicillin plus compression verus povidone-iodine plus compression</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3886351023583918" CI_START="0.8073447549553883" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.14258813929290148" LOG_CI_START="-0.09294097184283713" LOG_EFFECT_SIZE="0.024823583725032145" METHOD="MH" MODIFIED="2013-12-02 15:16:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6795035380920755" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="0.4131406927463678">
<NAME>Frequency of complete healing</NAME>
<GROUP_LABEL_1>Amox. + compress.</GROUP_LABEL_1>
<GROUP_LABEL_2>Povidone + compress.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pov + comp</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours amox + comp</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3886351023583918" CI_START="0.8073447549553883" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.14258813929290148" LOG_CI_START="-0.09294097184283713" LOG_EFFECT_SIZE="0.024823583725032145" ORDER="3579" O_E="0.0" SE="0.1383509657690362" STUDY_ID="STD-Daroczy-2006" TOTAL_1="21" TOTAL_2="21" VAR="0.019140989729225025" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2013-12-02 15:16:33 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Levamisole versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6207340386322242" CI_START="1.0617982640698311" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3118279569892473" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.20971175326239644" LOG_CI_START="0.026042010979229726" LOG_EFFECT_SIZE="0.1178768821208131" METHOD="MH" MODIFIED="2013-12-02 15:16:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.011877622398407704" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="29" WEIGHT="100.0" Z="2.5157594353290653">
<NAME>Frequency of complete healing</NAME>
<GROUP_LABEL_1>Levamisole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levamisole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6207340386322242" CI_START="1.0617982640698311" EFFECT_SIZE="1.3118279569892473" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="22" LOG_CI_END="0.20971175326239644" LOG_CI_START="0.026042010979229726" LOG_EFFECT_SIZE="0.1178768821208131" ORDER="3580" O_E="0.0" SE="0.10788851579701948" STUDY_ID="STD-Morias-1979" TOTAL_1="30" TOTAL_2="29" VAR="0.011639931840883723" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2013-11-26 15:33:28 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Cadexomer iodine versus standard care</NAME>
<DICH_OUTCOME CHI2="0.9054675426346765" CI_END="3.6041147721850364" CI_START="1.300927256052026" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1653385742361984" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.5567986125326022" LOG_CI_START="0.11425301279644122" LOG_EFFECT_SIZE="0.3355258126645217" METHOD="MH" MODIFIED="2013-11-26 15:06:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8241082941149921" P_Q="1.0" P_Z="0.0029588520462742363" Q="0.0" RANDOM="NO" SCALE="170.91" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="106" WEIGHT="100.00000000000001" Z="2.971980781632708">
<NAME>Frequency of complete healing at 4 to 12 weeks</NAME>
<GROUP_LABEL_1>Cadexomer iodine</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cadex iod.</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.818052224814858" CI_START="1.0843572365218868" EFFECT_SIZE="2.2857142857142856" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" LOG_CI_END="0.6828715031812094" LOG_CI_START="0.03517238210212659" LOG_EFFECT_SIZE="0.3590219426416679" MODIFIED="2013-09-05 16:36:23 +0100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.3804616698842109" STUDY_ID="STD-Laudanska-1988" TOTAL_1="33" TOTAL_2="33" VAR="0.14475108225108224" WEIGHT="43.485795962122566"/>
<DICH_DATA CI_END="31.455858516002134" CI_START="0.5086492868048897" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4977015427613454" LOG_CI_START="-0.2935815601054206" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2013-09-05 16:36:39 +0100" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="1.0522085616183026" STUDY_ID="STD-Lindsay-1986" TOTAL_1="14" TOTAL_2="14" VAR="1.1071428571428572" WEIGHT="6.212256566017509"/>
<DICH_DATA CI_END="3.638816951106324" CI_START="0.7563543773166749" EFFECT_SIZE="1.6589861751152073" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.5609602091658067" LOG_CI_START="-0.1212746753282912" LOG_EFFECT_SIZE="0.21984276691875773" MODIFIED="2013-09-05 16:36:52 +0100" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.4007481482689768" STUDY_ID="STD-Ormiston-1985" TOTAL_1="31" TOTAL_2="30" VAR="0.1605990783410138" WEIGHT="44.19867786314097"/>
<DICH_DATA CI_END="28.120367063732807" CI_START="0.34332186037305323" EFFECT_SIZE="3.107142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4490209853631926" LOG_CI_START="-0.46429854281039384" LOG_EFFECT_SIZE="0.4923612212763993" MODIFIED="2013-11-26 15:01:03 +0000" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="1.1238933619335767" STUDY_ID="STD-Steele-1986" TOTAL_1="28" TOTAL_2="29" VAR="1.2631362889983577" WEIGHT="6.103269608718956"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.044439199605436665" CI_END="15.053651079271626" CI_START="1.3990986808740353" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.5892857142857135" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="1.1776418455295874" LOG_CI_START="0.14584834712060063" LOG_EFFECT_SIZE="0.661745096325094" METHOD="MH" MODIFIED="2013-11-26 15:33:28 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8330387391373903" P_Q="1.0" P_Z="0.011934935648380822" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="66" WEIGHT="100.0" Z="2.514062276498401">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Cadexomer iodine</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cadexomer iodine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard care</GRAPH_LABEL_2>
<DICH_DATA CI_END="20.921832425624558" CI_START="1.1949240148477909" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.3205997192719987" LOG_CI_START="0.07734028940003874" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-07-01 15:52:05 +0100" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-Ormiston-1985" TOTAL_1="30" TOTAL_2="30" VAR="0.5333333333333333" WEIGHT="66.07142857142857"/>
<DICH_DATA CI_END="32.31704792622697" CI_START="0.4443509455475393" EFFECT_SIZE="3.789473684210526" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5094316823035145" LOG_CI_START="-0.35227389134663567" LOG_EFFECT_SIZE="0.5785788954784394" MODIFIED="2013-11-26 15:33:28 +0000" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="1.093575069553315" STUDY_ID="STD-Skog-1983" TOTAL_1="38" TOTAL_2="36" VAR="1.195906432748538" WEIGHT="33.92857142857142"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2013-12-02 15:16:54 +0000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Cadexomer iodine versus dextranomer</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.0856514782910125" CI_START="0.5476963331374048" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.48934687130497584" LOG_CI_START="-0.26146016669130223" LOG_EFFECT_SIZE="0.11394335230683679" METHOD="MH" MODIFIED="2013-12-02 15:16:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.551915104526586" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0" Z="0.5948928432934217">
<NAME>Frequency of complete healing</NAME>
<GROUP_LABEL_1>Cadexomer Iodine</GROUP_LABEL_1>
<GROUP_LABEL_2>Dextranomer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dextranomer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CI</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0856514782910125" CI_START="0.5476963331374048" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.48934687130497584" LOG_CI_START="-0.26146016669130223" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2013-09-06 13:07:30 +0100" MODIFIED_BY="[Empty name]" ORDER="3589" O_E="0.0" SE="0.4410277706737916" STUDY_ID="STD-Kero-1987" TOTAL_1="14" TOTAL_2="13" VAR="0.19450549450549454" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2013-12-02 15:17:05 +0000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Cadexomer iodine versus hydrocolloid dressing</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.9141120459611605" CI_START="0.48052184108305296" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.5926332536792018" LOG_CI_START="-0.3182868676285788" LOG_EFFECT_SIZE="0.13717319302531158" METHOD="MH" MODIFIED="2013-12-02 15:17:05 +0000" MODIFIED_BY="Dolores Matthews" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5549947755901015" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="48" WEIGHT="100.0" Z="0.5902921928829178">
<NAME>Frequency of complete healing</NAME>
<GROUP_LABEL_1>Cadexomer Iodine</GROUP_LABEL_1>
<GROUP_LABEL_2>Hydrocolloid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hydrocolloid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CI</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.914112045961161" CI_START="0.4805218410830529" EFFECT_SIZE="1.3714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5926332536792019" LOG_CI_START="-0.31828686762857883" LOG_EFFECT_SIZE="0.13717319302531158" ORDER="3590" O_E="0.0" SE="0.5350789883835132" STUDY_ID="STD-Hansson-1998" TOTAL_1="56" TOTAL_2="48" VAR="0.28630952380952385" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2013-12-02 15:17:14 +0000" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Cadexomer iodine versus paraffin gauze</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.557758511433713" CI_START="0.3909673237445177" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.40785953853881635" LOG_CI_START="-0.4078595385388163" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2013-12-02 15:17:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="45.69" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="49" WEIGHT="100.0" Z="0.0">
<NAME>Frequency of complete healing</NAME>
<GROUP_LABEL_1>Cadexomer Iodine</GROUP_LABEL_1>
<GROUP_LABEL_2>Paraffin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paraffin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CI</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.557758511433713" CI_START="0.3909673237445177" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.40785953853881635" LOG_CI_START="-0.4078595385388163" LOG_EFFECT_SIZE="0.0" ORDER="3593" O_E="0.0" SE="0.47915742374995496" STUDY_ID="STD-Hansson-1998" TOTAL_1="56" TOTAL_2="49" VAR="0.22959183673469388" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2013-12-02 15:17:34 +0000" MODIFIED_BY="Marrissa Martyn-St James" NO="12">
<NAME>Cadexomer iodine dressing versus silver dressing</NAME>
<DICH_OUTCOME CHI2="1.3894199868388804E-30" CI_END="1.1869905373339171" CI_START="0.8111315794921246" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9812265331664579" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="85" I2="100.0" I2_Q="100.0" ID="CMP-012.01" LOG_CI_END="0.07444725678100689" LOG_CI_START="-0.09090869004011297" LOG_EFFECT_SIZE="-0.00823071662955302" METHOD="MH" MODIFIED="2013-12-02 15:17:25 +0000" MODIFIED_BY="Marrissa Martyn-St James" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.8453010701050324" Q="1.2758677565095321E-33" RANDOM="NO" SCALE="45.69" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="141" TOTAL_2="140" WEIGHT="100.0" Z="0.19511736313094485">
<NAME>Frequency of complete healing</NAME>
<GROUP_LABEL_1>Cadexomer Iodine</GROUP_LABEL_1>
<GROUP_LABEL_2>Silver</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours silver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CI</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1869905373339174" CI_START="0.8111315794921247" EFFECT_SIZE="0.981226533166458" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="85" LOG_CI_END="0.07444725678100697" LOG_CI_START="-0.09090869004011291" LOG_EFFECT_SIZE="-0.008230716629552971" MODIFIED="2011-11-29 13:00:17 +0000" MODIFIED_BY="Marrissa Martyn-St James" ORDER="43" O_E="0.0" SE="0.09713090168786358" STUDY_ID="STD-Miller-2010" TOTAL_1="141" TOTAL_2="140" VAR="0.00943441206269742" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0629214053056066" CI_START="0.8883707775306359" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9717346938775511" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="0.026501153042587947" LOG_CI_START="-0.051405735767332754" LOG_EFFECT_SIZE="-0.012452291362372409" METHOD="MH" MODIFIED="2013-12-02 15:17:34 +0000" MODIFIED_BY="Marrissa Martyn-St James" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5309582617802396" Q="0.0" RANDOM="NO" SCALE="45.69" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="107" WEIGHT="100.0" Z="0.6265438902276187">
<NAME>Participant satisfaction</NAME>
<GROUP_LABEL_1>Cadexomer Iodine</GROUP_LABEL_1>
<GROUP_LABEL_2>Silver</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours silver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CI</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0629214053056066" CI_START="0.8883707775306359" EFFECT_SIZE="0.9717346938775511" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="98" LOG_CI_END="0.026501153042587947" LOG_CI_START="-0.051405735767332754" LOG_EFFECT_SIZE="-0.012452291362372409" MODIFIED="2013-07-01 15:22:36 +0100" MODIFIED_BY="Marrissa Martyn-St James" ORDER="88" O_E="0.0" SE="0.045762892132266614" STUDY_ID="STD-Miller-2010" TOTAL_1="100" TOTAL_2="107" VAR="0.0020942422963094696" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2013-12-02 15:21:00 +0000" MODIFIED_BY="Marrissa Martyn-St James" NO="13">
<NAME>Povidone-iodine plus sugar versus growth factor</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5207973478584975" CI_START="0.21625203961833248" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5734767025089605" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="0.18207134648532985" LOG_CI_START="-0.6650397877206755" LOG_EFFECT_SIZE="-0.2414842206176728" METHOD="MH" MODIFIED="2009-11-10 14:44:17 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2638037941559407" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="32" WEIGHT="100.0" Z="1.1174457662842232">
<NAME>Frequency of complete healing at 4 weeks</NAME>
<GROUP_LABEL_1>Pov iodine + sugar</GROUP_LABEL_1>
<GROUP_LABEL_2>Growth factor</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours growth factor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PI + sugar</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5207973478584975" CI_START="0.21625203961833248" EFFECT_SIZE="0.5734767025089605" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.18207134648532985" LOG_CI_START="-0.6650397877206755" LOG_EFFECT_SIZE="-0.2414842206176728" MODIFIED="2009-11-03 10:57:01 +0000" MODIFIED_BY="Sue O'Meara" ORDER="40" O_E="0.0" SE="0.49759727350035" STUDY_ID="STD-Ishibashi-1996" TOTAL_1="31" TOTAL_2="32" VAR="0.2476030465949821" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2013-12-02 15:21:14 +0000" MODIFIED_BY="Marrissa Martyn-St James" NO="14">
<NAME>Povidone-iodine plus compression versus hydrocolloid plus compression</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2262989150128483" CI_START="0.6922883206015615" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9213861386138614" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="0.08859634401407819" LOG_CI_START="-0.1597129951848662" LOG_EFFECT_SIZE="-0.03555832558539398" METHOD="MH" MODIFIED="2013-12-02 15:17:49 +0000" MODIFIED_BY="Dolores Matthews" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5745654773239195" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="99" WEIGHT="100.0" Z="0.5613404451298836">
<NAME>Frequency of complete healing</NAME>
<GROUP_LABEL_1>Iodine-based topical</GROUP_LABEL_1>
<GROUP_LABEL_2>Hydrocolloid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hydrocolloid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Iodine-based</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2262989150128483" CI_START="0.6922883206015616" EFFECT_SIZE="0.9213861386138614" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="50" LOG_CI_END="0.08859634401407819" LOG_CI_START="-0.15971299518486615" LOG_EFFECT_SIZE="-0.03555832558539398" ORDER="1" O_E="0.0" SE="0.14585813499651243" STUDY_ID="STD-Smith-1992" TOTAL_1="101" TOTAL_2="99" VAR="0.021274595544660845" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2013-12-02 15:21:28 +0000" MODIFIED_BY="Marrissa Martyn-St James" NO="15">
<NAME>Povidone-iodine plus compression versus moist or foam dressings plus compression</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7491265621242627" CI_START="0.09147422688823888" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="0.24282123500387298" LOG_CI_START="-1.038701252347948" LOG_EFFECT_SIZE="-0.3979400086720376" METHOD="MH" MODIFIED="2013-07-07 14:10:53 +0100" MODIFIED_BY="Marrissa Martyn-St James" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2235201392776368" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.21722106744527">
<NAME>Complete healing at 4 weeks</NAME>
<GROUP_LABEL_1>Povidone iodine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other dressings</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other dressings</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours povidone iodine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7491265621242627" CI_START="0.09147422688823888" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.24282123500387298" LOG_CI_START="-1.038701252347948" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2011-08-04 14:31:56 +0100" MODIFIED_BY="Marrissa Martyn-St James" ORDER="96" O_E="0.0" SE="0.752772652709081" STUDY_ID="STD-Kuznetsov-2009" TOTAL_1="15" TOTAL_2="15" VAR="0.5666666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2013-12-02 19:57:06 +0000" MODIFIED_BY="Marrissa Martyn-St James" NO="16">
<NAME>Peroxide-based topical preparation versus control</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-016.01" MODIFIED="2013-12-02 19:57:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="169.26" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean percentage ulcer area remaining</NAME>
<GROUP_LABEL_1>Peroxide based topical</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline soak</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline soak</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-016.01.01" MODIFIED="2013-12-02 19:57:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>10% benzoyl peroxide dressing vs normal saline dressing</NAME>
<CONT_DATA CI_END="-18.684562227360843" CI_START="-42.11543777263917" EFFECT_SIZE="-30.400000000000006" ESTIMABLE="YES" MEAN_1="64.3" MEAN_2="94.7" ORDER="3598" SD_1="14.0" SD_2="12.7" SE="5.9773740053638935" STUDY_ID="STD-Beitner-1985a" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-016.01.02" MODIFIED="2013-12-02 19:57:06 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>20% benzoyl peroxide dressing vs normal saline dressing</NAME>
<CONT_DATA CI_END="-21.980986216213857" CI_START="-46.219013783786146" EFFECT_SIZE="-34.1" ESTIMABLE="YES" MEAN_1="59.6" MEAN_2="93.7" ORDER="3597" SD_1="12.3" SD_2="15.2" SE="6.183283917143059" STUDY_ID="STD-Beitner-1985a" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2013-12-03 14:27:51 +0000" MODIFIED_BY="[Empty name]" NO="17">
<NAME>Honey products versus alternatives</NAME>
<DICH_OUTCOME CHI2="0.4456242508414251" CI_END="1.3830545919859436" CI_START="0.9625598470634673" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.153807963459438" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="108" I2="0.0" I2_Q="100.0" ID="CMP-017.01" LOG_CI_END="0.14083932293673215" LOG_CI_START="-0.01657225876345804" LOG_EFFECT_SIZE="0.06213353208663703" METHOD="MH" MODIFIED="2013-06-29 13:02:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5044203115912762" P_Q="0.0" P_Z="0.12179700079205531" Q="9.0105625809095E-32" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="241" TOTAL_2="235" WEIGHT="100.0" Z="1.5472747787264665">
<NAME>Complete healing at 12 weeks</NAME>
<GROUP_LABEL_1>Honey</GROUP_LABEL_1>
<GROUP_LABEL_2>Alternatives</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alternatives</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours honey</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1565582556709284" CI_START="0.8243588009287008" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="18" LOG_CI_END="0.33376119435060086" LOG_CI_START="-0.08388372113400108" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-06-29 13:01:10 +0100" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.24532669073132907" STUDY_ID="STD-Gethin-2008" TOTAL_1="54" TOTAL_2="54" VAR="0.060185185185185175" WEIGHT="16.44325290437891"/>
<DICH_DATA CI_END="1.3587027777621858" CI_START="0.9207275389728806" EFFECT_SIZE="1.118478906714201" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="90" LOG_CI_END="0.13312446328482777" LOG_CI_START="-0.035868866900545686" LOG_EFFECT_SIZE="0.04862779819214105" MODIFIED="2013-06-29 13:02:04 +0100" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.0992675186813642" STUDY_ID="STD-Jull-2008" TOTAL_1="187" TOTAL_2="181" VAR="0.00985404026515499" WEIGHT="83.55674709562109"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7419906799525084" CI_END="1.0387957448028957" CI_START="0.4877486582816767" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7118084227910818" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-017.02" LOG_CI_END="0.016530161969580483" LOG_CI_START="-0.3118039166062594" LOG_EFFECT_SIZE="-0.1476368773183394" METHOD="MH" MODIFIED="2013-12-03 14:27:51 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3890239679347761" P_Q="1.0" P_Z="0.0779657781547297" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="241" TOTAL_2="235" WEIGHT="100.0" Z="1.7626130287116417">
<NAME>Incidence of ulcer infection during the 12-week trial period</NAME>
<GROUP_LABEL_1>Honey</GROUP_LABEL_1>
<GROUP_LABEL_2>Alternatives</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours honey</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours alternatives</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2353264188385988" CI_START="0.20237566054406847" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.0917817293927529" LOG_CI_START="-0.6938417207207153" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-06-29 14:17:20 +0100" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="0.46147910349544863" STUDY_ID="STD-Gethin-2008" TOTAL_1="54" TOTAL_2="54" VAR="0.21296296296296297" WEIGHT="22.791081750619323"/>
<DICH_DATA CI_END="1.1755739567151584" CI_START="0.5100396679789038" EFFECT_SIZE="0.774331550802139" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="40" LOG_CI_END="0.07024995628779808" LOG_CI_START="-0.2923960456385399" LOG_EFFECT_SIZE="-0.1110730446753709" MODIFIED="2013-06-29 13:46:18 +0100" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.21302005665819185" STUDY_ID="STD-Jull-2008" TOTAL_1="187" TOTAL_2="181" VAR="0.04537754453865926" WEIGHT="77.20891824938067"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="26.30370299899801" CI_START="0.6706280100817732" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-017.03" LOG_CI_END="1.4200168921713734" LOG_CI_START="-0.1735183113755724" LOG_EFFECT_SIZE="0.6232492903979004" METHOD="MH" MODIFIED="2013-07-02 15:53:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.12524449223468306" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="6" WEIGHT="100.0" Z="1.5331273006722044">
<NAME>Participants with MRSA eradication at 4 weeks</NAME>
<GROUP_LABEL_1>Honey</GROUP_LABEL_1>
<GROUP_LABEL_2>Alternatives</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alternatives</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours honey</GRAPH_LABEL_2>
<DICH_DATA CI_END="26.303702998998" CI_START="0.6706280100817733" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.4200168921713732" LOG_CI_START="-0.1735183113755723" LOG_EFFECT_SIZE="0.6232492903979004" MODIFIED="2013-06-29 14:05:18 +0100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.9360504666899515" STUDY_ID="STD-Gethin-2008" TOTAL_1="10" TOTAL_2="6" VAR="0.8761904761904761" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5565980175894412" CI_START="1.0509567626180838" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.279029793735676" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="84" I2="0.0" I2_Q="0.0" ID="CMP-017.04" LOG_CI_END="0.19217647301592916" LOG_CI_START="0.021584849098993483" LOG_EFFECT_SIZE="0.1068806610574613" METHOD="MH" MODIFIED="2013-09-06 17:04:16 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.014051272019461014" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="187" TOTAL_2="181" WEIGHT="100.00000000000001" Z="2.455949964090356">
<NAME>Participants reporting at least 1 adverse event</NAME>
<GROUP_LABEL_1>Honey</GROUP_LABEL_1>
<GROUP_LABEL_2>Alternatives</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours honey</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours alternatives</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5565980175894412" CI_START="1.0509567626180838" EFFECT_SIZE="1.279029793735676" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="84" LOG_CI_END="0.19217647301592916" LOG_CI_START="0.021584849098993483" LOG_EFFECT_SIZE="0.1068806610574613" MODIFIED="2013-06-29 14:25:31 +0100" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.10020636433096539" STUDY_ID="STD-Jull-2008" TOTAL_1="187" TOTAL_2="181" VAR="0.010041315452430172" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2013-11-26 15:05:17 +0000" MODIFIED_BY="[Empty name]" NO="18">
<NAME>1% silver sulphadiazine cream versus placebo cream</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="45.404066686713364" CI_START="0.7425519957412205" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.806451612903226" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="1.6570947528681907" LOG_CI_START="-0.129273130330124" LOG_EFFECT_SIZE="0.7639108112690334" METHOD="MH" MODIFIED="2013-07-02 16:00:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.09368088365267285" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="30" WEIGHT="100.0" Z="1.6762926512174237">
<NAME>Complete healing at 4 weeks</NAME>
<GROUP_LABEL_1>1% silver sulphadiazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 1% placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1% SSD</GRAPH_LABEL_2>
<DICH_DATA CI_END="45.404066686713364" CI_START="0.7425519957412205" EFFECT_SIZE="5.806451612903226" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6570947528681907" LOG_CI_START="-0.129273130330124" LOG_EFFECT_SIZE="0.7639108112690334" MODIFIED="2013-06-27 17:34:49 +0100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="1.0493213372543246" STUDY_ID="STD-Bishop-1992" TOTAL_1="31" TOTAL_2="30" VAR="1.1010752688172043" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2013-11-26 15:05:17 +0000" MODIFIED_BY="[Empty name]" NO="19">
<NAME>1% silver sulphadiazine cream versus 0.4% tripeptide copper complex cream</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="228.32318132239575" CI_START="0.787162906637684" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="13.40625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="2.3585500070194163" LOG_CI_START="-0.10393537928977967" LOG_EFFECT_SIZE="1.1273073138648182" METHOD="MH" MODIFIED="2013-07-02 16:00:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.07273123285388662" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="32" WEIGHT="100.0" Z="1.794513581252341">
<NAME>Complete healing at 4 weeks</NAME>
<GROUP_LABEL_1>1% silver sulphadiazine</GROUP_LABEL_1>
<GROUP_LABEL_2>0.4% tripeptide CC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.4% TCC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1% SSD</GRAPH_LABEL_2>
<DICH_DATA CI_END="228.32318132239575" CI_START="0.7871629066376844" EFFECT_SIZE="13.40625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3585500070194163" LOG_CI_START="-0.10393537928977942" LOG_EFFECT_SIZE="1.1273073138648182" MODIFIED="2013-06-27 17:43:35 +0100" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="1.4464761054172735" STUDY_ID="STD-Bishop-1992" TOTAL_1="31" TOTAL_2="32" VAR="2.0922931235431235" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2013-11-26 15:05:17 +0000" MODIFIED_BY="[Empty name]" NO="20">
<NAME>1% silver sulphadiazine cream versus non-adherent dressing</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.096567718228414" CI_START="0.5715434630190003" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7916666666666666" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-020.01" LOG_CI_END="0.04003545657424699" LOG_CI_START="-0.24295073809180118" LOG_EFFECT_SIZE="-0.10145764075877708" METHOD="MH" MODIFIED="2013-07-02 16:01:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.15990462923422538" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.4053923872736818">
<NAME>Complete healing at 12 weeks</NAME>
<GROUP_LABEL_1>1% silver sulphadiazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-adherent dressing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NAD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1% SSD</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.096567718228414" CI_START="0.5715434630190003" EFFECT_SIZE="0.7916666666666666" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" LOG_CI_END="0.04003545657424699" LOG_CI_START="-0.24295073809180118" LOG_EFFECT_SIZE="-0.10145764075877708" MODIFIED="2013-06-27 18:20:06 +0100" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.16622749155109215" STUDY_ID="STD-Blair-1988" TOTAL_1="30" TOTAL_2="30" VAR="0.02763157894736841" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2013-11-26 15:05:17 +0000" MODIFIED_BY="[Empty name]" NO="21">
<NAME>Silver dressing (Avance) versus silver dressing (Acticoat 7)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9965801800903877" CI_START="0.6810484632081674" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" I2_Q="100.0" ID="CMP-021.01" LOG_CI_END="0.47662590269158706" LOG_CI_START="-0.1668219827201008" LOG_EFFECT_SIZE="0.1549019599857432" METHOD="MH" MODIFIED="2013-07-02 16:02:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.34533668438534526" Q="2.1570415377137047E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.9436732005497906">
<NAME>Complete healing at 12 weeks</NAME>
<GROUP_LABEL_1>Acticoat 7</GROUP_LABEL_1>
<GROUP_LABEL_2>Avance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Avance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Acticoat 7</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9965801800903877" CI_START="0.6810484632081674" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.47662590269158706" LOG_CI_START="-0.1668219827201008" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2013-06-27 19:11:39 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Chaloner-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.14285714285714285" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" MODIFIED="2013-12-03 11:14:16 +0000" MODIFIED_BY="[Empty name]" NO="22">
<NAME>Silver dressing versus non-antimicrobial dressing</NAME>
<DICH_OUTCOME CHI2="4.805712276840742" CI_END="1.4506716480543864" CI_START="0.9516962559375837" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1749888408185687" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="76" I2="37.57429019508032" I2_Q="0.0" ID="CMP-022.01" LOG_CI_END="0.16156912327479322" LOG_CI_START="-0.021501639240443515" LOG_EFFECT_SIZE="0.07003374201717487" METHOD="MH" MODIFIED="2013-06-28 12:45:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.18658943425798347" P_Q="1.0" P_Z="0.133726105677529" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="213" TOTAL_2="211" WEIGHT="100.0" Z="1.4995689117185818">
<NAME>Complete healing at 4 to 12 weeks</NAME>
<GROUP_LABEL_1>Silver</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-antimicrobial</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-antimicrobial</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours silver</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7866934687116443" CI_START="1.037071365203334" EFFECT_SIZE="1.7" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.44508919972566785" LOG_CI_START="0.015808643030879917" LOG_EFFECT_SIZE="0.2304489213782739" MODIFIED="2013-06-28 12:28:14 +0100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.2521615239755452" STUDY_ID="STD-Dimakakos-2009" TOTAL_1="21" TOTAL_2="21" VAR="0.06358543417366946" WEIGHT="13.103454195852217"/>
<DICH_DATA CI_END="3.2383621065182635" CI_START="0.2993696886675925" EFFECT_SIZE="0.9846153846153847" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5103254089850305" LOG_CI_START="-0.5237921743029674" LOG_EFFECT_SIZE="-0.0067333826589683786" MODIFIED="2013-06-28 12:28:51 +0100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.6074457873879648" STUDY_ID="STD-J_x00f8_rgensen-2005" TOTAL_1="65" TOTAL_2="64" VAR="0.36899038461538464" WEIGHT="6.602515680080575"/>
<DICH_DATA CI_END="1.315967218689774" CI_START="0.8235281709022857" EFFECT_SIZE="1.0410264533502296" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="59" LOG_CI_END="0.11924507095007883" LOG_CI_START="-0.08432154007873834" LOG_EFFECT_SIZE="0.017461765435670244" MODIFIED="2013-06-28 12:29:40 +0100" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.11957603498930329" STUDY_ID="STD-Michaels-2009" TOTAL_1="107" TOTAL_2="106" VAR="0.014298428143763085" WEIGHT="77.67333928489676"/>
<DICH_DATA CI_END="13.118449215931964" CI_START="0.6860567016617917" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1178824983955729" LOG_CI_START="-0.16363998895624793" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-06-28 12:30:17 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.7527726527090809" STUDY_ID="STD-Wunderlich-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.5666666666666665" WEIGHT="2.6206908391704435"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2784216730935993" CI_START="0.9550351375312167" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.104960460100647" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="78" I2="0.0" I2_Q="99.99999999999999" ID="CMP-022.02" LOG_CI_END="0.10667412463040614" LOG_CI_START="-0.0199806496150086" LOG_EFFECT_SIZE="0.04334673750769875" METHOD="MH" MODIFIED="2013-07-02 16:02:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.17973586034963174" Q="3.4795425470367697E-32" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="107" TOTAL_2="106" WEIGHT="100.0" Z="1.3415687623078574">
<NAME>Complete healing at 6 months</NAME>
<GROUP_LABEL_1>Silver</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-antimicrobial</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-antimicrobial</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours silver</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2784216730935993" CI_START="0.9550351375312167" EFFECT_SIZE="1.104960460100647" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="78" LOG_CI_END="0.10667412463040614" LOG_CI_START="-0.0199806496150086" LOG_EFFECT_SIZE="0.04334673750769875" MODIFIED="2013-06-28 14:03:46 +0100" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.07439764134300046" STUDY_ID="STD-Michaels-2009" TOTAL_1="107" TOTAL_2="106" VAR="0.0055350090374017315" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1611973037240793" CI_START="0.9416734982182124" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0456905503634475" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="90" I2="0.0" I2_Q="0.0" ID="CMP-022.03" LOG_CI_END="0.06490601873807776" LOG_CI_START="-0.026099651879910785" LOG_EFFECT_SIZE="0.019403183429083464" METHOD="MH" MODIFIED="2013-07-02 16:03:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.40328881546499096" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="107" TOTAL_2="106" WEIGHT="100.0" Z="0.8357620013826021">
<NAME>Complete healing at 12 months</NAME>
<GROUP_LABEL_1>Silver</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-antimicrobial</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-antimicrobial</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours silver</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1611973037240793" CI_START="0.9416734982182124" EFFECT_SIZE="1.0456905503634475" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="90" LOG_CI_END="0.06490601873807776" LOG_CI_START="-0.026099651879910785" LOG_EFFECT_SIZE="0.019403183429083464" MODIFIED="2013-06-28 14:06:31 +0100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.05345718140634136" STUDY_ID="STD-Michaels-2009" TOTAL_1="107" TOTAL_2="106" VAR="0.0028576702439104887" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3173729315533602E-31" CI_END="1.6960112532346545" CI_START="0.3788852900921086" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8016194331983805" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="100.0" I2_Q="0.0" ID="CMP-022.04" LOG_CI_END="0.22942872952535326" LOG_CI_START="-0.4214922555216226" LOG_EFFECT_SIZE="-0.09603176299813468" METHOD="MH" MODIFIED="2013-12-03 11:14:16 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.5630512394162369" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="90" WEIGHT="100.0" Z="0.5783153444796276">
<NAME>Ulcer recurrence within first year</NAME>
<GROUP_LABEL_1>Silver</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-antimicrobial</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-antimicrobial</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours silver</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6960112532346547" CI_START="0.3788852900921087" EFFECT_SIZE="0.8016194331983806" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.22942872952535331" LOG_CI_START="-0.4214922555216225" LOG_EFFECT_SIZE="-0.09603176299813461" MODIFIED="2013-06-28 16:40:25 +0100" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="0.38235420872743514" STUDY_ID="STD-Michaels-2009" TOTAL_1="95" TOTAL_2="90" VAR="0.14619474093158305" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.1624662650021464" CI_END="-0.9406852878895986" CI_START="-8.463820006792465" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.702252647341032" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-022.05" MODIFIED="2013-12-03 11:14:16 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6868961847148798" P_Q="1.0" P_Z="0.014281341860005962" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="81" UNITS="" WEIGHT="100.00000000000001" Z="2.4501078817157205">
<NAME>Change in ulcer surface area (cm squared) at 4 weeks</NAME>
<GROUP_LABEL_1>Silver</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-antimicrobial</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours silver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours non-antimicrobial</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.7270356900995019" CI_START="-9.672964309900498" EFFECT_SIZE="-5.2" ESTIMABLE="YES" MEAN_1="-6.5" MEAN_2="-1.3" MODIFIED="2013-06-28 14:40:30 +0100" MODIFIED_BY="[Empty name]" ORDER="82" SD_1="13.4" SD_2="9.0" SE="2.282166583254932" STUDY_ID="STD-Lazareth-2008" TOTAL_1="51" TOTAL_2="48" WEIGHT="70.72074396123712"/>
<CONT_DATA CI_END="3.4516648268785826" CI_START="-10.451664826878583" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="-9.5" MEAN_2="-6.0" MODIFIED="2013-06-28 14:42:16 +0100" MODIFIED_BY="[Empty name]" ORDER="83" SD_1="17.9" SD_2="11.7" SE="3.5468329427032472" STUDY_ID="STD-Meaume-2005" TOTAL_1="38" TOTAL_2="33" WEIGHT="29.27925603876289"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-022.06" MODIFIED="2013-12-03 11:14:12 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="89" TOTAL_2="81" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in ulcer surface area (%) at 4 weeks</NAME>
<GROUP_LABEL_1>Silver</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-antimicrobial</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours silver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours non-antimicrobial</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.0599667921569953" CI_START="-37.940033207843" EFFECT_SIZE="-19.5" ESTIMABLE="YES" MEAN_1="-28.1" MEAN_2="-8.6" MODIFIED="2013-06-28 14:59:24 +0100" MODIFIED_BY="[Empty name]" ORDER="84" SD_1="36.7" SD_2="54.6" SE="9.408353088778995" STUDY_ID="STD-Lazareth-2008" TOTAL_1="51" TOTAL_2="48" WEIGHT="0.0"/>
<CONT_DATA CI_END="26.67621201417511" CI_START="-11.67621201417511" EFFECT_SIZE="7.5" ESTIMABLE="YES" MEAN_1="-21.0" MEAN_2="-28.5" MODIFIED="2013-06-28 15:00:50 +0100" MODIFIED_BY="[Empty name]" ORDER="85" SD_1="45.4" SD_2="37.0" SE="9.783961422472363" STUDY_ID="STD-Meaume-2005" TOTAL_1="38" TOTAL_2="33" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.003828988376888288" CI_END="0.03011758129894279" CI_START="-0.2777695517964419" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.12382598524874955" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-022.07" MODIFIED="2013-12-03 11:14:08 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9506593824729246" P_Q="1.0" P_Z="0.11490697073842236" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="81" UNITS="" WEIGHT="100.0" Z="1.5765158420085676">
<NAME>Healing rate (cm squared per day)</NAME>
<GROUP_LABEL_1>Silver</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-antimicrobial</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours silver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours non-antimicrobial</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.07591952204451578" CI_START="-0.3159195220445158" EFFECT_SIZE="-0.12000000000000001" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.08" MODIFIED="2013-06-28 15:08:11 +0100" MODIFIED_BY="[Empty name]" ORDER="86" SD_1="0.42" SD_2="0.56" SE="0.09996077662135834" STUDY_ID="STD-Lazareth-2008" TOTAL_1="51" TOTAL_2="48" WEIGHT="61.74014751250465"/>
<CONT_DATA CI_END="0.11887994286497786" CI_START="-0.37887994286497795" EFFECT_SIZE="-0.13000000000000003" ESTIMABLE="YES" MEAN_1="-0.34" MEAN_2="-0.21" MODIFIED="2013-06-28 15:09:48 +0100" MODIFIED_BY="[Empty name]" ORDER="87" SD_1="0.64" SD_2="0.42" SE="0.12698189600835072" STUDY_ID="STD-Meaume-2005" TOTAL_1="38" TOTAL_2="33" WEIGHT="38.25985248749535"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.9010691017263035" CI_END="1.3298656167535343" CI_START="0.3610487595215608" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6929259204700303" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="61" I2="62.030454848894685" I2_Q="0.0" ID="CMP-022.08" LOG_CI_END="0.12380775762043673" LOG_CI_START="-0.4424341428002029" LOG_EFFECT_SIZE="-0.15931319258988313" METHOD="MH" MODIFIED="2013-06-28 17:06:23 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.04810126966679007" P_Q="1.0" P_Z="0.2700797795226325" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2600286163085069" TOTALS="YES" TOTAL_1="365" TOTAL_2="341" WEIGHT="100.00000000000001" Z="1.1028788915348973">
<NAME>Proportion of participants reporting any type of adverse event</NAME>
<GROUP_LABEL_1>Silver</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-antimicrobial</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours silver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours non-antimicrobial</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.633852120362532" CI_START="0.3059181643502935" EFFECT_SIZE="1.3128205128205128" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7508054432615028" LOG_CI_START="-0.5143947353628395" LOG_EFFECT_SIZE="0.11820535394933156" MODIFIED="2013-06-28 16:59:38 +0100" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.7431848477658287" STUDY_ID="STD-J_x00f8_rgensen-2005" TOTAL_1="65" TOTAL_2="64" VAR="0.5523237179487179" WEIGHT="13.618672528099234"/>
<DICH_DATA CI_END="0.5786323829655068" CI_START="0.1080133118020215" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="20" LOG_CI_END="-0.23759726486417898" LOG_CI_START="-0.9665227177917458" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2013-06-28 17:00:24 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.42817441928883765" STUDY_ID="STD-Kerihuel-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.18333333333333335" WEIGHT="24.95288652222698"/>
<DICH_DATA CI_END="2.0155182480154195" CI_START="0.4587188500665355" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.30438673450421594" LOG_CI_START="-0.3384534131017766" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2013-06-28 17:01:09 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.3776074848138111" STUDY_ID="STD-Lazareth-2008" TOTAL_1="52" TOTAL_2="50" VAR="0.14258741258741262" WEIGHT="27.4781916855727"/>
<DICH_DATA CI_END="1.4388777411399718" CI_START="0.5262774218172117" EFFECT_SIZE="0.8702004757050629" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.1580238942813162" LOG_CI_START="-0.2787852615436787" LOG_EFFECT_SIZE="-0.060380683631181244" MODIFIED="2013-06-28 17:02:17 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.2565838603717955" STUDY_ID="STD-M_x00fc_nter-2006" TOTAL_1="218" TOTAL_2="197" VAR="0.06583527740329305" WEIGHT="33.950249264101096"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" MODIFIED="2013-12-02 15:22:07 +0000" MODIFIED_BY="[Empty name]" NO="23">
<NAME>Chloramphenicol-containing ointment versus enzymatic cleanser</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9897798294895074" CI_START="0.016147158035865767" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.12642045454545456" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-023.01" LOG_CI_END="-0.004461400828622918" LOG_CI_START="-1.7919039041657756" LOG_EFFECT_SIZE="-0.8981826524971994" METHOD="MH" MODIFIED="2013-07-02 15:54:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.04886725853356433" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="88" TOTAL_2="89" WEIGHT="100.0" Z="1.969748002687069">
<NAME>Complete healing at 4 weeks</NAME>
<GROUP_LABEL_1>Chloramphenicol ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>Enzymatic cleanser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours enzymatic cleanse</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chloramphenicol</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9897798294895074" CI_START="0.016147158035865767" EFFECT_SIZE="0.12642045454545456" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.004461400828622918" LOG_CI_START="-1.7919039041657756" LOG_EFFECT_SIZE="-0.8981826524971994" MODIFIED="2013-06-29 16:30:45 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="1.0499525744433336" STUDY_ID="STD-Fischer-1984" TOTAL_1="88" TOTAL_2="89" VAR="1.1024004085801837" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.835522400939471" CI_START="0.522163732100894" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.022727272727273" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-023.02" LOG_CI_END="0.8940679565521753" LOG_CI_START="-0.28219329623472456" LOG_EFFECT_SIZE="0.3059373301587254" METHOD="MH" MODIFIED="2013-12-02 15:22:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.30794390425275986" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="88" TOTAL_2="89" WEIGHT="100.0" Z="1.019545865710964">
<NAME>Participants discontinuing treatment because of ineffectiveness or allergy</NAME>
<GROUP_LABEL_1>Chloramphenicol ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>Enzymatic cleanser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chloramphenicol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours enzymatic cleanse</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.835522400939471" CI_START="0.5221637321008941" EFFECT_SIZE="2.022727272727273" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8940679565521753" LOG_CI_START="-0.28219329623472444" LOG_EFFECT_SIZE="0.3059373301587254" MODIFIED="2013-06-29 16:41:43 +0100" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.6909416824741317" STUDY_ID="STD-Fischer-1984" TOTAL_1="88" TOTAL_2="89" VAR="0.47740040858018384" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" MODIFIED="2013-12-06 15:06:43 +0000" MODIFIED_BY="[Empty name]" NO="24">
<NAME>Framycetin sulphate-containing ointment versus enzymatic cleanser</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.014225615496031" CI_START="0.23413260409158299" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6867283950617284" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-024.01" LOG_CI_END="0.3041081147166722" LOG_CI_START="-0.6305381044959957" LOG_EFFECT_SIZE="-0.1632149948896617" METHOD="MH" MODIFIED="2013-07-02 15:56:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.4936421459929484" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="89" WEIGHT="100.0" Z="0.6845274824737455">
<NAME>Complete healing at 4 weeks</NAME>
<GROUP_LABEL_1>Framycetin ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>Enzymatic cleanser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours enzymatic cleanse</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours framycetin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.014225615496031" CI_START="0.23413260409158299" EFFECT_SIZE="0.6867283950617284" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.3041081147166722" LOG_CI_START="-0.6305381044959957" LOG_EFFECT_SIZE="-0.1632149948896617" MODIFIED="2013-06-29 16:34:57 +0100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.5490158157389226" STUDY_ID="STD-Fischer-1984" TOTAL_1="81" TOTAL_2="89" VAR="0.30141836593147453" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.668895112628121" CI_START="0.8046888701525594" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9300411522633745" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-024.02" LOG_CI_END="1.0281194455411804" LOG_CI_START="-0.09437200546409195" LOG_EFFECT_SIZE="0.46687372003854416" METHOD="MH" MODIFIED="2013-12-02 15:22:37 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.1030167416576112" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="89" WEIGHT="100.0" Z="1.6304011505553726">
<NAME>Participants discontinuing treatment because of ineffectiveness or allergy</NAME>
<GROUP_LABEL_1>Framycetin ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>Enzymatic cleanser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours framycetin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours enzymatic cleanse</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.668895112628121" CI_START="0.8046888701525594" EFFECT_SIZE="2.9300411522633745" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.0281194455411804" LOG_CI_START="-0.09437200546409195" LOG_EFFECT_SIZE="0.46687372003854416" MODIFIED="2013-06-29 16:44:21 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.6593570347427923" STUDY_ID="STD-Fischer-1984" TOTAL_1="81" TOTAL_2="89" VAR="0.43475169926480783" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" MODIFIED="2013-12-06 15:05:55 +0000" MODIFIED_BY="[Empty name]" NO="25">
<NAME>Chloramphenicol-containing ointment versus framycetin sulphate-containing ointment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5424796768192588" CI_START="0.0219707677963062" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18409090909090908" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-025.01" LOG_CI_END="0.18821945062852327" LOG_CI_START="-1.6581547658435984" LOG_EFFECT_SIZE="-0.7349676576075377" METHOD="MH" MODIFIED="2013-07-02 15:57:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.11867332176919047" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="88" TOTAL_2="81" WEIGHT="99.99999999999999" Z="1.5603663936175747">
<NAME>Complete healing at 4 weeks</NAME>
<GROUP_LABEL_1>Chloramphenicol ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>Framycetin ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours framycetin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chloramphenicol</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5424796768192588" CI_START="0.0219707677963062" EFFECT_SIZE="0.18409090909090908" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.18821945062852327" LOG_CI_START="-1.6581547658435984" LOG_EFFECT_SIZE="-0.7349676576075377" MODIFIED="2013-06-29 16:38:15 +0100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="1.084569354455499" STUDY_ID="STD-Fischer-1984" TOTAL_1="88" TOTAL_2="81" VAR="1.1762906846240178" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9040776681660532" CI_START="0.2502894596854761" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6903409090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-025.02" LOG_CI_END="0.2796846594728142" LOG_CI_START="-0.6015574392324519" LOG_EFFECT_SIZE="-0.16093638987981884" METHOD="MH" MODIFIED="2013-12-02 15:23:20 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.47406863393072296" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="88" TOTAL_2="81" WEIGHT="100.0" Z="0.715874850803826">
<NAME>Participants discontinuing treatment because of ineffectiveness or allergy</NAME>
<GROUP_LABEL_1>Chloramphenicol ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>Framycetin ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chloramphenicol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours framycetin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9040776681660527" CI_START="0.25028945968547617" EFFECT_SIZE="0.6903409090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.27968465947281407" LOG_CI_START="-0.6015574392324519" LOG_EFFECT_SIZE="-0.16093638987981884" MODIFIED="2013-06-29 16:45:59 +0100" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.5176459709982147" STUDY_ID="STD-Fischer-1984" TOTAL_1="88" TOTAL_2="81" VAR="0.2679573512906846" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" MODIFIED="2013-12-15 18:27:59 +0000" MODIFIED_BY="Marrissa Martyn-St James" NO="26">
<NAME>Mupirocin versus control</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3452615705961373" CI_START="0.5569197335406777" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-026.01" LOG_CI_END="0.37019128727770284" LOG_CI_START="-0.2542073933223293" LOG_EFFECT_SIZE="0.05799194697768673" METHOD="MH" MODIFIED="2013-12-02 15:22:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.7158064239433395" Q="0.0" RANDOM="NO" SCALE="57.42" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.3640690827866448">
<NAME>Frequency of complete healing</NAME>
<GROUP_LABEL_1>Topical mupirocin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mupirocin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3452615705961373" CI_START="0.5569197335406775" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.37019128727770284" LOG_CI_START="-0.25420739332232944" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="3601" O_E="0.0" SE="0.36677487580777607" STUDY_ID="STD-Cameron-1991" TOTAL_1="15" TOTAL_2="15" VAR="0.13452380952380955" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="158.00751897143903" CI_START="0.7657863422428124" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-026.02" LOG_CI_END="2.1986777538538482" LOG_CI_START="-0.11589238353739796" LOG_EFFECT_SIZE="1.0413926851582251" METHOD="MH" MODIFIED="2013-12-15 18:27:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.07778417781949461" Q="0.0" RANDOM="NO" SCALE="578.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="1.763690046544969">
<NAME>Eradication of gram-positive bacteria</NAME>
<GROUP_LABEL_1>Topical mupirocin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mupirocin</GRAPH_LABEL_2>
<DICH_DATA CI_END="158.00751897143903" CI_START="0.7657863422428124" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.1986777538538482" LOG_CI_START="-0.11589238353739796" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2013-06-29 17:28:12 +0100" MODIFIED_BY="[Empty name]" ORDER="3602" O_E="0.0" SE="1.359589956010579" STUDY_ID="STD-Cameron-1991" TOTAL_1="5" TOTAL_2="5" VAR="1.8484848484848484" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" MODIFIED="2013-11-26 15:05:18 +0000" MODIFIED_BY="Marrissa Martyn-St James" NO="27">
<NAME>Topical antibiotics versus herbal ointment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="85.83246253101137" CI_START="0.23013538045254459" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.444444444444445" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-027.01" LOG_CI_END="1.9336515726005183" LOG_CI_START="-0.6380166088232434" LOG_EFFECT_SIZE="0.6478174818886375" METHOD="MH" MODIFIED="2013-07-02 15:58:36 +0100" MODIFIED_BY="Marrissa Martyn-St James" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.32342131087596315" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="15" WEIGHT="100.0" Z="0.9874516022158119">
<NAME>Complete healing at 7 weeks</NAME>
<GROUP_LABEL_1>Herbal ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>Topical antibiotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours top. antibiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours herbal ointment</GRAPH_LABEL_2>
<DICH_DATA CI_END="85.83246253101137" CI_START="0.23013538045254459" EFFECT_SIZE="4.444444444444445" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9336515726005183" LOG_CI_START="-0.6380166088232434" LOG_EFFECT_SIZE="0.6478174818886375" MODIFIED="2011-07-12 13:21:38 +0100" MODIFIED_BY="Marrissa Martyn-St James" ORDER="221" O_E="0.0" SE="1.510610619731122" STUDY_ID="STD-Bini_x0107_-2010" TOTAL_1="17" TOTAL_2="15" VAR="2.2819444444444446" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="137.3476787584144" CI_START="0.4659707435796698" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-027.02" LOG_CI_END="2.1378213240337525" LOG_CI_START="-0.33164135004986556" LOG_EFFECT_SIZE="0.9030899869919435" METHOD="MH" MODIFIED="2013-07-02 15:59:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.15170656237147231" Q="0.0" RANDOM="NO" SCALE="150.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="15" WEIGHT="100.0" Z="1.4335295429883632">
<NAME>Participants with bacterial eradication at 7 weeks</NAME>
<GROUP_LABEL_1>Herbal ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>Topical antibiotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours top.antibiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours herbal ointment</GRAPH_LABEL_2>
<DICH_DATA CI_END="137.3476787584144" CI_START="0.4659707435796696" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1378213240337525" LOG_CI_START="-0.3316413500498657" LOG_EFFECT_SIZE="0.9030899869919435" MODIFIED="2013-06-29 18:02:15 +0100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="1.450574598794101" STUDY_ID="STD-Bini_x0107_-2010" TOTAL_1="17" TOTAL_2="15" VAR="2.104166666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-028" MODIFIED="2013-12-03 11:17:42 +0000" MODIFIED_BY="Marrissa Martyn-St James" NO="28">
<NAME>Ethacridine lactate versus control</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7319107849798336" CI_START="1.2120120290883707" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4488259746095944" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-028.01" LOG_CI_END="0.23852551667157915" LOG_CI_START="0.08350693017744314" LOG_EFFECT_SIZE="0.16101622342451113" METHOD="MH" MODIFIED="2013-12-03 11:17:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="4.669348108466139E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="124" WEIGHT="100.0" Z="4.071589168446384">
<NAME>Number of responsive ulcers</NAME>
<GROUP_LABEL_1>Ethacridin lactate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EL</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7319107849798336" CI_START="1.2120120290883707" EFFECT_SIZE="1.4488259746095944" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="69" LOG_CI_END="0.23852551667157915" LOG_CI_START="0.08350693017744314" LOG_EFFECT_SIZE="0.16101622342451113" MODIFIED="2013-12-02 15:19:25 +0000" MODIFIED_BY="[Empty name]" ORDER="3599" O_E="0.0" SE="0.09105868506103436" STUDY_ID="STD-Geske-2005" TOTAL_1="129" TOTAL_2="124" VAR="0.008291684125044642" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.221119032948935" CI_START="0.5027205521067338" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0566939890710383" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-028.02" LOG_CI_END="0.34657183363521343" LOG_CI_START="-0.29867335968122455" LOG_EFFECT_SIZE="0.023949236976994488" METHOD="MH" MODIFIED="2013-12-03 11:17:42 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8843208775202596" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="119" WEIGHT="100.0" Z="0.14549396855128283">
<NAME>Participants reporting at least 1 adverse event</NAME>
<GROUP_LABEL_1>Ethacridin lactate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.221119032948935" CI_START="0.5027205521067339" EFFECT_SIZE="1.0566939890710383" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.34657183363521343" LOG_CI_START="-0.2986733596812245" LOG_EFFECT_SIZE="0.023949236976994488" MODIFIED="2013-06-29 18:48:46 +0100" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.37902022056929496" STUDY_ID="STD-Geske-2005" TOTAL_1="122" TOTAL_2="119" VAR="0.143656327600397" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.341518118673149" CI_START="1.8490715824148676" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-028.03" LOG_CI_END="0.6376416178252069" LOG_CI_START="0.2669537241640538" LOG_EFFECT_SIZE="0.4522976709946303" METHOD="MH" MODIFIED="2013-12-03 11:17:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.7275819911560861E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="119" WEIGHT="100.00000000000001" Z="4.782930117761886">
<NAME>Participant satisfaction (treatment rated as excellent)</NAME>
<GROUP_LABEL_1>Ethacridin lactate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EL</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.341518118673149" CI_START="1.8490715824148676" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="21" LOG_CI_END="0.6376416178252069" LOG_CI_START="0.2669537241640538" LOG_EFFECT_SIZE="0.4522976709946303" ORDER="3600" O_E="0.0" SE="0.21774390367122845" STUDY_ID="STD-Geske-2005" TOTAL_1="122" TOTAL_2="119" VAR="0.047412407585985215" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-12-15 18:03:42 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-12-03 14:38:42 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeEAAAPeCAYAAAA7+aJfAACAAElEQVR42uydD2RX3x//vyQfSTKS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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-12-06 13:29:29 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWsAAAdfCAIAAABkH0+uAABveklEQVR42u3dv44lRfav/ZKQEEYb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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-12-06 13:29:29 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyIAAAEZCAMAAABcsWErAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-11-26 15:06:34 +0000" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-008.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 8 Cadexomer iodine versus standard care, outcome: 8.1 Frequency of complete healing at 4 to 12 weeks.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuoAAADACAMAAABlEbbtAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-12-03 15:09:36 +0000" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-017.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 18 Honey products versus alternatives, outcome: 18.1 Complete healing at 12 weeks.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArYAAACgCAMAAADOzd9xAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2013-12-03 15:09:36 +0000" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-022.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 23 Silver dressing versus non-antimicrobial dressing, outcome: 23.1 Complete healing at 4 to 12 weeks.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAu8AAADACAMAAACDOH2pAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-12-16 15:19:34 +0000" MODIFIED_BY="Sue O'Meara">
<APPENDIX ID="APP-01" MODIFIED="2013-12-16 15:19:34 +0000" MODIFIED_BY="Sue O'Meara" NO="1">
<TITLE MODIFIED="2013-12-04 15:26:58 +0000" MODIFIED_BY="[Empty name]">Search methods used in the first update of this review 2009</TITLE>
<APPENDIX_BODY MODIFIED="2013-12-16 15:19:34 +0000" MODIFIED_BY="Sue O'Meara">
<SUBSECTION>
<HEADING LEVEL="3">Electronic searches</HEADING>
<P>For this update the following electronic databases were searched for all relevant studies, regardless of language, date of publication or publication status:</P>
<P>Cochrane Wounds Group Specialised Register (searched 24/09/09)<BR/>The Cochrane Central Register of Controlled Trials (CENTRAL) - <I>The Cochrane Library</I> Issue 3 2009<BR/>Ovid MEDLINE - 1950 to September Week 3 2009<BR/>Ovid EMBASE - 1980 to 2009 Week 38<BR/>EBSCO CINAHL - 1982 to September Week 3 2009</P>
<P>The following shows the search strategy used with CENTRAL:</P>
<P>#1 MeSH descriptor Anti-Infective Agents explode all trees<BR/>#2 MeSH descriptor Penicillins explode all trees<BR/>#3 MeSH descriptor Cephalosporins explode all trees<BR/>#4 MeSH descriptor Aminoglycosides explode all trees<BR/>#5 MeSH descriptor Quinolones explode all trees<BR/>#6 MeSH descriptor Clindamycin explode all trees<BR/>#7 MeSH descriptor Metronidazole explode all trees<BR/>#8 MeSH descriptor Trimethoprim explode all trees<BR/>#9 MeSH descriptor Mupirocin explode all trees<BR/>#10 MeSH descriptor Neomycin explode all trees<BR/>#11 MeSH descriptor Fusidic Acid explode all trees<BR/>#12 MeSH descriptor Framycetin explode all trees<BR/>#13 MeSH descriptor Polymyxins explode all trees<BR/>#14 MeSH descriptor Chlortetracycline explode all trees<BR/>#15 (antibiotic* or antimicrobial* or antibacterial* or penicillin* or cephalosporin* or aminoglycoside* or quinolone* or clindamycin or metronidazole or trimethoprim or mupirocin or "pseudomonic acid" or neomycin or "fusidic acid" or framycetin or polymyxin* or chlortetracycline):ti,ab,kw<BR/>#16 MeSH descriptor Antisepsis explode all trees<BR/>#17 antiseptic*:ti,ab,kw<BR/>#18 MeSH descriptor Soaps explode all trees<BR/>#19 MeSH descriptor Iodophors explode all trees<BR/>#20 MeSH descriptor Chlorhexidine explode all trees<BR/>#21 MeSH descriptor Alcohols explode all trees<BR/>#22 MeSH descriptor Hydrogen Peroxide explode all trees<BR/>#23 MeSH descriptor Benzoyl Peroxide explode all trees<BR/>#24 MeSH descriptor Gentian Violet explode all trees<BR/>#25 MeSH descriptor Hypochlorous Acid explode all trees<BR/>#26 MeSH descriptor Hexachlorophene explode all trees<BR/>#27 MeSH descriptor Potassium Permanganate explode all trees<BR/>#28 MeSH descriptor Silver explode all trees<BR/>#29 MeSH descriptor Silver Sulfadiazine explode all trees<BR/>#30 (&#8220;soap&#8221; or &#8220;soaps&#8221; or iodophor* or povidone or iodine or chlorhexidine or betadine or &#8220;alcohol&#8221; or disinfectant* or "hydrogen peroxide" or "benzoyl peroxide" or "gentian violet" or hypochlorit* or eusol or dakin* or hexachlorophene or benzalkonium or "potassium permanganate" or "silver sulfadiazine" or "silver sulphadiazine"):ti,ab,kw<BR/>#31 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30)<BR/>#32 MeSH descriptor Leg Ulcer explode all trees<BR/>#33 (varicose NEXT ulcer*) or (venous NEXT ulcer*) or (leg NEXT ulcer*) or (foot NEXT ulcer*) or (stasis NEXT ulcer*) or ((lower NEXT extremit*) NEAR/2 ulcer*) or (crural NEXT ulcer*):ti,ab,kw<BR/>#34 (#32 OR #33)<BR/>#35 (#31 AND #34)</P>
<P>The search strategies for Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL can be found in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>, <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> and <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> respectively. The Ovid MEDLINE search was combined with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximizing version (2008 revision); Ovid format. The EMBASE and CINAHL searches were combined with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Searching other resources</HEADING>
<P>The reference lists of included studies and review articles were examined to identify additional references for both the original review and the update.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-12-04 15:25:29 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-09-17 14:55:31 +0100" MODIFIED_BY="[Empty name]">Ovid MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-12-04 15:25:29 +0000" MODIFIED_BY="[Empty name]">
<P>1 exp Anti-Infective Agents/ (614173)<BR/>2 exp Penicillins/ (16923)<BR/>3 exp Cephalosporins/ (12724)<BR/>4 exp Aminoglycosides/ (48702)<BR/>5 exp Quinolones/ (22074)<BR/>6 exp Clindamycin/ (2024)<BR/>7 exp Metronidazole/ (4816)<BR/>8 exp Trimethoprim/ (3822)<BR/>9 exp Mupirocin/ (640)<BR/>10 exp Neomycin/ (1890)<BR/>11 exp Fusidic Acid/ (473)<BR/>12 exp Framycetin/ (166)<BR/>13 exp Polymyxins/ (2141)<BR/>14 exp Chlortetracycline/ (351)<BR/>15 (antibiotic$ or antimicrobial$ or antibacterial$ or penicillin$ or cephalosporin$ or aminoglycoside$ or quinolone$ or clindamycin or metronidazole or trimethoprim or mupirocin or pseudomonic acid or neomycin or fusidic acid or framycetin or polymyxin$ or chlortetracycline).ti,ab. (191275)<BR/>16 exp Antisepsis/ (710)<BR/>17 antiseptic$.ti,ab. (2623)<BR/>18 exp Soaps/ (697)<BR/>19 exp Iodophors/ (1188)<BR/>20 exp Chlorhexidine/ (3330)<BR/>21 exp Alcohols/ (210358)<BR/>22 exp Hydrogen Peroxide/ (28460)<BR/>23 exp Benzoyl Peroxide/ (498)<BR/>24 exp Gentian Violet/ (991)<BR/>25 exp Hypochlorous Acid/ (3254)<BR/>26 exp Hexachlorophene/ (30)<BR/>27 exp Potassium Permanganate/ (526)<BR/>28 exp Silver/ (7101)<BR/>29 exp Silver Sulfadiazine/ (434)<BR/>30 exp Honey/ (1518)<BR/>31 (soap$1 or iodophor$ or povidone or iodine or chlorhexidine or betadine or alcohol$1 or disinfectant$ or hydrogen peroxide or benzoyl peroxide or gentian violet or hypochlorit$ or eusol or dakin$ or hexachlorophene or benzalkonium or potassium permanganate or silver sulfadiazine or silver sulphadiazine or honey$).ti,ab. (159344)<BR/>32 or/1-31 (982110)<BR/>33 exp Leg Ulcer/ (10032)<BR/>34 (varicose ulcer$ or venous ulcer$ or leg ulcer$ or stasis ulcer$ or (lower extremit$ adj ulcer$) or crural ulcer$ or ulcus cruris).ti,ab. (3777)<BR/>35 or/33-34 (10770)<BR/>36 32 and 35 (1383)<BR/>37 randomized controlled trial.pt. (248241)<BR/>38 controlled clinical trial.pt. (40205)<BR/>39 randomized.ab. (202576)<BR/>40 placebo.ab. (93758)<BR/>41 clinical trials as topic.sh. (81126)<BR/>42 randomly.ab. (139357)<BR/>43 trial.ti. (75545)<BR/>44 or/37-43 (560427)<BR/>45 (animals not (humans and animals)).sh. (1653788)<BR/>46 44 not 45 (509737)<BR/>47 36 and 46 (165)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-12-04 15:25:06 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-09-17 14:55:41 +0100" MODIFIED_BY="[Empty name]">Ovid EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-12-04 15:25:06 +0000" MODIFIED_BY="[Empty name]">
<P>1 exp Antiinfective Agent/ (1364874)<BR/>2 exp Penicillin G/ (33954)<BR/>3 exp Cephalosporin/ (10924)<BR/>4 exp Aminoglycoside/ (7100)<BR/>5 exp Quinolone/ (2425)<BR/>6 exp Clindamycin/ (23558)<BR/>7 exp Metronidazole/ (31416)<BR/>8 exp Trimethoprim/ (8460)<BR/>9 exp Pseudomonic Acid/ (3886)<BR/>10 exp Neomycin/ (7156)<BR/>11 exp Fusidic Acid/ (3695)<BR/>12 exp Framycetin/ (597)<BR/>13 exp Polymyxin/ (1362)<BR/>14 exp Chlortetracycline/ (1375)<BR/>15 (antibiotic$ or antimicrobial$ or antibacterial$ or penicillin$ or cephalosporin$ or aminoglycoside$ or quinolone$ or clindamycin or metronidazole or trimethoprim or mupirocin or neomycin or fusidic acid or framycetin or polymyxin$ or chlortetracycline).ti,ab. (285818)<BR/>16 exp antisepsis/ (1455)<BR/>17 antiseptic$.ti,ab. (4015)<BR/>18 exp Soap/ (2050)<BR/>19 exp Iodophor/ (205)<BR/>20 exp Chlorhexidine/ (7046)<BR/>21 exp Alcohol/ (106780)<BR/>22 exp Hydrogen Peroxide/ (47414)<BR/>23 exp Benzoyl Peroxide/ (2117)<BR/>24 exp Gentian Violet/ (2153)<BR/>25 exp Hypochlorous Acid/ (1376)<BR/>26 exp Hexachlorophene/ (470)<BR/>27 exp Potassium Permanganate/ (1499)<BR/>28 exp Silver/ (17835)<BR/>29 exp Silver Sulfadiazine/ (1903)<BR/>30 exp Honey/ (2797)<BR/>31 (soap$1 or iodophor$ or povidone or iodine or chlorhexidine or betadine or alcohol$1 or disinfectant$ or hydrogen peroxide or benzoyl peroxide or gentian violet or hypochlorit$ or eusol or dakin$ or hexachlorophene or benzalkonium or potassium permanganate or silver sulfadiazine or silver sulphadiazine or honey$).ti,ab. (242236)<BR/>32 or/1-31 (1667271)<BR/>33 exp Leg Ulcer/ (6146)<BR/>34 (varicose ulcer$ or venous ulcer$ or leg ulcer$ or stasis ulcer$ or (lower extremit$ adj ulcer$) or crural ulcer$ or ulcus cruris).ti,ab. (5715)<BR/>35 or/33-34 (8168)<BR/>36 32 and 35 (1624)<BR/>37 exp Clinical trial/ (803713)<BR/>38 Randomized controlled trial/ (291695)<BR/>39 Randomization/ (51287)<BR/>40 Single blind procedure/ (15938)<BR/>41 Double blind procedure/ (87430)<BR/>42 Crossover procedure/ (32553)<BR/>43 Placebo/ (170444)<BR/>44 Randomi?ed controlled trial$.tw. (83428)<BR/>45 RCT.tw. (11057)<BR/>46 Random allocation.tw. (935)<BR/>47 Randomly allocated.tw. (14665)<BR/>48 Allocated randomly.tw. (1229)<BR/>49 (allocated adj2 random).tw. (266)<BR/>50 Single blind$.tw. (9924)<BR/>51 Double blind$.tw. (92426)<BR/>52 ((treble or triple) adj blind$).tw. (248)<BR/>53 Placebo$.tw. (140784)<BR/>54 Prospective study/ (208229)<BR/>55 or/37-54 (1111238)<BR/>56 Case study/ (17028)<BR/>57 Case report.tw. (171644)<BR/>58 Abstract report/ or letter/ (521196)<BR/>59 or/56-58 (705463)<BR/>60 55 not 59 (1082630)<BR/>61 animal/ (732590)<BR/>62 human/ (8857186)<BR/>63 61 not 62 (490450)<BR/>64 60 not 63 (1059985)<BR/>65 36 and 64 (317)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2012-03-09 11:33:35 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2009-09-17 14:56:08 +0100" MODIFIED_BY="[Empty name]">EBSCO CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-03-09 11:33:35 +0000" MODIFIED_BY="[Empty name]">
<P>S30 S26 and S29<BR/>S29 S27 or S28<BR/>S28 TI ( varicose ulcer* or venous ulcer* or leg ulcer or stasis ulcer* or crural ulcer* or cruris) or AB ( varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or cruris)<BR/>S27 (MH "Leg Ulcer+")<BR/>S26 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25<BR/>S25 TI ( soap* or iodophor* or povidone or iodine or chlorhexidine or betadine or alcohol* or disinfectant* or hydrogen peroxide or benzoyl peroxide or gentian violet or hypochlorit* or eusol or dakin* or hexachlorophene or benzalkonium or potassium permanganate or silver sulfadiazine or silver sulphadiazine or honey*) or AB ( soap* or iodophor* or povidone or iodine or chlorhexidine or betadine or alcohol* or disinfectant* or hydrogen peroxide or benzoyl peroxide or gentian violet or hypochlorit* or eusol or dakin* or hexachlorophene or benzalkonium or potassium permanganate or silver sulfadiazine or silver sulphadiazine or honey*)<BR/>S24 (MH "Honey")<BR/>S23 (MH "Silver Sulfadiazine")<BR/>S22 (MH "Silver")<BR/>S21 (MH "Hexachlorophene")<BR/>S20 (MH "Gentian Violet")<BR/>S19 (MH "Hydrogen Peroxide")<BR/>S18 (MH "Alcohols+")<BR/>S17 (MH "Chlorhexidine")<BR/>S16 (MH "Povidone-Iodine")<BR/>S15 (MH "Iodine")<BR/>S14 (MH "Soaps")<BR/>S13 TI antiseptic*<BR/>S12 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11<BR/>S11 TI ( antibiotic* or antimicrobial* or antibacterial* or penicillin* or cephalosporin* or aminoglycoside* or quinolone* or clindamycin or metronidazole or trimethoprim or mupirocin or pseudomonic acid or neomycin or fusidic acid or framycetin or polymyxin* or chlortetracycline ) or AB ( antibiotic* or antimicrobial* or antibacterial* or penicillin* or cephalosporin* or aminoglycoside* or quinolone* or clindamycin or metronidazole or trimethoprim or mupirocin or pseudomonic acid or neomycin or fusidic acid or framycetin or polymyxin* or chlortetracycline )<BR/>S10 (MH "Polymyxins+")<BR/>S9 (MH "Neomycin")<BR/>S8 (MH "Mupirocin")<BR/>S7 (MH "Trimethoprim+")<BR/>S6 (MH "Metronidazole")<BR/>S5 (MH "Clindamycin")<BR/>S4 (MH "Aminoglycosides+")<BR/>S3 (MH "Cephalosporins+")<BR/>S2 (MH "Penicillins+")<BR/>S1 (MH "Antiinfective Agents+")</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2013-12-06 15:05:29 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2013-06-18 16:12:07 +0100" MODIFIED_BY="[Empty name]">Risk of bias criteria</TITLE>
<APPENDIX_BODY MODIFIED="2013-12-06 15:05:29 +0000" MODIFIED_BY="[Empty name]">
<P>The following descriptions of risk of bias criteria are paraphrased from the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Adequacy of the sequence generation (randomisation)</HEADING>
<P>Low risk: adequate sequence generation was reported using methods such as random number tables, computerised random number generator, dice throwing, coin tossing or dealing previously shuffled cards.</P>
<P>High risk: a system involving alternation, date of birth, date of presentation or case record number was used for the allocation of participants. Such studies were considered as quasi-randomised and were excluded from the review.</P>
<P>Unclear risk: study authors did not describe one of the adequate methods but mentioned randomisation.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Adequacy of allocation concealment </HEADING>
<P>Low risk: a group allocation method was described that would not allow an investigator or a participant to know or influence allocation to an intervention group up to and including the point of randomisation. Adequate methods include central randomisation by a third party and serially numbered, opaque, sealed envelopes that have been opened sequentially, once the envelope has been irreversibly assigned to the participant.</P>
<P>High risk: group allocation methods such as alternation, date of birth, date of presentation or case record number cannot be adequately concealed. A classification of high risk may also be given if reference is made to the use of unsealed envelopes, or if information in the trial report indicates that investigators or participants could have known or influenced group allocation.</P>
<P>Unclear risk: the trial report mentioned randomisation or allocation concealment, but no information on the methods used was provided.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Blinding of participants </HEADING>
<P>Low risk: explicit statement that participants were blind or inclusion of any information in the trial report suggests that participants were not aware of treatment allocation.</P>
<P>High risk: explicit statement indicates that participants were not blind to treatment allocation.</P>
<P>Unclear risk: terms such as 'open' or 'double-blind' are used with no further explanation or with no reference at all to blinding of participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Blinding of outcome assessors</HEADING>
<P>Low risk: explicit statement that outcome assessors were blind or inclusion of any information in the trial report suggests that outcome assessors were not aware of treatment allocation.</P>
<P>High risk: explicit statement indicates that outcome assessors were not blind to treatment allocation.</P>
<P>Unclear risk: terms such as 'open' or 'double-blind' are used with no further explanation or with no reference at all to blinding of outcome assessors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Incomplete outcome data addressed (description of withdrawals) </HEADING>
<P>Low risk: numbers of withdrawals per group are provided, together with reasons; or it is clear from the report that no withdrawals occurred.</P>
<P>High risk: some withdrawal is evident or mentioned, but numbers per group, or reasons, or both, are not provided.<BR/>
</P>
<P>Unclear risk: trial report is unclear about whether any withdrawals occurred.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Incomplete outcome data addressed (withdrawal rate acceptable) </HEADING>
<P>Low risk: RCT report states that withdrawal rate did not exceed 20% per treatment group; or outcome data are missing in all treatment groups, but reasons are reported and balanced across groups (and therefore are unlikely to be related to treatment); or it is clear that no withdrawals occurred.<BR/>
</P>
<P>High risk: RCT report states that withdrawal rate exceeded 20% in at least one treatment group; or differential proportions of incomplete outcome data across groups are likely to be related to treatment outcome; or, even if incomplete outcome data are balanced in numbers across groups, reasons for missing outcomes differ.</P>
<P>Unclear risk: withdrawal rates are not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7. Incomplete outcome data addressed (use of intention-to-treat (ITT) analysis) </HEADING>
<P>We defined ITT analysis as analysis conducted when all trial participants were analysed in the group to which they were randomly assigned, regardless of which (or how much of) treatment they actually received, and regardless of other protocol irregularities, such as ineligibility.<I> </I>
</P>
<P>Low risk: RCT report stated that ITT was undertaken, and this was confirmed on study assessment, or it was not stated but it was evident from study assessment that ITT was undertaken.</P>
<P>High risk: ITT was not confirmed on study assessment (participants who were randomly assigned were not included in the analysis because they did not receive the study intervention, they withdrew from the study or they were not included because of protocol violation), regardless of whether the analysis was described as ITT. Analyses described as 'as treated' or 'per protocol' or similar, unless the numbers of switches or missing data are too small to reveal any important difference in the estimated treatment effect.</P>
<P>Unclear risk: analysis is described as ITT, but this cannot be confirmed on study assessment, or it is not reported and cannot be confirmed by study assessment. ITT is not done, but a small number of participants are excluded from the analysis, and it is difficult to judge the impact of this on estimates of treatment effect, particularly in smaller trials. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">8. Comparability at baseline</HEADING>
<P>Findings from prognostic studies have suggested that the two most important predictors of delayed healing in participants with venous leg ulceration are baseline ulcer duration and wound surface area; participants with larger and more chronic wounds are more likely to experience longer times to healing (<LINK REF="REF-Margolis-2000" TYPE="REFERENCE">Margolis 2000</LINK>; <LINK REF="REF-Margolis-2004" TYPE="REFERENCE">Margolis 2004</LINK>). In addition, the presence of infection may impede healing (<LINK REF="REF-Doughty-2007" TYPE="REFERENCE">Doughty 2007</LINK>). Data on ulcer area and duration are likely to be positively skewed, with large proportions of people having smaller ulcers and wounds of relatively short duration at the start of treatment. Therefore it is much easier to make a meaningful assessment of baseline data if median values with interquartile ranges are provided for these variables. When mean values are reported, it is difficult to interpret the data and to decide whether any observed between-group differences are clinically important. When imbalances occur, primary investigators should attempt to adjust for the pertinent variables in their analyses. Responses to this assessment criterion were as follows:</P>
<P>Low risk: groups appeared to be similar at baseline for ulcer infection status, ulcer duration and surface area (with median values and interquartile ranges reported for duration and area); or differences were observed but were adjusted for in the analysis.</P>
<P>High risk: group imbalance was observed at baseline for ulcer infection status, ulcer duration or surface area, and no adjustment was made.</P>
<P>Unclear risk: information on one or more predictive variables was not provided, or the information was difficult to interpret (e.g. only mean values provided for ulcer area/duration).</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;42 articles reporting 45 RCTs included in the review in total:&lt;/p&gt;&lt;p&gt;22 articles reporting 23 RCTs for original review (23 RCTs so far)&lt;/p&gt;&lt;p&gt;3 articles reporting 4 RCTs for first review update (27 RCTs so far)&lt;/p&gt;&lt;p&gt;18 articles (including 1 already identified during the first review update) reporting 18 RCTs for second review update (45 RCTs so far)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;258 full text articles in total assessed for eligibility:&lt;/p&gt;&lt;p&gt;115 for original review&lt;/p&gt;&lt;p&gt;39 for first review update&lt;/p&gt;&lt;p&gt;104 for second review update&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1128 records identified in total:&lt;/p&gt;&lt;p&gt;426 for original review&lt;/p&gt;&lt;p&gt;202 for first review update&lt;/p&gt;&lt;p&gt;500 for second review update&lt;/p&gt;">
<OUT TEXT="&lt;p&gt;870 records excluded in total, on the basis of titles and abstracts:&lt;/p&gt;&lt;p&gt;311 for original review&lt;/p&gt;&lt;p&gt;163 for first review update&lt;/p&gt;&lt;p&gt;396 for second review update&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;216 full text articles excluded in total on the basis of full text reports:&lt;/p&gt;&lt;p&gt;93 for original review&lt;/p&gt;&lt;p&gt;36 for first review update&lt;/p&gt;&lt;p&gt;87 for second review update&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>